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Abstract 
Alexander J. Grenning and Jon A. Tunge 
Department of Chemistry, April 2012 
University of Kansas 
 
 Presented herein is the development of new methods for Pd-catalyzed allylic alkylation 
with a central focus on reactions that generate molecular complexity rapidly with little waste 
byproduct.  With this simply stated, yet challenging goal in mind, we present the decarboxylative 
allylation (DcA) of nitroalkanes and the conceptually novel deacylative allylation (DaA, or retro-
Claisen) reaction. The main unifying themes of this research are (a) Pd-catalyzed allylation, (b) 
in-situ generation of nucleophilic and electrophilic coupling partners, and (c) “green” synthetic 
methods. 
 Regarding the former topic, DcA of nitroalkanes, we have developed methods for the 
synthesis of both tertiary and secondary allylated nitroalkanes using decarboxylation as a 
strategy. Carbon dioxide is the only byproduct and the organic building blocks prepared by this 
method are easily converted into nitrogen-containing heterocycles by functional group pairing. 
  The conceptually new deacylative allylation (DaA) reaction has been shown to be a 
useful method for allylation of various in situ generated nucleophiles. The reaction leads to 
similar products as can be accessed by the DcA method, but has many added benefits. For 
example, both nucleophilic and electrophilic coupling partners are prepared in situ by a single 
retro-Claisen event. Furthermore, DaA substrate synthesis begins from commercial/readily 
available active methylene nucleophiles (β-dicarbonyl compounds) and can utilize robust 
iv 
methods previously developed for these compounds (e.g. Cu/Pd-catalzyed arylation, Tsuji-Trost 
allylation, etc.). The DaA reaction itself directly couples allylic alcohols, which is desirable due 
to their availability and reduced toxicity compared to other allylating agents. In terms of utility, 
DaA can rapidly construct 1,6-heptadienes (cycloisomerization substrates) via 1-pot 3-
component coupling. We have also utilized the reaction to construct an important intermediate en 
route to the drug verapamil as well an asymmetric DaA reaction that allows formal access to (+)-
hamigeran and other enantioenriched tetralone derivatives. 
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Chapter 1. Palladium-catalyzed decarboxylative allylation (DcA) of 
nitroalkanes1 
 
1.1 Introduction to palladium-catalyzed decarboxylative allylation 
 
 The olefin (C=C) functional group is an extremely versatile functional group capable of 
undergoing a multitude of synthetic transformations.  This diverse reactivity makes their 
incorporation in a given synthetic intermediate desirable. Furthermore, olefins are often 
considered “latent” functional groups as their reactivity requires specific conditions or catalysts 
for activation. Therefore alkenes are usually quite stable, a benefit when performing multi-step 
synthesis. 
 
 One important derivative of the olefin is the allyl motif (C=C−C).   Allyl installation on a 
molecular scaffold can occur by both nucleophilic2-8 (allyl anion) as well as electrophilic9-13 
(allyl cation) methods.  Regarding the electrophilic sources of an allylic group, classically, allyl 
halide can be utilized.  Though installation can be simple from the allylic halide, problems arise 
when considering toxicity, regioselectivity, as well as when asymmetric induction is desired.  
The contemporary solution to these problems is transition metal-catalyzed allylic alkylation from 
allylic acetates and carbonates, which are much less toxic reagents than comparable allylic 
halides.9-11,13 Importantly, the reduced toxicity of alkyl acetates stems from their reduced 
reactivity: a metal is required to activate the allyl acetate to a metal-π-allyl complex, which are 
OAc
M
simple
coordination
OAc
M M2+
(1.1)
oxidative
addition
poor
electrophile
good
electrophile
2 
quite reactive (eq. 1). Furthermore, chiral ligands can be placed on the metal allowing for 
asymmetric allylic alkylation reactions.9-11,13 Another attractive approach to access metal-π-allyl 
complexes is by metal-catalyzed C-H activation of simple olefins.12  
 Arguably, some of the most utilized methods for allylic alkylation are the metal-catalyzed 
Tsuji-Trost9,13 and decarboxylative10 allylation (DcA) methods. They have become mainstays in 
the organic chemist’s toolbox for allylation of diverse nucleophiles.  The Tsuji-Trost allylation, 
in general, is useful for the allylation of highly stabilized anions such as active methylene S1a as 
shown in Scheme 1. In this process, Pd(0), a common metal for allylic acetate activation, 
performs an oxidative addition on the allylic acetate transforming it into a Pd-π-allyl complex, 
which is a good electrophile.  Concurrently, an external base deprotonates the active methylene 
compound S1a.  These activated intermediates then undergo a coupling reaction to produce the 
desired product S1b as well as regenerate the Pd catalyst.  This general type of reaction has been 
widely researched, utilized, and reviewed9,14-16 and will not be covered in too much more detail.  
 
 One challenge to the Tsuji-Trost allylation is its limitation to highly stabilized “active 
methylene” nucleophiles (DMSO pKa values 8-16).  Fortunately, it was discovered that Pd-
EWGEWG
R
OAc
Pd(0)
Pd
EWGEWG
R Pd
base
OAc
Base-H
EWGEWG
R
oxidative
addition
reductive
elimination
Pd(0)
PdPd
OAc
EWG
R R
oxidative
addition
reductive
elimination
EWG O
R R
O
EWG O
R R
O
decarboxylation
EWG
R R
CO2
+
++
S1a 
(DMSO pKa ~8-16)
S2c
(DMSO pKa 16-33)
Scheme 1.  General mechanism of Tsuji-Trost allylation Scheme 2.  General mechanism of decarboxylative allylation
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3 
catalyzed decarboxylative allylation can occur on appropriately substituted allyl carboxylates to 
generate less-stabilized nucleophiles (DMSO pKa values 16-32). Furthermore, the electrophilic 
coupling partner is also generated in situ (Scheme 2).10 The general mechanism is as follows: an 
allyl α-EWG acetate (S2a) undergoes oxidative addition with Pd(0) generating a carboxylate 
(S2b) and a Pd-π-allyl complex.  The carboxylate, substituted with an EWG, will decarboxylate 
to generate the active nucleophile (S2c).   Though not necessarily a thermodynamically favorable 
process, decarboxylation is considered irreversible due to the loss of CO2.  Similar to the Tsuji-
Trost reaction, the active nucleophile S2c and the Pd-π-allyl complex  couple together producing 
the desired product S2d and regenerate the active catalyst.   It is important to point out two 
unique implications of this approach to allylation:  first, reactive intermediates are generated in 
situ and therefore do not require an external base for nucleophile activation.  Secondly, this type 
of coupling only produces carbon dioxide as a byproduct.  Thus, this approach to coupling is 
quite environmentally benign. 
  
 The DcA approach to coupling has yielded general allylation methods for various carbon-
centered nucleophiles including ketone and ester enolates,17,18 nitrile-stabilized anions,19 imine 
anions,20,21 and the nucleophile relevant to this dissertation, the nitronate anion.1 Numerous 
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asymmetric methods have been developed for allylation of cyclic enolates (eq. 1.2) as well as 
“trapped” E or Z preformed acyclic enolates (eq. 1.3).10 In addition to simple allylation, the 
coupling partners generated in situ can be funneled down alternative reaction pathways such as 
interceptive DcA (IDcA)10 or protonation pathways22 (Scheme 3).  Importantly, this general 
approach to allylation has been extensively utilized in natural product synthesis.10   
 We have quite recently reviewed the aforementioned topics in detail.10  In the 
forthcoming sections (1.2-4) my contribution to this field of research will be discussed. 
Specifically, the development, scope and utility of the DcA of nitroalkanes will be discussed. 
 
1.2 Rapid Decarboxylative allylation (DcA) of nitroalkanes 
 
 
 We envisioned that a DcA reaction of allyl nitroacetate would be useful as it would allow 
for facile nitrogen incorporation into a chemical building block (Scheme 4, S4a è S4b). 
Moreover, nitro groups are readily reduced, and thus, with various α-substitutions, diverse and 
useful homoallylic amino derivatives could quickly be prepared (S4c-d).23 Aside from simple 
amines such as S4c, we envision rapid access to lactams S4d and cyclic amines S4e by 
functional group pairing with esters or ketones.24 Potentially, by acrylation and ring-closing 
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metathesis of S4e, the indolizidine core could also rapidly be accessed. This is a very common 
core structure found in various natural products such as indolizidine 167B25 and the cylindricine 
family26 of natural products (Scheme 4, top right). 
 
 Regarding the DcA reaction of allyl nitroacetates, a single result was published by Tsuji 
and coworkers in 1987 (Scheme 5).27 Their conditions yielded a mixture of the desired C-
allylated nitroalkane S5a as well as the regioisomeric O-allylated species S5b in 80% yield (1:1 
C:O allylation) (Scheme 5).  To begin improving upon Tsuji’s initial result, we synthesized our 
own allyl nitroacetate S6a in 3-steps from isobutyric acid by α-bromination,28 DCC-coupling 
with allyl alcohol, and Kornblum nitration29 (Scheme 6). We were pleased to find that, by simply 
using the commercially available Pd(PPh3)4 in DCM, we could achieve synthesis of the desired 
product S6b in 82% yield with no detectable amount of the undesired O-allylated byproduct 
(Scheme 6).  Interestingly, compared to other DcA reactions of allyl acetoacetates (Table 1), the 
reaction went unprecedentedly quick; complete conversion occurred in < 5 minutes and could 
visually be monitored by the effervescence of carbon dioxide.   
 
 To help understand this dramatic rate enhancement, it is useful to compare the pKa 
change and the rate of reaction between the previously studied DcA systems with the nitroacetate 
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substrate.  As shown in Table 1, the intermediate carboxylate (T1a - T1e) is always a lower pKa 
than that of the corresponding decarboxylated anionic nucleophile (T1f - T1j).  In terms of pKa 
change, decarboxylation is thermodynamically uphill in energy.  Interestingly, the rate of 
reaction and the harshness of reaction conditions required for DcA reaction to occur appears to 
trend with this change in pKa such that the smaller the pKa change, the gentler/more rapid the 
decarboxylative allylation will occur. For example, the decarboxylative allylation reaction 
requires more pressing conditions for sulfones and nitriles (T1a-b) than it does for ketones (T1d) 
or nitro-compounds (T1e), which, under the conditions we developed, is extremely rapid and 
chemically efficient (Scheme 6).  
 
  With working conditions in hand for the DcA reaction of nitroacetates, we began to test 
the scope of the reaction.  In order to fully examine the scope, we needed a robust method for 
efficient access to α,α-dialkyl nitroacetates.  Using the previously mentioned approach from α,α-
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dialkylacetic acid (Scheme 6), we could produce a few starting materials in a stepwise fashion 
(Scheme 7, S7a-d), which was undesirable. Even more problematic was the limitation to 
commercially available carboxylic acid starting materials.   
 
 We wished to find a common intermediate for producing diverse substrates: as shown in 
Scheme 8, alkyl α-nitroacetate esters undergo a myriad of unique alkyl30 (and aryl31) substitution 
reactions and, thus, we thought that allyl nitroacetate 8a would be a good template to begin our 
substrate diversification.  Furthermore, nitroacetic acid can be easily prepared on multi-gram 
scale from nitromethane32,33 and its DCC-coupling reaction (nitroacetic acid è S8a) is known.34 
Upon a literature survey, we found a diverse array of reactions that can be performed on a 
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nitroacetate substrate.  For example, nitroacetates undergo Michael additions (S8b),35,36 
Knoevenagel condensations and tandem Knoevenagel/Diels-Alder reactions37 (S8c) to synthesize 
nitroacetate substituted 6-membered rings.  They have also been utilized in various metal-
catalyzed reactions such as Tsuji-Trost allylations38-42 (S8d), and more recently, in Pd-catalyzed 
Buchwald-Hartwig arylation reactions (S8e).31    In a recent study by Waser, he had shown that a 
new reagent, EBX, can be used to transfer acetylene to a nitroacetate (S8f).43 Quite surprisingly, 
it was interesting to discover that the classical alkylation of nitroacetates (with alkyl halides) is 
only sparsely reported and reactions typically occur in low yields.39  An interesting trend in the 
alkylation of nitroacetate is that alkylation reactions that work well (e.g. Michael addition, 
Knoevenagel, Tsuji-Trost, etc) involve π*-electrophiles. The outlier is the only reaction that 
performs poorly: alkylation from alkyl halides, which requires σ*-orbital overlap by the 
nitroacetate nucleophile.  
 With the potential diversifying reactions outlined, it became clear that a few reactions 
could present some potential challenges toward substrate synthesis and, at least at first, should be 
avoided. That is, substrates that require a transition metal for their alkylation (or arylation) 
reaction might be problematic with our starting material allyl nitroacetate due to competing paths 
for Pd oxidative addition (Scheme 9).  With that said, we thought it would be challenging to 
incorporate aryl groups and allyl groups via their known Pd-catalyzed methods.31,39  We found 
this potential limitation to be unfortunate, yet intriguing, as aryl and allyl group incorporation 
would be useful and allow for more diverse couplings.  In Chapter 3, our attempts, failures, and 
eventual successes in sequential Pd-catalysis made possible by deacylative (retro-Claisen) 
allylation will be discussed.44 
9 
 
 Now that the allowed transformations for substrate diversification have been outlined, the 
scope of the deacylative allylation will be discussed.  Not surprisingly, simple dialkyl substituted 
nitroacetates were exceptional substrates (e.g. T2a and T2b).  Substitution on the allyl moiety 
was generally accepted. For example, terminal alkyl (T2c) and aryl (T2d) substituted allylic 
nitroacetate were acceptable coupling partners. β-substitution was also acceptable, as determined 
by the successful DcA reaction of β-methylallyl nitroacetate T2e.  Functionally dense allylated 
nitroalkanes could easily be prepared by tethering ketone (T2f and T2h) and ester (T2g and T2i) 
functional groups by Michael addition.  Furthermore, we also took advantage of the 
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aforementioned Knoevenagel/Diels-Alder reaction to quickly prepare allylated 
nitrocyclohexenes (T2j-m). 
 Interestingly, the cinnamyl nitroacetate required a higher-catalyst loading to give a clean 
reaction (e.g. Table 2, T2d and T2l). As shown in Scheme 10, when 5 mol% of Pd was utilized a 
1.2 : 1 mixture of desired product S10a and cinnamaldehyde S10b was isolated (entry 1). We 
presume that the cinnamaldehyde is due to O-allylation, forming intermediate S10c, followed by 
Hass-Bender oxidation.45-47 Aside from using higher catalyst loadings (entry 4), by simply 
increasing the reaction concentration, the desired product can be favored (entries 2-3).  To 
explain this mechanistically, we suggest that O-allylation is reversible. At higher concentrations 
of Pd, reionization of the O-allylated species S12c (to the nitronate and Pd-π-allyl complex) 
occurs more efficiently than Hass-Bender oxidation, which allows for irreversible product 
formation by C-allylation. 
 
 In addition to the substrates in Table 2, we prepared a few other unique allyl nitroacetates 
to test in the DcA reaction.  As shown in Scheme 11, a fluorinated allyl nitroacetate S11b 
performed excellently in DcA providing S11c in near quantitative yield. Access to DcA substrate 
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S11b was achieved from allyl α-nitro-α-phenyl acetate S11a, which in turn is derived from 
phenylacetic acid by bromination,48 DCC coupling with allyl alcohol, and Kornblum nitration.43 
α-Fluorination with Selectfluor yields the desired starting substrate S11b. In another example, 
substrate S12b was prepared by a Knoevenagel/“failed” Diels-Alder sequence with furan as the 
“diene” (Scheme 12).  Though the reaction of allyl nitroacetate, formaldehyde, and furan lead to 
a product, it did not give the expected [4+2] product. Rather, it underwent an electrophilic 
aromatic substitution reaction to produce the monosubstituted nitroacetate S12a. We then 
performed a Michael addition (S12b) in excellent yield (87%) followed by the DcA reaction to 
produce the densely functionalized allylated nitroalkane S12c in near quantitative yield. 
 
 By utilizing terminally substituted dieneophiles in the Knoevenagel/Diels-Alder reaction 
of allyl α-nitroacetate, we could test the diastereoselectivity of the DcA transformation (Scheme 
13).  Under Knoevenagel/Diels-Alder conditions we could produce a 2:1 mixture of allyl 
nitroacetate diastereomers S13a/b that were separable by chromatography.  Under DcA 
conditions, we realized that the reaction was stereoconvergent in that both diastereomers lead to 
a single relative diastereomer S13c (6.5:1 dr). Moreover, the allylation occurred from the least 
hindered face (opposite of benzyloxy group), suggesting steric control in the allylation.  The 
stereochemistry was determined by nOe studies and further confirmed by X-ray 
crystallography.49 It is important to note that the poorly selective Diels-Alder reaction (2:1 dr in 
this case) can be resolved using this decarboxylative allylation method (S13a/b, 2:1 dr è S13c, 
O2N O
O O2N O
O
O
O2N O
O
CO2Me
O
O2N
CO2Me
OO
HCHO,
Knoevenagel/
Diels-Alder
conditionsa
CO2Me
(b) Pd(0)
DcA
(a) THF:AcOH (1:1), formalin, furan !, 40% (unoptimized) (b) methyl acrylate, TBAB, DIEA, MeCN, 84%
Scheme 12. Decarboxylative allylation of a functionally dense allyl nitroacetate
S12a S12b S12c, 93%
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6.5:1 dr).  The scope of this steroconvergent reaction is shown in Table 3. Simple allylic 
substitution (T3a) by DcA was well tolerated. Other benzyloxy substituted substrates performed 
well with a wide array of terminally substituted (T3c-d) as well as β-substituted allylic acetates 
(T3b) providing excellent yields (75 – 97%) and good diastereoselectivities (> 6.5:1).  We also 
performed the Diels-Alder DcA sequence with cyclopentadiene as the dieneophile (T3e-f) 
Again, good yields and diastereoselectivities were observed with these substrates. 
 
 Thus far, the successes of the DcA reaction of allyl α-nitroacetates have been discussed. 
However, there were some general limitations. First, β-elimination is possible (Scheme 14). We 
witnessed (by 1H NMR, 100% conv.) formation of nitroalkene S14a when a β-acetyloxy group 
was present on the nitroalkane.  Thus β- (to the nitronate anion) leaving groups should be 
avoided. Next, prenyl nitroacetate was not a viable coupling partner due to β-elimination, 
producing isoprene and the undesired 2° nitroalkane S14b.  Only a trace amount of the desired 
prenylated nitroalkane was formed in this reaction. In addition to elimination-type reactions, we 
O2N CO2Allyl
OBn
AllylO2C NO2
OBn
O2N O
O
OBn
HCHO
Knoevenagel/
Diels-Alder
Conditionsa
2:1 dr (seperable) NO2OBn
OBn
N
O O
Pd
Scheme 13. Decarboxylative allylation is stereoconvergent and diastereoselective
Allylation occurs from least 
hindered face of nitronate-anion
Pd(0)b
Pd(0)b
(a) THF:AcOH (1:1), formalin, diene, !,  70% (b) 5 mol% Pd(PPh3)4, DCM (0.2M)
S13c, 92%
6.5:1 drS13a
S13b
NO2
R
NO2
R
O
O 5 mol% Pd(PPh3)4
DCM, <5 min, rt
NO2 NO2
NO2
OBn
NO2
OBn
NO2
OBn
Ph NO2
OBn
Table 3. Diasteroselective DcA reactions
T3a, 92%
6.5 : 1 dr
T3b, 75%
6.5 : 1 dr
T3c, 97%
6.5 : 1 dr
T3d, 82%
7 : 1 dr
T3e, 95%
8 : 1 dr
T3f, 95%
8 : 1 dr
R
R
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also found 2° allylated nitroalkane synthesis via DcA problematic due to competing over 
allylation (Scheme 15).   
 
 
1.3 Synthesis of 2° allylated nitroalkanes from prenyl nitroacetate 
 
 The Pd-catalyzed allylation of 1° nitroalkanes (to produce 2° allylated nitroalkanes) is a 
known process,42,50-53 though it is not without its downfall: excessive amounts of the nitro 
compound are required to avoid over-allylation to the 3° diallylated nitroalkane.  This is 
especially undesirable when the nitroalkane to be allylated is precious.   
 As stated at the end of section 1.2, it was similarly challenging to prepare 2° nitroalkanes 
via DcA from the allyl α-monoalkylated nitroacetate due to over-allylation (Scheme 15).  
However, we also noticed that prenyl nitroacetates undergo β-hydrogen elimination producing 2° 
nitroalkanes (Scheme 14). We envisioned that we could take advantage of the prenyl 
nitroacetates aptitude for elimination to produce functionally dense allylated 2° nitroalkanes 
rapidly using a 1-pot Tsuji-Trost allylation/decarboxylative protonation of prenyl nitroacetate 
O2N O
O
OAc
HCHO
NO2
OAc
O
O
OAc
N
O O NO2
Pd
Knoevenagel/
Diels-Alder
conditionsa !-Elim.
(a) THF:AcOH (1:1), formalin, diene, ",  70% (b) 5 mol% Pd(PPh3)4, DCM (0.2M)
Pd(0)b
Scheme 14. !-Elimination is problematic when generating nitronate anions via DcA
PdH !-Elim.
on Nu
on 
electrophile
Pd(0)bNO2
OBn
O
O
OBn
N
O O
OBn
NO2
only trace prenylation
S14a
S14b
O2N
O
O
O
O2N
O
O2N
O
5 mol% Pd(PPh3)4
DCM, rt, < 5min
isolated an inseperable mixture of 
mono and bis allylated nitroalkane
Scheme 15. Preparation of 2° nitroalkanes is challenging via DcA
~2 : 1
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sequence (Scheme 18). Furthermore, Tsuji-Trost allylation of active methylenes, such as 
nitroacetate, is an extremely facile process.  In our approach from S16a, mild Tsuji-Trost 
allylation occurs to form S16b. Furthermore, over allylation is obviously avoided as the α-
position is now fully substituted.  From the allylated intermediate S16b, the same Pd catalyst 
from the Tsuji-Trost allylation can then remove the prenyl carboxylate via decarboxylative 
protonation, yielding the desired product S16c. 
 
 To test this hypothesis we prepared monoalkylated prenyl nitroacetate S17a by Michael-
addition with MVK using a known method (Scheme 17).35 We found that a smooth reaction 
between allyl methyl carbonate and S17a occurred producing S17b in 77% isolated yield [-40 
°C, DCM, Pd(PPh3)4 cat.]. This compound could then be converted to the desired allylated 2° 
nitroalkane S17c by Pd-catalyzed decarboxylative protonation in 75% yield.  Interestingly, about 
25% of the prenylated 3° nitroalkane was also formed.  
 
 On a multi-gram scale with propyl vinyl ketone, we prepared S18a by Michael addition 
(Scheme 18). We then turned to developing the 1-pot Pd-catalyzed Tsuji-Trost/decarboxylative 
protonation reaction.  We realized that with a base additive (0.5 equiv.), the reaction went 
O2N O
O
R
O2N O
O
R
O2N
R
Pd(0)
Tsuji-Trost allylation
MeO2CO
Pd(0)
decarboxylative
protonation
Scheme 16. Tsuji-Trost/DcA can synthesize 2° nitroalkanes
single-pot sequential palladium-catalysis
S16a
S16b S16c
isoprene + CO2
O2N O
O
COMe
Michael addition
65-85% Yieldsa
MeO2CO
7.5 mol%
Pd(PPh3)4
-40 °Cb
O2N O
O
MeOC
S17b 77%
O2N
COMe
S17c, 75%d
Pd(PPh3)4c
S17a
Scheme 17. Tsuji-Trost/DcA can synthesize 2° nitroalkanes
(a) prenyl nitroacetate:MVK (1 : 1.1 equiv), 5 mol% Yb(OTf)3, 10 mol% NaOH and proline, H2O (b) the reactants are added at -40 °C and the reaction is quenched 
at -40 °C by addition of water and extraction (c) 5 mol% Pd(PPh3)4, rt, 30min. (d) crude NMR shows a ~3:1 mixture of S19c and prenylated nitroalkane
DCM, rt, 30min
15 
smoother giving less of the prenylated byproduct.  Under the conditions outlined in Scheme 18, 
we could prepare gram quantities of the 2° allylated nitroalkane S18b containing a pendant 
ketone. Moreover, this specific nitroalkane S18b was prepared to quickly access the indolizidine 
core as outlined in section 1.3 of this chapter (Scheme 20). 
 
 Though content with this approach to 2° nitroalkanes, scope studies were abandoned due 
to the discovery of an even simpler approach to these useful compounds: Tsuji-Trost/retro-
Claisen condensation.44 This reaction will be discussed in Chapter 3 of this dissertation, as retro-
Claisen based methodologies became a central theme of my research. 
 As stated, in the next section, I will outline the utility of the various 2° and 3° allylated 
nitroalkanes that we prepared via DcA (section 1.2) and by Tsuji-Trost/decarboxylative 
protonation (Section 1.3). 
 
1.4 Nitro-group reduction to produce useful amino derivatives 
 
 Through this first chapter, I have described how various, relatively complex, allylated 
nitroalkanes can be prepared quickly by decarboxylative methods.  In a few cases, we performed 
some nitro group selective reductions to give rise to homoallylic amines and derivatives thereof 
(Schemes 19 and 20).  For example, by reduction of S19a, we prepared a protected 1,2-amino 
alcohol (S19b).  Moreover, using a functional group pairing strategy,24 both imines (S19d) and 
O2N O
O
COPr
MeO2CO
DCM, -40 °C - rt
O2N O
O
ROC
O2N
COPr
Scheme 18. Single pot synthesis of functionally dense 2° nitroalkane S18b
(a) prenyl nitroacetate:propyl vinyl ketone (1:1.1 equiv), 5 mol% Yb(OTf)3, 10 mol% NaOH and proline, H2O
0.5 equiv. DBU
Pd(PPh3)4
Michael addition
S18a 65-75%a
up to 3 gram-scale
S18b
71-90% Yields
up to gram-scale
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lactams (S19f) can be prepared from nitro ketones (S19c) and esters (S19e) by reduction, 
respectively. 
 
 Utilizing the functionalized 2° allylated nitroalkane prepared by Tsuji-
Trost/decarboxylative protonation (Scheme 18), we could utilize all appended functional groups 
to rapidly construct the indolizidine core as a single diastereomer and in good yield.  Starting 
from S20a, reduction of the nitro group leads directly to a cyclic imine, and by further reduction 
using DIBAL at -40 °C, we could access the pyrollidine S20b as a single diastereomer. Due to 
challenges with this substrate’s purification it was first acrylated then purified by column 
chromatography yielding the acrylamide S20c. Moreover, this was the only chromatographic 
event in this 3-step sequence. From S20a, S20c was prepared in 60% overall yield. Upon 
acrylate installation, the molecule is poised to undergo a ring-closing metathesis to synthesize the 
5-6-fused ring system found in various indolizidine containing alkaloids. This is done with 
Grubbs’ 2nd-generation catalyst yielding the desired compound S20d in 84% isolated yield. 
Overall, this sequence is rapid and generally good yielding.    
O2N
MeOC
O
O2N
MeO2C
O
OMe
BnO
H2N
N
O
H
NO
O
OEt
BnO
O2N
S19b, 97%
S19f, 95%
S19d, 99%
functional-group
pairing
Zn/HCla
Zn/HCla
Zn/HCla
(a) standard reaction conditions: 20 equiv. Zn dust and 40 equiv. HCl, iPrOH, 60 oC, 1h.
Scheme 19. Synthesis of various amino derivatives
S19a
S19c
S19e
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 To conclude, we have developed a practical method for the rapid synthesis of a diverse 
array of allylated 3° nitroalkanes via decarboxylative allylation. We utilized robust methods, 
such as Michael addition and Knoevenagel/Diels-Adler for α-alkylation to produce structurally 
diverse nitro-compounds. Furthermore, nitro-group reduction along with functional group 
pairing can transform these compounds into various homoallylic amine derivatives. We also 
devised a novel single pot Tsuji-Trost/decarboxylative protonation reaction for the synthesis of 
2° nitroalkanes that can be utilized to access the indolizidine core found in numerous alkaloid 
natural products.  
 
1.5 References for Chapter 1 
 
1 Grenning, A. J.; Tunge, J. A. "Rapid Decarboxylative Allylation of Nitroalkanes." Org. 
Lett. 2010, 12, 740-742. 
2 Denmark, S. E.; Fu, J. "Catalytic Enantioselective Addition of Allylic Organometallic 
Reagents to Aldehydes and Ketones." Chem. Rev. 2003, 103, 2763-2794. 
3 Jeganmohan, M.; Cheng, C.-H. "Transition metal-catalyzed three-component coupling of 
allenes and the related allylation reactions." Chem. Comm. 2008, 3101-3117. 
4 Kanai, M.; Shibasaki, M.; Shibuguchi, T.; Wada, R. "Cu(I)-catalyzed asymmetric 
allylation of ketones and ketimines." Pure Appl. Chem. 2008, 80, 1055. 
5 Han, S. B.; Kim, I. S.; Krische, M. J. "Enantioselective iridium-catalyzed carbonyl 
allylation from the alcohol oxidation level via transfer hydrogenation: minimizing pre-
activation for synthetic efficiency." Chem. Comm. 2009, 7278-7287. 
6 Tietze, L. F.; Kinzel, T.; Brazel, C. C. "The Domino Multicomponent Allylation Reaction 
for the Stereoselective Synthesis of Homoallylic Alcohols." Acc. Chem. Res. 2009, 42, 
367-378. 
7 Roy, U. K.; Roy, S. "Making and Breaking of Sn−C and In−C Bonds in Situ: The Cases 
of Allyltins and Allylindiums." Chem. Rev. 2010, 110, 2472-2535. 
HN NO
O2N
COPr
NO
(a) 20 equiv. Zn dust and 40 equiv. HCl, iPrOH, 60 oC, 1h (b) 3 equiv. DIBAL, -40 °C-rt (c) 1 equiv. acryloyl chloride, 1.2 equiv. pyridine, DCM, 0 °C-rt (d) Grubbs II, 
Tol, 60  °C DCE
a,b O Cl
c
RCM
d
3-steps
60% Yield 84% Yield
Scheme 20. Toward indolizidine alkaloids
(±)-S20dS20a S20b S20c
18 
8 Yus, M.; González-Gómez, J. C.; Foubelo, F. "Catalytic Enantioselective Allylation of 
Carbonyl Compounds and Imines." Chem. Rev. 2011, 111, 7774-7854. 
9 Trost, B. M. "Pd- and Mo-Catalyzed Asymmetric Allylic Alkylation." Org. Process Res. 
Dev. 2012, 16, 185-194. 
10 Weaver, J. D.; Recio, A.; Grenning, A. J.; Tunge, J. A. "Transition Metal-Catalyzed 
Decarboxylative Allylation and Benzylation Reactions." Chem. Rev. 2011, 111, 1846-
1913. 
11 Guerrero, R. I.; Rosas-Hernandez, A.; Martin, E. "Recent advances in the application of 
chiral phosphine ligands in Pd-catalyzed asymmetric allylic alkylation." Molecules 2011, 
16, 970-1010. 
12 Jensen, T.; Fristrup, P. "Toward Efficient Palladium-Catalyzed Allylic C-H Alkylation." 
Chem. Eur. J. 2009, 15, 9632-9636. 
13 Mohr, J. T.; Stoltz, B. M. "Enantioselective Tsuji Allylations." Chem. Eur. J. 2007, 2, 
1476-1491. 
14 Tsuji, J. "Catalytic reactions via π-allylpalladium complexes." Pure Appl. Chem. 1982, 
54, 197-206. 
15 Trost, B. M. "Transition metal templates for selectivity in organic synthesis." Pure Appl. 
Chem. 1981, 53, 2357-2370. 
16 Trost, B. M.; Van Vranken, D. L. "Asymmetric Transition Metal-Catalyzed Allylic 
Alkylations." Chem. Rev. 1996, 96, 395-422. 
17 Tsuda, T.; Chujo, Y.; Nishi, S.; Tawara, K.; Saegusa, T. "Facile generation of a reactive 
palladium(II) enolate intermediate by the decarboxylation of palladium(II) .beta.-
ketocarboxylate and its utilization in allylic acylation." J. Am. Chem. Soc. 1980, 102, 
6381-6384. 
18 Burger, E. C.; Tunge, J. A. "Asymmetric Allylic Alkylation of Ketone Enolates: An 
Asymmetric Claisen Surrogate." Org. Lett. 2004, 6, 4113-4115. 
19 Recio, A.; Tunge, J. A. "Regiospecific Decarboxylative Allylation of Nitriles." Org. Lett. 
2009, 11, 5630-5633. 
20 Burger, E. C.; Tunge, J. A. "Synthesis of Homoallylic Amines via the Palladium-
Catalyzed Decarboxylative Coupling of Amino Acid Derivatives." J. Am. Chem. Soc. 
2006, 128, 10002-10003. 
21 Yeagley, A. A.; Chruma, J. J. "C−C Bond-Forming Reactions via Pd-Mediated 
Decarboxylative α-Imino Anion Generation." Org. Lett. 2007, 9, 2879-2882. 
22 Mohr, J. T.; Hong, A. Y.; Stoltz, B. M. "Enantioselective protonation." Nat. Chem. 2009, 
1, 359-369. 
23 Ono, N. in The Nitro Group in Organic Synthesis     159-181 (John Wiley & Sons, Inc., 
2002). 
24 Comer, E.; Rohan, E.; Deng, L.; Porco, J. A. "An Approach to Skeletal Diversity Using 
Functional Group Pairing of Multifunctional Scaffolds." Org. Lett. 2007, 9, 2123-2126. 
25 Michael, J. P. "Indolizidine and quinolizidine alkaloids." Nat. Prod. Rep. 2004, 21, 625-
649. 
26 Weinreb, S. M. "Studies on Total Synthesis of the 
Cylindricine/Fasicularin/Lepadiformine Family of Tricyclic Marine Alkaloids." Chem. 
Rev. 2006, 106, 2531-2549. 
27 Tsuji, J.; Yamada, T.; Minami, I.; Yuhara, M.; Nisar, M.; Shimizu, I. "Palladium-
catalyzed decarboxylation-allylation of allylic esters of .alpha.-substituted .beta.-keto 
19 
carboxylic, malonic, cyanoacetic, and nitroacetic acids." J. Org. Chem. 1987, 52, 2988-
2995. 
28 Zhang, L. H.; Duan, J.; Xu, Y.; Dolbier Jr, W. R. "A simple and efficient method of 
preparing α-bromo carboxylic acids." Tetrahedron Lett. 1998, 39, 9621-9622. 
29 Ito, M.; Okui, H.; Nakagawa, H.; Mio, S.; Iwasaki, T.; Iwabuchi, J. "Synthesis of N-
oxydihydropyrrole derivatives." Heterocycles 2002, 57, 881-894. 
30 Ono, N. in The Nitro Group in Organic Synthesis     126-158 (John Wiley & Sons, Inc., 
2002). 
31 Metz, A. E.; Berritt, S.; Dreher, S. D.; Kozlowski, M. C. "Efficient Palladium-Catalyzed 
Cross-Coupling of Highly Acidic Substrates, Nitroacetates." Org. Lett. 2012, 14, 760-
763. 
32 Vanier, S. b. F.; Larouche, G.; Wurz, R. P.; Charette, A. B. "Formal Synthesis of 
Belactosin A and Hormaomycin via a Diastereoselective Intramolecular 
Cyclopropanation of an α-Nitro Diazoester." Org. Lett. 2010, 12, 672-675. 
33 Kuster, G. J. T.; van Berkom, L. W. A.; Kalmoua, M.; van Loevezijn, A.; Sliedregt, L. A. 
J. M.; van Steen, B. J.; Kruse, C. G.; Rutjes, F. P. J. T.; Scheeren, H. W. "Synthesis of 
Spirohydantoins and Spiro-2,5-diketopiperazines via Resin-Bound Cyclic α,α-
Disubstituted α-Amino Esters." J. Comb. Chem. 2005, 8, 85-94. 
34 Sylvain, C.; Wagner, A.; Mioskowski, C. "An efficient procedure for the esterification of 
nitroacetic acid: Application to the preparation of Merrifield resin-bound nitroacetate." 
Tetrahedron Lett. 1999, 40, 875-878. 
35 Aplander, K.; Ding, R.; Krasavin, M.; Lindstroem, U. M.; Wennerberg, J. "Asymmetric 
lewis acid catalysis in water: α-amino acids as effective ligands in aqueous biphasic 
catalytic Michael additions." Eur. J. Org. Chem. 2009, 810-821. 
36 Keller, E.; Feringa, B. L. "Highly efficient ytterbium triflate-catalyzed Michael additions 
of α-nitro esters in water." Synlett 1997, 842-844. 
37 Wade, P. A.; Murray Jr, J. K.; Shah-Patel, S.; Carroll, P. J. "Generation and in situ Diels-
Alder reactions of activated nitroethylene derivatives." Tetrahedron Lett. 2002, 43, 2585-
2588. 
38 Dahnz, A.; Helmchen, G. "Iridium-catalyzed enantioselective allylic substitutions with 
aliphatic nitro compounds as prenucleophiles." Synlett 2006, 697-700. 
39 Fu, Y.; Etienne, M. A.; Hammer, R. P. "Facile Synthesis of α,α-Diisobutylglycine and 
Anchoring its Derivatives onto PAL-PEG-PS Resin." J. Org. Chem. 2003, 68, 9854-
9857. 
40 Genet, J. P.; Blart, E.; Savignac, M. "Palladium-catalyzed cross-coupling reactions in a 
homogeneous aqueous medium." Synlett 1992, 715-717. 
41 Genet, J. P.; Ferroud, D. "Alkylation of α-nitroacetates catalyzed by complexes of 
palladium." Tetrahedron Lett. 1984, 25, 3579-3582. 
42 Wade, P. A.; Morrow, S. D.; Hardinger, S. A. "Palladium catalysis as a means for 
promoting the allylic C-alkylation of nitro compounds." J. Org. Chem. 1982, 47, 365-
367. 
43 Fernández González, D.; Brand, J. P.; Waser, J. "Ethynyl-1,2-benziodoxol-3(1  H)-one 
(EBX): An Exceptional Reagent for the Ethynylation of Keto, Cyano, and Nitro Esters" 
Chem. Eur. J. 2010, 16, 9457-9461. 
20 
44 Grenning, A. J.; Tunge, J. A. "Deacylative Allylation of Nitroalkanes: Unsymmetric 
Bisallylation by a Three-Component Coupling." Angew. Chem. Int. Ed. 2011, 50, 1688-
1691. 
45 Hass, H. B.; Bender, M. L. "The Reaction of Benzyl Halides with the Sodium Salt of 2-
Nitropropane.1 A General Synthesis of Substituted Benzaldehydes." J. Am. Chem. Soc. 
1949, 71, 1767-1769. 
46 Klein, T. A.; Schkeryantz, J. M. "Tandem Hass–Bender/Henry reaction for the synthesis 
of dimethylnitro alcohols from benzylic halides." Tetrahedron Lett. 2005, 46, 4535-4538. 
47 Trost, B. M.; Richardson, J.; Yong, K. "Palladium-Catalyzed Chemo- and 
Enantioselective Oxidation of Allylic Esters and Carbonates." J. Am. Chem. Soc. 2006, 
128, 2540-2541. 
48 Carpino, L. A.; McAdams, L. V., III. "α-α-Dibromodibenzyl sulfone." Org. Syn. 1970, 
50, 31-35. 
49 Chen, L.; Shi, M.; Li, C. "Cu(I)-Catalyzed Intramolecular C-C Coupling of Activated 
Methylene Compounds with Vinyl Halides: Efficient Synthesis of Functionalized 
Alkylidenecyclobutanes." Org. Lett. 2008, 10, 5285-5288. 
50 Trost, B. M.; Surivet, J.-P. "Asymmetric Alkylation of Nitroalkanes." Angew. Chem. Int. 
Ed. 2000, 39, 3122-3124. 
51 Trost, B. M.; Surivet, J.-P. "Diastereo- and Enantioselective Allylation of Substituted 
Nitroalkanes." J. Am. Chem. Soc. 2000, 122, 6291-6292. 
52 Deardorff, D. R.; Savin, K. A.; Justman, C. J.; Karanjawala, Z. E.; Sheppeck, J. E.; 
Hager, D. C.; Aydin, N. "Conversion of Allylic Alcohols into Allylic Nitromethyl 
Compounds via a Palladium-Catalyzed Solvolysis: An Enantioselective Synthesis of an 
Advanced Carbocyclic Nucleoside Precursor." J. Org. Chem. 1996, 61, 3616-3622. 
53 Aleksandrowicz, P.; Piotrowska, H.; Sas, W. "Palladium catalyzed C-allylation of 
nitroalkanes." Tetrahedron 1982, 38, 1321-1327. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
21 
Chapter 1 appendix 
Experimental methods and spectral analysis for Ch. 1 compounds. 
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General information: 
 
*Note: Products are named after their Table or Scheme location in Chapter 1 (e.g. T2a = 
substrate a in Table 2 or S13c = substrate c in Scheme 13). If a compound has not specifically 
been named and referred to in Chapter 1 text, it will be given an Appendix name (A-1, A-2, etc.) 
They are similarly named in the spectral analysis section of this appendix.   
  
All reactions were run in flame-dried glassware.  CH2Cl2 and Toluene were dried over 
activated alumina. THF was dried over sodium in the presence of benzophenone indicator. 
Anhydrous DMSO and DMF were purchased from Aldrich Chemical Company.  Commercially 
available reagents were used without additional purification unless otherwise stated. Compound 
purification was effected by flash chromatography using 230x400 mesh, 60Å porosity silica 
obtained from Sorbent Technologies. 1H NMR and 13C NMR spectra were obtained on a Bruker 
Avance 400 or a Bruker Avance 500 DRX spectrometer equipped with a QNP Cryoprobe and 
referenced to residual protio solvent signals. Structural assignments are based on 1H, 13C, DEPT-
135, COSY, HSQC, nOe, and IR spectroscopies.  Mass Spectrometry was performed using an 
Agilent 5890A Series II GC System. 
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Decarboxylative allylation of allyl nitroacetates: General Procedure: 
 
Procedure A:  
 In a glove box, A flame dried 10 mL Schlenk flask equipped with a stir bar is charged 
with Pd(PPh3)4 (5 mol%, 0.01 mmol, 11.5 mg).  The flask is removed from the glove box and 
attached to a Schlenk-argon line whereupon 1 mL of DCM is added. To this stirred solution, allyl 
nitroacetic ester (0.2 mmol) is added dropwise via syringe (1 mL disposable syringe was 
commonly used).  The syringe is washed with DCM to ensure complete transfer.  Effervescence 
was observed immediately upon addition of the substrate.  After reaction for approximately 5 
minutes, cuprous chloride (CuCl, ~5-10 mg) was added to complex the triphenylphosphine, 
O2N O
O
R R
O2N R
R R
R
5 mol% Pd(PPh3)4, DCM (0.2 M)
O2N O2N
Et
O2N
Et
Pr O2N
Et
PhO2N
T2a, 82% T2b, 90% T2c, 87% T2e, 81%T2d, 87%a
O2N
MeOC COMe
O2N
MeO2C CO2Me
O2N
MeOC COMe
O2N
MeO2C CO2Me
T2h, 94%b T2i, 99%bT2f, 88% T2g, 92%
O2N O2N O2N Ph O2N
T2j, 90% T2k, 91% T2l, 93%a T2m, 91%b
O2N
F Ph
NO2 NO2
NO2
OBn
NO2
OBn
NO2
OBn
Ph NO2
OBn
S13c, 90%
O2N
CO2Me
O
S14c, 93%
T3a, 92%
6.5 : 1 d.r.
T3b, 75%
6.5 : 1 d.r.
T3c, 97%a
6.5 : 1 d.r.
T3d, 82%b
7 : 1 d.r.
T3e, 95%
8 : 1 d.r.
T3f, 95%
8 : 1 d.r.
Procedure A
(a) 10 mol% catalyst loading (b) isolated as a mixture of crotyl isomers
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allowing for facile purification of product 2 by filtration of the mixture through a silica plug 
using 95:5 hexane:ethyl acetate as an eluent.  Evaporation of solvent under reduced pressure 
provided compounds in >95% purity. 
*NOTE: 10 mol % Pd(PPh3)4 was necessary for cinnamyl esters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
Preparation of various allyl nitroacetates: 
Substrate synthesis 1: from α,α-dialkyl carboxylic acids: 
 
 
α-Bromination of dialkyl acetic acid:1 
 
Esterification of A-1 − A-3 via DCC/DMAP coupling. 
 
General procedure B: 
In a 50-mL round-bottom flask, DCC (1.032g, 5 mmol) and DMAP (10 mol%, 0.5 mmol, 
61 mg) are dissolved in ~10 mL of dry DCM.  In a separate vessel mix the carboxylic acid (5 
mmol) and the allyl alcohol (5 mmol) and dissolve in 10 mL of dry DCM.  Add the reactants 
dropwise to the stirring solution of DCC/DMAP. The addition time was approximately 5 min. 
R
R
OH
O
Br
R
O
OH
R
Br
R
O
O
R
HO
O2N
R
O
O
R
DCC/DMAP
NaNO2
R
R
O
OH Br
R
O
OH
R
Br
O
OH
Br
Me
O
OH
Et
Br
O
OH
NBS, TFA, H2SO4
A-1 A-2 A-3Tetrahedron Lett. 1998, 39, 9621-9622.
Br
R
O
OH
R
Br
R
O
O
R
DCC, DMAP (cat.), DCM
HO R Procedure B
Br
O
O
R
Br
Me
O
O
Et
Ph Br
Me
O
O
Et
Br
O
O Br
Me
O
O
Et
Pr
A-4, 86% >1.5 g A-5, 98%, 1.16g A-6, >2.5g, 91% A-7, 70%, >2.5g A-8, 40%, >1.5g
A-1 - A-3 A-4 - A-8
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Rinse the transfer vessel with 5 mL of DCM to ensure complete reactant transfer to reaction 
vessel.  Let the reaction stir overnight (~12h). 
 After the allotted reaction time, Add ~2mL of 3M HCl and continue stirring for 10mins.  
Filter the reaction mixture through a pad of silica gel using excess DCM to ensure complete 
transfer.  The DCM was dried over MgSO4 and the solvent was evaporated yielding the desired 
product.  The material could often be used as is, or further purified by column chromatography. 
 
Nitration of α-Bromo acetic esters A-4 − A-8 by the Kornblum-reaction:2 
 
Procedure C: 
 A 10 mL flame-dried Schlenk flask is equipped with a stir bar and attached to an argon 
line.  Allyl α-bromo acetate (3 mmol) is added to this flask followed by 5 mL of DMSO.  To the 
stirring solution is added NaNO2 (3.9 mmol, 268mg).  The vessel is then heated at 80 °C until 
completion (as determined by TLC analysis, 1-3h).  
 After the allotted reaction time, the reaction mixture is transferred to a seperatory funnel 
with the aid of 20 mL DCM.  an extra 20 mL of DCM is added and the organic layer is extracted 
with water (2 x 20 mL).  The organic layer is then brine washed (20 mL), dried over MgSO4, and 
the volatiles are removed by rotary evaporation.  The crude product residue is purified by column 
chromatography to yield the desired compound.   
Br
R
O
O
R
R
NaNO2, DMSO, 80 oC
O2N
O
O R
O2N
O
O
O2N
Me
O
O
Et
Ph
O2N
Me
O
O
Et
O2N
O
O
Procedure C
O2N
Me
O
O
Et
Pr
S6a, 41%, 532mg S7a, 374mg, 58% S7d, 800mg, 36%S7b, 894mg, 41% S7c, 37%, 370mg
A-4 - A-8  Heterocycles 2002, 57, 881-894.
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Substrate synthesis 2. Synthesis from allyl nitroacetate:3-5 
 
The procedure in References 3 and 4 was used to prepare nitroacetic acid.  The DCC-
coupling of nitroacetic acid with various alcohols was reported by Sylvain and Wagner (ref. 4) 
 
Knoevenagel/Diels0Alder cyclization of A-9 - A-14:6 
 
OH
O
O2N
NO2-CH3
O
O
O2N
>12 g
DCC, THF
R
O
O
O2N O
O
O2N Ph O
O
O2N Pr
O
O
O2NO
O
O2N
A-9, 82%, >8 g A-10, 55%, >1 g A-11, 45%, 900 mg
A-12, 72%, >1 g A-14, 84%, >3 g
(65%, >12g)
% Yielda
(a) Yield is of the DCC-coupling reaction
O
O
O2N
HO Ri. KOH
ii. Tartaric acid
A-13, 91%, >1 g
Org. Lett. 2010, 12, 672-675.
& J. Comb. Chem. 2005, 8, 85-94. Tetrahedron Lett. 1999, 40, 875-878.
O
O
O2N
Formalin, THF, AcOH
O
O
O2N
µW, 150 °C, 15 min O
O
O2N
O
O
O2N
O
O
O2N
O
O
O2N
Ph O
O
O2N
O2N
OBn
O
O
O2N
OBn
O
O
O2N
OBn
O
O Ph
O2N
OBn
O
O
O
O
O2N
A-15, 52%, 248 mg A-16, 71%, 362 mg A-17, 60%, 189 mg A-18, 57%, 290 mg
A-19, 69%, 212 mg
(2:1)
A-20, 77%, 254 mg
(1:1.3)
A-23, 90%, 201 mg
(5.5:1)
A-21, 80%, 315 mg
(1:1)
A-22, 56%, 187 mg
(1:1.2)
Yield, (d.r.)
A-9 ! A-14
Tetrahedron Lett. 2002, 43, 2585-2588.
29 
 
Michael addition to allyl nitroacetate SI-14 and SI-17 
 
General procedure D: 
 In a 50 mL round bottom flask add TBAB (10 mol%, 0.3 mmol, 96 mg), DIEA (1.05 
equiv., 3.1 mmol, 400 mg) and 15 mL of Dry MeCN.  While stirring, add in the substrate allyl 
nitroacetate (3mmol) and Michael accepter (2.2 equiv., 6.6 mmol).  Cap and stir the reaction 
mixture overnight. 
 After the allotted reaction time, transfer the reaction mixture to a seperatory funnel with 
the aid of chloroform (~20 mL) to ensure complete reaction mixture transfer.  Add in ~50 mL of 
chloroform and extract the organic layer with sat. NaHCO3 (2 x 30 mL).  Wash the organic layer 
with brine, dry over MgSO4 and evaporate off the organic layer leaving the crude, oily product 
residue.  The reaction mixture if purified by column chromatography (15% EtOAc in hexanes). 
 
Preparation of S14b: 
 
O2N O
O O
R
O2N O
O
ROC COR
Procedure D
O2N O
O
MeOC COMe
O2N O
O
MeO2C CO2Me
O2N O
O
MeO2C CO2Me
O2N O
O
MeOC COMe
A-24, 183 mg, 86% A-25, 77% A-26, 653 mg, 99% A-27, 553 mg, 88%
DIEA, TBAB, MeCN, 12 h
O2N O
O O2N O
O
O
O2N O
O
O
CO2Me
Formalin, THF, AcOH
µW, 150 °C, 15 min
O S14a, 40%, 89 mg S14b, 84% 86 mg
DIEA, TBAB, MeCN, 12 h
Procedure E
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*S14b was prepared using the method reported by Wade for performing 
Knoevenagel/Diels-Alder reactions.6  Interestingly, Knoevenagel/Aromatic substitution occurred 
instead.  
Procedure E: 
 In a 10 mL round bottom flask is added TBAB (10 mol%, 0.03 mmol, 10.5 mg), DIEA 
(1.1 equiv., 0.33 mmol, 49 mg), and 1.5 mL of MeCN.  To this stirring mixture is added allyl 
nitroacetate SI-32 (0.33 mmol, 75 mg) followed by methyl acrylate (1.1 equiv, 0.37 mmol, 32 
mg).  The reaction vessel is capped and allowed to stir overnight (12 h).   
 After the allotted reaction time, the mixture is transferred to a seperatory funnel with the 
aid of ~10 mL of chloroform.  An additional 10 mL of chloroform is added and the organic layer 
is extracted with NaHCO3 (2 x 10 mL).  The organic layer is brine washed (10 mL), dried over 
MgSO4, and the chloroform is evaporated by rotary evaporation. The crude oily residue is 
purified by column chromatography (15% EtOAc in hexanes) to yield 86 mg of the desired 
product SI-33 (84% isolated yield).  
 
Substrate synthesis 3: synthesis of fluorinated allyl nitroacetate S13b.8 
 
Procedure F: 
 In a flame-dried 100 mL Schlenk flask equipped with a stir bar and attached to an argon 
line is added 50mL of phloroglucinol (1,3,5-trihydroxybenzene, 37.1 mmol, 4.7 g), NaNO2 (74.2 
O
OH
Ph
Br
O
O
Ph
Br
O
O
Ph
O2N
O
O
Ph
O2N
F
A-28
Procedure B
DCC/DMAP
HO
Phloroglucinol
NaNO2, DMF Selectfluor®
TEA, MeOH
Procedure G
A-29, 86%, >11 g S13a, 47%, 4.5 g S13b, 77%, 120 mg
Procedure F
Chem. Eur. J. 2010, 16, 9457-9461.
31 
mmol, 5.12 g) and dry DMF (~50 mL).  While stirring add in allyl bromoacetete A-29 neat and 
dropwise.  The reaction mixture is stirred for 4h. 
 After the allotted reaction time, the reaction mixture is transferred to a seperatory funnel 
with the aid of 50 mL of water and hexanes to ensure complete transfer.  An extra 150 mL of 
water is added.  The water layer is extracted with hexanes (2 x 200 mL).   The organic layer is 
extracted with brine, dried over MgSO4, and the volatile organics are removed by rotary 
evaporation.  The product is purified by column chromatography (15% EtOAc in hexanes) 
yielding 4.5 grams (47% yield) of the desired product S13a. 
 
Procedure G:   
In a 10 mL round bottom flask is added allyl nitroacetate S13a (0.5 mmol, 110 mg), 
Selectfluor® (1.5 mmol, 531 mg), and 5 mL of methanol.  By Pasteur pipette, add ~5−7 drops of 
TEA. A rapid reaction occurs.  The methanol is removed by rotary evaporation and the crude 
mixture is subjected to column chromatography (10% EtOAc in hexanes) to yield the pure 
product S13b (120 mg, 72% yield). 
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Tsuji-Trost/decarboxylative protonation sequence: 
Substrate synthesis: mono-Michael addition to prenyl nitroacete:7 
 
Procedure H: 
 In a 100 mL round bottom flask equipped with a stir bar is added triphenylphosphine (10 
mol%, 3 mmol, 787 mg), prenyl nitroacetate A-14 (30 mmol, 5.2 g) and 30 mL of THF.  Propyl 
vinyl ketone (30 mmol, 2.95 g) is then added dropwise. The reaction is capped and allowed to 
stir for 12h.  
 After the allotted reaction time, the solvent is evaporated and the crude residue is 
subjected to column chromatography (5% EtOAc in hexanes) to yield the desired product. 
 
Procedure I:  
 Adapted from Wennerberg’s mono-Michael addition of various “malonate-type” 
nucleophiles.7 
In a 50 mL round bottom flask equipped with a stir bar is added NaOH (12 mol%, 2.4 
mmol, 95 mg), proline (12 mol%, 276 mg), and Yb(OTf)3 (5 mol%, 1 mmol, 620 mg). 20 mL of 
water is added and the catalyst mixture is stirred for ~10 min.  To this mixture is added prenyl 
nitroacetate A-14 (20.6 mmol, 3.6 g) and propyl vinyl ketone (21 mmol, 2.15 g).  The reaction 
mixture is then stirred for 4 h with stirring. 
 After the allotted reaction time, the reaction mixture is acidified with 1 M HCl (~20 mL) 
and transferred to a seperatory funnel with the aid of ~20 mL of CHCl3 to ensure complete 
O2N O
O
O2N O
O
PrOC
O
Pr
Procedure H
10 mol % PPh3
Procedure I
cat. NaOH, Proline & Yb(OTf)3
S20a
Procedure H: 70%, >6 g
Procedure I: 65!71%, >3 g
A-14 Eur. J. Org. Chem. 2009, 810-821.
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transfer.  The water layer is extracted with chloroform (2 x 25 mL). The organic layer is then 
washed with brine, dried over MgSO4 and the volatiles are removed by rotary evaporation.  The 
crude, oily product is purified by column chromatography (5 % EtOAc in hexanes). 
 
Tsuji-Trost/decarboxylative protonation of S20a 
 
In a glove box, Pd(PPh3)4 (5 mol%, 0.33mmol, 375 mg) is charged into a 50 mL Schlenk 
flask.  The flask is capped with a septum, removed from the glove box, and attached to a Schlenk 
line.  Under argon, dichloromethane (20 mL) and DBU (50 mol%, 3.25 mmol, 495 mg) is added.  
The reaction vessel was then cooled to -40 °C and stirred.  In 5 mL dichloromethane, an 
equimolar (6.5 mmol) mixture of allyl acetate (755 mg) and substituted prenyl acetate (1.76 g) is 
added dropwise over 5 min.  The reaction mixture was stirred at this temperature for 15 min. and 
then allowed to slowly warm to room temperature where it is stirred for an additional 30 min.   
After the allotted reaction time, the reaction mixture was transferred to a separatory funnel, 
further diluted with dichloromethane (~50 mL) and washed with 1 N HCl (25mL) followed by 
brine (25 mL).  The organic layer was collected, dried over MgSO4, evaporated, and subjected to 
silica gel chromatography (15:85 Et2O:pentane) to provide 1.17 g of the desired product S20b 
(90% Yield). 
 
 
 
O2N O
O
PrOC
MeO2CO
DCM, -40 °C ! rt
0.5 Equiv. DBU
Pd(PPh3)4 O2N
COPr
S20b, 71!91% Yields
>1g ScalesS20a
Procedure J
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Reduction of various nitro compounds: 
From tertiary allylated nitroalkanes 
 
Procedure K: 
 In a 20 mL round bottom flask equipped with a stir bar, nitro compound (0.15 mmol) was 
dissolved in isopropanol (3 mL).  To this solution 1 M HCl (1.5 mL) and zinc dust (190 mg, 3 
mmol) was added and the mixture was stirred vigorously for 2 h at 50 oC.  After cooling the 
mixture to room temperature, saturated K2CO3 (4 mL) was added and the resulting mixture was 
stirred for an additional 20 min.  The solids were removed by filtration and the remaining 
solution was extracted with chloroform (3 x 20 mL).  The organic layers were combined and 
washed with brine (1 x 20 mL), dried over anhydrous MgSO4 and reduced by rotary evaporation 
yielding 3 in >95% purity. 
 
 Synthesis of the indolizidine core 
 
 
O2N
MeOC
O
O2N
MeO2C
O
OMe
BnO
H2N
N
O
H
NO
O
OEt
BnO
O2N
S21b, 97%
S21f, 95%
S21d, 99%
20 Equiv. Zn Dust
10 Equiv. HCl, i-PrOH
S21a S21c
S21e
Procedure K
Procedure K
Procedure K
HN NO
O2N
COPr
NO
i. Zn/HCl- Procedure K
ii. DIBAL, DCM,
-40 oC (ref 10)
Procedure L
O Cl Grubbs II
S21d, 84%, 38mgS21a S21b 120 mg S21c, 118 mg
Pyridine, DCM
Procedure M
Tol, 60 °C, 1 h
Procedure N
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Procedure L: 
In a flame-dried 25 mL Schlenk flask equipped with a stir bar, 426mg (~0.540 mL) of 
neat DIBALH was added under argon using a 5 mL syringe.  The used syringe was rinsed with 
dichloromethane (1 mL) to ensure complete DIBALH transfer.  An additional 4 mL of 
dichloromethane was then added and the reaction vessel was cooled to -78 °C.  At this 
temperature, a solution of substrate imine (174 mg in 3 mL of DCM) was added dropwise over a 
minute.  After rinsing the transfer syringe with a small amount of DCM to ensure complete 
substrate transfer to the reaction mixture, the vessel was capped and stirred at -78 °C for 3 h.  
Next, the flask was removed from the dry ice acetone bath and allowed to slowly warm to room 
temperature.  After stirring at room temperature for ~1 h, the mixture was cooled to 0 °C and 10 
mL dichloromethane and 10 mL of a saturated solution of Rochelle salt was slowly added.  
Again the mixture was allowed to slowly warm to room temperature and stir overnight.   
 The resulting dichloromethane/water mixture was transferred to a separatory funnel and 
extracted with DCM (40 mL)/water (25 mL) followed by a brine (25 mL) wash.  The organic 
layer was separated and dried over MgSO4 and the solvent was evaporated.  The 2° amine S21b 
(120 mg, 79% yield, 2-steps) was isolated as a yellow solid.  
 
Procedure M: 
 In a flame-dried 10 mL Schlenk flask equipped with a stir bar was added substrate 2° 
amine S21b (100 mg, 0.76 mmol), dichloromethane (4 mL) and triethylamine (77 mg, 0.76 
mmol).  The mixture was stirred and cooled to 0 °C.  Acryloyl chloride (69 mg, 0.76 mmol) was 
added as a solution in DCM (1 mL).  The mixture was removed from the ice bath and slowly 
warmed to room temperature.  After stirring at room temperature for an hour, the mixture was 
36 
transferred to a separatory funnel and extracted with  dichloromethane (25 mL) and 1 N HCl (25 
mL).  The organic layer was dried over MgSO4 and evaporated. Silica gel chromatography 
(25:75 EtOAc:hexanes) yielded the desired amide S21c (118 mg, 76% yield) as a 1:1.2 mixture 
of amide E/Z isomers. 
 
Procedure N: 
In a glove box, a flame dried 10 mL Schlenk flask was charged with Grubbs’ second-
generation catalyst (10.6 mg, 0.0125 mmol, 5 mol%).  The vessel was capped, removed from the 
glove box, and 5 mL of toluene was added followed by the substrate amide 8 (52 mg).  The 
vessel was recapped and heated at 60 °C until reaction completion was determined by TLC (~3 
h).  
 After the allotted reaction time, the solvent was evaporated and the desired compound S21d 
(37 mg, 84% yield) was obtained via silica gel chromatography (50:50 EtOAc:hexanes). 
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Spectral Data: 
 
Decarboxylative allylation products:  
 
T2a 
 
 
 
1H NMR (500 MHz, CDCl3) 
 
δ 5.61 (m, 1H), 5.10 (m, 2H), 2.56 (d, J = 7.4 Hz, 2H), 1.50 (s, 6H). 
 
13C NMR (126 MHz, CDCl3) 
 
δ 130.1, 119.4, 86.7, 44.0, 24.4. 
 
IR (Thin Film, NaCl) 
 
Found:  3090, 1650, 1537 and 1356 (NO2) cm-1. 
 
GC-MS m/z (%): 83 (12) [M-NO2], 43[base fragment]. 
 
T2b 
 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 5.70 (m, 1H), 5.17 (m, 2H), 2.74 (d, J = 7.2 Hz, 2H), 2.52 (m, 2H), 2.84 (m, 6H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 131.5, 119.88, 99.26, 43.44, 36.73, 24.21. 
 
IR: (Thin Film, NaCl) Found:  3100, 1650, 1537 and 1355 (NO2) cm-1. 
 
GC-MS: m/z (%):109 (28) [M-NO2], 67(100)[base fragment]. 
 
T2c 
 
NO2
O2N
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1H NMR (400 MHz, CDCl3): 
 
δ 5.55 (m, 1H), 5.28 (m, 1H), 2.68 (dd, J = 13.9 Hz, 1H), 2.48 (dd, J = 14.2, 7.7 Hz, 1H), 2.13 – 
1.94 (m, 3H), 1.86 – 1.79 (m, 1H),1.52 (s, Hz, 3H), 1.38 (q, J = 14.1 Hz, 2H), 0.90 (m, 6H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 136.5, 122.4, 91.7, 42.6, 34.5, 32.4, 22.3, 21.1, 13.6, 8.3. 
 
IR: (Thin Film, NaCl) Found:  3100, 1640, 1537 and 1388 (NO2) cm-1. 
 
GC-MS: m/z (%):139 (10) [M-NO2], 55(100)[base fragment]. 
 
T2d 
 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 7.33 (m, 5H), 6.50 (d, J = 15.7 Hz, 1H), 6.06 (dt, J = 15.2, 7.5 Hz, 1H), 2.93 (dd, J = 14.1 Hz, 
1H), 2.71 (dd, J = 14.1, 7.1 Hz, 1H), 2.12 (dt, J = 14.1, 7.1 Hz, 1H), 1.90 (dq, J = 14.1, 7.4 Hz, 
1H), 1.59 (s, 3H), 0.96 (t, J = 7.1 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 135.0, 133.5, 126.9, 126.1, 124.6, 120.7, 90.3, 41.1, 31.1, 19.8, 6.4. 
 
IR: (Thin Film, NaCl) Found:  3100 ,1537 and 1380 (NO2), 1494, 1467, 1448, 1356,  
1371(1494-1371 are aromatic). 
 
GC-MS: m/z (%):173 (14) [M-NO2], 91(100)[base fragment]. 
 
T2e 
 
 
 
 
O2N
Ph
O2N
NO2
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1H NMR (500 MHz, CDCl3) 
 
δ 4.85 (s, 1H), 4.65 (s, 1H), 2.79 (d, J = 14.2 Hz, 1H), 2.40 (d, J =14.2 Hz, 1H), 2.03 (dq, J = 
14.2, 7.3 Hz, 1H), 1.69 (dq, J = 14.2, 7.3 Hz, 1H), 1.61 (s, 3H), 1.45 (s, 3H), 0.83 (t, J = 14.2 
Hz, 3H). 
 
13C NMR (126 MHz, CDCl3) 
 
δ 138.6, 115.7, 90.5, 46.5, 32.5, 22.3, 19.6, 7.3. 
 
IR: (Thin Film, NaCl) Found:  3100, 1655, 1537 and 1355 (NO2) cm-1. 
 
GC-MS: m/z (%): 111 (10) [M-NO2], 55(75), 69(100)[base fragment]. 
 
T2f 
 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 5.59 – 5.49 (m, 1H), 5.13 (m, 2H), 2.59 (d, J = 7.3, Hz, 2H), 2.37 (t, J = 7.3 Hz, 2H), 2.11 (m, 
s, 10H). 
 
13C NMR (126 MHz, CDCl3) 
 
δ 205.1, 129.2, 119.9, 91.3, 38.8, 36.5, 29.0, 28.2. 
 
IR (Thin Film, NaCl) Found:  1720, 1650, 1552 (NO2), 1449(NO2), 1350, 1190. 
 
GC-MS: m/z (%): 195(6) [M-NO2], 43 (100)[base fragment]. 
 
T2g 
 
 
 
 
1H NMR (500 MHz, CDCl3): 
O2N
O
O
O2N
OCH3
O
OCH3
O
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δ 5.56 (m, 1H), 5.19 – 5.10 (m, 2H), 3.62 (s, 6H), 2.61 (d, J = 7.3, 2H), 2.21 (m, 8H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 170.7, 128.4, 119.6, 90.5, 50.4, 37.9, 28.9, 26.8. 
 
IR: (Thin Film, NaCl) Found:  Found: 3031, 3002, 2954, 1667, 1639, 1539(NO2), 1438(NO2), 
1379, 1353, 1319, 1261, 1199, 1176. 
 
GC-MS: m/z (%): 226 (19) [M-NO2], 43 (100)[base fragment]. 
 
T2h 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 5.60 (dd, J = 15.1, 6.5 Hz, 1H), 5.23 (m, 1H), 2.60 (d, J = 7.3 Hz, 2H), 2.44 (t, J = 7.8 Hz, 4H), 
2.17 (m, 10H), 1.69 (d, J = 6.5 Hz, 3H). 
 
T2i 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 5.64 (m, 1H), 5.27 (m, 1H), 3.72 (s, 6H), 2.65 (m, 2H), 2.29 (m, 8H), 1.70 (d, J = 5.7 Hz, 3H). 
 
T2j 
 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 5.70 – 5.52 (m, J = 17.5, 10.2, 7.4 Hz, 1H), 5.07 (dm, 2H), 2.70 (d, J = 18.2 Hz, 1H), 2.50 (m, 
2H), 2.26 (m, 1H), 2.20 (d, J = 17.6  Hz, 1H), 2.07 – 1.89 (m, 2H), 1.89 – 1.79 (m, 1H), 1.57 (s, 
3H), 1.52 (s, 3H). 
 
O2N
MeOC COMe
O2N
MeO2C CO2Me
O2N
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13C NMR (126 MHz, CDCl3): 
 
δ 130.6, 124.8, 121.9, 120.2, 90.2, 43.2, 38.9, 30.7, 28.5, 19.0, 18.4. 
 
IR: (Thin Film, NaCl) Found:  3082, 1643, 1539 and 1365, 1438 cm-1. 
 
T2k 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 4.85 (m, 1H), 4.64 (m, 1H), 2.69 (d, J = 17.7 Hz, 1H), 2.60 (d, J = 14.1 Hz, 1H), 2.49 (d, J = 
14.1 Hz, 1H), 2.33 – 2.26 (m, 1H), 2.23 (d, J = 17.6 Hz, 1H), 2.03 – 1.90 (m, 2H), 1.88 – 1.80 
(m, 1H), 1.63 (s, 3H), 1.57 (s, 3H), 1.52 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 138.2, 123.6, 121.0, 115.6, 89.0, 46.1, 38.3, 30.2, 27.7, 22.4, 17.8, 17.3. 
 
IR: 
 
(Thin Film, NaCl) Found:  3090, 1640, 1537 and 1370 cm--1. 
 
GC-MS: m/z (%):163 (20) [M-NO2], 107(100)[base fragment]. 
 
T2l 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 7.31 (m, 5H), 6.47 (d, J = 15.6 Hz, 1H), 6.1 (m, 1H), 2.78 (m, 3H), 2.53 – 2.29 (m, 2H), 2.09 
(s, 2H), 2.05 – 1.93 (m, 1H), 1.67 (s, 3H), 1.63 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 136.6, 135.0, 128.7, 127.6, 126.3, 124.8, 122.1, 121.9, 90.4, 42.6, 39.1, 30.6, 28.7, 18.9, 18.5. 
 
IR: (Thin Film, NaCl) Found:  1643, 1535, 1450, 1370 cm-1. 
 
GC-MS: m/z (%): 225 (11) [M-NO2], 117(100)[base fragment]. 
O2N
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T2m 
 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 5.45 (m, 1H), 5.25 (m, 1H), 2.68 (d, J = 18.3 Hz, 1H), 2.50 – 2.37 (m, 2H), 2.27 – 2.21 (m, 
1H), 2.18 (ddd, J = 17.6, 1.7, 0.9 Hz, 1H), 2.07 – 1.87 (m, 2H), 1.86 – 1.77 (m, 1H), 1.59 (ddt, J 
= 6.5, 1.6, 1.0 Hz, 3H), 1.56 (dd, J = 1.7, 0.9 Hz, 3H), 1.53 – 1.51 (m, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 131.0, 124.8, 123.3, 121.9, 90.6, 42.4, 38.8, 30.4, 28.7, 19.0, 18.5, 18.0. 
 
IR (Thin Film, NaCl) Found:  1643, 1535, 1438, 1365 cm-1. 
 
GC-MS: m/z (%):163 (21) [M-NO2], 107(100)[base fragment]. 
 
T3a 
 
 
 
(Major diastereomer) 1H NMR (500 MHz, CDCl3): 
 
δ 7.22 (m, 5H), 5.85 (m, 1H), 5.75 (m, 1H), 5.52 (m, 1H), 5.07 (m, 2H), 4.49 (dd, J = 11.5, 23 
Hz, 2H), 4.04 (d, J = 5.2, 1H), 2.64 (dd, J = 14.6, 6.9 Hz, 1H), 2.30 (m, 3H), 2.10 (dd, J = 14.6 
6.9 Hz 1H), 2.97 (m, 1H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 135.8, 129.5, 128.3, 126.3, 125.8, 125.7, 121.8, 118.5, 89.9, 73.0, 70.1, 36.0, 22.1, 19.6. 
 
IR: (Thin Film, NaCl) Found:  2918, 2846, 1542 (NO2), 1454 (NO2), 1367, 1305, 1089, 1062. 
 
GC-MS: m/z (%):173 (14) [M-NO2], 91(100)[base fragment]. 
 
(Minor diastereomer) 1H NMR (500 MHz, CDCl3): 
 
δ 7.31 – 7.14 (m, 5H), 5.88 – 5.83 (m, 1H), 5.79 – 5.73 (m, 1H), 5.53 (m, 1H), 5.07 (dd, 2H), 
4.50 (q, 2H), 4.04 (d, J = 5.3 Hz, 1H), 2.65 (dd, J = 14.6, 6.9, Hz, 1H), 2.35 – 2.27 (m, 3H), 2.10 
O2N
O2N
OBn
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(dd, 14.6,6.9 Hz, 1H), 2.05 – 1.93 (m, 1H). 
 
13C NMR (126 MHz, CDCl3) 
 
δ 136.1, 134.7, 133.4, 129.9, 129.8, 128.6, 126.8, 126.6, 126.1, 126.0, 124.6, 122.2, 122.2, 119.7, 
118.8, 90.4, 90.2, 73.31, 73.27, 70.4, 36.3, 35.6, 28.0, 22.5, 22.4, 20.1, 19.9, 12.4. 
 
T3b 
 
 
 
(Major Diastereomer) 1H NMR (500 MHz, CDCl3): 
 
δ 7.48 – 7.09 (m, 5H), 5.94 – 5.82 (m, J = 9.8, 4.1, 1.9 Hz, 1H), 5.82 – 5.70 (m, 1H), 4.85 (s, 
1H), 4.68 (s, 1H), 4.48 (q, J = 11.5 Hz, 2H), 4.00 (d, J = 5.2 Hz, 1H), 2.74 (d, J = 14.6 Hz, 1H), 
2.46 – 2.21 (m, 3H), 2.21 – 1.96 (m, 2H), 1.61 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 139.2, 137.8, 131.5, 128.3, 127.9, 127.8, 123.8, 116.6, 91.4, 75.5, 72.2, 41.6, 24.3, 22.6, 21.9. 
 
IR: (Thin Film, NaCl) Found:  2918, 2846, 1654, 1542 (NO2), 1454 (NO2), 1089, 1062. 
 
GC-MS: m/z (%): 241 (1) [M-NO2], 91(100)[base fragment]. 
 
(Minor Diastereomer) 1H NMR (500 MHz, CDCl3): 
 
δ 7.41 – 7.14 (m, 6H), 5.89 – 5.80 (m, 2H), 4.88 – 4.82 (m, 1H), 4.66 (m,1H), 4.63 (d, J = 11.3 
Hz, 1H), 4.49 (d, J = 11.3 Hz, 1H), 4.41 – 4.37 (m, 1H), 2.91 (d, J = 14.3 Hz, 1H), 2.57 (d, J = 
14.4 Hz, 1H), 2.35 (m,1H), 2.17 – 2.10 (m, 2H), 2.09 – 2.01 (m, 1H), 1.63 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 137.7, 136.4, 129.8, 126.8, 126.2, 126.1, 123.0, 114.8, 90.3, 71.3, 69.6, 41.7, 25.2, 22.0, 21.5. 
 
T3c 
 
 
 
1H NMR (500 MHz, CDCl3): 
O2N
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δ 7.21 (m, 10H), 6.38 (d, J = 15.7 Hz, 1H), 5.92 (m, 2H), 5.76 (m, 1H), 4.51 (q, J = 11.5 Hz, 
2H), 4.09 (d, J = 5.2 Hz, 1H), 2.82 (dd, J = 14.7, 6.8 Hz, 1H), 2.47 (dd, J = 14.7, 8.2 Hz, 1H), 
2.34 (m, 2H), 2.15 (dd, J = 12.4, 5.9 Hz, 1H), 2.02 (m, 1H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 137.8, 136.5, 135.1, 131.6, 128.6, 128.3, 127.9, 127.8, 127.78, 126.4, 123.9, 121.4, 92.1, 75.0, 
72.1, 37.3, 24.2, 21.8. 
 
IR: (Thin Film, NaCl) Found:  1350, 1675, 1660, 1650, 1540 (NO2), 1440 (NO2), 1269. 
 
GC-MS m/z (%): 303 (14) [M-NO2], 91(100)[base fragment]. 
 
T3d 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.23 (m, 5H), 5.85 (m, 1H), 5.75 (m, 1H), 5.55 (m, 1H), 5.15 (m, 1H), 4.48 (m, 2H), 4.02 (d, J 
= 5.2 Hz, 1H), 2.56 (dd, J = 7.0 Hz, 1H), 2.26 (m, 3H), 2.11 (dd, 6.2 Hz, 1H), 1.97 (m, 1H), 1.58 
(d, J = 3.5 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 137.9, 131.5, 131.2, 128.3, 127.8, 127.7, 123.9, 122.6, 92.2, 75.1, 72.1, 36.9, 24.1, 21.6, 18.0. 
 
IR: (Thin Film, NaCl) Found:  3050, 2910, 1650, 1635, 1540 (NO2), 1452 (NO2), 1087, 1060. 
 
GC-MS: m/z (%): 241 (1) [M-NO2], 150 [M-NO2-Bn+] (5), 91(100)[base fragment]. 
 
T3e 
 
 
 
(Major Diastereomer) 1H NMR (500 MHz, CDCl3): 
 
δ 6.27 (dd, J = 5.7, 3.1 Hz, 1H), 5.91 (dd, J = 5.7, 2.8 Hz, 1H), 5.65 (m, 1H), 5.05 (m, 2H), 3.19 
(s, 1H), 2.86 (m, 2H), 2.60 (dd, J = 14.4, 7.0 Hz 1H), 2.20 (dd, J = 13.4, 3.4 Hz, 1H), 1.81 (dd, J 
= 13.4, 3.4 Hz, 1H), 1.61 (ddt, J = 9.2, 3.5, 1.8 Hz 1H), 1.50 (d, J = 9.2 Hz, 1H). 
 
O2N
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13C NMR (126 MHz, CDCl3): 
 
δ 139.7, 133.7, 131.2, 119.6, 99.5, 51.4, 48.1, 45.4, 42.1, 36.4. 
 
IR: (Thin Film, NaCl) Found:  2920, 1543 (NO2), 1454 (NO2), 1367, 1300, 1090 cm-1. 
 
GC-MS: m/z (%): 133 (8) [M-NO2], 66 (71), 91(100)[base fragment]. 
 
T3f 
 
 
 
(Major Diastereomer) 1H NMR (500 MHz, CDCl3): 
 
δ 6.29 (dd, J = 5.7, 3.1 Hz, 1H), 6.02 (dd, J = 5.7, 2.8 Hz, 1H), 5.68 (m, 1H), 5.07 (m, 2H), 3.17 
(s, 1H), 2.72 (dd, J = 14.6, 7.1 Hz, 1H), 2.45 (dd, J = 14.6, 7.1 Hz, 1H), 2.42 (s, 1H), 2.28 (q, J 
= 7.1 Hz, 1H), 1.61 (d, J = 9.5 Hz, 1H), 1.54 – 1.49 (m, 1H), 1.17 (d, J = 7.1 Hz 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 139.6, 135.3, 131.5, 119.7, 100.5, 49.5, 48.9, 44.3, 42.8, 41.1, 16.5. 
 
IR: (Thin Film, NaCl) Found:  2918, 1542 (NO2), 1450(NO2). 
 
GC-MS: m/z (%):147 (7) [M-NO2], 91(75), 66(100)[base fragment]. 
 
S13c 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.59 (m, 2H), 7.39 (m, 3H), 5.65 (m, 1H), 5.21 (m, 2H), 3.31 (m, 1H), 3.29 – 3.05 (m, 7.6Hz, 
1H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 132.3(d, JCF = 23.4 Hz), 129.9 (d, JCF = 1 Hz), 127.8 (d, JCF = 1.0 Hz), 126.3 (d, JCF = 3.3 Hz), 
124.3 (d, J = 8.6 Hz), 121.4 (d, JCF = 23 Hz), 119.0 (d, JCF = 242.0 Hz), 40.4 (d, JCF = 21.3 Hz). 
 
IR: (Thin Film, NaCl) Found:  1645, 1539 and 1353 (NO2), 1458, 1388, 1261, 972 (C-F) cm1. 
 
GC-MS: m/z (%):149 (71) [M-NO2], 129 (100)[base fragment]. 
O2N
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S14c 
 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.28 (s, 1H), 6.24 (d, J = 3.2 Hz, 1H), 6.07 (d, J = 3.2 Hz, 1H), 5.65 (m, 1H), 5.16 (m, 2H), 
3.62 (s, 3H), 3.24 (dd, J = 37.4, 15.4 Hz, 2H), 2.58 (d, J = 15.4, 2H), 2.44 – 2.07 (m, 4H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 172.3, 148.6, 142.4, 130.2, 121.3, 110.6, 109.4, 92.7, 51.9, 40.1, 33.5, 31.0, 28.5. 
 
IR: (Thin Film, NaCl) Found:  1540 (NO2), 1437 (nitro NO2). 
 
GC-MS: m/z (%): 221(20) [M-NO2], 81 (100)[base fragment]. 
 
 
GC-MS: m/z (%):149 (21) [M-NO2], 107(100)[base fragment]. 
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O
CO2CH3
47 
Decarboxylative allylation intermediates and substrates 
 
A-1 
 
 
 
1H NMR (400 MHz, CDCl3) δ 1.98 (s, 6H). 
 
13C NMR (126 MHz, CDCl3)δ 173.75, 61.54, 13.97. 
 
A-2 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 2.19 (m, 2H), 1.94 (s, 3H), 1.07 (t, J = 7.4 Hz, 3H). 
 
A-4 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 5.94 (m, 1H), 5.39 (dm, J = 17.49 Hz, 1H), 5.28 (ddd, J = 10.5, 2.5, 1.3 Hz, 1H), 4.67 (dt, J = 
5.6, 1.4 Hz, 2H), 1.95 (s, 6H). 
 
A-5 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 5.96 (m, 1H), 5.41 (dm, J = 17.16 Hz, 1H), 5.30 (dm, J = 9.94 Hz, 1H), 4.71 (dt, J = 5.6, 1.4 
Hz, 2H), 2.33 (m, 3H), 2.02 (m, 2H), 1.81 (m, 2H). 
 
Br
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A-6 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.43 (d, J = 6.94 Hz, 2H), 7.36 (t, J =  6.89, 2H), 7.30 (d, J = 7.39, 1H), 6.74 (d, J = 15.9 Hz, 
1H), 6.33 (dt, J = 15.9, 6.4 Hz, 1H), 4.87 (dd, J = 6.4, 1.2 Hz, 2H), 2.21 (qd, J = 7.3, 3.4 Hz, 
2H), 1.94 (s, 3H), 1.04 (t, J = 7.4 Hz, 3H). 
 
A-7 
 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 5.83 (dd, J = 14.5, 7.6 Hz, 1H), 5.60 (m, 1H), 4.64 (d, J = 6.46 Hz, 2H), 2.17 (qd, J = 7.3, 1.9 
Hz, 2H), 2.06 (dd, J = 13.5, 6.7 Hz, 2H), 1.90 (s, 3H), 1.44 (m, 3H), 1.02 (t, J = 7.59, Hz, 3H), 
0.93 (t, J = 7.59 Hz, 3H). 
 
A-8 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 5.07 (s, 1H), 4.99 (s, 1H), 4.62 (s, 2H), 2.20 (qd, J = 7.3, 3.3 Hz, 2H), 1.93 (s, 3H), 1.82 (s, 
3H), 1.03 (t, J = 7.4 Hz, 3H). 
 
S6a 
 
 
 
1H NMR (500 MHz, CDCl3): 
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δ 5.90 (m, 1H), 5.35 (dd, J = 17.2, 1.3 Hz, 1H), 5.30 (dd, J = 10.74, 1.3 Hz 1H), 4.71 (m, 2H), 
1.84 (s, 6H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 167.44, 130.65, 119.45, 89.34, 67.04, 24.02. 
 
S7a 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 5.90 (ddt, J = 16.3, 10.7, 5.7 Hz, 1H), 5.35 (dm, J = 16.86 1H), 5.30 (dd, J = 10.5, 1.0 Hz, 
1H), 2.72 (m, 2H), 2.42 (dt, J = 8.1, 5.1 Hz, 2H), 1.85 (m, 4H). 
 
S7a 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 5.89 (m, 1H), 5.34 (ddd, J = 17.2, 2.7, 1.4 Hz, 1H), 5.29 (dd, J = 10.5, 1.1 Hz, 1H), 4.70 (dt, J 
= 5.7, 1.3 Hz, 2H), 2.70 (m, 2H), 2.41 (m, 2H), 1.83 (m, 4H). 
 
13C NMR (126 MHz, CDCl3) 
 
δ 167.49, 130.70, 119.36, 99.57, 67.00, 36.47, 24.60. 
 
S7b 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 5.73 (m, 1H), 5.46 (m, 1H), 4.56 (dd, J = 6.6, 0.9 Hz, 2H), 2.23 (dt, J = 14.9, 7.4 Hz, 1H), 2.11 
(dt, J = 14.9, 7.4 Hz, 1H), 1.96 (apparent q, J = 7.38 Hz, 2H), 1.69 (s, 3H), 1.34 (m, 2H), 0.88 (t, 
J = 7.29 Hz, 3H), 0.83 (t, J = 7.29 Hz, 3H). 
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13C NMR (126 MHz, CDCl3): 
 
δ 167.33, 137.97, 122.51, 93.22, 67.23, 34.24, 29.77, 21.91, 20.72, 13.56, 8.10. 
 
S7c 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 4.91 (s, 1H), 4.90 (s, 1H), 4.55 (s, 2H), 2.26 (dt, J = 14.9, 7.4 Hz, 1H), 2.13 (m, 1H), 1.72 (s, 
3H), 1.67 (s, 3H), 0.89 (t, J = 7.5 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 69.64, 29.80, 20.74, 19.32, 8.10. 
 
S7d 
 
 
 
1H NMR (500 MHz, CDCl33): 
 
δ 7.42 (m, 2H), 7.36 (m, 2H), 7.30 (m, 1H), 6.69 (d, J = 15.9 Hz, 1H), 6.27 (dt, J = 15.8, 7.25, 
1H), 4.87 (d, J = 6.54 Hz, 2H), 2.36 (dt, J = 14.9, 7.3 Hz, 1H), 2.24 (dq, J = 14.8, 7.4 Hz, 1H), 
1.80 (s, 3H), 0.95 (overlapping methyl signals, 6H). 
 
A-9 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 5.94 (ddt, J = 16.4, 10.4, 5.9 Hz, 1H), 5.41 (dd, J = 17.2, 1.2 Hz, 1H), 5.35 (d, J = 10.4 Hz, 
1H), 5.22 (s, 2H), 4.78 (d, J = 5.9 Hz, 2H). 
 
A-10 
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1H NMR (400 MHz, CDCl3): 
 
δ 7.43 (m, 2H), 7.35 (m, 3H), 6.74 (d, J = 16.1 Hz, 1H), 6.30 (dt, J = 16.1, 7.26 Hz, 1H), 5.23 (s, 
2H), 4.94 (d, J = 6.7 Hz, 2H). 
 
A-11 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 5.87 (dt, J = 15.74, 7.62 Hz, 1H), 5.59 (dt, J = 15.74, 7.62 Hz, 1H), 5.19 (s, 2H), 4.72 (d, J = 
6.7 Hz, 2H), 2.07 (dd, J = 14.1, 6.8 Hz, 2H), 1.44 (dq, J = 14.7, 7.4 Hz, 2H), 0.92 (t, J = 7.4 Hz, 
3H). 
 
A-12 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 5.23 (s, 2H), 5.04 (d, J = 5.2 Hz, 2H), 4.70 (s, 2H), 1.80 (s, 3H). 
 
A-13 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 5.89 (dd, J = 15.2, 6.6 Hz, 1H), 5.61 (m, 1H), 5.18 (s, 2H), 4.70 (d, J = 6.85 2H), 1.77 (d, J = 
6.5 Hz, 3H) 
 
A-14 
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1H NMR (400 MHz, CDCl3): 
 
δ 5.37 (tm, J = 7.56 1H), 5.18 (s, 2H), 4.77 (d, J = 7.4 Hz, 2H), 1.80 (s, 3H), 1.75 (s, 3H). 
 
A-15 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 5.90 (ddd, J = 15.8, 10.9, 5.5 Hz, 1H), 5.37 (d,  J = 17.54 Hz, 1H), 5.30 (d, J = 10.9 Hz, 1H), 
4.71 (d, J = 5.7 Hz, 2H), 2.92 (d, J = 17.5 Hz, 1H), 2.76 (d, J = 17.1 Hz, 1H), 2.59 (m, 1H), 2.35 
(m, 1H), 2.10 (s, 2H), 1.68 (s, 3H), 1.62 (s, 3H). 
 
A-16 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 4.89 (s, 2H), 4.54 (d, J = 4.6 Hz, 2H), 2.83 (d, J = 17.5 Hz, 1H), 2.68 (d, J = 17.5 Hz, 1H), 
2.49 (ddd, J = 7.5, 6.8, 1.7 Hz, 1H), 2.27 (dt, J = 13.88, 6.8 Hz, 1H), 2.01 (s, 2H), 1.66 (s, 3H), 
1.59 (s, 3H), 1.53 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 165.87, 137.67, 123.99, 120.03, 113.04, 91.06, 68.64, 36.20, 28.09, 27.05, 18.25, 17.72, 17.52. 
 
A-17 
 
 
 
1H NMR (500 MHz, CDCl3): 
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δ 7.32 (d, J = 5.2, 3.4 Hz, 2H), 7.27 (m, 2H), 7.22 (m, 1H), 6.59 (d, J = 15.9 Hz, 1H), 6.16 (dt, J 
= 15.9, 6.5 Hz, 1H), 4.77 (dd, J = 6.5, 0.9 Hz, 2H), 2.84 (d, J = 17.7 Hz, 1H), 2.68 (d, J = 17.5 
Hz, 1H), 2.50 (dtd, J = 13.76, 5.65, 1.65 Hz,  1H), 2.27 (dt, J = 13.76, 7.33 Hz, 1H), 2.01 (s, 
2H), 1.59 (s, 3H), 1.53 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 167.00, 135.81, 135.46, 128.66, 128.38, 126.74, 124.98, 121.47, 121.06, 92.11, 67.11, 37.22, 
29.10, 28.06, 18.74, 18.56. 
 
A-18 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 5.74 (m, 1H), 5.47 (m, 1H), 4.54 (d, J = 6.12 Hz, 2H), 2.82 (d, J = 17.6 Hz, 1H), 2.65 (d, J = 
17.6 Hz, 1H), 2.49 (dtd, J = 13.6, 5.6, 1.8 Hz, 1H), 2.23 (dt, J = 13.6,  8.22 Hz, 1H), 2.00 (s, 
2H), 1.65 (d, J = 6.93 Hz, 3H), 1.59 (s, 3H), 1.54 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 167.02, 132.78, 124.93, 123.67, 121.07, 92.09, 67.23, 37.16, 29.04, 28.02, 18.72, 18.54, 17.81. 
 
A-19 Diastereomers were separated and both are reported: 
 
 
 
Major diastereomer: 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.32 (m, 5H), 5.97 (s, 2H), 5.85 (m, 1H), 5.32 (d, J = 17.2 Hz, 1H), 5.25 (d, J = 10.4 Hz, 1H), 
4.72 (m, 3H), 4.67 (m, 1H), 4.59 (dd, J = 11.5, 3.5 Hz, 1H), 2.70 (d, J = 14.4 Hz, 1H), 2.51 (m, 
1H), 2.32 (d, J = 18.9 Hz, 1H), 1.97 (m, 1H). 
 
Minor diastereomer: 
O
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1H NMR (500 MHz, CDCl3): 
 
δ 7.32 (m, 5 H), 5.90 (m, 3H), 5.35 (d, J = 17.2 Hz, 1H), 5.31 (d, J = 10.4 Hz, 1H), 4.73 (d, J = 
4.7 Hz, 1H), 4.69 (m, 2H), 4.61 (q, J = 11.5 Hz, 2H), 2.61 (td, J = 12.5, 6.0 Hz, 1H), 2.53 (dd, J 
= 13.0, 6.1 Hz, 1H), 2.42 (dt, J = 19.4, 5.11 Hz, 1H), 1.99 (m, 1H). 
 
A-20 Reported as a 1:1.3 mixture 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.24 (m, 11H), 5.88 (dd, J = 3.9, 2.1 Hz, 1H), 5.86 (ddd, J = 4.5, 2.3, 1.1 Hz, 1H), 5.83 (dd, J 
= 4.6, 1.9 Hz, 1H), 4.89 (m, 3H), 4.86 (m, 1H), 4.63 (m, 4H), 4.51 (m, 4H), 4.43 (d, J = 12.8 Hz, 
1H), 2.61 (dd, J = 14.5, 5.6 Hz, 1H), 2.52 (m, 1H), 2.43 (m, 2H), 2.33 (m, 1H), 2.20 (m, 1H), 
1.89 (m, 2H), 1.65 (s, 3H), 1.62 (s, 2H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 164.82, 164.63, 138.66, 138.55, 137.44, 137.42, 130.74, 130.42, 128.42, 128.41, 127.91, 
127.88, 127.64, 124.49, 123.22, 114.56, 114.31, 93.60, 93.11, 72.57, 72.02, 71.96, 70.95, 69.81, 
69.73, 24.99, 23.71, 23.56, 21.64, 19.33. 
 
A-21 Reported as a 1:1 mixture 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.23 (m, 19H), 6.58 (d, J = 15.9 Hz, 1H), 6.54 (dt, J = 15.9, 1.2 Hz, 1H), 6.12 (m, 2H), 5.88 
(d, J = 3.29 Hz, 2H), 5.86 (ddd, J = 4.7, 2.4, 1.3 Hz, 1H), 5.83 (dd, J = 4.7, 2.0 Hz, 1H), 4.75 
(m, 4H), 4.65 (m, 3H), 4.51 (m, 3H), 2.60 (dd, J = 14.0, 5.4 Hz, 1H), 2.46 (overlapping qd/m, J 
= 12.54, 5.58 Hz,  3H), 2.31 (dt, 1H), 2.22 (m, 1H), 1.89 (m, 2H). 
 
13C NMR (126 MHz, CDCl3): 
 
O2N
OBn
O
O
O2N
OBn
O
O Ph
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δ 164.93, 164.71, 137.45, 135.79, 135.76, 135.72, 135.51, 130.70, 130.43, 128.68, 128.62, 
128.45, 128.44, 128.41, 128.32, 127.90, 127.87, 127.53, 126.76, 126.73, 124.49, 123.20, 121.51, 
121.19, 93.58, 93.10, 72.57, 72.09, 71.98, 70.89, 67.19, 67.16, 25.06, 23.69, 23.56, 21.62. 
 
A-22 Reported as a 1:1.2 mixture of diastereomers 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.24 (m, 10H), 5.87 (m, 2H), 5.85 (ddd, J = 4.6, 2.3, 1.2 Hz, 1H), 5.82 (dd, J = 4.7, 1.9 Hz, 
1H), 5.72 (dddd, J = 15.3, 12.8, 7.7, 6.6 Hz, 2H), 5.44 (m, 2H), 4.63 (m, 2H), 4.59 (s, 1H), 4.52 
(m, 6H), 2.58 (dd, J = 5.5 Hz, 1H), 2.48 (m, 1H), 2.41 (m, 2H), 2.30 (m, 1H), 2.19 (s, 1H), 1.88 
(m, 2H), 1.81 (t, J = 2.3 Hz, 1H), 1.65 (ddt, J = 6.6, 1.9, 1.0 Hz, 2H), 1.58 (ddt, J = 6.5, 2.0, 1.0 
Hz, 2H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 164.89, 164.68, 137.51, 137.48, 133.22, 132.83, 130.64, 130.37, 128.41, 128.40, 128.06, 
127.88, 127.87, 127.86, 127.77, 127.56, 124.50, 123.75, 123.46, 123.27, 93.54, 93.07, 72.55, 
72.11, 72.05, 71.47, 70.90, 67.30, 67.28, 57.74, 25.00, 23.65, 23.53, 21.60, 17.80, 17.74. 
 
A-23 Major Diastereomer reported: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 6.36 (s, 1H), 5.92 (s, 1H), 5.81 (m, 1H), 5.26 (dd, J = 17.2, 1.2 Hz, 1H), 5.21 (d, J = 10.5 Hz, 
1H), 4.63 (d, J = 4.65 Hz, 2H), 3.64 (s, 1H), 2.96 (s, 1H), 2.30 (m, 2H), 2.14 (m, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 167.82, 141.05, 132.98, 130.60, 119.43, 67.11, 51.88, 49.26, 41.72, 37.49. 
 
A-24 
 
O2N
OBn
O
O
O
O
O2N
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1H NMR (500 MHz, CDCl3): 
 
δ 5.91 (m, 1H), 5.38 (dd, J = 17.2, 1.3 Hz, 1H), 5.33 (dd, J = 10.4, 1.1 Hz, 1H), 4.70 (dt, J = 5.9, 
1.2 Hz, 2H), 2.55 (m, 4H), 2.47 (m, 4H), 2.17 (s, 7H). 
 
A-25 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 5.91 (m, 1H), 5.38 (d, J = 17.2 Hz, 1H), 5.34 (d, J = 10.4 Hz, 1H), 4.72 (d, J = 5.9 Hz, 2H), 
3.72 (s, 7H), 2.57 (m, J = 8.4, 2.1 Hz, 5H), 2.43 (m, 5H). 
 
A-26 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 5.77 (m, 1H), 5.50 (m, 1H), 4.54 (dt, J = 6.79, 2H), 2.45 (m, J = 7.0, 5.5, 2.4 Hz, 4H), 2.36 (m, 
4H), 2.08 (s, 6H), 1.67 (dm, J = 6.6 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 210.50, 205.63, 166.10, 133.58, 123.43, 94.47, 67.52, 37.68, 29.96, 28.45, 17.82. 
 
A-27 
 
 
O2N O
O
MeOC COMe
O2N O
O
MeO2C CO2Me
O2N O
O
MeOC COMe
O2N O
O
MeO2C CO2Me
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1H NMR (500 MHz, CDCl3): 
 
δ 5.83 (m, 1H), 5.55 (m, 1H), 4.63 (dt, J = 6.68, 1.0 Hz, 2H), 3.70 (s, 6H), 2.53 (m, 4H), 2.39 
(m, 4H), 1.74 (dm, J = 6.6 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 171.95, 165.73, 133.67, 123.33, 94.12, 67.65, 52.06, 29.56, 28.52, 17.81. 
 
S14a 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.35 (dd, J = 1.9, 0.8 Hz, 1H), 6.31 (dd, J = 3.2, 1.9 Hz, 1H), 6.18 (dq,  J = 3.23, 0.74 Hz, 1H), 
5.89 (ddt, J = 17.1, 10.4, 5.9 Hz, 1H), 5.47 (dd, J = 9.5, 5.4 Hz, 1H), 5.36 (dq, J = 17.2, 1.5 Hz, 
1H), 5.32 (dq, J = 10.4, 1.1 Hz, 1H), 4.73 (d, J = 5.77 Hz, 2H), 3.67 (dd, J = 16.0, 9.5 Hz, 1H), 
3.54 (dd, J = 16.0, 5.30 Hz, 1H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 163.40, 147.59, 142.65, 130.30, 120.04, 110.63, 108.56, 86.25, 67.53, 29.17. 
 
S14b 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.27 (dd, J = 1.9, 0.8 Hz, 1H), 6.23 (dd, J = 3.2, 1.9 Hz, 1H), 6.09 (dd, J = 3.2, 0.6 Hz, 1H), 
5.82 (ddt, J = 17.1, 10.4, 5.9 Hz, 1H), 5.29 (ddd, J = 17.2, 2.7, 1.4 Hz, 1H), 5.24 (dq, J = 10.4, 
1.1 Hz, 1H), 4.63 (ddd, J = 5.9, 2.5, 1.2 Hz, 2H), 3.62 (s, 3H), 2.39 (m, 4H). 
 
13C NMR (126 MHz, CDCl3): 
 
O2N O
O
O
O2N O
O
O
CO2Me
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δ 171.97, 165.44, 146.77, 142.97, 130.42, 120.01, 110.69, 109.95, 94.12, 67.47, 52.00, 33.34, 
28.73, 28.58. 
 
A-29 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 7.58 (m, 2H), 7.39 (m, 3H), 5.92 (ddt, J = 17.1, 10.5, 5.7 Hz, 1H), 5.40 (s, 1H), 5.34 (ddd, J = 
17.2, 2.9, 1.5 Hz, 1H), 5.28 (ddd, J = 10.5, 2.4, 1.2 Hz, 1H), 4.70 (ddt, J = 5.6, 4.1, 1.3 Hz, 2H). 
 
S13a 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 7.52 (m, 5H), 6.22 (s, 1H), 5.91 (ddt, J = 16.3, 11.6, 5.8 Hz, 1H), 5.37 (dd, J = 16.85, 1.1 Hz, 
1H), 5.31 (d, J = 9.91 Hz, 1H), 4.78 (m, 2H). 
 
S13b 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.64 (m, 2H), 7.48 (m, 1H), 7.42 (m, 3H), 5.85 (m, 1H), 5.32 (dq, J = 17.29, 1.1 Hz, 1H), 5.27 
(dq, J = 10.4, 1.1 Hz, 1H), 4.77 (d, 2H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 160.9 ( J = 27.49 Hz), 131.8 (J = 1.0 Hz), 129.74, 128.70(J = 1.56 Hz) , 126.49, 126.42 
120.65, 112.5 (J = 250.6 Hz), 68.50. 
 
S20a 
 
O
O
Ph
Br
O
O
Ph
O2N
O
O
Ph
O2N
F
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1H NMR (500 MHz, CDCl3): 
 
δ 5.35 (t, J = 6.7 Hz, 1H), 5.26 (dd, J = 8.3, 6.1 Hz, 1H), 4.75 (m, 2H), 2.60 (m, 2H), 2.49 (m, 
2H), 2.40 (t, J = 7.3 Hz, 2H), 1.79 (s, 3H), 1.74 (s, 3H), 1.64 (dt, J = 14.8, 7.3 Hz, 2H), 0.94 (t, J 
= 7.4 Hz, 3H). 
 
 
S20b 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 5.64 (m, 1H), 5.10 (dq, J = 9.1, 1.3 Hz, 1H), 5.08 (m, 1H), 2.62 (m, 1H), 2.45 (m, 1H), 2.40 
(m, 2H), 2.30 (q, J = 7.3 Hz, 2H), 2.05 (m, 2H), 0.84 (t, J = 7.3 HZ, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 208.8, 131.2, 119.7, 87.2, 44.9, 38.1, 38.0, 26.9, 17.2, 13.7. 
GC-MS: GC: single peak at 5.62. MS: [M-NO2] Found: 153.2 (parent ion, M-NO2, 5% of base 
peak), 81.1 (33% base peak), 71.1 (base peak, 100%), 67.1 (45% base peak), 43.2 (75% base 
peak). 
 
 
 
 
 
 
 
 
 
 
 
 
O2N O
O
PrOC
O2N
COPr
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Amines and derivatives thereof: 
 
 
S21b 
 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.26 (m, 5H), 5.78 (m, 1H), 5.72 (m, Hz, 1H), 4.84 (m, 1H), 4.65 (m, 2H), 4.48 (d, J = 11.5 
Hz, 1H), 3.62 (s, 1H), 2.14 (d, J = 3.1 Hz, 2H), 2.12 – 2.06 (m, 1H), 2.05 – 1.93 (m, 1H), 1.76 (s, 
3H), 1.70 (m, 1H), 1.59 (s, 2H), 1.46 (m, 1H). 
 
13C NMR (126 MHz, CDCl3) 
 
δ 142.4, 138.8, 129.6, 128.3, 127.7, 127.6, 125.6, 115.1, 78.2, 77.3, 77.0, 76.8, 71.2, 53.3, 46.1, 
31.3, 25.5, 23.2. 
 
IR (Thin Film, NaCl) Found: υmax 3070, 3031,2920,2850,1643, 1600, 1500, 1456, 1388, 1315, 
1215, 1089, 1068, 1024, 891, 769, 740, 698 cm-1. 
 
HRMS: Calc. HRMS for C17H21O3N (M + H) 287.1521; Found (M + H) 287.1531. 
 
S12d 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 5.58 (m, 1H), 5.09 (dd, J = 7.29, 14.19 Hz, 2H), 2.59 (d, J = 7.3 Hz, 2H), 2.50 (m, 2H), 2.42 
(m, 2H), 2.25 (dd, J = 13.8, 8.4 Hz, 1H), 2.09 (s, 3H), 2.08 – 1.98 (m, 2H), 1.96 (t, J = 1.5 Hz, 
3H), 1.88 – 1.74 (m, 2H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 206.8, 142.8, 131.0, 118.9, 76.8, 40. 7, 36.8, 30.0, 28.97, 28.89, 24.4, 11.8. 
 
IR: (Thin Film, NaCl) Found: υmax 3082, 2921, 1710, 1608, 1433, 1359, 1218, 1170,9978, 918, 
H2N
OBn
N
O
OCH3
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775 cm-1. 
 
HRMS: Calc. HRMS for C12H19ON (M + H) 194.1545; Found (M + H) 194.1543. 
 
S21f 
 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 6.88 (s, 1H), 5.78 – 5.61 (m, 1H), 5.09 (m, 2H), 3.61 (s, 3H), 2.31 (m, 4H), 2.20 (m, 2H), 1.84 
(m, 4H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 176.7, 172.7, 131.2, 118.8, 60.0, 50.9, 43.7, 33.5, 29.4, 29.1, 27.8. 
 
IR (Thin Film, NaCl) Found: υmax 3087, 2948, 1731, 1693, 1438, 1373, 1311, 1220, 1201, 1174, 
773 cm-1. 
 
HRMS: Calc. HRMS for C11H17O3N (M + Na) 234.1106; Found (M + Na) 234.1111. 
 
S22b 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 5.74 (m, 1H), 5.03 (ddd, J = 17.1, 3.3, 1.5 Hz, 1H), 4.97 (d, J = 10.09 Hz, 1H), 3.07 (quint, J = 
6.66 Hz, 1H), 2.99 (quint, J = 6.66 Hz 1H), 2.29 (dt, J = 13.4, 6.7 Hz, 1H), 2.21 (dt, J = 13.9, 
7.0 Hz, 1H), 1.82 (m, 2H), 1.52 (m, 1H), 1.38 (m, 2H), 1.29 (m, 3H), 0.87 (t, J = 7.11 Hz, 3H). 
 13C NMR (126 MHz, CDCl3): 
 
δ 135.68, 116.75, 59.36, 58.66, 40.08, 38.15, 30.86, 30.28, 20.58, 14.21. 
 
S22c Exists as a mixture of amide E/Z isomers 
NH
O
O
OCH3
HN
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1H NMR (500 MHz, CDCl3) 
 
δ 6.48 (m, 2H), 6.43 (d, J = 2.7 Hz, 2H), 6.40 (d, J = 2.7 Hz, 1H), 5.79 (m, 2H), 5.69 (d, J = 2.7 
Hz, 1H), 5.67 (d, J = 2.8 Hz, 1H), 5.14 (m, 2H), 5.07 (m, 2H), 4.19 (broad s, 1H), 4.12 (broad s, 
1H), 3.99 (broad s, 1H), 3.91 (broad s, 1H), 2.78 (s, 1H), 2.43 (s, 1H), 2.18 (m, 2H), 2.07 (m, 
2H), 1.96 (m, 4H), 1.86 (m, 1H), 1.78 (m, 2H), 1.73 (m, 2H), 1.64 (m, 2H), 1.38 (m, 9H), 0.97 
(m, 7H).  
 
13C NMR (126 MHz, CDCl3): 
 
δ 164.53, 135.06, 134.25, 129.13, 129.02, 127.40, 117.93, 117.01, 58.39, 58.13, 57.90, 57.37, 
40.81, 38.95, 38.82, 37.48, 29.31, 29.22, 28.67, 28.00, 19.88, 19.66, 14.12, 14.00. 
 
S22d 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 6.45 (ddd, J = 9.6, 6.3, 2.0 Hz, 1H), 5.85 (dd, J = 9.7, 2.9 Hz, 1H), 3.97 (m, 1H), 3.56 (ddd, J 
= 19.0, 10.5, 4.8 Hz, 1H), 2.37 (ddd, J = 17.1, 6.3, 4.4 Hz, 1H), 2.01 (m, 2H), 1.82 (m, 1H), 1.74 
(m, 2H), 1.61 (ddd, J = 19.5, 11.3, 6.8 Hz, 1H), 1.24 (m, 4H), 0.86 (t, J = 7.2 Hz, 3H).  
 
13C NMR (126 MHz, CDCl3): 
 
δ 163.93, 138.71, 126.77, 57.77, 56.11, 36.26, 31.10, 31.08, 27.60, 19.66, 14.12. 
 
 
 
 
 
 
NO
NO
63 
Crystallographic data: 
Crystal structure of T3c obtained: 
 
 
 
 
 
 
 
NO2
OBn
Ph
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Chapter 2. Mild-functionalization/retro-Claisen: a review of synthetic tactics 
involving retro-Claisen condensation reactions. 
 
2.1 Introduction to retro-Claisen condensation 
  
 The retro-Claisen condensation is a nucleophile-induced C−C cleavage reaction of β-
dicarbonyl compounds (Scheme 1). The retro-Claisen condensation of α,α-dialkyl β-ketoesters 
was first reported by Dieckman1,2 (1900) and mechanistic studies were reported by Adkins3-5 in 
the 1930’s. Synthetic strategies involving retro-Claisen condensation came sometime thereafter 
in the early-mid 20th century.6  This review will focus on how the retro-Claisen cleavage reaction 
can be utilized to not only produce useful synthetic intermediates, but also expedite and simplify 
the synthesis of various complex chemical entities. 
 
 β-dicarbonyl compounds (active methylene compounds) and similar compounds (e.g. α-
cyano or nitro esters), are an extremely useful class of chemical reactants as they can easily be 
utilized as nucleophilic coupling partners in various chemical reactions both classic and modern. 
Though complex β-dicarbonyl compounds are usually prepared by Claisen condensation, many 
β-dicarbonyl compounds are commercially available (e.g. acetylacetone, ethyl acetoacetate, 
cyanoacetic acid esters, etc.). Moreover, the relatively low pKa of these active methylene 
nucleophile (DMSO pKa 8-16) renders their functionalization simple and mild (hence the 
descriptor “active methylene”). For example, they can be deprotonated by mild bases, such as 
EtO
O O
R
Claisen condensation
retro-Claisen condensation EtO
O O
REtO
OEt
R R R R
Scheme 1. The Claisen/retro-Claisen equillibrium
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acetates, carbonates, or phosphates, and coupled with various electrophiles. To compare, mono-
carbonyl compounds (such as ethyl acetate) have a much higher pKa and require strong bases for 
enolate formation and functionalization. Importantly, these stronger bases are often more 
expensive and sensitive to moisture, both of which are undesirable qualities when considering a 
synthetic transformation. 
 
 In terms of chemical structure and therapeutics, it is arguable that α,α-functionalized 
mono-carbonyl compounds are much more desired than their α,α-functionalized β-dicarbonyl 
counterparts.  For example, there are many drugs that have a single carbonyl (or carbonyl 
derivative, e.g. cyano) and α-substitution, for example, ibuprofen, verapamil, clopidogrel, and 
bicalutamide (Scheme 2). 
 
 This review will focus on how the robust reactivity of active methylene compounds can 
be used in tandem (1 or 2 pot reactions) with retro-Claisen condensation to prepare diverse 
mono-carbonyl chemical building blocks. In general, this synthetic strategy is as follows 
(Scheme 4): starting from a commercially available or readily available β-dicarbonyl compound, 
mild and diverse α,α-disubstitution occurs to give the non-enolizable β-dicarbonyl S4a. S4a can 
then be converted into a more relevant chemical structure by retro-Claisen condensation.  
EtO
O
OEt
O
EtO
O
EtO
O
OEt
O
R
pKa = 16.4 pKa = 29.5
EtO
O
R
K2CO3, R!X, rt LDA, R!X, -78 °C
simple alkylation more challengingalkylation
Scheme 2. Generalized conditions for alkylation of malonate vs. ethyl acetate
O
OH
NC N
H
OMe
OMe
OMe
OMe
ibuprofin verapamil
NCl
OMe
O
S
Scheme 3. Examples of important carbonyl derivatives containing !-complexity
clopidogrel
H
N
O
HO O2
S
FNC
F3C
bicalutamide
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Moreover, the retro-Claisen reaction prepares another anion S4b (a new nucleophilic coupling 
partner) that can be used for further diversification.  The first section of this review will focus on 
retro-Claisen condensation/protonation methodologies, and the latter sections, 2.4 and Chapter 3, 
(my contribution to this field of research), will focus on how the anion generated by retro-
Claisen C−C cleavage can react with other electrophiles. 
 
 
2.2 Alkylation/retro-Claisen condensation strategies 
 
2.2.1. The Wilds-Woodward Reaction 
 
 Some of the earliest use of strategic retro-Claisen condensation in synthesis was reported 
by Wilds in 1943.7-9 The reaction about to be described is the Wilds-Woodward modification of 
the Robinson annulation. In this process, formylation via Claisen condensation allows for mild 
and directed Michael addition preparing S5a, which often does not need to isolated.  Upon the 
addition of methanolic base, the labile aldehyde is removed (S5b) and aldol condensation occurs 
giving the desired product (S5c). 
ZEWG
R1 R2
HEWG
R1 R2
Z ! H+
H+
Section 2.2-3
& Ch. 3.2
Section 2.4 &
Chapter 3.3
Scheme 4. Claisen condensation, functionalization, retro-Claisen condensation synthetic sequence
Claisen-
condensation
EWG
OH
R
EWG
R1 R2
R
OR1-X, R2-X EWG
R1 R2
S4b
new nucleophilic
coupling partner
-OEt
simple
substitution
ready C-C cleavage
RCO2EtS4a
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 The question is, why did such a modification need to be invented?  The answer is quite 
simple: the Robinson annulation using classic conditions (alkaline) can often have limitations. 
For example, higher pKa ketones, such as cyclohexanone, can be challenging to alkylate under 
alkaline conditions and polymerization of the methyl vinyl ketone can be problematic.10 There 
are many modifications of this useful reaction that can be used to circumvent these problems,11 
with one of them being the Wilds-Woodward reaction. Regarding the Wilds-Woodward 
modification, by introducing the formyl group, the C-C bond formation (via Michael addition) 
becomes a trivial process as the pKa of the α-carbon has been drastically altered. Furthermore, 
the formyl group was chosen because under the basic conditions required for the aldol 
condensation, the aldehyde is readily cleaved, allowing access to the Robinson annulation 
product. 
 
 Above, it was stated that the first examples of the Wilds-Woodward reaction were 
published in 19437 and 1946.8  However, these early publications tinkered with other cleaving 
groups that had various problems associated with them (e.g. challenges attaching (Claisen 
condensation) or detatching them (retro-Claisen cleavage).  With that said, the actual first 
publication where the Robinson annulation was facilitated by a “traceless” formyl group was 
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published in 1949 (Scheme 6).9 Wilds used the reaction to construct steroid analogs lacking the 
C-ring. Also, he used methyl vinyl ketone generated in situ from the corresponding Mannich 
base S4a, as this was common practice in performing Robinson annulations at this time.10 
 The reaction commonly includes Woodward’s name since he famously used it in an 
important step in his historic synthesis of cortisone (Scheme 7).12  In these studies, he noted the 
importance of reaction conditions as well as the simplified use of methyl vinyl ketone and thus 
made important contributions to its development too. 
 
 The Wilds-Woodward reaction saw much use in the steroid-synthesis heyday (ca. 
1950s).7-9,12-15 However, it saw miniminal use16,17 in other applications until the latter part of the 
20th century.  As shown in Scheme 6, it has recently found use as a general strategy for the 
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Scheme 7. Woodward used Wilds' modification to synthesize cortisone (1952).
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synthesis of cyclohexane containing complex natural products.18-24   Banwell and coworkers18 
(S8a) and Trauner and Mulzer20 (S8b) have demonstrated the reaction’s utility for synthesis of 
benzosubarones and tetralones, respectively.  De Groot and coworkers have utilized the reaction 
on numerous occasions to annulate carvone and derivativies thereof (S8c).19,22 Amos Smith and 
coworkers utilized the Wilds-Woodward reaction en route to penitrem alkaloids (S8d).23  In 
Wright’s use of the reaction (S8e),24 he uses the newly constructed cyclic enone to perform a 
vinylogous enolate alkylation to construct the dense multicyclic core of platensimycin.  
 Aside from use in total synthesis, Zimmerman demonstrated that the reaction can be 
utilized in an iterative fashion to rapidly construct cyclic polyeneones (Scheme 9).17  These 
molecules were then utilized in organic photochemical studies. 
 
 
2.2.2. General alkylation/retro-Claisen condensation 
 
 Using a similar approach to the Wilds-Woodard reaction, a carbonyl can be used as a 
traceless, readily cleavable, activating group for alkylation of various ketone compounds.  
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Scheme 9. Iterative Wilds-Woodward reactions (Zimmerman, 1989)
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 We will begin with an example of bisalkylation/retro-Claisen condensation of 
acetylacetone to prepare an important intermediate en route to the anthracyclinone family of 
antibiotics (Scheme 10).25 This is a prime example of how simple β-diketones can serve as a 
template for mild, sequential alkylations and by retro-Claisen reaction, prepare useful α,α-dialkyl 
ketones.  Researches at the University of Manitoba first coupled an equivalent of a benzyl 
bromide derivative to acetylacetone and further quaternized the α-position with allyl bromide. 
This 2-step sequence was performed in a single pot. Without purification of this intermediate, the 
retro-Claisen reaction to S10a was promoted using sodium hydroxide in methanol.  A single 
purification was performed over this 3-step sequence and 152 g (55% yield) of the desired 
product was isolated. An analogous approach would involve from dialkylation of acetic esters 
and 2-step saponification/decarboxylation (acetoacetic ester synthesis). 
 In another example of alkylation/retro-Claisen reaction, researches at Searle and Co. 
reported a simple 2-step procedure for introducing a methyl group onto the steroid core by 
formylation and methylation/retro-Claisen reaction (Scheme 11).26 Moreover, the reaction occurs 
with complete diastereoselectivity. In addition to the formyl activating/cleaving group, the 
researchers reported the incorporation of an oxalyl group to promote the reaction sequence. 
 
 An analogous reaction to retro-Claisen condensation is the retro-Dieckman condensation. 
Though upon C−C cleavage, the activating group will still be tethered to the molecule and thus 
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examples:Scheme 11.  Claisen/methylation/retro-Claisen of steroids (Searle and Co., 1961)
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provided added functional complexity.  For example, substituted cyclohexanones can be 
prepared by Dieckman/alkylation/retro-Dieckman as shown by Duthaler (1982).27-29  Again, the 
Dieckman condensation is strategic allowing mild alkylation only at the α-position of S12a. One 
could imagine, under common ketone alkylation conditions (e.g. LDA, MeI), methylation could 
occur at either α- or α’-positions. Regarding the retro-Dieckman reaction, the cis diastereomer 
S12b underwent the C−C cleavage reaction under mild conditions (K2CO3, MeOH, rt) leading to 
trans-α,β-disubstituted cyclohexanone S12c.  Interestingly, the trans-isomer S12d did not 
undergo retro-Dieckman condensation. This reaction dichotomy can be easily explained by the 
orbital orientation in each of the cis- and trans-decalin systems. In the case of the cis-decalin 
S12b, the pertinent orbitals are rigidly aligned to allow for rapid and mild cleavage. Conversely, 
in the trans-isomer S12d, the pertinent orbitals are locked perpendicular to one another, making 
this retro-Claisen condensation much higher in energy as no resonance stabilization would occur 
as the carbanion is being formed. Furthermore, as the cis-decalin S12b is prochiral, Duthaler also 
developed a retro-Claisen condensation based desymmetrization of this species.  This is 
discussed in the “desymmetrization of prochiral diketones” section of this review (section 2.2.3) 
as there are several papers on desymmetrization of diketones via retro-Claisen condensation in 
the literature.  
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Scheme 12. Facile retro-Claisen of cis-decalin-1,8-diones (Duthaler, 1982)
X
96% yield
R = Me and H (3:1)
K2CO3
MeOH(aq)O
CO2Me
1. Dieckman condensation, 2. Methylation (87% yield, 1.7:1 dr)
steps 1-2
!!'
S12a
S12b S12c
S12d
73 
 
 The Dieckman condensation was also used strategically to alkylate at both sides of a 
ketone using a series of alkylations and Dieckman/retro-Dieckman reactions.30-33 As shown by 
Meyer, this can be done in a single pot and in high yield over the course of the transformation 
(Scheme 13).34 Starting from dimethyl adipate S13a and initiated by Dieckman condensation, a 
β-diketone is prepared in situ, which is methylated by addition of methyl iodide (S13b).  Next, a 
single equivalent of methoxide is added to promote a retro-Dieckman condensation, proton-
transfer, and a second Dieckman condensation reaction, which gives rise to another β-diketone 
(S13c). This can again be alkylated by addition of methyl iodide leading to S14d. This 1-pot, 
multi-step sequence occurs in 80% yield on large scale.   
 
 A similar Dieckman/alkylation/retro-Dieckman cascade was utilized by Taber and 
coworkers to prepare an important intermediate en route to estrone (Scheme 14).35 The formal 
enantioenriched Dieckman substrate S14a was however prepared by a Rh-catalyzed C−H 
insertion reaction.  
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Scheme 13. Single pot dimethylation of ! and !' positions of cyclopentanones (Meyer, 1965)
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 Another approach to alkylate both α- and α’-positions of a carbonyl involves starting 
from β-ketoglutaric esters (Scheme 15, S15a).  These molecules function as bisnucleophiles and 
can couple with biselectrophiles. The central ketone can then be cleaved upon retro-Claisen 
condensation to prepare some interesting chemical structures. For example, in pioneering work, 
Cook and coworkers demonstrated that 2 equivalents of β-ketoglutarate can condense with α-
keto ketones or aldehydes to synthesize fused 5-membered rings.36-38  Upon decarboxylation and 
Dieckman condensation, tetraquinane cores S15b-c were quickly constructed. Furthermore, 
Cook noted that retro-Dieckman of these structures occured mildly and without the requirement 
of quaternarization leading to fused dicyclopentadiones S16a-b (Scheme 16).38 The retro-Claisen 
condensation of non-quaternized β-diketones is somewhat unique as enolization can occur (see 
section 2.2.7 for retro-Claisen condensation of other non-quaternary β-diketones). In this case, 
retro-Claisen reaction is mild, presumably due to the ridged carbonyl alignment as previously 
discussed in Duthaler’s work on cis-decalinones (Scheme 12).27 
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 In a conceptually similar example published by the Rodriguez research group, a cyclic β-
ketoglutarate derivative was coupled with 1,4-dihaloalkanes, and upon retro-Claisen reaction, 
ring expanded cyclooctanes were produced (Scheme 17).39 The dialkylation was found to go in 
high yield using K2CO3 or DBU as the base. The retro-Claisen reaction then occurred in neutral 
refluxing methanol leading to the desired cyclooctane ring compounds. In general, β-ketoesters 
where the ketone is located at the bridging carbon are extremely labile due to the increased strain 
of bicyclic systems. This facile cleavage is well exploited and further discussed in section 2.2.4.  
 
 Although the reaction above was done using a cyclic β-ketoglutarate derivative, 
Rodriguez’s major focus in annulation/retro-Claisen chemistry has involved the MARDi 
reaction, which doesn’t require the β-ketoglutarate for formal dianion formation.40-44 MARDi 
stands for Michael-Aldol-Retro-Dieckman. Using the MARDi reaction, acrolein derivatives can 
annulate a β-ketoester at the α- and α’-positions, and undergo ring expansion via the reactions 
outlined in its name: Michael addition, aldol reaction, and retro-Dieckman condensation 
(Scheme 18).  Rodriguez has published a beautiful review of this reaction and will not be 
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Scheme 17. Dianion/cation cyclization/retro-Claisen ring expanstion (Rodriguez, 2001)
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covered in nearly as much detail here.45  Thus, I direct the reader there for the nuances of this 
useful transformation. 
 In similar vein to Rodriguez’s approach to dialkylation of the α- and α’-positions of β-
dicarbonyl compounds, Tenaglia has reported that a Tsuji-Trost-like annulation can occur with 
allyl dimethyl carbonates (Scheme 19).46 In this process, 2-consecutive Pd-catalyzed allylations 
occured: the first at the more stabilized α-position and second at the less stabilized α’-position 
leading the annulated intermediate S19a.  In the presence of sodium methoxide, a uniquely 
substituted cycloheptanone S19b was prepared in 43% yield over the 2-step sequence.  The 
reaction can also proceed from the allyl diacetate though base is required and the reaction 
performed noticeably poorer. 
 
 Another ring-expansion technique that complements classic approaches to macrocyclic 
lactones involves a retro-Claisen reaction with a pendant alcohol (Scheme 20).47,48 Mahajan has 
developed an approach to 11-membered rings by alkylation followed by 
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macrolactonization/retro-Claisen condensation between cyclohexan-1,3-diones S20a and 1-
chloro-4-acetoxy-cis-butene S20b derivatives (Scheme 20). 
 At Synthex Research Company, principles from the Mahajan’s work were utilized to 
make various sized lactones (Scheme 21).49 Upon quaternarization with allyl bromide (other 
alkylating agents had significant O-alkylation problems), the intramolecular C−C cleavage/ring-
expansion occurred giving reasonable yields of various macrocyclic lactams.  Normal problems 
with macrocyclic ring closures, such as oligomerization, kept the yield modest.  
 
 
2.2.3. Desymmetrization of prochiral diketones via retro-Dieckman condensation  
 
 Above in Scheme 12, Duthaler described how prochiral decalindione S12b underwent 
facile retro-Claisen reaction leading to a trans-α,β-disubstituted cyclohexanone S12c.  He was 
also quite interested in performing a desymmetrization of this diketone to quickly prepare 
enantioenriched analogs from this readily available diketone.27-29  He envisioned two possible 
desymmetrizing asymmetric retro-Claisen reactions: (a) retro-Claisen condensation using chiral 
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bases28 (Scheme 22) and (b) via chiral diol desymmetrization/retro-Claisen reaction (Scheme 
23).29 
 
 In the first approach, Duthaler and Maienfisch were able to desymmetrize the 
decalindione S22a using the sodium salt of ephedrine S22b as a chiral nucleophile (Scheme 
22).28  Hydrolysis of the intermediate ephedrine amide S22c and esterification with 
diazomethane lead to the desired enantioenriched dione S22d-f. Using this method, the 
enantioenriched trans-disubstituted cyclohexanone S22c was isolated in a good yield over the 3-
steps (54% yield, 86% ee).  Also, moderate diastereoselectivity (3:1 dr) was observed in this 
process.  Unfortunately, only poor to modest enantioselectivity was achieved for the 5-membered 
ring analogs S22d-e.  In addition to ephedrine, N-methylephedrine S22g and prolinol S22h salts 
were studied: they provided reasonable, but lower ee’s than the ephedrine salt.   
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 In another approach, a chiral diol condensation reaction was used to desymmetrize the 
prochiral dione S23a (Scheme 23).29 Relatively good diastereoselectivities, which corresponds to 
enantioselectivity, were observed upon the condensation of decalin S23a with the chiral 1,2-diol 
S23b. Importantly, the unwanted diastereomer (corresponding to the unwanted enantiomer) 
could be removed chromatographically, giving the enantiomerically pure diastereomer S23c in 
good isolated yields (~75% yield). Upon exposure of the β-ketoacetal to an equivalent of 
methanesulfonic acid, an acid catalyzed retro-Claisen reaction occurred through intermediate 
S23e.  Basic and alcoholic work-up then produced the enantio- and diastereo-enriched trans-
disubstituted cyclohexanone in excellent yield and with perfect chirality transfer from the 
enantiopure starting material. 
 	  
 
 More recently, Grogan took advantage of Nature’s method of converting a prochiral 
camphor β-diketone to a chiral metabolite using 6-oxocamphor hydrolase with other exogenous 
substrates (Scheme 24).50-53 Using this enzyme, exogenous bridged β-diketones S24a could 
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Scheme 24. Enzymatic desymmetrization of achiral !-diketones via retro-Claisen (Grogan, 2001)
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80 
undergo enzymatic retro-Claisen cleavage reaction to the enantioenriched cycloalkane S24b-c.  
The bridge was found to be quite important for asymmetry using the wild-type enzyme, 
potentially due to the substrate-enzyme binding and recognition mechanism, but also to prevent 
the enolization of the β-diketones (Bredt’s rule).  Nonetheless, good to excellent ee’s (86−94%) 
were observed using the enzymatic retro-Claisen reaction.  In a follow-up study,52,53 it was 
reported that other substrates could participate in enzymatic retro-Claisen condensation (Scheme 
25). Specifically, this method could produce enantioenriched cyclopentanones that were 
challenging to access using Duthaler’s approach (Scheme 22). 
 
2.2.4. Pericyclization/retro-Claisen condensation reactions 
  
 The previous section focused on access to β-ketoesters by classic Claisen or Dieckman 
condensation methods and how they can be utilized in functionalization/retro-Claisen 
methodologies.  β-ketoesters can be accessed by others methods too. This section will highlight 
how Diels-Alder and related pericyclic transformations can be utilized synergistically with retro-
Claisen condensation to make useful chemical entities rapidly. In general, these cyclic β-diketo 
esters are considered highly reactive toward retro-Claisen C−C cleavage due to the strain from 
the ketone (sp2 atom) within the bicycle.  A similarly reactive comparison would be to 
norbornane, which has a highly reactive olefin due to strain.  
 To begin, in the synthesis of showdomycin (Scheme 26), Kozikowski and coworkers 
utilized a Diels-Alder cyclization (between an allene derivative and furan) and a dihydroxylation 
to prepare the oxo-bridged cyclohexane.54 Most importantly, these initial transformations set 4-
contiguous stereocenters.  The allene was chosen strategically as the dieneophile because (a) it is 
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electron deficient allowing for a high yielding, polarized Diels-Alder cyclization and (b) upon 
ozonolysis, afforded an advanced β-diketoester S26a that underwent mild alkylation to S26b. 
The oxo-bridged cyclohexane was converted into the tetrahydrofuran S26c by a mild NaHCO3-
catalyzed retro-Claisen reaction. From here, the complex metabolite is prepared in a few more 
steps.  This early example utilizing pericyclization and retro-Claisen condensation in conjunction 
nicely demonstrates how the stereospecificity of cycloaddition and C−C fragmentation via retro-
Claisen reaction can be used to create useful monocyclic compounds with complete stereocontrol 
around the ring. 
 
 More recently, other researches have adopted the [4+2]/retro-Claisen strategy to make 
various complex 5-membered rings.55-60 For example in Scheme 27,55 Avenoza and Peregrina 
utilized a Diels-Alder reaction between Danishefsky’s diene and an amino acid based dienophile 
followed by a few chemical manipulations and a chiral resolution to arrive at an amino-bridged 
cyclohexane containing the built-in β-ketoester S27a. From here, they reported that different 
bases could selectively form either cis- or trans-2,5-dialkylpyrrolidines by control of the 
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protonation in the retro-Claisen reaction. Having access to either diastereomer, the researchers 
could now produce various carbapenem antibiotics. 
 Shortly thereafter, Gelmi56,57 and Pelligrino58,59,61 reported that a similar [4+2]/retro-
Claisen sequence could allow access to cyclopentyl containing amino acids (Scheme 28). Single 
enantiomers of these compounds could then be obtained by chiral resolution. Importantly, 
cyclopentyl amino acids have a range of interesting biological activities and this approach allows 
rapid access to them. 
 
 One downside to the Diels-Alder/retro-Claisen sequences outlined above is that various 
chemical manipulations were required to arrive at the advanced β-ketoester. An improved 
procedure by Moreno-Vargas involves a [4+2] cyclization between a cyclic diene and an 
acetylene derivative (Scheme 29).60 Simple hydrolysis leads to a β-ketosulfonyl compound S29a 
in excellent yield. Treatment of S29a with acid or base commences the mild retro-Claisen 
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reaction to the cyclopentanoid structures S29b-d in quantitative yields. Also, these building 
blocks have a tosyl group tether for further chemical manipulation.  
 The previous examples had the reactive ketone within the cyclohexane ring.  Depending 
on the substrate and reaction, the reactive carbonyl can be located at the bridging carbon, and 
upon retro-Claisen C−C cleavage, produce a ring expanded compounds.  Some aspects of this 
reactivity has been discussed in the previous section where the bridgehead ketone was accessed 
by alkylation methods (Schemes 17−19). 
 Büchi had much interest in the [5+2] cyclization between quinone ketals and olefins.62-64 
This reaction lead to highly substituted 7-membered rings with a ketone bridge (Scheme 30).  By 
retro-Claisen cleavage, reduced-tropalones, such as S30a, with 3-stereocenters (from the [5+2] 
cyclization) could be prepared with excellent selectivity.  Furthermore, by oxidation, interesting 
and biologically active tropolone methyl ethers could quickly be prepared.  Thus, this represents 
a concise route to these important biologically active compounds. 
 
 As the tropolone structure is known to be biologically active and can be prepared quickly 
by the aforementioned methods, researches at MIT and Boston University wished to make a 
library of them using Buchi’s [5+2] method followed by retro-Claisen condensation with a 
diverse array of amines (Scheme 31).65 
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 The manzamenone class of natural products are dimeric fatty-acid based compounds with 
a unique structure. It was proposed by the metabolite’s isolator, Kobayashi,66 and later 
expounded on by Whitehead,67,68 that these dimeric natural products could arise from a homo 
Diels-Alder reaction of highly reactive cyclopentadienone (S32aèb) followed by a retro-Claisen 
condensation leading to the natural product (Scheme 31). Whitehead confirmed this hypothesis 
by making a simplified analog S32c as well the natural product starting from furfural S32d. 
 
 Thus far, we have covered fragmentation of bicyclic ring systems where the reactive 
carbonyl is in the cyclohexane ring as well as at the bridging carbon. The final location to be 
discussed is an acetal at the bridgehead location that can undergo retro-Claisen condensation 
(Scheme 33).69 
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 Montaña has developed a [4+3] cyclization between 2-methoxyfuran and α,α’-dibromo 
acetone derivatives (Scheme 33).69  This reaction leads to an oxo-bridging cycloheptane (S33a) 
containing an acetal at the bridgehead. Upon exposure to HCl (aq), S33a breaks down via retro-
Claisen condensation and hydrolysis to the substituted butenolide S33b. Again, the stereocenters 
set from the cyclization are transferred to the chemical building block butenolide. 
 To conclude on pericyclization/retro-Claisen condensation, chemical complexity can 
rapidly be developed utilizing the stereospecificity of the pericyclization and transferring this 
information to a more useful chemical building block via retro-Claisen reaction. 
 
2.2.5. α-Nitro-ketone alkylation/retro-Claisen condensation 
 
 Although the cleavage of α-nitroketones has been known since the early 20th century,70 
these reports didn’t comment on the synthetic potential of such a C−C cleavage reaction.  
Synthetically useful cleavages of α-nitroketones began appearing in the 1950’s and 60’s.71-75 For 
example, Breslow (of Hercules Inc.) reported that 2-nitrocyclohexanone S34a could rapidly, and 
in a high yield, be converted into an important synthetic intermediate S34b for the production of 
nylon 6 (Scheme 34). The sequence is as follows: an extremely mild retro-Claisen reaction 
occurs on nitrocyclohexanone to prepare the 6-nitrohexanoic acid, which is reduced to the nylon 
6 precursor S34b. In general, the retro-Claisen reaction of nitro-ketones is extremely mild due to 
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Scheme 33. [4+3] cyclization retro-Claisen (Moñtana, 2004)
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the low pKa of the nitronate anion (pKa = 17 in DMSO) generated by retro-Claisen. Interestingly, 
quaternarization of this compound was not necessary; aspects of retro-Claisen condensation of 
related enolizable β-ketoesters are discussed in section 2.2.7 of this chapter. 
 
 A well-utilized strategy in organic synthesis is mild functionalization/retro-Claisen 
protonation of nitroketones (Scheme 35). As α-nitroketones are excellent nucleophiles, and their 
C−C cleavage is mild, this strategy has seen much utility.76-80  The general strategy is outlined in 
Scheme 35 and is as follows: a nitroketone couples with an electrophile forming the fully 
substituted α-nitroketone.  Next, a nucleophile (intramolecular or intermolecular) can then 
perform the retro-Claisen condensation to prepare (often ring-expanded in the case of retro-
Dieckman condensation) diverse nitroalkanes. This reaction has been reviewed on multiple 
occasions,76-80 with recent reviews by Robert Ballini, a major contributor to the development and 
utility of nitroketone retro-Claisen reactions and nitro group chemistry in general. To keep this 
review concise, only a few recent examples will be discussed herein. I direct the reader to 
Ballini’s excellent and thorough reviews on this subject matter. 
 
 A recent example of this functionalization/retro-Claisen approach to nitroalkane synthesis 
was reported by Zanoni and Vidari in the improved synthesis of nitro-containing fatty acid  (E)-
12-nitrooctadec-12-enoic acid (Scheme 36).81  Importantly, synthetic nitro-containing fatty acids 
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have been shown to be excellent ligands for the peroxisome proliferator-activated receptor-γ 
(PPARγ). Starting form 2-nitrocyclododecanone S36a a mild Henry/retro-Claisen sequence 
followed by methylation of the carboxylic acid with diazomethane allows facile access to S36b.  
From this intermediate, the desired nitro-containing fatty acid S36c is prepared in 2 steps by 2-
consecutive hydrolysis reactions. The basis of this work (Henry/retro-Claisen) was provided by 
Ballini and involved the reaction of 2-nitrocyclohexane derivatives with formaldehyde in the 
presence of water.77,82 
 
 Another reaction originally reported by Ballini (and others) is the Michael addition/retro-
Claisen reaction.83 In a recent example,84 Menéndez utilized this simple reaction to initiate a 
domino reaction leading to complex macrolactones in a single pot from 2-nitroalkanones and 
acroleins (Scheme 37). In this reaction, 2-nitrocycloalkanones are converted to S37a by a tandem 
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Scheme 36. Preparation of nitro-containing fatty acids via Henry/retro-Claisen condensation (Zanoni & Vidari, 2010)
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Michael/retro-Claisen reaction.  Through an intramolecular O-nitronate aldol reaction followed 
by tautomerization, condensation and macrolactonization, products S37c-e are generated in good 
yield over this multi-step, 1-pot, synthetic sequence.  In general, at least a 6-carbon tether on the 
nitro-containing fragment was required for the reaction, presumably due to the necessity to 
minimize ring strain in the macrolactone.  Moreover, a β-alkyl substitution on the acrolein was 
also required.  The R-acrolein substitution allows the linear nitroalkane to access the correct 
geometry for intramolecular O-nitronate aldol reaction.  Following these general guidelines, 
various complex macrolactones (S37c-e) can be prepared from simple starting materials in a 
single pot. 
 In three similar studies by three different research groups,85-87 it was reported that 
thiourea based organocatalysts can promote the asymmetric Michael/retro-Claisen reaction of 2-
nitroacetophenone S38a derivatives and β,γ-unsaturated α-keto esters S38b. Interestingly, the 
reaction is extremely specific to the oxalyl derived Michael acceptor (S38b); other α,β-
unsaturated ketones and aldehydes failed to give a reasonable result (S38g could never be 
isolated in acceptable yields).  However, using various nitroketones S38a and oxalyl derived 
Michael acceptors S12b, the reaction was general.  Regarding the Michael acceptor, various 
aromatic substitution patterns (S38c) including ortho-substitution (S38d) were acceptable.  
Moreover, the Yan group (conditions B) was able to couple aliphatic substituted Michael 
acceptors (S38e).  Regarding the nitroketone, in addition to 2-nitroacetophenone derivatives 
(S38a), aliphatic nitroketones were also compatible couplings partners (S38f). Although the full 
synthetic utility was not disclosed, it was shown by Yan that the trapped enolate can be freed to 
the α-ketoester S39a under hydrolytic conditions without affecting the stereocenter (Scheme 39).  
89 
 
 Finally, we have made our own contribution to this field of research, a Tsuji-Trost 
allylation/retro-Claisen of α-nitroketones.88 However, this presented in the 3rd chapter of this 
dissertation. 
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2.2.6. C−X bond formation/retro-Claisen condensation 
 
 The previous sections have dealt with adding carbon-based electrophiles to β-dicarbonyl 
compounds and derivatives thereof.  Heteroatomic electrophiles can also be added to active 
methylene nucleophiles forming a C−X bond and by retro-Claisen C−C cleavage, reveal the 
useful chemical building block containing a new heteroatom. Moreover, due to the nature of the 
C−X bond formed, where X is an electronegative atom, the retro-Claisen reaction is generally 
quite mild due to the anion stabilizing effect of the X-atom. The C−X bond formation/retro-
Claisen condensation sequence has the same underlying principles as alkylation/retro-Claisen 
reaction and will be discussed in this section. 
 To begin, Gupta of Pfizer Inc., reported a general method for preparing α,α-dichloro 
acetates (Scheme 40).89 By treating ethyl acetoacetate S40a with sulfonyl chloride, ethyl α,α-
dichloro acetoacetate S40b was prepared quantitatively and on the large scale.  Treatment of this 
compound with a mild base, such as potassium acetate, facilitated retro-Claisen condensation and 
upon protonation, the α,α-dichloro acetate S40c was made in high isolated yield. 
 
 C−F bond formation/retro-Claisen (e.g. with Selectfluor) can also occur on β-dicarbonyl 
compounds (Scheme 41).  In a powerful example, C−F bond formation, asymmetric Mannich 
reaction and retro-Claisen condensation rapidly, enantioselectively, and diastereoselectively 
leads to α-fluoro-β-amino acids S41a.90  This example represents how a β-ketoester can be used 
to its full potential by performing successive diversifying reactions. 
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 Though it will be discussed in a forthcoming section, Colby has another useful example 
of C−F bond formation/retro-Claisen condensation.91,92 This is discussed in the section where the 
anions generated by retro-Claisen C−C cleavage are utilized in to make new C−C and C−X 
bonds (section 2.3). 
 In addition to halogens, nitrogen electrophiles have also been shown to couple with β-
dicarboxyl species, and upon retro-Claisen condensation, prepare extremely useful α-amino 
carbonyl derivatives. This general structure is found in amino acids, extremely important 
biological building blocks. 
 
 The nitrosation/retro-Claisen reaction of β-ketoesters to prepare α-oxime esters was first 
reported first in 1909, and reviewed in 1953.93  This reaction was exhumed in 2004 by Wyeth, 
when it was used to synthesize a unique amino acid capreomycidine S25d (Scheme 25).94 
Treatment of the desired methyl acetoacetate S42a with nitrosonium ion (NaNO2 and HCl) 
allows for C−N bond formation (S42b). The acetyl group is then cleaved by water leading to the 
desired α-oxime ester S42c.  In 2 steps, this compound is converted to the desired amino acid, 
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capreomycidine S42d.  This reaction was developed for the specific purpose of making 
carpreomycidine and no scope studies were performed. 
 
 Using a different source of electrophilic nitrogen, Pellacani demonstrated in 2007 that 
protected amino acid derivatives could be prepared from trifluoroacetylacetone or acetate 
derivatives S43a via C−N bond formation and retro-Claisen cleavage of the trifluoroacetyl unit 
in situ (Scheme 43).95 They primarily focused on glycine-related amino acids (S43a-c), though 
an alanine amino acid (S43d) as well as camphor based amino ketone could be synthesized in 
good yield (S43e).  Though no mechanism is suggested, it can be presumed to proceed by C−N 
bond formation followed by retro-Claisen condensation, promoted either by the CaO base or the 
para-nitrophenylsulfone (NsO-) leaving group. 
 
2.2.7. Retro-Claisen condensation on non-quaternary β-ketoesters 
  
 The retro-Claisen reaction of most of the examples discussed already in this review have 
focused on α,α-disubstituted β-dicarbonyl compounds.  The retro-Claisen reaction of less 
substituted compounds is generally more challenging due to problematic enolization rendering 
the carbonyls much less reactive toward C−C cleavage.  However, there are some examples of 
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retro-Claisen condensation of mono-substituted β-dicarbonyl compounds, and they will be 
discussed in this section. 
 Early examples of this type of retro-Claisen reaction were reported by Claisen,96 Ritter97 
and Hercules Inc.75 (Scheme 44).  Ritter and coworkers reported that a catalytic amount of 
ethoxide in refluxing ethanol could allow for retro-Claisen condensation to occur on an 
enolizable ethyl acetoacetate. To compare, fully quaternized ethyl acetoacetates undergo retro-
Claisen condensation with ease.6 Researchers at Hercules Inc. reported a mild retro-Claisen 
reaction for enolizable nitroketones.75 The reaction went with a much milder base than the Ritter 
example, NaHCO3, presumably due to the high stability of the nitronate anion generated upon 
retro-Claisen C−C cleavage. Claisen96 and Shriner’s98 method for the production of ethyl 
benzoylacetate from the tricarbonyl also went under mild conditions again due to the high 
stability of the anion generated. In general, the retro-Claisen reaction is facilitated by high 
temperature and anion stabilization. 
 
 There are a few useful methods of acylation/retro-Claisen reaction involving intermediary 
tricarbonyl compounds. As introduced above, Claisen96 and Shriner,98 have reported a method 
for ketone transposition (Scheme 45) from ethyl acetoacetate and a given acyl chloride. In the 
presence of base, acylation occurs to the tricarbonyl compound S45a. Hydrolysis then removes 
the most electrophilic carbonyl (the acetyl unit) and yields the desired product S45b. 
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 In a conceptually similar approach, β-ketothioesters could be converted to mixed 
thio/amide malonates S46b through a tricarbonyl by reaction with an isocyanate followed by 
retro-Claisen condensation (Scheme 46).99 The thioester was strategically utilized to allow for 
late-stage diversification to mixed malonic amides and esters S4c-f. In general, this 2-step 
sequence went in good overall yield. 
 
 Using an indium catalyst, Kuninobu, Takai, and coworkers reported a very interesting 
retro-Claisen reaction of β-diketones (Scheme 47).100 In this reaction, an alcohol (or water) 
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attacks the internal ketone of S47a selectively over the exocyclic ketone. This endocyclic 
nucleophilic attack is opposite to what is observed in all the other reactions presented throughout 
this review.  This unique reactivity is presumably due to the favorable exo-enolization of the β-
diketone S47a. Upon catalyst binding, hemiacetal formation, and proton transfer, the 
intermediate S47b is now poised to undergo retro-Claisen condensation leading the product 
S47c. A similar strategy has also been developed using FeCl3 as the catalyst,101 which is 
attractive since iron is very abundant and inexpensive. 
 
 Using a cobalt catalyst, dibenzoylmethane derivatives S48a can undergo 
Knoevenagel/Michael and retro-Claisen condensation yielding symmetric 1,3-benzoylpropanes 
(a 1,5-diketone, Scheme 48).102 With di-para-tolylmethane the reaction went smoothly to the 
desired product S48b.  Using the para-nitrophenyl substrate the isolated yield was reasonable 
(S48c), however, premature retro-Claisen condensation of the starting material (leading to nitro 
substituted acetophenone S48d and benzoate S48e) was a competing reaction.  Furthermore, a 
diketone having para-methoxyphenyl substitution underwent the retro-Claisen reaction too 
slowly, though the authors report that good yields of the Knoevenagel/Michael adduct can be 
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isolated with this substrate.  In general, a delicate balance of reactivity is required for this 
reaction to progress smoothly under these reaction conditions. 
 
 A unique PPh3-catalyzed reaction sequence coupling propiolate S49a and ortho-hydroxy 
containing mixed dibenzoylmethanes S49b involving a retro-Claisen reaction was reported by 
Xue (Scheme 49).103 In this sequence, the PPh3 activates the propiolate S49a by conjugate 
addition, the resulting anion, deprotonates the dibenzoylmethane S49b to activate both the 
starting materials for coupling. A second conjugate addition occurs as shown by the curved 
arrow.  The resulting phosphonium ylide then deprotonates the phenol to form intermediate 
S49c, which is predisposed for retro-Claisen condensation.  Through proton transfer and 
elimination, the product S49d is generated.  Interestingly, electron rich benzoyl derivatives gave 
the best yield.  For example dimethoxybenzoyl (S49d) vs. para-fluorobenzoyl (S49e) gave 
drastically different yields.  This is an interesting result as retro-Claisen reaction is usually more 
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facile with more electrophilic carbonyls.  Nonetheless, using the most effective benzoyl transfer 
group (3,4-dimethyoxybenzoyl), various substitution patterns (S49f-g) were tolerated and the 
reactions went in good yield. 
 Regarding the retro-Dieckman step of the PPh3-catalyzed reaction above (Scheme 49), 
full quaternarization was likely not required due to the (a) neutral reaction conditions and the (b) 
favorable transition-state geometry of the acyl transfer (acyl transfer goes though a 6-membered 
ring).  A similarly favorable 6-membered ring acyl transfer transition-state was observed in the 
coupling of α-nitroketones and Michael acceptors.85-87  This was previously discussed in Scheme 
38. 
 Finally, enolizable α-aryl β-dicarbonyl compounds also undergo retro-Claisen reaction 
without the requirement of quaternarization. This reaction is well-studied due to the importance 
of the products prepared, α-aryl monocarbonyl compounds, and the attractive synthetic route. 
The next section of this review will focus on this topic. 
 To conclude, the retro-Claisen condensation of enolizable β-dicarbonyl derivatives is less 
common, but can be favored using general tactics such as: (a) high temperature, (b) highly 
stabilized post-retro-Claisen anions, (c) Lewis acid catalysts (c) and acyl transfer through 
thermodynamically favorable transition-states. 
 
2.3 Transition metal-catalyzed arylation/retro-Claisen condensation strategies 
 
 Transition metal-catalyzed enolate arylation is a heavily researched area in synthetic 
chemistry primarily due to the utility of α-aryl carbonyl functionality  (for example, see 
ibuprofen, verapamil and clopidogrel in Scheme 2) but also due to the attractive retrosynthetic 
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disconnection.  The arylation of active methylene nucleophiles (β-dicarbonyl compounds) has 
been known since the early 20th century.104 For example, the Cu-catalyzed arylation of sodium 
ortho-bromobenzoate was reported by Hurtly in 1927.104 Active methylene compounds are 
commonly employed in arylation reactions due to their low pKa’s, which render their activation 
simple.  More recently, methodologies for arylation of less stabilized monocarbonyls have been 
developed, however, the conditions required to do so can be challenging and require more 
expensive/sensitive bases and specialized catalysts.105,106 
 
 An attractive, yet underutilized, alternative strategy for the synthesis of α-aryl 
monocarbonyl compounds is by (a) arylation of the active methylene compound followed by (b) 
retro-Claisen reaction (Scheme 50).  This synthetic strategy was first outlined in 1927, by 
Hurtley,104 for the coupling of various active methylene compounds with ortho-bromobenzoic 
acid. Scope and method improvements were reported in 1972 and 1974 by Dodds107 (Scheme 51) 
and McKillop 108,109 (Scheme 52), respectively.  
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Scheme 50. !-Aryl ketone synthesis using an arylation/ retro-Claisen strategy
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 In these seminal papers,104,107-109 the importance and requirement of an ortho-carboxylate 
is outlined (Scheme 15).  It is suggested that the formation of a Cu-arene chelate S51a facilitates 
C−C bond formation between the picoline derivative and the active methylenes (S51b). In these 
examples, both bromo- (e.g. S51c) and chloro- (S51e) picolinic acids were viable coupling 
partners. Regarding the active methylene coupling partner, acetylacetone (S51c), 
dibenzoylmethane (S51d), ethyl acetoacetate (S51e) and acetoacetamide (S51f) were all 
excellent coupling partners. 
 
 McKillop opted to use a copper(I) source rather than the Cu(0) or Cu(II) precatalyst that 
had been used in previous papers for the arylation/retro-Claisen reaction (Scheme 52).108,109  He 
noted that the various Cu(0) or Cu(II) sources previously utilized gave irreproducible results. 
Moreover, ethanol and ethoxide were removed from the system to avoid concomitant formation 
of aryl ethyl ether byproducts. In this case, NaOH was added after the arylation reaction went to 
completing to promote the retro-Claisen condensation. 
 Cu(I)-catalyzed active methylene arylation sat dormant until the early 1990s when the 
importance of a polar aprotic solvent (such as DMSO) was noted by Miura.110 It was this 
breakthrough that allowed de Koning to devise a Cu(I)-catalyzed method for a relatively general 
1-pot arylation/retro-Claisen reaction in 2007 (Scheme 53).111 Interestingly, as the previous 
retro-Claisen reactions have been water/alcohol mediated, the retro-Claisen condensation in this 
Br
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O2N CO2H
CO2HH3CO
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0.5-2h 0.5h
88% 87% 88% 89%
Scheme 52. Method improvement for !-arylation/retro-Claisen (McKillop, 1974)
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sequence is thought to be base-mediated as no water or alcohol is present. Regarding the scope, 
the communication focuses on simple phenyl (S53a) and para-substituted aryl iodides (S53b-d) 
and bromides. Both electron rich and poor aryl iodides worked quite well (S53a-d), whereas 
electron deficient aryl bromides were the only viable coupling partners under these conditions 
(S53c).  Moreover, alkyl ortho-substitution was not well tolerated (S53e).  Unlike ortho-
carboxylate substitution (Schemes 51-52), there is no potential for Cu-ion chelation with this aryl 
halide. Thus, only a negative steric effect is observed. 
 
 In 2010, Lei further developed this Cu(I)-catalyzed arylation/retro-Claisen reaction and 
expanded the scope to other active methylene derivatives (Scheme 54), though he believes the 
reaction to proceed by a different mechanism (Scheme 55).112 As opposed to the previously 
mentioned arylation of ethyl acetoacetate by de Koning (Scheme 53),111 water is present and 
plays a key role in this reaction (Scheme 54).  Similar to de Koning’s findings, aryl iodides are 
better coupling partners than the corresponding bromides (S54a-c), though they were tolerated.  
He also demonstrated that chemoselective retro-Claisen reaction occurs for the acetyl group over 
the various benzoyl groups, allowing access to diverse aryl ketones (S54f-g). 
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 Lei and coworkers noted that phenyl acetylacetone S55a, the presumed intermediate in 
the arylation/retro-Claisen reaction presented in scheme 54, did not undergo retro-Claisen 
cleavage under the reaction conditions (Scheme 55, top).  Moreover, it was never witnessed as a 
byproduct.  To explain this, Lei offers the following mechanistic hypothesis (Scheme 19):  the 
active catalyst is the Cu-acetylacetone complex S55b.  This species undergoes oxidative addition 
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Scheme 54. Cu-catalyzed arylation/retro-Claisen condensation of acetylacetone derivatives (Lei, 2010)
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with the aryl halide generating S55c. The retro-Claisen occurs from here to generate the Cu-
carbenoid S55d, which by reductive migration and a final ligand exchange generates the desired 
product S55f and the active catalyst.  He also concluded that water performs the retro-Claisen 
reaction as acetate ion was detected using react-IR technologies. 
 Zhao has quite recently reported the arylation/retro-Claisen reaction of β-
ketophosphonates leading to α-aryl phosphonates (Scheme 56).113 However, he was limited to 
electron deficient aryl iodides (S56a-d) as para-iodoanisole failed to give a reasonable result 
(S56e). He did however show that various acyl derivatives could be cleaved.  For example, S56a 
was prepared by arylation and retro-Claisen cleavage of an acetyl, propionyl, and a benzoyl 
group. As shown by S56e, there was a significant amount of the non-deacylated byproduct for 
this electron rich aromatic system.  First, the retro-Claisen reaction, in this case, was potentially 
more challenging due to the increased pKa of the phosphonate-stabilized anion.  Moreover, this 
result suggests that arylation occurs before the deacylation event, and a mechanism similar to 
Lei’s is probably not the major route to product formation, in this case. 
 
 In addition to Cu-catalyzed arylation, there are also some examples of Pd-catalyzed 
arylation/retro-Claisen reaction in the literature too. The earliest example where tandem Pd-
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Scheme 56. Cu-catalyzed !-arylation/retro-Claisen of "-ketophosphonates (Zhao, 2011)
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catalyzed arylation/retro-Claisen cleavage was utilized to afford α-arylated mono-esters was in 
2001, when Kondo and coworkers reported the coupling of aryl iodides and malonate 
nucleophiles followed by base induced retro-Claisen cleavage (Scheme 57).114 This work was 
further elaborated by Cetinkaya and coworkers in 2004. Again, the reaction was significantly 
broadened and simplified by Gooβen in 2011 (Scheme 58 and 59).   
 In Kondo’s initial report on the arylation/retro-Claisen reaction of malonate and aryl 
iodides, high temperature and excessive Cs2CO3 were utilized to promote both reactions 
(Scheme 54, cond. A). Nonetheless, both electron poor (S57a) and electron rich (S57b) aryl 
bromides could be coupled in good yield.  Cetinkaya notably extended the reaction to aryl 
chlorides and their conditions (cond. B) could also couple the sterically hindered 2-bromo 
mesitylene (S57c).115 Though these initial reports were quite promising, the scope that was 
investigated was slim. 
 
 With excellent scope, Gooβen and coworkers recently reported a practical strategy for 
arylation/retro-Claisen condensation of ethyl malonate from diverse aryl bromides and 
chlorides.116 Using the same catalyst system used by Kondo, two complimentary conditions were 
developed to allow both electron rich and poor haloarenes (Schemes 58 and 59, respectively) 
with various substitution patterns to couple cleanly and predictably. 
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 The first conditions (Pd/tBu3, K3PO4, 18-crown-6) coupled electron rich aryl halides with 
malonate nucleophiles (Scheme 58).  As an electron rich aromatic is being added to the 
malonate, a highly reactive nucleophile for retro-Claisen condensation was required due to the 
heighted pKa of aryl ester enolate anion to be generated.  18-crown-6 as an additive was found to 
be quite effective in promoting said cleavage reaction. As product S58a shows, aryl chlorides, 
bromides and iodides were all excellent coupling partners under these conditions. Moreover, 
various electron donating groups were compatible at the para (S58b) and meta (S58c) positions 
of the arene. Some ortho-substitution was tolerated (S58d). Unfortunately, these conditions were 
problematic with electron deficient and sterically encumbered aryl bromides (e.g. S58b, R = CN, 
and S58e).  The major product in these cases was simply metal-catalyzed protodehalogenation. 
 
 Unwilling to allow his coupling reaction to be limited to electron rich arenes, Gooβen and 
coworkers went back to the drawing board and redesigned their conditions for sterically hindered 
EtO
O
OEt
O X
R
6.6 equiv.
(solvent)
1 mol% Pd/PtBu3
2.8 equiv.K3PO4
0.5 equiv.18-Crown-6
160 °C, 8 h
OEt
OR
OEt
O
OEt
OR
OEt
OEt
OEt
O
S
OEt
O
S58a
X = Cl,  83%
X = Br, 87%
X = I, 89%
S58b, (X = Br)
R = OMe, 94%
R = NMe2 96%
R = CN, 15%
(X = Br)
S58c, 94%
(X = Br)
S58d, 88%
(X = Br)
S58e, 15%
Scheme 58. Conditions for arylation/retro-Claisen of electron rich haloarenes and ethyl malonate (Goo!en, 2011)
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and electron poor aromatics.  The employment of a milder base combination (1:1, K-
2CO3:KHCO3) could promote both the arylation and the retro-Claisen cleavage of sterically 
demanding (S59a) and electron deficient substrates (S59b-e).  As an electron deficient aryl 
bromide is added to the malonate, it is understandable that a milder base can promote the retro-
Claisen reaction as the anion generated upon retro-Claisen condensation has added stability. This 
reaction was quite general with various aryl chlorides and bromides (S59b) as well as various 
electron withdrawing functional groups including cyano, nitro, trifluoromethyl and ketone EWG-
groups (e.g. S59b-c) Interestingly, these conditions were shown to nicely promote arylation of 
moderately electron rich aryl bromides, however the milder base combination could not promote 
the retro-Claisen cleavage reaction to any appreciable level (S59f). 
 
 In addition to the aforementioned coupling/retro-Claisen reaction of malonate and aryl 
halides, α-aryl esters can be accessed by the coupling of ethyl acetoacetate with aryl chlorides 
and bromides, as disclosed by de Koning (Scheme 60).117 In these examples, the state of the art 
(at this time) ligand was utilized. Using the tBuMePhos ligand (L1) reported by Fox and 
Buchwald in 2000, the reaction proceeds cleanly and in good yield with aryl bromides and 
chlorides. Regarding the retro-Claisen step, it is mediated by potassium phosphate.  Moreover, 
the rate of retro-Claisen cleavage was seen to correspond with the concentration of phosphate, 
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such that as more tribasic phosphate is added, the more rapid the retro-Claisen reaction becomes. 
Unfortunately, a full scope study was not performed on this useful reaction. 
 Though not classically a “retro-Claisen” reaction as a dibenzyl anion is generated instead 
of an enolate or derivative thereof, the following Pd-catalyzed arylation/C−C cleavage fits nicely 
into this review to show that retro-Claisen C−C cleavage is not necessarily limited to enolates.118 
 
  It was shown by Leadbeater in 2009 that benzylphenones S61a can be arylated in water 
using ligandless PdCl2 (synthesizing intermediate diaryl ketone S61b) and converted into 
diarylmethanes (S61c-k) via retro-Claisen condensation.118 Regarding the aryl bromide coupling 
partner, electron rich (S61c) and poor (S61d) aromatics were compatible. Some ortho-
substitution was allowed on the aryl bromide. For example, 2-napthyl bromide (S61e) was an 
excellent coupling partner, though ortho-methyl substitution (S61f) was not well-tolerated. 
Aromatics containg 1° amines were not compatible coupling partners as shown in the failed 
coupling of the aniline derivative (S61g). Regarding the α-aryl acetophenone S61a, the reaction 
worked best with electron withdrawing substitutions (S61h-j) on the aromatic ring, this further 
stabilizes the anion generated upon retro-Claisen condensation. Conversely, the higher pKa para-
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methyoxy containing benzylphenone (S61k) reacted poorly.  Thus, the limitation does not appear 
to be in the retro-Claisen reaction in this case, but rather the initial Pd-catalyzed arylation. 
Potentially, the increased pKa makes the active enolate more challenging to generate. 
 To conclude this section, there have been some extremely useful transition metal-
catalyzed arylation/retro-Claisen C−C cleavage methods developed leading to α-aryl ketones and 
esters and even diarylmethanes.  This work spans almost 100 years and is still actively being 
researched with major contributions published within the last year.   
 
2.4  Methodologies based on a retro-Claisen condensation/functionalization strategy 
  
 The previous sections have focused on how active methylene nucleophiles can be used as 
a platform for functionalization. Then, one of the carbonyls can be removed by retro-Claisen 
condensation/protonation. This next section will focus on how an acyl transfer event can promote 
further coupling reactions between the in situ generated anion and various electrophiles. 
Currently, there are two main subdivisions of this type of general reaction: acyl 
transfer/elimination and retro-Claisen C−C cleavage as a means to generate discrete carbanions 
for C−X or C−C bond formation. The former subdivision is significantly more researched and 
will be discussed first. 
 
2.4.1. Retro-Claisen condensation(acyl transfer)/elimination 
 
 We will begin our discussion on acyl transfer/elimination with a general outline of the 
reaction (Scheme 62).  The fundamental feature of this reaction is that an internal nucleophile, 
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commonly in a 1,3-relationship with the acyl unit to be transferred, attacks the acyl group 
forming a tetrahedral intermediate S62a (THI).  From here one of two mechanisms can be at play 
to reach the final elimination product S62b. The first possible mechanism is an “E2-like” 
concerted mechanism where the new π-bond forms as the leaving group is released. The second 
possibility involves an “E1cb-like” mechanism, where the acyl group is transferred completely to 
the internal nucleophile, forming a discrete carbanion. Furthermore, this transfer also activates 
the internal nucleophile for elimination. Importantly, both the anion and the leaving group are 
activated in situ for elimination by a single acyl transfer event.   In many of the publications 
about to be described, it is not always clear the exact mechanism of C−C bond fragmentation as 
no mechanistic studies were performed to gain insight into the reaction.  However, like any 
common E2 vs. E1cb mechanistic consideration, it will depend on how stabilizing the electron 
withdrawing (EWG) group is and the energetics of the 4-membered ring intermediate S62a. 
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Though the general reaction outline is well suited for describing most of the reactions in 
this section, we will begin our discussion with an outlier, as it is an early example of acetyl 
transfer/elimination.  In 1945, Nield described an extremely simple, yet ingenious, method to 
prepare α-bromo vinyl ketones starting from a simple starting material, acetyl ethyl pyruvate 
S63a (Scheme 63).119 Reaction of S63a with formaldehyde leads to the aldol product with 
subsequent transesterification to the 5-membered ring. Bromination of the β-diketone followed 
by retro-Claisen elimination (loss of oxalic acid) leads to the desired product S63b. Nield 
reported that the reaction worked well with other aldehydes (e.g. S63c-d) aside from simple 
formaldehyde and could also be used to prepare α-bromoacrylates (S63e).  McMurry later 
utilized this method to prepare α-thio (S63f) and selenyl (S63g) containing vinyl ketones.120 
 
 Alkylation of sp2 carbanions is not a trivial process. Using principles from the reaction 
designed by Nield above, Baraldi has designed various sp2 carbanion synthons derived from a 
Michael-Dieckman adduct of thioglycolate and α,β-unsaturated ketones and esters (Schemes 64-
65).121,122 For example, by treating methyl acrylate with methyl thioglycolate, a Michael-
Dieckman condensation occurs yielding S64a.  This cycloadduct can undergo mild alkylation 
reactions to S64b. Then, by treatment with dilute KOH, the retro-Dieckman-Michael reaction 
occurs to form the substituted acrylate (S64c-f) in good yields. The retro-Dieckman-Michael 
reaction also regenerates the thioglycolate. Aside from acrylate, other cyclic enones could also 
S
O O
OMe
S
O O
OMe
R O
OMeR
HS
O
OHMichael-Dieckman
simple alkylation
retro-
Dieckman-Michael
K2CO3, RX 5 % KOH (aq)
O
OMe
O
OMe
O
OMeEtO2C
O
OMe
OEt
EtO2CPh
Scheme 64. Preparation of substituted acrylates via alkylation/retro-Dieckman-Michael (Baraldi, 1982)
2-step
yields
S64c, 65% S64d, 63% S64e, 66% S64f, 59%
S64a S64b S64c-f
110 
participate in this reaction sequence (Scheme 65).  Interestingly, the retro-Claisen reaction was 
completely chemoselective for the thioglycolate ketone. 
 
 A major breakthrough in the preparation of mono-carbonyl diazo compounds was the 
realization that they could be prepared by an acetyl cleavage approach (Scheme 66).123-125 Of 
course, the challenge of direct diazo formation of a monocarbonyl derivative is the heightened 
pKa in comparison to a β-dicarbonyl compound.  It was reported in the 1960’s that reaction of an 
α-alkyl-β-formylketone S66a with a sulfonyl azide in the presence of base leads directly to the 
monocarbonyl-diazo compound S66b.  The reaction mechanism of this transformation is as 
follows: nucleophilic attack of the β-formylketone ketone on the mesyl azide allows for C−N 
bond formation. The nucleophilic azide cyclizes onto the aldehyde to form an intermediary 
triazole.  1,4-formyl transfer/elimination then provides the diazo ketone and the sulfonyl 
formamide byproduct.  This is a major area of research due to the utility of diazo compounds, 
and important developments have been made by Hendrickson,123 Doyle,126,127  Taber, 125 and 
Danheiser.128 History has shown that the formyl transfer agent works reasonably well,123 
however, Danheiser improved this method by introducing the use of trifluoroacetyl as a more 
effective transfer agent (S66d).128 Other notable cleavable substrates are the oxalyl124 (S66c) and 
benzoyl group127 (S66e) containing ketone substrates.  
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 Commonly, reactions of β-trifluoroacetyl ketones (S66d) go smoother and in higher yield 
than their formyl-derived analogs due to the increased electrophilicity of the transferring ketone. 
For comparison purposes, Danheiser ran a series of contrast studies (Scheme 67).128 For 
example, α-tetralone S67a and Wieland-Miescher S67b diazo complexes were formed in 
noticeably better yields starting from the trifluoroacetyl analog.  However, sometimes the 
cleaving groups worked comparably well as in the example of the tert-butylcyclohexanone S67c. 
 
 In a rather interesting example, Taber and coworkers demonstrated that benzoylacetone 
derivatives underwent chemoselective cleavage at the phenyl ketone; an unexpected results since 
an acetyl is more electrophilic than a benzoyl group.127 Nonetheless, unsymmetric 
benzoylacetone derivatives S68a could be converted into useful diazo ketone derivatives S68b-e. 
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 In a conceptually similar reaction, formal aldol condensation products can be made in a 
mild fashion from β-formyl ketones and analogs thereof (S69a-d) via aldol, 1,3-formyl 
transfer/elimination to the desired product S69e (Scheme 69).120,129-131  Pioneering work on this 
reaction was done in the 1970’s by McMurry120 (S69a) and Ueno129 (S69bb). A significant 
improvement was published just last year by Colby and coworkers utilizing “trifluoroacetate 
release” as a strategy (S69d).131  The deacylative (Ueno) and “trifluoroacetate release” strategy 
(Colby) go by the general mechanism shown in Scheme 69. However the deoxalylative strategy 
by McMurry is slightly unique (Scheme 70).   
 
 Regarding the seminal deoxalylative strategy described by McMurry,120 the initial aldol 
condensation first leads to a 5-membered carbocycle S70a (Scheme 70) as described in the work 
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by Nield (Scheme 63).119 Addition of aqueous base then allows for facile retro-
Claisen/elimination transformation into the desired α,β-unsaturated carbonyl product S70b-g.  
This reaction worked best with formaldehyde as the aldol coupling partner, though other 
aldehydes could be utilized to form product in noticeably lower yield (e.g. S70c). 
 
 Colby’s contribution to this reaction was quite significant as it allows for a much more 
general and high yielding synthesis of the desired exomethylene ketones (Scheme 71).131 This 
improvement is analogous with Danheiser’s contribution to diazo ketone synthesis (Scheme 
67).128  Similar to the Danheiser publication, Colby performed a contrast study to show that 1,3-
trifluoroacetyl transfer is more effective than analogous formyl transfer.  For example, the 
trifluoroacetate release strategy was noticeably more effective than the deformylation strategy at 
installing exomethylene functional groups on ketone containing naturals S71a-c.  For example, 
sclareolide S71a, a steroid derivative S71b, and on the eburnamonine S71c were all 
functionalized in reasonable yield. Considering that there is an adjacent quaternary center on the 
eburnamonine scaffold, the 26% yield of exomethyleneylated natural product is quite impressive. 
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 In 1999, Rainier utilized a similar reaction for the preparation of cis-disubstituted 
cyclopentanoid structures (Scheme 72).132 Notably, he performed the aldol reaction with alkyl 
and aryl aldehydes, previous examples discussed mostly focused on formaldehyde as the aldol 
coupling partner. Moreover, he utilized a facile Diels-Alder cycloaddition to construct the β-
dicarbonyl compounds that undergoes the 1,3-acyl transfer/elimination. 
 
 Yamamoto and coworkers performed a C−N bond formation on β-ketoesters followed by 
in situ 1,3-acyl transfer/elimination to construct highly functionalized α-imino (or keto upon 
hydrolysis) esters (Scheme 73).133 This cleavage/elimination reaction occured with complete 
X
O
CO2Et
X
O
CO2Et
X
O
X
CO2H
EtO2C
R3
aldol
THI 1,3-acyl transfer
/eliminationR
1
R2
R3
O
R2
R1
O
CO2Me
EtO2C
OMe
O
CO2Me
EtO2C
iPr
OMe
Ph
O
CO2Me
EtO2C
Ph
O
CO2Me
EtO2C
iPr
CO2Me
EtO2C
Ph
CO2Me
EtO2C
iPr
91% yield
E:Z 1:0
91% yield
E:Z 3:1
83% yield
E:Z 0:1
78% yield
E:Z 0:1
56% yield
E:Z 3:1
45% yield
E:Z 1:2
Scheme 72.  Aldol/1,2-acyl transfer elimination (Rainier, 1999)
CO2Et
O
RRO
Diels-Alder
O
CO2Et
O
N Ph
O
N
O
Ph
CO2Et
NaH, THF N
OO
CO2Et
Ph
NHO
O
CO2Et
Ph
1,3-acyl transfer
/elimination
optional
hydrolysis
OHO
O
CO2Et
(  )n
R
(  )n
R
(  )n
R
NHO
O
CO2Et
Ph
OHO
O
CO2Et
O
HO
O
CO2Et
from carvone derivative
HO2C
O
CO2Et
O
CO2Me
O
HO2C
from cyclohexanone derivative
from camphor derivative from cyclooctanone derivative
quantitative yields, no chromatography required
Scheme 73. Nitrosobenzene initiated 1,3-acyl transfer/elimination (Yamamoto, 2008)
(-NH2Ph)
S73a S73b S73c
S73d S73e
115 
efficiency in almost all disclosed results.  In addition to being able to cleave cyclic β-ketoesters 
(S73a,e), this cleavage strategy could be used to fragment ketone containing natural products 
such as carvone S73c and camphor S73d. 
 The final 2-examples in this section involve Cu-catalyzed arylation/retro-Claisen 
elimination to make aromatic compounds (Schemes 74-75).134,135   Ma reported the coupling of 
N-trifluoroacetyl ortho-iodoaniline with acetoacetic esters producing to 2-
trifluoromethylindoles.134 In this process, the Ullman-type arylation occurs first. The α-aryl 
acetoacetate anion S74a then adds into the trifluoromethylacetyl group. Acetyl 
transfer/elimination then produces the desired indole product S74b. The reaction was generally 
acceptable of various electronic and substitution patterns on the aniline derivative (S74b).  
Furthermore, various alkyl acetoacetates were utilized (S74c). 
 
 Based on the method first reported by Hurtley and fully developed by McKillop, Xi 
reported the preparation of isocoumarins from ortho-bromobenzoic acids and β-diketones via 
arylation/acyl transfer/elimination (Scheme 75).135 The reaction mechanism is as follows: 
Following Cu-catalyzed arylation, the carboxylate attacks into the ketone giving intermediate 
S75a. Acyl transfer/elimination produces the isocoumarin S75b.  Regarding the scope, various β-
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diketones (S75b) were compatible nucleophiles and various substitution patterns on the 
bromobenzoate were generally acceptable (S75c). 
 
 
2.4.2. Functionalization/retro-Claisen condensation/functionalization 
  
 The final section of this review will focus on how a retro-Claisen C−C cleavage event 
can prepare an anion that can be captured with other nucleophiles in a single-pot, thus making a 
new C−C or C−X bond.  Thus, an α-EWG ketone can function as a differentiated trinucleophile 
(Scheme 76). This is a relatively unexplored area of research. Furthermore, in the next chapter of 
this dissertation, will be presented our work in this field: deacylative allylation (DaA), where 
both nucleophile and allylic acetate electrophile are prepared in situ by retro-Claisen reaction and 
coupled together via Pd-catalysis.88,136,137 
 
 It is not surprising that the earliest examples of this type of reactivity were first 
discovered with α-nitroketones.  Recall from section 2.2.5 that the retro-Claisen condensation of 
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O
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α-nitroketones is an extremely mild C−C cleavage reaction. Furthermore, the nitronate anion is 
an excellent nucleophile. As reported by Klager71 and Feuer,72 α,α-dinitro ketones can absorb 4 
equivalents of bromine leading to 1,1,4,4-dibromo-1,4-dinitrobutanes (n = 1) and derivatives 
thereof (Scheme 77). In this process an initial dibromination (2 equivalents) occurs to the fully 
substituted cyclopentanone. By retro-Claisen/decarboxylation 2-new anions are formed for 
further bromination (2 equivalents). This reaction worked well with various cyclic ketones 
including cyclopentanone and hexanone. In Feuer’s article, the reaction was extended to mono-
nitrated ketones, for example, of 2-nitro-α-tetralone S78a (Scheme 78).72 
 
 In addition to these seminal publications, Ballini developed a similar approach that not 
only allows retro-Claisen bromination (S79a), but a method for retro-Claisen chlorination (S79b-
c) as well (Scheme 79).138 Though most examples were performed with α-nitrocyclohexanone 
(S79a-b,d), 2-nitro-α-tetralone (S79c) could also utilized. Furthermore, Ballini also 
demonstrated that the reaction was not limited to the synthesis of dihaloalkanes: by alkylating 
(e.g. with methyl vinyl ketone) the α-nitroketone and then performing a retro-Claisen 
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chlorination, chiral and multi-functional nitroalkanes (S79d) could be produced. Importantly, 
this represents the first example where the formal “dianion” is differentiated as the α-nitroketone 
is utilized in 2 distinct C−C and C−X bond formations. 
 
 Quite recently, a retro-Claisen halogenation protocol on in situ generated α,α-difluoro 
enolate anions was reported by Colby (Scheme 80).  This process utilizes “trifluoroacetate 
release” (a specific type of retro-Claisen condensation) as a unique method to generate otherwise 
challenging to generate, α,α-difluoro enolate anions S80a. His approach allows for halogenation 
(bromination S80b, iodination S80c-d and chlorination S80e-f) of difluoro acetophenone 
derivatives. Iodination of α,α-difluoro acetone derivative S80d was successful as was 
chlorination (S80f), however, in the chlorination attempts, over-chlorination of both α- and α’-
positions occurred without control. 
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 In addition to retro-Claisen condensation/halogenation protocols, retro-Claisen 
condensation/C−C bond formation began appearing in late 2010139 and early 2011.88,91,136,140 The 
first examples utilized α-nitroketones as the retro-Claisen substrate of choice.88,136,139,140 This is 
not surprising as α-nitroketone retro-Claisen condensation is extremely mild and nitronate anions 
are excellent nucleophiles.  
 
 To the best of our knowledge, Menéndez and coworkers reported the first retro-Claisen 
C−C cleavage/C−C bond forming reaction (Scheme 81). They utilized cyclic nitroketones S81a 
as differentiated dianion equivalents to couple with dielectrophiles (phthalaldehyde derivatives 
S81b) via Henry reaction, retro-Claisen condensation and a second Henry reaction leading to the 
functionalized indane derivatives S81c-e.  Within the parameters tested (cyclic nitroketones and 
phthalaldehyde derivatives), the reaction was generally good yielding over the 1-pot, 3-step 
sequence with reasonable diastereoselectivities (>3:1 dr). 
 Cyclic and acyclic α-nitroketones (and other α-EWG-ketones) have also been used as 
differentiated dianion equivalents in Pd-catalyzed bisallyation leading to useful 1,6-heptadienes.  
This research was reported by us and will be discussed thoroughly in the next chapter of this 
dissertation. 
 Trifluoroacetate release is an effective method for the generation of α,α-difluoro enolate 
anions, as previously shown in Scheme 80.  These anions can be generated in situ and coupled 
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with aldehydes leading to aldol products (Scheme 82). For example, the in situ generated α,α-
difluoro acetophenone anions can be coupled with aromatic (S82a), α,β-unsaturated (S82b), and 
alaphatic aldehydes (S82c). α,α-Difluoro acetone based anions can also be generated and coupled 
with aldehydes (S82d).  It is important to point out that in this case no α to α’-enolate 
transposition occurred.  Recall from Scheme 80, that chlorination of α,α-difluoro acetone 
derivatives lead to chlorination at both α and α’-positions. 
 
 Though not fully developed, Colby demonstrated that trifluoroacetate release can be used 
to generate other enolates in addition to α,α-difluoro enolates (Scheme 82). α-Bromo enolates 
can be generated via trifluoroacetate release and undergo Darzens reactions leading to epoxide 
S83a as a single diastereomer, though this is the only example disclosed to date. 
 
 As shown throughout this section, retro-Claisen C−C cleavage is an effective technique 
to generate anions that can be utilized to perform further chemical reactions.  Though less 
studied than the first sections of this review, retro-Claisen functionalization methodologies 
include eliminations (via acyl transfer/elimination) and C−X and C−C bond forming reactions.   
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2.5 Conclusions 
 
 As shown throughout this review, the retro-Claisen reaction can be used strategically in 
conjunction with various C−C or C−X bond forming reactions to rapidly construct chemical 
building blocks. The first section of this review focused on how β-dicarbonyl compounds (active 
methylene nuclephiles) can be utilized to perform mild α-substitution reactions. Then, one of the 
carbonyl groups can be removed by retro-Claisen condensation to reveal the monocarbonyl 
chemical building block. The ketone, in this case, is used as a readily available activating and 
cleaving group. The final sections of this review demonstrated how a retro-Claisen reaction can 
promote further chemical reaction besides simple protonation, as a new carbanion is formed.  
This is a powerful, yet currently under utilized strategy for the construction of useful chemical 
compounds.  Currently, methods for retro-Claisen/elimination are in the literature where an 
intramolecular acetyl transfer facilitates an elimination reaction.  Also presented were methods 
where the discrete carbanion generated upon retro-Claisen is involved in further C−X or C−C 
bond formation. The field of retro-Claisen/C−C bond formation is a new field of chemistry, with 
first publications appearing in late 2010 and early 2011.  
 We have also published work in the field of retro-Claisen/C−C bond formation: we have 
named our approach to coupling “deacylative (retro-Claisen) allylation.”  Our work will be 
presented in the next chapter of this dissertation.88,136,141 
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Chapter 3. Synthetic studies in retro-Claisen condensation and allylation 
methodologies1-3 
 
3.1 Introduction 
  
 Chapter 2 of this dissertation reviewed the utility of the retro-Claisen condensation to 
synthesize useful monocarbonyl chemical building blocks (Scheme 1).  This approach’s 
attractions include (a) diverse methodologies for α,α-disubstitution of active methylene 
compounds (e.g. simple alkylation, transition metal-catalyzed arylation, or C−X bond forming 
reactions),  (b) commercially/readily available active methylene starting materials, and (c) mild 
C−C cleavage, as α,α-disubstituted active methylenes are unstable in the presence of 
nucleophiles (such as alkoxide) and undergo retro-Claisen condensation. 
 
 In the final sections of chapter 2, we outlined how retro-Claisen can be utilized to 
promote further C−X or C−C bond forming reactions (Scheme 2). Essentially, this approach 
allows an α-EWG ketone S2a to be functionalized selectively up to 3-different times (twice as 
the active methylene nucleophile and again by retro-Claisen functionalization) leading to the 
quaternary compound S2b. Retro-Claisen C−C bond formation is a new field of research (first 
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publications in late 2010 and early 2011) that holds much potential as it can generate α-EWG 
stabilized carbanions in situ for coupling. As shown in Scheme 3, other approaches to the 
generation of these types of nucleophilic coupling partners include (a) deprotonation (S3a) (b) 
decarboxylation (S3b)  (c) and “Reformatsky-like” (oxidative) methods (S3c). 
 
 The 3rd chapter of this dissertation will focus on our contributions to the field of retro-
Claisen C−C cleavage chemistry. Namely, the amalgamation of retro-Claisen condensation and 
palladium-catalyzed allylic alkylation methodologies, the latter has been a central theme of the 
Tunge research lab since its beginnings.4-20 We have developed allylation/retro-Claisen methods 
that resemble the general reaction outlined in Scheme 1, where a ketone is simply used as an 
activating/cleaving group that can be replaced with a proton. However, the bulk of the work 
about to be presented in this chapter is unique and involves the in situ formation of both 
nucleophilic and electrophilic coupling partners initiated by a retro-Claisen condensation event 
(Scheme 4). These intermediates are then coupled back together, synthesizing a quaternary 
carbon. 
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3.2 Tsuji-Trost allylation/retro-Claisen reactions1 
 
 2° allylated nitroalkanes are useful synthetic building blocks.21-28 As shown in chapter 1 
and summarized in Scheme 5, we were able to efficiently convert nitroalkane S5a into the 
indolizidine core (S5b) rapidly.29 S5a was prepared by a 2-step, 1-pot Tsuji-Trost 
decarboxylative protonation strategy from prenyl nitroacetate. Benefits to our approach include 
simple Michael addition from prenyl α-nitroacetate and the 2-step 1-pot allylation and in situ 
removal of the prenyl carboxylate via Pd catalyzed decarboxylative protonation. Throughout this 
sequence, reactants were utilized in equimolar fashion, which is uncommon in the preparation of 
2° nitroalkanes due to challenges from over alkylations.21-28 For example, other approaches to 2° 
allylated nitroalkanes by Tsuji-Trost reaction use excess (commonly 3-10 equiv.) of the 1° 
nitroalkane starting material.21-28 This approach is acceptable when the 1° nitroalkane is 
inexpensive and commercially available, although it does produce extra waste. However, the use 
of excess nitroalkane is undesirable when the nitroalkane to be allylated is precious. 
 
 Though content with our approach to 2° allylated nitroalkanes, there were some 
challenges. First, the conditions for Tsuji-Trost/decarboxylative protonation were somewhat 
tedious, requiring cooling of the reaction mixture to -40 °C for the Tsuji-Trost allylation. If this 
was not done properly, often complex mixtures were isolated. Next, though waste was benign, 
the prenyl carboxylate group consisted of 8 atoms that did not get incorporated into the chemical 
building block. From an atom economy perspective, this is unattractive.30 
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O
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O
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Scheme 5. Synthesis of useful amines from prenyl nitroacetete
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 As α-nitroketones are readily available31-34 and undergo retro-Claisen condensation to the 
nitroalkane, we wondered if an allylation/retro-Claisen strategy could produce 2° allylated 
nitroalkanes with increased ease (Scheme 6). What we found most attractive about this approach 
was that the highly reactive (to Pd) prenyl carboxylate was now removed from the molecule, yet 
the increased reactivity toward alkylation was retained, as nitroketones are also active 
methylenes (Scheme 7). Thus, after Pd-catalyzed allylation to disubstituted α-nitroacetone S6a 
and retro-Claisen condensation, analogous 2° allylated nitroalkanes (S6b) should be able to be 
produced with added simplicity.  Finally, little waste byproduct will be produced as substrates 
are used in equimolar fashion and the retro-Claisen condensation only produces acetate. 
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 We were pleased to find that our hypothesis proved true (Scheme 8). By allowing acyclic 
or cyclic α-nitroketones S8a-c to react with an equivalent of an allylic carbonate in the presence 
of palladium and 5 equiv. of MeOH, various 2° allylated nitroalkanes could be produced (S8d-
g). Regarding the allyl carbonate, simple (S8f-g) and terminally substituted (S8d-e) allylic 
systems were compatible.  By utilizing the cyclic ketones, 2° allylated nitroalkanes with pendant 
methyl esters could be obtained. 
 In addition to the Pd-catalyzed allylation of nitroalkanes, we thought it would be useful to 
extend this methodology to the allylation of ketones producing tertiary centers.  As ketones have 
a relatively high pKa (DMSO pKa ~25), palladium-catalyzed allylation commonly requires the 
use of strong bases (e.g. LDA or LiHMDS) and tedious reaction conditions (additives, cryogenic 
temperatures, etc.).35-46 Other approaches to the Pd-catalyzed allylation of ketones involve using 
trapped enolates (e.g. silyl enol ethers)47-50 or the decarboxylative allylation method.47,51-56 
However, in all of the above mentioned methods, over-allylation can often be an issue, so tertiary 
centers are considered more challenging to prepare than a quaternary center. With that said, 
branch-selective (or 1,3-disubstituted) monoallylation of ketones can occur.36,39,48,50,51 In general, 
simple allyl (no branching) inclusion is best suited for the synthesis of quaternary centers, though 
some methods do allow for the preparation of allylated tertiary centers.41,44-46 Another approach 
to allylation of enolates producing 2° allylated ketones is the combined transition metal/amine 
catalysis (enamine formation) method.57,58 Unfortunately, this approach requires excess of the 
ketone in order to achieve monoallylation. 
 Inspired by the Wilds-Woodward modification of the Robinson annulation (see chapter 
2), we have demonstrated that simple Claisen condensation with ethyl formate allows a Tsuji-
Trost allylation/retro-Claisen condensation reaction sequence to occur. Using this approach, 
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selective monoallylation of various ketone based chemical entities can be achieved under mild 
and simple reaction conditions using equimolar substrate ratios. The conditions are as follows: in 
the presence of Pd(0), the salt of the β-formyl ketone S9a is prepared in THF using an equivalent 
of NaH. Then, an equivalent of allyl acetate is added at room temperature and allowed to stir 
until complete consumption of starting material is observed by TLC (0.5-1h). The intermediate 
S9b undergoes retro-Claisen protonation to the desired products S9c-g upon the addition of 
dilute KOH in methanol. Using this straightforward procedure, simple ketones, such as the aldol 
condensation adduct (S9c) or the 3-ethoxy cyclohexene (S9d) could be monoallylated without 
complications.  Derived from a Wilds-Woodward reaction on α-tetralone, allylated product S9e 
could be prepared by this method in good yield and diastereoselectivity. Although S9e was 
isolated as a single diastereomer, the crude NMR did show ~4:1 dr.  This reaction sequence was 
also compatible on natural products. For example, plugone (S9f) and cholestenone (S9g) could 
be allylated in good yield with modest to excellent diastereoselectivity.  This project is still being 
investigated and thus, some information is not currently known about these compounds, such as 
the relative stereochemistry of the diastereomers.  However, this is actively being researched and 
will be reported in due course along with similar studies on branched selective allylation/retro-
Claisen, where the retro-Claisen protonation can resolve poorly diastereoselective branched 
allylation (Scheme 10). 
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3.3 Deacylative allylation (DaA): Pd catalyzed allylic alkylation via retro-Claisen1-3 
 
 The retro-Claisen condensation step in the above mentioned methodologies is promoted 
by methanol, which generates methyl acetate (or formate) as a byproduct.  If the retro-Claisen 
reaction on the pronucleophile S11a were to be promoted by an allylic alcohol S11b, not only 
would a nucleophilic coupling partner be prepared (the carbanion S11c), but, an allylic acetate 
S11d would also be generated in situ, which can be coupled to the carbanion in the presence of 
Pd(0), making a new C−C bond (Scheme 11). We have named this novel approach to allylic 
alkylation “deacylative allylation (DaA).” 
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 There are many potential benefits that the DaA approach to Pd-catalyzed allylic 
alkylation can offer (Scheme 11). First, the DaA substrate synthesis begins from inexpensive and 
commercially/readily available β-dicarbonyl compounds (and similar compounds, e.g. 
cyanoacetic esters or α-nitroketone). Second, diverse substitution reactions that have been 
developed for such active methylene compounds (simple alkylations, Pd59-64/Cu65-72 arylations, 
Tsuji-Trost allylation,73-75 etc.) can be used for α,α-disubstitution.  Third, coupling occurs 
directly from allylic alcohols: there are many commercially/readily available allylic alcohols and 
their direct application in synthesis is highly desired due to their availability and reduced toxicity 
(compared to allyl halides). Other approaches to the allylic alkylation using allyl alcohols usually 
require Lewis acid additives or acidic conditions.76 Furthermore, due to the intermolecularity of 
the proposed DaA transformation, many different allylic systems can be introduced onto a 
scaffold at a late stage, which is ideal for “library” diversification and analog synthesis.  Finally, 
the only byproduct of this transformation will be acetate salt, an environmentally benign 
material. 
 The DaA reaction hypothesis has many similarities to decarboxylative allylation (DcA), 
another contemporary approach to catalytic allyaltion.56 DcA is an extremely useful reaction that 
has garnered much attention from the synthetic community,47,51-56,77-83 including contributions 
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from our own lab.4-20 The reaction has much breadth and asymmetric variants have been 
developed too.56  Importantly, the reaction has seen much utility in total synthesis.56,84-89 To 
compare these two methods, both DaA and DcA access similar scaffolds: quaternary allylated 
nucleophiles. Also, coupling partners are generated in situ, in the case of DcA, by 
decarboxylation (DaA by retro-Claisen condensation). Furthermore, the reactions are similarly 
“green” as the only byproduct in DcA is carbon dioxide (DaA generates acetate).  Where DaA 
can improve on the DcA method is in the intermolecularity of the transformation and the direct 
coupling of allyl alcohols and readily available acetyl pronucleophiles (Scheme 11). In the realm 
of totally synthesis, the DcA approach often requires introduction of the allyl carboxylate moiety 
at a late-stage by transesterification85,86 or allyl enol carbonate formation,55,84,87,89 both of which 
add an extra synthetic manipulation into the total step count. 
 In the first chapter of this dissertation, I outlined how it might be challenging to perform 
Pd-catalyzed arylations90 or Tsuij-Trost allylations91 on allyl nitroacetate S12a, a DcA substrate, 
due to competing sites for Pd oxidative addition (Scheme 12).  We even attempted, with little 
success, to perform such a Tsuji-Trost reaction. Interestingly, with substrate S12a, an allylation 
using allyl methyl carbonate occurred followed by DcA reaction to the 1,6-heptadiene S12b.92 
We were intrigued by this reaction sequence as it efficiently prepared a 1,6-heptadienes in a 
single pot. 1,6-heptadienes are extremely useful and well-studied substrates for 
cycloisomerization reactions, although most studies involve simpler substrates derived from 
active methylenes, amines or ethers.93-97 Unfortunately, in our hands, substrate S12a was the 
only substrate we could perform the Tsuij-Trost/DcA sequence on. Furthermore, a search of the 
literature yielded a single example of 3-component bisallylation via Tsuji-Trost/DcA.98 This 
reaction sequence is challenging because it requires a delicate balance of reactivity: the 
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palladium catalyst must first perform oxidative addition of the allyl carbonate over the allyl 
nitroacetate (Scheme 12).  Though allylic carbonates are usually more reactive than allyl 
acetate,99 we could not extend this methodology to other substrates as complex mixtures of 
bisallylated nitroalkanes were isolated. 
 
 With the challenges of one-pot Tsuji-Trost/DcA bisallylation outlined, we began 
contemplating surrogate procedures and substrates where the highly reactive allyl carboxylate is 
removed from the active methylene nitroacetate, yet an unsymmetric bisallylation can still occur 
leading to useful and unique 1,6-heptadienes. Our hypothesis, outlined in Scheme 13, involves 
Tsuji-Trost and the newly devised deacylative (retro-Claisen) allylation (Scheme 11).  
 
 
3.3.1 The development of deacylative allylation (DaA) reactions: DaA of α-nitroketones1 
 
 Similar to the Tsuji-Trost allylation/retro-Claisen condensation of α-nitroketones already 
presented in Scheme 8, we were pleased to find that, under methanol-free conditions, allylated α-
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nitroketone S13a could easily be isolated. Thus, we have identified a simple substrate for Tsuji-
Trost allylation that bears a cleavable ketone.  Though the crude NMR was quite pure, we did 
notice a slightly reduced yield of 70% upon gram scale synthesis, presumably due the volatility 
of this low molecular weight molecule. 
 
 Having shown that the initial Tsuji-Trost is simple, we next turned to the development of 
the DaA reaction, which would furnish the desired 1,6-heptadiene (Scheme 14).  Using 5 equiv. 
of both K2CO3 and allyl alcohol in the presence of a catalytic amount of Pd(PPh3)4 our 
deacylative allylation hypothesis was realized, as S14a was isolated in 99% yield (Scheme 14, 
footnote a). Unfortunately, the equivalents of allyl alcohol could not be reduced and other allylic 
alcohols could not be utilized with this method.   Excitingly, using Cs2CO3 and a catalytic 
amount of Pd(PPh3)4, we did indeed isolated high yields of the desired deacylative allylation 
product with a variety of allylic alcohols in equimolar fashion (1 equiv. nitroketone, 1.1 equiv 
allyl alcohol, 1 equiv. Cs2CO3). Various commercially available allylic alcohols were viable 
coupling partners. For example simple allyl (S14a), cinnamyl (S14b), hexenyl (S14c), crotyl 
(S14d) and β-methylallyl (S14e) alcohol could all be coupled in good to excellent yield. Except 
in the case of crotyl alcohol, the allylation was completely selective for the linear product (> 20:1 
dr), which is expected with a palladium catalyst. Regarding the cinnamylated product S14b, a 10 
mol% catalyst loading was required to avoid problematic Hass-Bender oxidation.100-102 In 
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addition to the commercially available allylic alcohols, we prepared a dienyl allyl alcohol and 
utilized it in the DaA reaction (S14f). S14f could, hypothetically, be utilized in metal-catalyzed 
[4+2] reactions leading to structurally interesting fused ring systems.103-113 
 Although the DaA reaction of α,α-disubstituted nitroketones is quite facile with 1° allyl 
alcohols, we found it challenging to promote the reaction with a 2° allyl alcohol (Scheme 15). 
Under the same reaction conditions utilized to couple 1° allylic alcohols cleanly, a 2° allyl 
alcohol S15a only underwent the reaction to ~25% conversion. Thus, there appears to be a steric 
limitation in the retro-Claisen step of this synthetic sequence. 
 
 This 2-step Tsuji-Trost/DaA surrogate procedure has much more breadth compared to 
our original approach to nitro-containing 1,6-heptadienes, namely, the Tsuji-Trost/DcA attempt. 
The success of this approach stems from the use of nitroketones as opposed to reactive allyl 
nitroacetates, allowing simplified α,α-disubstitution by Pd catalyzed Tsuji-Trost allylation. In a 
second Pd-catalyzed event, the novel DaA reaction adds a second allyl equivalent to furnish the 
unsymmetric 1,6-heptadienes. Intrigued by this new approach to Pd-catalyzed allylic alkylation, 
we next investigated the scope of this reaction with various active methylene compounds. The 
next sections of this chapter will focus on other types of ketone pronucleophiles (α,α-
disubstituted active methylene substrates) that can participate in the DaA reaction. 
 As both Tsuji-Trost and DaA allylic alkylation events utilize Pd, the final section of 
Chapter 3 will focus on 1-pot 3-component bisallylation leading to 1,6-heptadienes, thus fully 
achieving an improved 1-pot surrogate procedure for our initial hypothesis (Tsuji-Trost/DcA). 
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3.3.2 DaA of β-diketones: generation and allylation of enolate anions including an 
asymmetric variant2,3 
 
 
 The success of the DaA reaction of α,α-disubstituted nitroketones is, in large, due to the 
facile retro-Claisen reaction of these starting materials: retro-Claisen reaction is facile due to the 
high stability of the nitronate anion that is generated in situ (DMSO pKa nitroalkane ~ 17).  We 
reasoned that other highly stabilized ketone pronucleophiles could also be viable coupling 
partners (Scheme 16). We began improving our scope by studying the DaA reaction of α-allyl-α-
aryl acetylacetone derivatives S16a.  Importantly, these substrates are readily available by an 
attractive synthetic sequence: Cu-catalyzed arylation65,66 and Pd-catalyzed Tsuji-Trost 
allylation.73,74 We were pleased to see that the para-nitrophenyl derivative (S16b-e) could be 
coupled with similar scope to the nitroacetate derivatives disclosed above.  The less electron 
withdrawing para-ketophenyl derivative could be coupled with allyl alcohol in good yield 
(S16f). Unfortunately, other alcohols with this substrate lead to complex mixtures. Furthermore, 
the limit of these conditions was met upon removing all electron withdrawing functionality from 
the phenyl ring (S16g). The major product in this case resulted from protonation.  Thus, under 
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Cs2CO3/allyl alcohol promoted retro-Claisen conditions, Pd-catalyzed allylation requires a 
stabilized anion with pKa < 20 (DMSO pKa). 
 
 As an unsatisfactory yield of the allylated phenyl acetone S16g was isolated under the 
Cs2CO3/allyl alcohol DaA conditions (Scheme 16), we decided to optimize the DaA reaction for 
this product (Scheme 17). Starting from phenylacetylacetone derivative S17a, we screened 
different solvents and bases to increase the yield of S17b (S17b = S16g). Using Cs2CO3 as the 
base, various nonpolar solvents poorly promoted the desired coupling reaction (Scheme 17, 
entries 1-3). However, 2e were delighted to see that the combination of Cs2CO3 and a polar 
aprotic solvent favored the desired product (entries 4-7). The best results were obtained when 
strong bases (such at tBuOK or NaH) were utilized in various solvents. As a complete 
deprotonation of allyl alcohol occurs when NaH is utilized, there are hypothetically no protons in 
solution, thus after retro-Claisen condensation, there is no chance of enolate protonation to the 
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undesired byproduct. Furthermore, under these conditions, retro-Claisen condensation occurred 
rapid, with alkoxide induced C−C cleavage complete in <1 min, as witnessed by TLC. 
 
 With our improved procedure in hand, we next tested the scope of the DaA reaction for 
the α-aryl acetylacetone derivatives (Scheme 18, S18a-q). The simple phenyl substituted 
substrate performed well with various commercially available allylic alcohols (S18a-d). Not 
surprisingly, electron withdrawing group containing substrates were excellent substrates (S18e-
p). Furthermore, para- and meta-substitution patterns are well tolerated throughout this scope 
study.  Though we mostly utilized commercially available allylic alcohols (e.g. allyl, cinnamyl, 
hexenyl, β-methylallyl), we were pleased to see that the cyclopropyl allyl alcohol was a viable 
coupling partner (S18k).  This product is a unique metal catalyzed [5+2] precursor substrate.114-
121 Though we were particularly interested in the synthesis of 1,6-dienes, as Tsuji-Trost/DaA is a 
unique avenue for their preparation, we could also quaternize the α-aryl acetylacetone derivative 
by simple alkylation and perform the DaA reaction (S18e,f,l,m). Finally, we were particularly 
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gratified that an electron rich α-aryl acetylacetone derivative could participate in DaA (S18q). 
The enolate generated by retro-Claisen in this case has an even higher pKa than what the reaction 
was developed for. 
 
 Interestingly, the benzoylacetone derivative S19a did not undergo selective retro-Claisen 
condensation. Rather a mixture of products was isolated corresponding to both benzoyl cleavage 
(S19b) and acetyl cleavage (S19c). However, a selective DaA reaction was observed for α-
acetyl-α-allyl-β-tetralone S20a. Various 1,6-heptadienes could be prepared in excellent yield 
from β-tetralone by Claisen condensation,31 Tsuji-Trost allylation, and DaA (Scheme 20). In 
addition to the previously studied allyl alcohols (S20b-f) we were even able to incorporate a 
prenyl motif by DaA reaction (S20g).  In general, Pd-catalyzed prenylation can be challenging 
due to β-elimination forming isoprene.56 
 As stated previously, we were particularly gratified by the successful DaA reaction on the 
para-methoxyphenyl acetylacetone substrate due to the increased pKa of the enolate generated 
upon retro-Claisen condensation (Scheme 18, S18q).  Furthermore, we were intrigued by the 
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chemoselective retro-Claisen condensation observed for the β-tetralone series of substrates 
(Scheme 20). With these results, we felt confidant that a DaA reaction of α-tetralone would be 
possible (Scheme 21, S21a è S21c).  However, we did envision this to be more challenging as 
the pKa of α-tetralone is relatively high (DMSO pKa = 25) compared to all the other substrates 
examined thus far (e.g. DMSO pKa for nitronates = 17, α-aryl acetone = 20).  Importantly, the 
allylation of α-tetralone is a useful reaction and asymmetric variants exist in the literature.47,52,54 
For example, Clive122,123 and Stoltz89 have shown that allylated tetralone S21d can be converted 
rapidly into hamigeran, a biologically active natural product (Scheme 21).  Stoltz’s approach 
allows for the key quaternary stereocenter to be set by an asymmetric DcA reaction using a Pd-
PHOX complex. 
 
 Previous approaches to the asymmetric allylation of tetralones have utilized allyl 
chloroformates (or other allyl phosgene derivatives) as the allylic source (Scheme 21, top). 
Compared to the reagents for allylation via the proposed retro-Claisen method (Ac2O and allyl 
alcohol, Scheme 21, bottom), allyl chloroformates (or allyl phosgene derivatives) are more toxic 
and expensive.  In our approach, following the reported procedures for Claisen condensation of 
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tetralones,124,125 we envisioned being able to utilize the β-diketone to perform diverse and mild 
alkylation reactions followed by a stereoconvergent asymmetric retro-Claisen allylation. 
 
 Before attempting such an asymmetric DaA transformation, we thought it would be 
useful to confirm that the racemic DaA reaction of α-tetralone derivatives was feasible, as this 
reaction has not been investigated. To begin our retro-Claisen allylation studies, we first 
performed a high yielding two-step Claisen condensation/methylation of α-tetralone with formyl 
acetate (22a) acetic anhydride (22b) and propionic anhydride (22c).  With substrates 22a-c in 
hand, the nature of the cleaving group on the Pd-catalyzed allylation reaction could be examined 
(Scheme 22, S22a-c è S22d).  We found that 2 equivalents of NaH gave the best results. 
Potentially, an excess of NaH is required to react with any unaccounted for proton sources from 
the THF solvent or elsewhere that could increase the yield of the undesired protonation 
byproduct (prot). Regarding the formyl substituted reactant S22a, using the monodentate ligated 
Pd(PPh3)4 catalyst, a 75:25 mixture of the desired product S22d and the protonation byproduct 
(prot) was isolated.  Utilizing the bidentate ligated Pd-complex (Pd-BINAP, entry 2), this ratio 
could be changed to favor the allylated product S22d (89:11 S22d:prot). The increased 
byproduct formation in entry 1 compared to entry 2 could possibly be due to a well known, albeit 
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undesired (in this case) side reaction: Pd-catalyzed allylic reduction by formate ion. This reaction 
prefers monodentate ligated palladium complexes as an extra coordination-site is required to 
accommodate the formate ion.126-131 Using the acetyl tetralone derivative S22b, the reaction went 
cleanly to the desired product in a 90% isolated yield using Pd(PPh3)4 as a catalyst.  The 
propanoyl substituted tetralone S22c was similarly effective (95% yield). 
 
 Having established our method for DaA reaction of the α-tetralone core, we next probed 
the scope of this reaction. We were pleased to see that various simple (S23c) and β-substituted 
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(S23d-e) allylic alcohols were viable coupling partners. Furthermore, other functional groups can 
be incorporated at the allyl’s β-position, as demonstrated by the coupling of the acrylate derived 
allyl alcohol (S23e). Unfortunately, under these conditions, terminally substituted allylic 
alcohols reacted poorly (S23f).  Though a modest ~50% yield was isolated, the remainder of the 
mass balance was the protonated byproduct, which in all other examples was < 5%. In addition 
to quaternization by methylation of the acetyl tetralone (S23c), starting materials could be 
prepared by Tsuji-Trost allylation and then undergo the DaA reaction to the 1,6-heptadienes 
S23g-n. Utilizing Tsuji-Trost allylation, β-phenylallyl (S23g), and its cinnamyl isomer (S23h) 
could be incorporated onto the tetralone core using their corresponding allyl acetates. A [5+2] 
precursor substrate could be prepared using cyclopropylallyl acetate (S23i) in the Tsuji-Trost 
reaction. Also, the crotyl group could also be installed (S23j) on to the tetralone core. In this 
case, Tsuji-Trost allylation lead to a 4:1 mixture of E-Z crotyl isomers and is carried through the 
DaA reaction. There are a number of natural allylic acetate based terpenes, such as gerenyl 
(S23k) prenyl (S23l-m) and (−)-myrtenyl (S23n) that could also be added via initial Tsuji-Trost 
allylation. Although a minor point, the corresponding bromides (or pseudo halides), which would 
be required to add such a terpene to allyl acetoacetate S24a (the analogous DcA substrate), are 
either more expensive or not commercially available (Scheme 24).  Thus, the DaA approach, as 
it tolerates Tsuji-Trost allylation at the active methylene position, allows for the direct 
incorporation of these important biological building blocks on to a given scaffold without going 
through the unnatural and toxic bromoterpenes. Finally, the tetralone core can be substituted with 
electron withdrawing groups (S23o) or donating groups (S23p-q). They can also be contracted or 
expanded, as in the case of the indanone (s23r) and benzosubarone (S23s) based substrates, 
respectively. Excitingly, preparation of S23q represents a formal racemic total synthesis of 
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hamigeran.  In many of the examples on Scheme 23, we ran the reaction on >0.5 gram scale (2-3 
mmol, ~10x scale up from standard conditions) to demonstrate that useful quantities could be 
prepared using the DaA method. Furthermore, the catalyst loading on these scale-up reactions 
could easily be reduced to 1 mol%, conserving the precious Pd metal. 
 
 Having demonstrated that the DaA reaction of α-tetralones has wide scope, we next 
turned to developing the asymmetric variant (Scheme 25). We were quite pleased to find that the 
commercially available tBuPHOX ligand L1 gave useful ee’s with the various cleaving groups 
(entries 1-3, 80-84% ee). Unfortunately, none of these cleaving groups greatly affected the 
enantioselectivity, Another commercial tBuPHOX ligand L2 also promoted the reaction, 
however with reduced ee (58-62% ee, entries 4-5). We also noticed that excess alkoxide had a 
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negative effective on the enantioselectivity (entry 6). Thus, in all the examples in entries 1-5, and 
in the next Scheme, a slight excess of the tetralone is utilized with respect to the allyl alcohol. 
 As shown in Scheme 26, using the commercially available tBuPHOX L1, or the in-house 
prepared fluorinated variant L3, good to excellent yields (57-88%) and ee’s (73-92% ee) of 1,6-
heptadiene tetralones could be achieved using 2-step Tsuji-Trost/asymmetric DaA. We chose to 
utilize ligand L3 as fluorinated PHOX ligands have been shown (primarily by Stoltz) to be 
excellent at promoting asymmetric allylic alkylation reactions.132-134  The simple tetralone core 
could undergo Tsuji-Trost allylation with various allylic acetates and then undergo asymmetric 
DaA with simple allyl alcohol or β-methylallyl alcohol (26a-c) producing tetralone based 1,6-
heptadienes. Furthermore, the tetralone core could also withstand various electron withdrawing 
and donating substitution patterns (S26d-e).  Due to the nature of the 2-step Tsuji-
Trost/asymmetric DaA transformation, by interconverting the allylic substitution patterns, both 
enantiomers can be prepared in enantioenriched form (e.g. S26a,d,e/ent-S26a,d,e). 
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 To further apply this new asymmetric reaction, we demonstrated that the Clive-Stoltz 
intermediate S27c for the production of (+)-hamigeran could easily be prepared in high yield and 
ee (Scheme 27). Starting from cresol and succinic anhydride, the required tetralone core S27a 
can be prepared by a known procedure.135-137 From here, acetylation with acetic anhydride and 
quaternization with methyl iodide leads to the required starting material S27b.  Using the 
conditions developed for successful asymmetric DaA, the allyl motif can be installed in 93% 
yield and 89% ee.  This result rivals the asymmetric DcA approach utilized by Stoltz where the 
hamigeran precursor was isolated in 99% yield and 92% ee. However, our approach benefits 
from the simplified substrate synthesis via Claisen condensation (Ac2O, BF3 OEt2), mild 
alkylation (K2CO3, MeI), and the direct coupling of allyl alcohol. To expound on the challenges 
of the DcA approach, using Stoltz’s method (which resembled Clive’s method with the exception 
of the allylation step), the α-methyl group was installed using highly basic enolate alkylation in 
the presence of HMPA. The origin of the allyl moiety was from allyl chloroformate, a toxic and 
sensitive phosgene derivative. 
 To conclude, we have thus far demonstrated that, not only can highly stabilized nitronate 
anions (pKa = 17) be generated and allylated by the DaA method (section 3.3), but much less 
stabilized enolates (pKa’s = 20-25) can be generated and participate in this reaction. A plethora 
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of quaternary allylated α-aryl acetones were prepared via Cu-catalyzed arylation, alkylation, and 
DaA reaction starting from the simple and commercially available acetylacetone.  Furthermore, 
over a 2-step Tsuji-Trost/DaA sequence useful 1,6-heptadienes can easily be prepared.  In 
addition to the DaA reaction of α-aryl acetylacetone derivatives, we have demonstrated that 
acetylated (by Claisen condensation) α- and β-tetralones can participate in DaA. The DaA 
reaction generating intermediary α-tetralone enolates has culminated in an asymmetric method 
allowing the synthesis of enantioenriched 1,6-heptadienes as well an important intermediate en 
route to (+)-hamigeran. Due to the simplicity of this transformation, its “green” nature, and the 
availability of the coupling partners (allylic alcohols, acetylacetone) we envision this reaction to 
be a useful synthetic tool.  
 In the following sections (sections 3.3.3 - 3.3.6), we will outline the extension of the DaA 
reaction to other types of carbon-centered nucleophiles. 
 
3.3.3 DaA of acetoacetate: generation and allylation of ester enolates2 
 
 We will begin our discussion of other nucleophiles that can be generated and allylated 
using DaA with ester enolates as they are quite similar to ketone enolates. As they are 
structurally similar with a similar pKa, we did not put too much effort into the scope 
development of this reaction.  What we did learn about this reaction is that retro-Claisen is, not 
surprisingly, chemoselective for the ketone carbonyl over the ester carbonyl when ethyl α-aryl 
acetoacetate S28a is the starting material (scheme 28, top). In this case, the DaA reaction of 
S28a and allyl alcohol produced the desired allylated product S28b in 80% isolated yield. 
Furthermore, substrate synthesis can begin from the commercially available ethyl acetoacetate 
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and use robust Cu-catalyzed arylation methodologies,67 similar to that of the acetylacetone 
derivatives disclosed above. 
 
 Using a cyclic aryl acetoacetate derivative S28c, the reaction was not chemoselective for 
the ketone over the carbonyl functionality when Cs2CO3 was used as the base (Scheme 2, 
bottom).  Rather, a 1:1 mixture of products (S28d and S28e) resulting from nonselective retro-
Claisen vs. transesterification was isolated. Product S28e was prepared by DaA reaction. The 
byproduct S28d results from transesterification of the phenyl ester to the allyl ester followed by 
decarboxylative allylation and hemiacetal formation. However, by switching the base from 
Cs2CO3 to NaH, a completely chemoselective retro-Claisen condensation reaction occurred and 
the DaA product S28e could be isolated in 75% yield. These few reactions outlined in Scheme 
28 demonstrate the potential of the DaA reaction of acetoacetate derivatives. 
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3.3.4 DaA of α-aryl cyanoacetone: generation and allylation of nitrile-stabilized anions2 
 
 We were quite interested in extending the DaA reaction to α-aryl cyanocarbonyl 
derivatives S29a leading to allylated α-quaternary nitriles S29b. Not only are the starting 
materials S29a readily available by robust methods (Claisen condensation31 or Pd-catalyzed 
arylation59,60), but S29a can be readily elaborated by classic alkylation,64,138 palladium-catalyzed 
arylation138 and Tsuji-Trost allylation methods.139-141 Thus, a DaA reaction of cyanoacetones 
could lead to a broad array of α-quaternary nitriles. Importantly, the α-quaternary nitrile motif is 
found on various drug molecules142,143 such as diphenozylate, anastrazole and verapamil, the 
latter which can be derived from an allylated nitrile F1a using a method reported by Nelson 
(Figure 1).144 Thus, rapid access to this scaffold using inexpensive carbon sources is an important 
development. Previous methods to access allylated quaternary nitriles has involved nitrile anion 
alkylation (via deprotonation with strong base),145,146 the DcA method (from allyl 
cyanoacetate),14 and Reformatsky-like methods (from α-hetroatom nitriles).147-149 
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To begin, we investigated the reaction of α-aryl cyanoacetone derivatives S30a, prepared 
by Claisen condensation/alkylation starting from benzyl cyanide derivatives. Using the 
conditions developed for the DaA reaction for β-diketones, the reaction was quite robust and 
produced the desired allylated nitrile efficiently (Scheme 30). Commonly the addition of simple 
allyl groups occurred rapidly (<30 min.) at room temperature when DMSO was utilized as the 
solvent (S30b-g), though reaction times needed to be extended for the electron rich aromatics 
(S30h-i).  Excitingly, the preparation of S30i represents allylation of the verapamil core, 
although in modest yield. In addition to simple allyl inclusion via DaA, cinnamyl (S30j, o), 
hexenyl (S30k), β-methylallyl (S30l), and prenyl (S30m) alcohols were all acceptable coupling 
partners. Though delighted by the incorporation of the prenyl moiety (S30m-n), prenylation and 
reverse-prenylation occurred with little selectivity. Although we focused on the rapid synthesis 
of 1,6-heptadienes as DaA allows a unique avenue for their preparation, in a few cases we 
demonstrated that alkylation under classic conditions (MeI, K2CO3, S30d,i) followed by DaA 
was also possible. In addition to the DaA reaction being chemically efficient (yields were 
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commonly >75%), the substrate synthesis was also quite effective: the 2-step Claisen 
condensation/alkylation sequence gave excellent yield of the starting substrate S30a. The sole 
exception to this was the pyridyl substrate (S30f, 2-steps, ~60% yield), which was a surprisingly 
sensitive material upon quaternization. 
 The ability to allylate the electron rich α-aryl nitriles (S30h-i) suggested that we should 
be able to apply this synthetic method to the production of a key intermediate en route to 
verapamil (Scheme 31). Starting from homoveratronitrile, the acetylated material S31a could be 
made in 92% yield.  Alkylation with 2-iodopropane then leads to the quaternarized starting 
cyanoacetone S31b in 70% yield. Unfortunately, there was some (~30%) O-alkylation. 
Nonetheless, the 70% yield of S31b is impressive considering the simple reaction conditions sets 
a quaternary center adjacent to the tertiary center (isopropyl).  Under the conditions utilized to 
couple the substrates in Scheme 30 (DMSO, NaH, cat. Pd(PPh3)4), decomposition occurred and 
only traces of the desired product could be isolated.  However, using conditions that effectively 
coupled the tetralone derivatives discussed in the previous section (2 equiv. NaH, THF, cat. 
Pd(PPh3)4), good yields of the verapamil precursor S31c could be isolated. Furthermore, the 
reaction could be performed on gram scale, suggesting that the DaA reactions of cyanoketones 
are reasonably scalable. From this intermediate verapamil can be synthesized following Nelson’s 
3-step protocol. 
 
NC
O
OMe
OMe
Claisena
K2CO3, 2-iodopropane
DMSO, rt, 5 h
70% yield +
~30% o-alkylation
NC
iPr
MeO OMe
O NC
IPr
MeO OMe
2.5 mol% Pd(PPh3)4
NaH
various solvents
1 or 2 equiv. NaH, DMSO: trace
2 equiv. NAH, THF: 65-80% yields
(up to gram-scale)
Scheme 31. Synthesis of a verapamil precursor via DaA reaction
S31a S31b S31c
(a) from homoveratronitrile and acetylimidazole, NaH, DMSO, rt, 92% yield
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3.3.5 Retro-Claisen allylation: generation and allylation of nitrile-stabilized anions from 
cyanoacetic esters2 
 
 
 Although we were pleased with the synthesis of the various allylated nitriles via DaA of 
cyanoacetones, the requirement to acetylate in order to perform the DaA reaction was clearly 
inefficient. Furthermore, in the case of the verapamil precursor S31c we were displeased with the 
propensity for cyanoketones to undergo O-alkylation with the sterically hindered 2-iodopropane 
alkylating agent.  With these challenges stated, we thought it might be possible to construct the 
same compounds starting from the readily available cyanoacetic esters S32a (Scheme 32). Using 
the robust method reported by Hartwig,60,138 Pd-catalyzed arylation to S32b occurs. From here, 
alkylation would prepare the starting substrate S32c.64 In order to access the desired quaternary 
allylated nitrile S32e, the retro-Claisen condensation would need to occur on an ester carbonyl. 
This C−C cleavage reaction is potentially more challenging due to the reduced electrophilicity of 
the ester carbonyl compared to the previously examined ketone analogues.  As Hartwig also 
reported the bisarylation of cyanoacetic esters (S32a è S32d),60,138 we envision this approach to 
allow us to access allylated geminal aryl nitriles S32f. Recall from Figure 1 that such a motif is 
found in many drug like molecules such as diphenozylate.143 
NC OEt
O
NC OEt
O
Ar1
NC OEt
O
Ar1 R
NC OEt
O
Ar1 Ar2
alkylation
arylation
Pd(0), Ar2-Br
K2CO3, R-X
arylation
Pd(0), Ar1-Br NC
Ar1 R O OEt
O
OH
Pd(0)
Pd(0)
NC
Ar1 R
NC
Ar1 Ar2
or
Scheme 32. Retro-Claisen allylation of cyanoacetic ester derivatives
S32a S32b
S32c
S32d
S32e S32f
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 We began to probe the retro-Claisen allylation using substrates S33c-d, prepared from 
cyano acetic esters S33a or S33b by Hartwig’s arylation method138 and Tsuji-Trost allylation.  
Using the ethyl cyanoacetate derivative S33c, we were able to realize the reaction when excess 
allyl alcohol was utilized. Interestingly, when the isopropyl cyanoacetate S33d was utilized, the 
equivalents of alcohol and base could be reduced to pseudo-stoichiometric quantities. To explain 
this, one must consider that fact that, in the case of substrate S33c, ethoxide is generated over the 
course of the reaction, which can promote formation of an unproductive byproduct, diethyl 
carbonate (Scheme 34). Therefore, the excess allyl alcohol can outcompete the in situ generated 
ethoxide for retro-Claisen condensation. Allyl alcohol can be reduced to a single equivalent in 
the case of the isopropyl cyanoacetate S33d because the in situ generated isopropoxide cannot as 
easily promote the unproductive reaction, as it is a 2° alcohol. 
 
 There was one more mechanistic question we wished to answer regarding this retro-
Claisen allylation reaction: does retro-Claisen allylation occur, as we assumed in the Schemes 
32-34, or can transesterification followed by DcA lead to the desired product (S35b, Scheme 
Ph
NC
O
OR AcO
1 mol% Pd(PPh3)4
2 equiv. K2CO3
THF, rt, 12 h Ph
NC
O
OR
S33a, R = Et
S33b, R = iPr
Ph
NC
2.5 mol% Pd(PPh3)4
X equiv. NaH, DMSO, rt
HOX equiv.
R = Et, X = 1.05, <50% S33e 
R = Et, X = 5, 75% S33e
R = iPr, X = 1.05, 85% S33e
Scheme 33. Pd-catalyzed retro-Claisen allylation of !-cyanoacetic esters
S33c, R = Et
S33d, R = iPr
S33e
NC OEt
O
Ph R
HO
Pd(0), NaH, DMSO, rt NC
Ph RO OEt
O
OEt CO2
+
+
NC
Ph R EtO OEt
O
Scheme 34. Ethoxide formation promotes an unproductive reaction pathway
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35)? As shown in Scheme 35, in the absence of palladium, we were able to isolate the protonated 
nitrile S35a. If tranesterification/DcA were the productive reaction pathway, the experiment 
would have produced allyl cyanoacetate S35b. Thus, retro-Claisen must occur preferentially over 
transesterification.  This result is consistent with the fact that the benzyl cyanide has a lower pKa 
than that of ethanol (DMSO pKa = 25 and 29 respectively). Thus, the nitrile-stabilized anion is a 
better leaving group than ethoxide. 
 
 Having demonstrated that the desired allylated quaternary α-aryl nitriles can be prepared 
by an alternate pathway starting from cyanoacetic acid derivatives, we wished to demonstrate the 
reaction’s utility in the preparation of the previously synthesized verapamil precursor substrate 
(Scheme 36). The required starting substrate is prepared by the general Pd-catalyzed arylation 
method reported by Hartwig, followed by alkylation with 2-iodopropane. We were particularly 
gratified to see how efficient this sequence was: 92% yield over the 2-steps. Furthermore, no O-
isopropylation was observed in this case, unlike when the analogous cyanoacetone was utilized 
(see Scheme 31).  The verapamil precursor could be prepared from S36a and allyl alkoxide in 
99% yield by flashing the reaction to 100 °C and stirring at room temperature for 12 h in the 
presence of catalytic Pd(PPh3)4.  The brief heating was required to promote the C−C cleavage 
event: simply stirring the substrate S36a in the presence of alkoxide at room temperature did not 
promote formation of the retro-Claisen condensation product S36b. However, S36b could be 
Ph
NC
O
OEt HO
NaH, DMSO, 5 min
Ph
NC
EtO2COno palladium
H3O
Ph
NC
100% conv.
75% isolated yield
Scheme 35. Retro-Claisen occurs on cyanoacetic esters- not transesterification
S35a
S35bPh
NC
O
O
transesterification pathway
not observed
retro-Claisen condensation observed
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prepared with excellent chemical efficiency by briefly heating the substrate in the presence of 
alkoxide. 
 
 In addition to the allylated quaternary α-aryl nitriles such as the verapamil precursor 
(Scheme 36), we wished to extend the retro-Claisen allylation of cyanoacetic ester derivatives to 
α,α-diaryl nitriles, as they to are medicinally relevant structural motifs (Scheme 37).143 We were 
please to see the retro-Claisen allylation worked well with various diaryl cyanoacetates S37a and 
allylic alcohols. For example, both chiral allylated diaryl nitriles (S37b-c) and geminal phenyl 
(S37d-f) substrates could be prepared. Regarding the allylic alcohol coupling partner, simple 
(S37b,d), hexenyl (S37c,e), and β-methylallyl (S37f) were all compatible under the reaction 
conditions developed. We were particularly satisfied with the substrate synthesis as it utilized 3-
consecutive Pd-catalyzed transformations (two-Pd catalyzed arylations followed by retro-Claisen 
allylation) beginning from readily available and inexpensive cyanoacetates, aryl bromides and 
allyl alcohols as the carbon sources.  
CO2iPrNC
a,b
CO2iPrNC
iPr
MeO OMe
NC
iPr
MeO OMe
92% 2-steps
Br
MeO OMe
3 equiv.
HO
2.5 mol% Pd(PPh3)4
3 equiv. NaH, THF, rtc
(a) Na3PO4, 2% Pd(dba)2 5% PtBu3, Tol, 100 oC, 12 h (b) 5 equiv. K2CO3, 5 equiv. 2-iodopropane, DMSO, rt, 1 h, (c) 1.05 equiv. allyl alcohol, flash reaction 
mixture to 100 oC (3 min) and leave at rt overnight
99% Yield
NC CO2iPr
iPr
MeO OMe
NC
OMe
OMe
HO
NC
iPr
MeO OMe
iPrO2CO
NaH
THF
rt, 1h: 0% conv. to S36b
100 °C, 3 min: 100% conv. to S36b (99% yield)
no Pd
Scheme 36. Development of a Pd-catalyzed retro-Claisen allylation for a verapamil precursor
S36a
S36a
S36b
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3.3.6 Conclusions on the DaA (retro-Claisen allylation) reaction 
 
 The DaA reaction is a new approach to Pd catalyzed allylic alkylation involving a retro-
Claisen condensation of an acetyl pronucleophile and an allylic alcohol. The retro-Claisen 
reaction generates both nucleophilic and electrophilic coupling partners in situ, which are 
coupled together in the presence of Pd. The DaA reaction is a particularly attractive choice 
method for the allylation of nucleophiles due to the direct coupling of commercially available 
allyl alcohols and readily available acetyl pronucleophiles. Regarding the origin of the acetyl-
pronucleophile, they can be derived from commercially/readily available active methylene 
compounds by robust α-alkylation and arylation methodologies. As shown herein, we initially 
confirmed our hypothesis via generation of nitronate anions (DMSO pKa ~ 17, Section 3.3.1) 
using allyl alcohols. The success of this reaction was hinged on the fact that retro-Claisen was 
facile due to the high stability of the nitronate leaving group. From these humble beginnings, we 
gradually extended the DaA reaction to include to α-aryl enolates (DMSO pKa ~20, Section 
3.3.2), α-tetralone enolates (DMSO pKa = 25, Section 3.3.2) and nitrile stabilized anions (DMSO 
pKa ~22-24, Sections 3.3.4 and 3.3.5).   
Ph
NC
O
OR
Ar
NC
O
OR
Ph
A Pd-cat.
arylation
ArBr, Pd(0)
Na3PO4, tol, 70 °C
2.5 mol% Pd(PPh3)4
X equiv. NaH & HO Ph
NC
Ar
R
R
S37b-f
DaA yieldTHF or DMSO, 30 min, rt
a
Ph
NC
CF3
Ph
NC Pr
CF3 Ph
NC
Ph Ph
NC
Ph
Pr
Ph
NC
Ph
S37b, R = Et, 99%
(a) if R = Et, X = 5 or if R = iPr X = 1.1
S37c, R = Et, 99% S37d, R = iPr, 99% S37e, R = iPr, 86% S37f, R = iPr, 62%
Scheme 37.  Synthesis of !,!-diaryl-!"allyl acetonitrile derivatives by sequential Pd-catalysis
B Pd-cat.
arylation C Pd-cat. retro-Claisen allylationS37a
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 The DaA reaction allows a unique and simple avenue for the synthesis of 1,6-heptadienes 
via 2-step Tsuji-Trost/DaA reaction. Thus, with all the nucleophiles investigated above, we 
demonstrated that these important cycloisomerization substrates can be made by the DaA 
method.  We also developed an enantioselective DaA reaction for tetralones that culminated in 
the synthesis of enantioenriched 1,6-heptadienes and an important intermediate en route to (+)-
hamigeran. Finally, the retro-Claisen allylation of α-aryl cyanoacetic esters allowed us to prepare 
an important intermediate en route to the drug verapamil. Made possible by the DaA reaction, 
the verapamil precursor was exclusively prepared (in 92% yield over 3-steps form commercial 
materials) from cyanoacetic acid, bromoveratrole, isopropyl bromide, and allyl alcohol, all of 
which are commercially available and inexpensive.  
 The final section of the original research section of this dissertation will demonstrate how 
1,6-heptadienes can be prepared by 1-pot Pd-catalyzed Tsuji-Trost/DaA reaction. 
  
3.4 3-component Tsuji-Trost allylation/retro-Claisen allylation: 1-pot synthesis of 1,6-
heptadienes1-3 
 
 In the previous sections, I have described how 1,6-heptadienes can be prepared rapidly 
using a 2-step Tsuji-Trost allyation/DaA reaction. We have demonstrated this sequence on α-
nitroketones, α-aryl-β-diketones, α- and β-tetralones, α-aryl α-cyanoacetones, and α-aryl α-
cyanoacetic acid esters. This 2-step procedure was developed as a surrogate process to our 
original, 1-step attempt: the Tsuji-Trost/DcA reaction. The challenge of our original approach 
stems from the similarly reactive allylic acetates (or carbonates) required for such a reaction 
sequence. Aside from the 2-step nature of our newly devised Tsuji-Trost/DaA approach to 1,6-
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dienes, allylic acetates and allyl alcohols have drastically different rates of reaction toward 
oxidative addition (allyl alcohols rarely form Pd-π-allyl complexes without the aid of Lewis acid 
additives).76,150-154 As this 2-step sequence utilizes Pd to promote both of the reactions, we 
reasoned that a 1-pot Pd-catalyzed bisallylation should be possible leading to these useful 1,6-
heptadienes with increased efficiency due to the differentiated reactivity of allylic acetates and 
alcohols toward Pd (Scheme 38). In general, this reaction should be straightforward, as the Tsuji-
Trost allylation of active methylene compounds in most examples above, was rapid and high 
yielding. Furthermore, the 3-component coupling should require 2 equiv. of base: the first to 
promote the Tsuji-Trost allylation and the second, for the DaA reaction. 
 
 Using the conditions developed for successful DaA reaction of nitroketones [Cs2CO3, 2.5 
mol% Pd(PPh3)4, DCM:DCE (1:1), 80 °C, 12h] the reaction was converted into a 3-component 
coupling with ease. The Tsuji-Trost reaction on S39a occurred rapidly at room temperature (<1 
min) and upon heating overnight, the DaA reaction yielded the 1,6-heptadienes S39b-l.  Though 
only a single equivalent of Cs2CO3 was utilized, the second equivalent of base is generated from 
the allyl tbutyl carbonate (tBuCO3−). Using cinnamyl carbonate and allyl alcohol, S39b could be 
prepared in high yield. The initial Tsuji-Trost reaction could also be done with cinnamyl acetate 
(footnote b), though an extra equivalent of base is required. Next, the reaction partners can be 
switched with little effect on the reaction outcome: using allyl carbonate and cinnamyl alcohol, 
S39b’ is prepared in similar yield to the S39b.  In general, the reaction partners can be switched 
using various allylic carbonates and alcohols (S39b-d, S30b’-d’) with little effect on the yield. 
EWG
O
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Arylations
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AcO EWG
Ar
R1
Base   Pd(0)Pd(0)
2 equiv. Base
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OHEWG
O
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Scheme 38. 3-component, 1-pot Pd-catalyzed bisallylation
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R2
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Regarding α-substitution on the nitroacetone, various aryl (S39e) and alkyl (S39f-i) substitution 
patterns were well tolerated. We were particularly satisfied with the coupling of the ester 
containing nitroketones (S39g-i) in the 3-component bisallylation. Not only are the nitro and 
ester moieties functional group paired, but this shows that the DaA reaction conditions can 
tolerate other electrophilic functional groups such as esters without undesired transesterification. 
Utilizing cyclic nitroketones such as S40a, 1,6-heptadienes with pendant carboxylic acids can be 
prepared (Scheme 40). As the 1,6-heptadiene containing the tethered carboxylate was 
challenging to purify, it was converted to the methyl ester S40b and subjected to column 
chromatography.  In addition to bisallylation, starting from unsubstituted nitroacetone S41a and 
utilizing 2 equiv. of cinnamyl carbonate and 1 equiv. of allyl alcohol, controlled trisallylation can 
occur yielding S41b in 81% yield. 
 
O2N
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O BocO
HO
2.5 mol% Pd(PPh3)4
1 equiv. Cs2CO3 O2N
R
O2N O2N
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Pr
O2N
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MeO2C
(a) 1:1:1.2 nitroacetone : allyl carbonate : allyl alcohol, 2.5 mol % Pd(PPh3)4, 1 equiv. Cs2CO3, DCM:DCE (1:1) 80 oC, 12 h. (b) 81% yield using 2 equiv. 
of Cs2CO3 and cinnamyl acetate. (c) 10 mol % Pd(PPh3)4
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Scheme 39. Pd-catalyzed 3-component bisallylation of nitroketones
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O
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(then esterify with Cs2CO3, MeI)
S40b, 65%
Scheme 40. 3-component bisallylation of !-nitrocyclhexanone
S40a
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 We next turned to the development of the 3-component bisallylation of α-aryl 
acetylacetone derivatives.  Though at first challenging, we realized that a lag time (10-15 min, 60 
°C) was required between the Tsuij-Trost allylation and addition of the allyl alcohol for the DaA 
reaction as the Tsuji-Trost allylation was not as rapid as the nitroketone substrates were.  
Furthermore, the allyl alcohol was injected as its salt in the solvent being utilized.  Nonetheless, 
using this adopted procedure the bisallylation could occur preparing S42a-g. Regarding the 
scope, various α-aryl acetylacetone derivatives were excellent coupling partners. Simple phenyl 
acetylacetone (S42a-b) provided the 1,6-diene in good yield. Various electron withdrawing 
groups on the arene ring were also tolerated at the para- and meta- positions (S42c-g).  
 
 Bisallylation of acetylated α- or β-tetralones was also possible.  Using the same 
procedure as outlined in Scheme 42, 1,6-heptadiene β-tetralones S43a-b were prepared using 
O2N
O BocO
Ph
HO
2.5 mol% Pd(PPh3)4
1 Equiv. Cs2CO3
DCM:DCE (1:1) 80 °C, 12 ha
O2N
Ph
Ph
Scheme 41. Controlled triallylation of nitroacetone
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O
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O
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S42f,  75%
S42e, 81%S42d, 82%
AcO NaO
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(a) 1:1:1.1 acetylacetone derivative, cinnamyl acetate, allylic alcohol, 2.1 equiv. NaH, 2.5 mol % Pd(PPh3)4, 60 oC THF (b) DMSO, (c) Cs2CO3
THF, 60oC, 10-15 min
Scheme 42. 3-component bisallylaiton of !-aryl acetylacetone derivatives
Cu-cat.
arylation S42a-g
60 °C, 1-12 h
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cinnamyl acetate and either allyl (S43a) or hexenyl (S43b) alcohol.  On the >1 gram scale, we 
demonstrated that 1,6-diene α-tetralones could also be prepared by Pd-catalyzed bisallylation. 
Notably, we identified a simpler procedure for the bisallylation reaction that didn’t require 
preformation and addition of the sodiated allyl alkoxide. Rather, both equivalents of the NaH 
were added at the beginning of the sequence and after Tsuji-Trost allylation was completed (~15 
min., 60 °C), the reaction mixture was cooled to 0 °C, and the allyl alcohol was added dropwise 
into the reaction mixture.  The reaction mixture is then warmed back to 60 °C to promote the 
DaA reaction. 
 
 Finally, α-aryl cyanoketones (Scheme 44) and esters (Scheme 45) can undergo Pd-
catalyzed bisallylation. The allyl alkoxide addition method was utilized that was developed for 
the 3-component coupling of α-aryl acetylacetone derivatives (Scheme 42). The cyanoketones 
were excellent coupling partners, providing good yields of the bisallylated compounds S44a-f. In 
addition to simply phenyl cyanoacetone (S44a-b), pyridyl (S44c-d), napthyl (S44e) and ortho-
chlorophenyl (S44f) starting materials were utilized. A gram scale reaction was also performed 
to demonstrate that this bisallylation is reasonably scalable. As the α-aryl cyano esters are more 
readily available via Hartwig’s method, we wished to demonstrate such a starting material could 
also be utilized in this Pd-catalyzed bisallylation (Scheme 45). 
S43a, 84%a S43b, 97%a
O
Ph
O
Ph
Pr
O
(a) same conditions as outlined in Scheme 42. (b) 3 mol% Pd(PPh3)4 2.1 equiv. NaH, 1 equiv. allyl acetate, 1 equiv. tetralone, 60 °C 15 min (Tsuji-
Trost). Then, 1.05 equiv. !"methyl allyl alcohol, 0 " 60 oC.
O
HO
Ph
Ph
OAc
S43c, 1.3 grams, 83%b
OH
O OH
or R
Claisen
2.5-3 mol% Pd(PPh3)4
2.1 equiv. NaHa
MeCNa  or THFb, 60 oC, 12 h
pdts S43a-c
Claisen
Scheme 43. Pd-catalyzed bisallylation of acetyltetralones
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 To conclude this section, 1,6-heptadienes can be prepared by single pot by the 3-
component coupling of a mono α-substituted active methylene compound, allyl acetate (or 
carbonate) and an allyl alcohol.  This process is made possible because of the differing reactivity 
of the 2 allylic systems. The palladium catalyst first couples the active methylene compound and 
the allyl acetate. Upon allyl alkoxide induced retro-Claisen condensation, 2 new coupling 
partners are generated for a second Pd-catalyzed allylic alkylation (DaA). We envision this 
reaction to find use amongst the organic community as it prepares unique 1,6-heptadienes using 
an extremely simple reaction manifold from commercially available starting materials. 
 
3.5 Conclusions 
  
 Active methylene compounds are attractive starting materials due to their 
commercial/ready availability and their heightened nucleophilic tendencies.  Upon α,α-
disubstition of these substrates, we have demonstrated that another coupling reaction can occur 
by deacylative allylation (DaA).  In this process, nucleophilic and electrophilic coupling 
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Scheme 44. 3-component bisallylation from !-aryl cyanoacetone
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Scheme 45. 3-component bisallylation from !-aryl cyanoacetic esters
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partners are generated in situ by a single allyl alkoxide induced retro-Claisen condensation 
event. In the presence of Pd, allylic alkylation occurs to a useful chemical building block. The 
DaA reaction is attractive due to the direct coupling of allylic alcohols, the ready availability of 
DaA substrates, and the minimal waste byproduct generated (only acetate). 
 We have demonstrated that the reaction can be utilized to generate and allylate nitronate 
anions, ketone and ester enolates, and nitrile-stabilized anions.  This type of reaction is 
particularly useful in the construction of 1,6-heptadienes by 1 or 2-pot sequential Tsuji-
Trost/DaA reaction. We have also demonstrated the reaction’s utility in the construction of an 
important synthetic intermediate en route to verapamil from simple starting materials utilizing 2 
consecutive Pd-catalyzed events (Pd-catalyzed arylation and DaA). An asymmetric DaA reaction 
of α-tetralone derivatives was also developed and utilized to construct enantioenriched 1,6-
heptadienes as well as a precursor to (+)-hamigeran. 
 We envision this reaction to be of synthetic utility due to the simplicity of the 
transformation and the importance of the substrates that it can prepare (allylated compounds, 1,6-
heptadienes). 
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General Information: 
 
*NOTE: Products are named after their Scheme location in Chapter 3. (e.g. S8b = substrate a in 
Scheme 8). If a compound has not specifically been named and referred to in Chapter 1 text, it 
will be given an Appendix name (A-1, A-2, etc.) They are similarly named in the spectral 
analysis section of this appendix.   
 
 All reactions were run in flame-dried glassware. Air free conditions were facilitated by 
the use of argon and a Schlenk line (vacuum gas manifold).  CH2Cl2 and toluene were dried over 
activated alumina.  THF was distilled over sodium. Anhydrous dichloroethane, acetonitrile, 
NMP, DMF and DMSO was purchased from Aldrich, stored in the glove box and used as is. 95% 
Sodium Hydride was purchased from Aldrich, stored in a glove box and used as is. 99% Cs2CO3 
was purchased from Aldrich and used as is. >99% allyl alcohol was purchased from Aldrich and 
stored over 3Å-MS in a sealed tube fitted with a rubber septum.  Commercially available 
substrates were used as is.  Non-commercially available substrates were prepared by the methods 
described in the “Substrate preparation procedures” section of this appendix. 
 Compound purification was effected by flash chromatography using 230x400 mesh, 60Å 
porosity silica obtained from Sorbent Technologies and in some cases when noted, Kugelrohr 
distillation. 1H NMR and 13C NMR spectra were obtained on a Bruker Avance 400 or a Bruker 
186 
Avance 500 DRX spectrometer equipped with a QNP Cryoprobe and referenced to residual 
protio solvent signals. 
 Regarding chiral resolution and ee determination, HPLC chiral resolution was performed 
using a Chiralcel OD-H column and hexanes/isopropyl alcohol mobile phase mixtures. Absolute 
configuration is assigned based on Stoltz’s work, as the same ligands are utilized and the same 
products are prepared.1 
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General procedures for Tsuji-Trost/retro-Claisen condensation: 
 
1. Representative procedure for Tsuji-Trost/retro-Claisen of α-nitroketones: 
 
 In a flame-dried 10 mL Schlenk flask under argon, combine Pd(PPh3)4, (14 mg, 2.5 mol 
%, 0.0125 mmol), K2CO3 (138 mg, 1 mmol) and DCM (1 mL). A solution of nitroacetone (59 
mg, 0.5 mmol) in DCM (1 mL), 3a, and hexenyl tert-butyl carbonate (0.51 mmol, 79 mg) were 
added with stirring followed by 5 equivalents (80 mg) of methanol. The resulting mixture was 
stirred overnight at 50 °C. After cooling the mixture to room temperature, the solution was 
filtered through a silica gel plug with 15% EtOAc/Hexanes as eluent. Evaporation of volatiles, 
and subjection of the residue to column chromatography (2 mol % EtOAc/hexanes) yielded S8d 
(65 mg, 83%). 
 
2. Representative procedure for Tsuji-Trost/retro-Claisen of β-formyl ketones: 
O2N
O
OCO2MePr
2.5 mol% Pd(PPh3)4
K2CO3,DCM, 40 °C
5-10 equiv. MeOH
O2N Pr
FW: 117.10
0.5 mmol, 58.5 mg
FW: 158.19
0.5 mmol, 79 mg
FW: 157.21
isoalted: 65mg of S8d
83% yield
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 A flame-dried 10 mL Schlenk flask equipped with a stir bar is brought into a glove box 
and charged with Pd(PPh3)4 (2 mol%, 0.01 mmol, 11.5 mg) and 95% NaH (1 equiv., 0.5 mmol, 
12.5 mg). The flask is capped, removed from the glove box and attached to a Schlenk-argon line. 
5 mL of dry THF is then added to the flask and substrate ketone (1 equiv., 0.5 mmol, 108 mg) is 
added neat.  Allyl acetate (0.6 mmol, 60 mg) is  then added and the vessel is stirred at room 
temperature for 1h (until completion, monitored by TLC).  Once the starting material has been 
completely consumed, ~5 mL of 5% KOH/MeOH is added and the vessel is stirred for 15 min.  
The contents are then transferred to a seperatory funnel.  EtOAc (~10 mL) is used to wash the 
reaction vessel to ensure complete transfer.  An extra 10 mL of EtOAc is added to the seperatory 
funnel and the organic layer is extracted with 1M HCl (~15 mL) followed by brine (~15 mL).  
The organic layer is collected, dried over MgSO4, evaporated and subjected to column 
chromatography (7% EtOAc in hexanes) to yield the desired product S9c (88 mg, 78% yield). 
 
General procedures for deacylative (retro-Claisen) allylation: 
 
3. Representative procedure for the DaA reaction of α-nitroketones: 
 
 In a glove box under an argon atmosphere, a flame-dried pressure vial equipped with a 
O OH
H OAc
O
1 equiv. NaH, THF, rt, 1h
2 mol% Pd(PPh3)4
PhPh
5 % KOH in MeOH
FW: 214.26
0.5 mmol, 108mg
FW: 100.12
0.6 mmol, 60mg
FW: 226.31
isolated 88mg of S9c
78% yield
O2N
O
HO
O2N
2.5 mol% Pd(PPh3)4
1 Equiv. Cs2CO3
DCM:DCE 1:1, 80 °C, 12h
FW: 157.17
1 mmol, 157 mg
FW: 58.08
1.1 mmol, 63 mg
FW: 155.19
isoalted 134 mg of S14a
87 % yield
189 
septum was charged with Pd(PPh3)4 (2.5 mol%, 14 mg, 0.0125 mmol) and Cs2CO3 (1 mmol, 
325 mg). Anhydrous DCE (2 mL) was added and the vial was sealed. After removing the vial 
from the glove box, a solution of α-nitroketone (1 mmol, 157.17 mg,) and allyl alcohol (1.1 
mmol, 63 mg) in dry DCM (0.5 mL) was added via syringe and the transfer vessel was washed 
with DCM (~0.5 mL) to ensure complete transfer of the substrates to the reaction mixture. The 
pressure vial was then submerged in an oil bath at 80 °C and left to stir overnight.  
 After the allotted reaction time, the vessel was cooled to room temperature and the 
resulting solution was diluted with 15% Et2O/pentane (~5 mL) and eluted through a silica plug 
with excess 15% Et2O/pentane (~50-75 mL). After removal of the volatiles via rotary 
evaporation, the crude oil was subjected to column chromatography (gradient column: 2% to 4% 
Et2O/pentane) yielding the desired product S14a (134 mg, 87% yield). 
 
4. Representative procedure for the DaA reaction of para-nitrophenyl acetylacetone: 
 
 A flame-dried 10 mL Schlenk flask is equipped with a stir bar, brought into a glove box, 
and charged with an Pd(PPh3)4 (2.5 mol%, 0.0125 mmol, 14 mg) and Cs2CO3 (0.5 mmol, 165 
mg). The flask is capped, removed from the glove box and attached to a Schlenk-argon line.  3 
mL of dry THF is added to the flask and allyl alcohol (0.55 mmol, 32 mg) is added neat using a 1 
mL disposable syringe.  Wash the transfer syringe with the reaction mixture solvent to ensure 
complete transfer.  The acetylacetone substrate (0.5 mmol, 65 mg) is then added neat. The vessel 
is capped, sealed, and heated at 60 °C overnight (12h). 
O O O2.5 mol% Pd(PPh3)4
1 equiv. Cs2CO3
THF, 60 °C, 3h
HO
FW: 261.27
0.5 mmol, 65 mg
FW: 58.08
0.55 mmol, 32 mg
S16b, FW: 259.30
isoalted 125 mg,  97% yield
O2N O2N
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 After the allotted reaction time, the reaction mixture is diluted with ~5 mL of 15% EtOAc 
in hexanes and filtered through a silica plug.  Wash the reaction vessel with the 15% EtOAc 
solution to ensure complete transfer to the plug.  ~25 mL of the transfer solution is then used to 
wash the silica. The volatile organics are then removed by rotary evaporation and the oily residue 
is subjected to column chromatography (7% EtOAc in Hexanes) yielding the desired product 
S16b (125 mg, 97% yield).  
5. Representative procedure for the DaA reaction of α-phenyl acetylacetone 
 
A 10 mL flame-dried Schlenk flask is equipped with a stir bar, brought into a glove box, 
and charged with Pd(PPh3)4 (2-3 mol %, 6-8 mg, FW:1155.57) and NaH (0.34 mmol, 8mg, FW: 
24.00) in a glove box.  The vessel is capped, removed from the glove box, and attached to a 
Schlenk-argon line. Dry, freshly distilled THF (3 mL) is added to the flask. Allyl alcohol (0.32 
mmol, 19mg) is added neat using a 1 mL disposable syringe. This transfer syringe is washed 
with the reaction mixture to ensure complete transfer.  Rapid effervescence occurs forming the 
alkoxide. Once H2 effervescence ceases, the acetylacetone pronucleophile (0.3 mmol, 65 mg) is 
added neat dropwise to the reaction mixture using a disposable 1 mL syringe.  Again, this 
syringe is rinsed with the reaction mixture to ensure complete transfer.  The reaction is then 
submerged in an oil bath at 60 °C where it is left to react for the indicted time.  
After the allotted reaction time, the reaction mixture is diluted with ~5 mL of 15% EtOAc 
in hexanes and filtered through a silica plug.  Wash the reaction vessel with the 15% EtOAc 
solution to ensure complete transfer to the plug.  ~25 mL of the transfer solution is then used to 
O O O2.5 mol% Pd(PPh3)4
1.05 equiv. NaH
THF, 60 °C, 3h
HO
FW: 216.28
0.3 mmol, 65 mg
FW: 58.08
0.32 mmol, 19 mg
FW: 214.30
isoalted 55 mg of S18a
84% yield
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wash the silica. The volatile organics are then removed by rotary evaporation and the oily residue 
is subjected to column chromatography (3% EtOAc in Hexanes) yielding the desired product 
S18a (55 mg, 84% yield). 
NOTE* if DMSO or MeCN is utilized as the solvent, dilute reaction mixture with EtOAc 
(~20 mL total volume) and perform extractions using 1N HCl (2 x ~25 mL) followed by brine 
(25 mL). Dry the organic layer, evaporate the volatiles and subject to column chromatography. 
6. Representative procedure for the DaA reaction of 2-formyl α-tetralone derivatives: 
 
Two flame-dried 10mL Schlenk flasks equipped with stir bars are flame dried and 
brought into a glove box.  The catalyst (Pd2dba3, 1.25 mol % 0.0063 mmol, 5.7 mg and rac-
BINAP, 3 mol%, 0.015 mmol, 9.5 mg) is loaded into one flask and NaH (2 equiv., 1 mmol, 25 
mg) is loaded into the other. Both are capped, removed from the glove box and attached to a 
Schlenk argon line. 2 mL of dry THF is added to the catalyst flask, which is then stirred for 10 
min at 40 °C to form the active catalyst. In the meantime, 3 mL of dry THF is added to the flask 
containing NaH.  To the NaH containing flask is added allyl alcohol (via syringe, 0.50 mmol, 29 
mg) and tetralone derivative 1a (via syringe, 0.51 mmol, 95mg) in subsequence. Both syringes 
used to transfer reagents are washed with the reaction mixture solvent and reinjected.  Directly 
after the final reagent addition, the preformed catalyst is then transferred via syringe and injected 
as a shot (no need to wash this syringe).   The vessel is capped, wrapped in parafilm and the 
vessel is completely closed and allowed to react for 5h. 
O
CHO
HO
1.25 mol% Pd2dba3
3 mol% rac-BINAP
NaH, THF, rt, 5h
O
FW:  200.28
isolated 83 mg of 22d
83% Yield
FW: 188.22
0.51 mmol, 95mg
FW: 58.08
0.50 mmol
29 mg
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 After the allotted reaction time as determined by TLC (5h), the reaction mixture is diluted 
with 15% EtOAc in hexanes and filtered through a SiO2 Plug with excess (50-75mL) of the 15% 
EtOAc in hexanes solvent mixture.  The solvent is evaporated and subjected to silica gel 
chromatography (3% EtOAc in Hexanes) to yield the pure product 22d (83 mg, 83% yield). 
 
 
 
7. Representative procedure for the DaA reaction of 2-acetyl α-tetralone derivatives: 
 
 A flame-dried 10mL Schlenk flask equipped with a stir bar is brought into a glove box 
and charged with NaH (2 equiv. 0.50, 12mg) and Pd(PPh3)4 (2.5 mol%, 0.0063 mmol, 7.2 mg).   
The flask is capped, removed from the glove box and attached a Schlenk argon line.  4 mL of dry 
THF is added to the flask and allyl alcohol (0.25 mmol, 15 mg) and tetralone 1b (0.255 mmol, 51 
mg) are added in subsequence. Both syringes used to transfer reagents should be washed with the 
reaction mixture and reinjected to ensure complete transfer. The vessel is capped, wrapped in 
parafilm and the system is completely sealed over argon and allowed to react for 5h. 
 After the allotted reaction time as determined by TLC, the reaction mixture is diluted 
with 15% EtOAc in hexanes and filtered through a SiO2 Plug with excess (50-75mL) of the 15% 
EtOAc in hexanes solvent mixture.  The solvent is evaporated and subjected to silica gel 
chromatography (3% EtOAc in Hexanes) to yield the pure product S22d (44 mg, 88% yield). 
 
O
Ac
HO
2.5 mol% Pd(PPh3)4
NaH, THF, rt, 5h
O
FW: 202.25
0.255 mmol 51mg
FW:  200.28
isolated 44mg of 22d
88% Yield
FW: 58.08
0.25 mmol
15 mg
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8. Representative procedure for the scale-up of the DaA reaction of 2-acetyl α-tetralone 
derivatives: 
 
A flame-dried 25mL Schlenk flask equipped with a stir bar is brought into a glove box 
and charged with NaH (2 equiv. 5 mmol, 120 mg) and Pd(PPh3)4 (1 mol%, 0.025 mmol, 29 mg).   
The flask is capped, removed from the glove box and attached to a Schlenk argon line.  5 mL of 
dry THF is added to the flask and it is cooled in an ice-bath. Once chilled, allyl alcohol (2.5 
mmol, 145 mg) and the substrate benzosubarone (2.5 mmol, 540 mg) are added consecutively. 
Both syringes used to transfer reagents should be washed with the reaction mixture and 
reinjected to ensure complete transfer of reagents. The vessel is capped, wrapped in parafilm and 
the system is completely sealed over argon and removed from the ice-bath. Once at room 
temperature the vessel is left to react in an oil bath at 40 °C for 12h. 
 After the allotted reaction time as determined by TLC, the reaction mixture is diluted 
with 15% EtOAc in hexanes and filtered through a SiO2 Plug with excess (100 mL) of the 15% 
EtOAc in hexanes solvent mixture.  The solvent is evaporated and subjected to silica gel 
chromatography (3% EtOAc in Hexanes) to yield the pure product S23s (496 mg, 93% yield). 
 
9. Representative procedure for the asymmetric DaA reaction of 2-acetyl α-tetralone 
derivatives: 
1 mol% Pd(PPh3)4
NaH, THF, 0 - 40 oC, 12h
O
O O
HO
FW: 216.28
2.5 mmol, 540 mg
FW: 58.08
2.5 mmol
145 mg
FW: 214.30
isolated 496 mg of S23s
93% Yield
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Two flame-dried 10mL Schlenk flasks equipped with stir bars are flame dried and 
brought into a glove box.  The catalyst (Pd2dba3, 2 mol % 0.005 mmol, 4.5 mg and tBuPHOX 
ligand, 5 mol%, 0.0125 mmol, 4.9 mg) is loaded into one flask and NaH (2 equiv. 0.50, 12mg) is 
loaded into the other. Both are capped, removed from the glove box and attached to a Schlenk 
argon line. 2 mL of dry THF is added to the catalyst flask, which is then stirred for 10 min at 40 
°C to form the active catalyst. In the meantime, 3 mL of dry THF is added to the flask containing 
NaH.  To the NaH containing flask is added allyl alcohol (via syringe, 0.30 mmol,  18.5 mg) and 
tetralone derivative 1a (via syringe, 0.31 mmol, 62mg) in subsequence. Both syringes used to 
transfer reagents are washed with the reaction mixture solvent and reinjected.  Directly after the 
final reagent addition, the preformed catalyst is then transferred via syringe and injected as a shot 
(no need to wash this syringe).   The vessel is capped, wrapped in parafilm and the vessel is 
completely closed and allowed to react for 5h. 
 After the allotted reaction time as determined by TLC (5h), the reaction mixture is diluted 
with 15% EtOAc in hexanes and filtered through a SiO2 Plug with excess (50-75mL) of the 15% 
EtOAc in hexanes solvent mixture.  The solvent is evaporated and subjected to silica gel 
chromatography (3% EtOAc in Hexanes) to yield the pure product 22d (83 mg, 83% yield, 80% 
ee). Using HPLC chiral resolution on a Chiralcel OD-H column, the ee was determined. 
 
10. Representative procedure for the synthesis of the (+)-hamigeran precursor: 
O
Ac
HO
2 mol% Pd2dba3
5 mol% tBuPHOX
NaH, THF, rt, 12h
O
FW:  200.28
isolated 45mg of 25d
75% Yield
FW: 202.25
0.31 mmol
61mg
FW: 58.08
0.30 mmol
18.5 mg
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 “Procedure 9” above is used to prepare the (+)-hamigeran precursor. Chiral resolution:  
 
 
 
 
11. Representative procedure for the DaA reaction of α-phenyl cyanoacetone derivatives: 
 
 “Procedure 5” was used to prepare allylated  nitriles via DaA. 
 
12. Representative procedure for the retro-Claisen allylation of ethyl α-phenyl 
cyanoacetate derivatives: 
 
 A flame-dried 10 mL Schlenk flask equipped with a stir bar is brought into a glove box 
and charged with Pd(PPh3)4 (2.5 mol%, 0.0125 mmol, 14 mg) and 95% NaH (0.5 mmol, 12.5 
mg). 3 mL of anhydrous DMSO is added to the vessel, which is then capped, removed from the 
O
Ac
HO
2 mol% Pd2dba3
5 mol% tBuPHOX
NaH, THF, rt
O
FW:  244.33
isolated 68mg
93% Yield, 92% ee
FW: 246.30
0.31 mmol
76 mg
FW: 58.08
0.30 mmol
18.5 mg
OMe OMe
NC
O
NC
2.5 mol% Pd(PPh3)4
1.05 equiv. NaH
DMSO, rt, 30min
HO
FW: 199.25
0.3 mmol, 60 mg
FW: 58.08
0.32 mmol, 19 mg
FW: 197.25
isolated 54mg of S30b
Ph
NC
O
OEt Ph
NC2.5 mol% Pd(PPh3)4
5 equiv. NaH, DMSO, rt, 30min
HO
FW: 58.08
2.5 mmol, 145 mg
S33c, FW: 229.27
0.5 mmol, 115 mg
S33e, FW: 197.28
isolated 74mg, 75% yield
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glove box and attached to a Schlenk-argon line.  Allyl alcohol (2.5 mmol, 145 mg) is dripped 
into the stirring reaction mixture.  The substrate ethyl cyanoacetate (0.5 mmol, 115 mg) is then 
added neat dropwise via syringe.  The vessel is then capped and stirred at rt for 30 min. 
 After the allotted reaction time (30 min.), the reaction mixture is transferred to a 
seperatory using EtOAc (total volume ~ 25 mL).  The organic layer is extracted with 1N HCl (2 
x 25 mL) followed by brine (25 mL).  The volatile organics are removed by rotary evaporation 
and the oily residue is subjected to column chromatography (3 % EtOAc in hexanes) to yield the 
desired product S33e (74 mg, 75% yield).   
 
13. Representative procedure for the retro-Claisen allylation of isopropyl α-phenyl 
cyanoacetate derivatives: 
 
 “Procedure 12” is utilized with the exception that the equivalents of allyl alcohol and 
NaH are reduced to 1.05 equiv. 
 
14. Representative procedure for the synthesis of a verapamil precursor via retro-Claisen 
allylation: 
 
A flame-dried 10 mL pressure vial is charged with NaH (0.70 mmol, 17.7 mg, 2 equiv.) 
Ph
NC
O
OiPr Ph
NC2.5 mol% Pd(PPh3)4
1.05 equiv. NaH, DMSO, rt, 30min
HO
FW: 58.08
0.55 mmol, 32mg
S33c, FW: 243.30
0.5 mmol, 122 mg
S33e, FW: 197.28
isolated 84mg, 85% yield
CO2iPrNC
iPr
MeO OMe
NC
iPr
MeO OMe
HO
2.5 mol% Pd(PPh3)4
3 equiv. NaH, THF, 12h
FW: 305.37
0.34 mmol, 105 mg
FW: 58.08
0.36 mmol, 21 mg FW: 259.348isolated 88mg, 99% yield
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in a glove box.  The vessel is capped with a rubber injectable septum capable of holding pressure 
(Biotage microwave vessel was used) and removed from the glove box. The vessel is connected 
to an argon line via needle to bleed the vessel of impending pressure from H2 effervescence. 1.5 
mL of THF is added and while stirring, a solution of allyl alcohol in 0.5 mL of THF is added.   
Rapid H2 effervescence occurs.  The transfer syringe is washed with an additional 0.5 mL 
portion of THF.  The cyanoacetate substrate is then added in 0.5 mL of THF via syringe.  The 
transfer vessel is washed with an additional 0.5 mL portion of THF. The argon bleed is removed 
and the vessel is placed in an oil bath at 100 °C for 10min. The vessel is then cooled to room 
temperature and THF solution of Pd(PPh3)4 is injected. The vessel is then stirred for 12 h. 
 After the allotted reaction time, the cap is removed and vessel’s contents are transferred 
to a seperatory funnel with the aid of 2 x 5 mL portions of EtOAc.  The organic layer is extracted 
with 0.5 M HCl and brine.  The organic layer is then dried over magnesium sulfate and 
evaporated. 
 88 mg (99% Yield) of pure product is obtained by silica gel chromatography: 11-13% 
EtOAc in Hexanes. 
 
General procedures for the 3-component unsymmetric bisallylation: 
 
15. 3- component bisallylation of α-nitroketones: 
 
 In a glove box under an argon atmosphere, a flame dried pressure vial equipped with a 
O2N
O BocO
HO
O2N
Ph Ph
S39b, FW: 231.29
isolated 103 mg, 89%
2.5 mol% Pd(PPh3)4
1 Equiv. Cs2CO3
DCM:DCE (1:1) 80 °C, 12ha
FW: 117.10
0.5 mmol, 59 mg
FW: 234.29
0.5 mmol, 117 mg
FW: 58.08
0.55 mmol, 32 mg
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septum was charged with Pd(PPh3)4 (14 mg, 0.0125 mmol) and Cs2CO3 (165 mg, 0.5 mmol). 
Anhydrous DCE (1 mL) was added and the vial sealed. After removing the vial from the glove 
box, a solution of α-methyl nitroacetone (58 mg, 0.5 mmol) and tert-butyl cinnamyl carbonate 
(117 mg, 0.5 mmol) in dry DCM (1 mL) was added via syringe and the transfer vessel was 
washed with 0.5 mL of DCM to ensure complete transfer of the substrates to the reaction 
mixture. Next, allyl alcohol (36 mg, 0.6 mmol) was injected via syringe and the resulting 
pressure vial was submerged in an oil bath at 80 °C and left to stir overnight.  
 After the allotted reaction time, the vessel was cooled to room temperature and the 
resulting solution was diluted with 15% EtOAc/hexanes (~5 mL) and eluted through a silica plug 
with excess 15% EtOAc/hexanes (~50-75 mL). After removal of the volatiles via rotary 
evaporation, the crude oil was subjected to column chromatography (gradient column: 2% 
EtOAc/Hexanes) yielding the pure product S39b as a colorless oil (103 mg, 89% Yield). 
 
16. 3-component bisallylation of α-phenyl acetylacetone derivatives: 
 
2 10 mL flame-dried Schlenk flasks equipped with stir bars are brought into a glove box. 
The first charged with Pd(PPh3)4 (2-3 mol%, 6-8 mg, FW:1155.57) and NaH (0.50 mmol, 12.5 
mg, FW: 24.00/95% purity). The other is charged with NaH (0.55 mmol, 13.5 mg, FW: 24.00) 
and capped.  The vessels are removed from the glove box. Outside the glove box the vessels are 
attached to a Schlenk apparatus.  Over argon, freshly distilled THF (3 mL) is added to the 
reaction mixture containing Pd and stirred.   α-phenyl acetylacetone (0.5 mmol, 88 mg) is added 
O
Ph
2.5 mol% Pd(PPh3)4
a equiv. NaH
O AcO HO
Ph Ph
Ph
O
THF, 60oC, 10-15min 60 °C, 1-12h
FW: 176.21
0.5 mmol,  88 mg
FW: 176.21
0.5 mmol, 88 mg
NaH +
FW: 58.08
0.52 mmol, 29 mg S42a, FW: 290.40isoalted 100mg, 69%
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neat to the reaction mixture. Cinnamyl acetate (0.5 mmol, 88 mg) is added neat dropwise to the 
reaction mixture. This transfer syringe is rinsed in the reaction mixture to ensure complete 
transfer of the acetate. This mixture is then submerged in an oil bath for 5-15 min. to allow the 
Tsuji-Trost to complete as monitored by TLC.  Once complete, remove from the oil bath and 
allow to warm to rt. 
 In the mean time, the other vessel, which only contains the NaH, is charged with 2 mL of 
dry THF and allyl alcohol (0.52 mmol, 29 mg) is added neat dropwise.  Rinse the transfer 
syringe in the alkoxide solution to ensure complete transfer of the substrate allyl alcohol.  
Transfer this alkoxide solution to the reaction mixture once the first Tsuji-Trost reaction is 
complete. 
 After the allotted reaction time as determined by TLC, work up the reaction as normal 
(see “procedure 3”). 100 mg of the desired product S42a is isolated by column chromatography 
(3 % EtOAc in hexanes). 
 
17. Improved procedure for scale-up 3-component bisallylation of α-tetralone 
derivatives: 
 
A flame-dried 25 mL Schlenk flask equipped with a stir bar is brought into a glove box 
and charged with NaH (2.1 equiv. 10.5 mmol, 253 mg) and Pd(PPh3)4 (3 mol%, 0.15 mmol, 173 
mg). The flask is capped, removed from the glove box and attached to a Schlenk argon line. 10 
mL of dry THF is then added.  Acetyl tetralone (5 mmol, 940 mg) is added as a solid slowly as 
O O
HO
PhPh
OAc
OH 2.5 mol% Pd(PPh3)4
a equiv. NaH
THF, 60 oC, 10-15min
then 0 oC - 60 oC 12h
FW: 188.22
5 mmol, 941.1 mg
S43c, FW: 316.44
isolated 1.3 g, 83%
FW: 176.21
5 mmol, 881.1 mg
FW: 72.11
5.2 mmol, 375 mg
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effervescence occurs.  Once effervescence ceases and all tetralone has been added, cinnamyl 
acetate (5 mmol, 880mg) is added dropwise and the mixture is heated at 60 °C for 10 min to 
allow the Tsuji-Trost reaction to complete (TLC analysis showed product/reagent overlap, thus 
mini-workup/1H-NMR was used to determine reaction completion).  Once the initial Tsuji-Trost 
reaction is complete, cool the vessel in an ice-bath and slowly drip in β-methylallyl alcohol (5 
mmol, 361 mg) via syringe. Rinse the syringe with the reaction solvent and reinject to ensure 
complete alcohol transfer.  Cap the vessel and completely seal the vessel over argon.  The vessel 
is then heated in an oil bath at 60 °C for 12h. 
 After the allotted reaction time (12h), the reaction mixture is diluted with 15% EtOAc in 
hexanes and filtered through a pad of silica gel with excess 15% EtOAc in hexanes (100mL). 
The solvent is evaporated and subjected to silica gel chromatography (3% EtOAc in Hexanes) to 
yield the pure product S43c (1.3 g, 83% yield). 
 
18. 3- component bisallylation of α-phenyl cyanoketone derivatives: 
 
“Procedure 16” is used to prepare nitrile based 1,6-heptadienes. 
 
Synthesis of α-nitroketones: 
 
19. Synthesis of α-nitroketones from nitroalkanes:2 
NC
O
Ph
NC
Ph
Ph
AcO Ph
2.5 mol% Pd(PPh3)4
1 equiv. NaH
DMSO, 60 °C 0.5h
FW: 159.18
0.5 mmol, 65 mg
FW: 176.21
0.5 mmol, 88 mg
S44a, FW: 273.37
isolated 117 mg, 86%
HO
60 °C, 1-12h
NaH +
FW: 58.08
0.52 mmol, 29 mg
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20. Synthesis of α-nitroketones from cyclic enol acetates:3 
 
 
21. Tsuji-Trost allylation of α-nitroketones: 
 
A flame-dried 10-mL Schlenk flask equipped with a stir bar is brought into a glove box 
and charged with Pd(PPh3)4 (2.5 mol%, 0.050mmol, 57 mg). The vessel is then capped, removed 
from the glove box, and attached to a Schlenk-argon line. The catalyst is then dissolved in 1 mL 
of anhydrous DCM. A mixture of nitroketone (234 mg, 2mmol) and allyl tert-butyl carbonate 
(234 mg, 1 mmol) is dissolved in 1 mL of DCM and injected into the reaction mixture. The 
N
N
O
2 equiv. NaH, DMSO, rt
R
O2N
O
O2N
O O2N
O
O2N
O
Bn
O2N
O
CO2Me
O2N
O
Ph
R
O2N
1.05 equiv
Known procedure:
J. Org. Chem. 1982, 47, 4040-4045.
S41a S8a A-2 (S40a) A-3 (S40a)A-1 (S40a)
AcO O
NO2
O NO2
known procedure:
Synthesis 1983, 545-546.
OAc NH4NO3, CF3CO2OCOCF3
or or
S8b = S40a S8c
O2N
O
BocO
2.5 mol% Pd(PPh3)4 DCM, 10min, rt O2N
O
FW: 117.10
2 mmol, 234 mg A-4 FW: 157.17isolated 220 mg, 70%
FW: 158.19
316 mg
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syringe is then washed with 100 µL of DCM and reinjected. Rapid effervescence ensues upon 
injection.  The mixture is stirred for 10 min. Without reaction work-up, the mixture is put 
directly onto a silica gel column and eluted with EtOAc/Hexanes (3.5 % EtOAc).  220 mg of 
product was isolated upon evaporation (70% Yield). 
 
 
 
 
 
Synthesis of β-carbonyl ketones: 
 
22. Formylation of ketones by Claisen condensation:4 
  
 A flame-dried 500 mL Schlenk flask equipped with a stir bar is brought into a glove box 
and charged with 95% NaH (72 mmol, 1.82g). The vessel is capped, removed from the glove box 
and attached to a Schlenk-argon line.  200 mL of dry THF is added and the slurry is stirred. 1 mL 
of EtOH is added to the reaction vessel dropwise.  The ketone (70 mmol) is loaded into a 
dripping funnel and dissolved in 100 mL of ethyl formate.  Slowly (over 30 min.) drip the 
substrate mixture into the reaction vessel. After complete addition the dripping funnel is removed 
O
1 equiv. NaH, HCO2Et (5-10 equiv), EtOH (cat), THF
O
H
OH
Ph O
H
OH
EtO
O
H
OH
O
H
OH
O
H
OH
O
C8H17
H
H HHO
HO
H
OH
A-5, 84% A-8, 91% A-9, 75% A-10, 99%
S9a (A4-9)
A-6 A-7
R RModified from the known procedure:
J. Am. Chem. Soc. 1944, 66, 218-222.
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and replaced with a rubber septum.  The reaction mixture is left to stir over argon for 12h (do not 
seal, pressure builds up over time). 
 After the allotted reaction time, add 200 mL of water and transfer to a seperatory funnel. 
A small amount (~10 mL) of 1N NaOH is added to the seperatory funnel. Wash the reaction 
flask with 150 mL of EtOAc and transfer into seperatory funnel. Extract the water layer with 2 x 
150 mL of EtOAc and discard the organic layer.  The basic water layer is acidified with 1N HCl 
until acidic. The now acid water layer is extracted with 2 x 200 mL portions of Et2O.  The ether 
layer is dried over MgSO4 and the volatiles are evaporated to yield the desired product.  
Commonly, the β-formyl ketone was of sufficient purity for direct use in the next reaction.  
However, purification by Kugelrohr distillation could also be performed. 
 
23. Synthesis of latter cyclohexanone A-11 by Wilds-Woodward reaction:5 
 
 A 20 mL µW vial is equipped with a stir bar and charged with PPh3 (1 mol% 0.2 mmol, 
52 mg).  β-formyl α-tetralone (20 mmol) is then added to the vessel. Methyl vinyl ketone (100 
mmol, ~ 8 mL) and ~5 mL of THF are added in subsequence to the reaction vessel. The vial is 
then capped with a rubber septum capable of with standing moderate pressure and submerged in 
an oil bath at 100 °C for 30 min.   
 After the allotted reaction time, the contents are cooled and poured directly into a 500 mL 
round-bottom flask. The original vial is washed with 2 x 5 mL of MeOH to ensure complete 
O OH
H
1 mol% PPh3
THF, 100 oC
Sealed Tube
O
COMe
CHO
3.5-6.3g
O
MeOH, KOH
100 oC, 12h
O
MeOC
100% conv. to retro-
Claisen PDT after 1 
min. as observed by 
mini-workup/1H NMR
A-11, 86-91%
Modifed procedure from the known method:
J. Am. Chem. Soc. 1949, 71, 3946-3950.
204 
transfer to the new vessel. An additional 100 mL of MeOH and a stir bar are then added to the 
round-bottom flask.  While stirring, a 1:1 mixture of MeOH:H2O containing 3.33 g of KOH is 
poured in over 1 min. Immediately after pouring in the basic solution the reaction mixture turns 
dark red (NMR analysis shows complete aldehyde removal).  The vessel and its contents are then 
refluxed over night. 
 After reaction overnight, cool the reaction mixture to room temperature and transfer the 
reaction mixture to a seperatory funnel.  Wash the reaction vessel with 2 x 400 mL portions of 
water and 1 x 500 mL portion of EtOAc to ensure complete transfer.  1N HCl is added until the 
reaction mixture is acidic (~20 mL). Collect the organic layer and rewash the water layer with an 
addition 100 mL of EtOAc.  Combine the organic layer, dry over MgSO4, and evaporate.  Silica 
gel chromatography yields the pure product (20 % EtOAc in hexanes). 
 
 24. Cu-catalyzed arylation of acetylacetone:6 
 
 
25. Synthesis of β-acetyl-diketones:7 
O O I
R
10 mol% CuI, 10 mol% proline
DMSO, 80oC, 12h
O O
O O
COMe
O O
NO2
O O
CN
O O
OMe
O O
F F
O O
NO2
O O
COMe
known procedure:
Synlett 2005, 2005, 2731-2734.
A-12 A-13 A-14 A-15 A-16 A-17 A-18
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 A flame-dried 500 mL Schlenk flask equipped with a stir is attached to a Schlenk-argon 
line and α-tetralone derivative (14 mmol) is added. 25 mL of acetic anhydride is then added and 
the reaction mixture is stirred.  Via syringe, 7.5 mL of BF3 OEt2 is added dropwise over 1 min. 
The reaction vessel is then capped and stirred 2h. 
 After the allotted reaction time, a large “handful” of ice is added piece by piece to quench 
the reaction.  40 mL of MeOH is then added to this ice slurry followed by 30 g of NaOAc. The 
reaction mixture is then heated at 70 °C for 45 min.  The reaction mixture is then poured into a 
seperatory funnel.  The reaction flask is then washed with 200 mL of EtOAc to ensure complete 
transfer. An additional 100 mL of EtOAc is added to the seperatory funnel.  The organic layer is 
then extracted with 3 x 100 mL portions 1N HCl followed by brine (~50 mL).  The organic layer 
is dried over MgSO4, and the volatiles are removed by rotary evaporation.  Residual acetic acid 
is removed azeotropically with toluene.  Column chromatography yields the desired β-acetyl 
tetralone derivative.    
 
26. Synthesis of acetyl-β-tetralone: 
O OH
Et
O HO
O OH
OMe
O OH
O 1. BF3•OEt2
O
O
RR
O
O
R
OBF2
Ice, NaOAc (s)
MeOH, 70oC, 0.5-1h
O
R
OH
uncharacterized
Quench Slowly with
CAUTION
O OH
MeO
O OH
F
A-23, 91%A-22, 60%
modified from known procedure:
Synth. Commun. 1998, 28, 2181-2190.
commercially
available
100% conv.
A-19
100% conv.
A-20
100% conv.
A-21
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 A flame-dried 500 mL Schlenk flask equipped with a stir bar is brought into a glove box 
and charged with 95% NaH (30 mmol, 760 mg). The vessel is capped, removed from the glove 
box and attached to a Schlenk-argon line. 30 mL of anhydrous DMSO is added to the NaH and 
the mixture is stirred. β-Tetralone (15 mmol, 2.2g) is added neat dropwise over 5 min and H2 
effervescence occurs. An additional 5 mL of DMSO is utilized to rinse the sides of the flask. 
Once H2 effervescence ceases acetyl imidazole (16 mmol, 1.76 g) is added as a solid over 5 min. 
Again, 5 mL of DMSO is used to rinse the sides of the flask.  The reaction mixture is then stirred 
for 30 min. 
 After the allotted reaction time, The reaction mixture is Diluted with 150 mL of EtOAc 
followed by 150 mL of 1N HCl.  The biphasic mixture is then transferred to a seperatory funnel.  
The water-layer is extracted by with 2 x 100 mL portions of EtOAc.  The organic layers are 
collected, dried over MgSO4, and the volatiles are removed by rotary evaporation.  The crude 
acetylated β-tetralone A-24 is used as is. 
 
27. Methylation of β-diketones: 
N
N
O 2 equiv. NaH, DMSO (0.5 M), rt, 30min
O O OH
FW: 146.19
15 mmol, 2.2 g
FW: 110.11
16 mmol, 1.76 g
A-24, FW: 188.22
isoalted 2 g, 72% yield
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 A 25 mL Schlenk flask equipped with is charged with K2CO3 (9 mmol), flame-dried and 
attached to a Schlenk-argon line.  The β-diketone (3 mmol) is then added to the reaction vessel.  
6 mL of DMSO is then added to the vessel. While stirring, 5 equiv. of MeI is added as a shot. 
The reaction vessel is seal and stirred at room temperature for an hour. 
 The reaction mixture is then diluted with EtOAc (~20 mL) and transferred to a seperatory 
funnel. The reaction vessel is then washed with an addition 20 mL of EtOAc to ensure complete 
transfer.  The organic layer is then extracted with 2 x 25 mL portions of 1N HCl followed by 
brine (1 x 25 mL).  The organic layer is dried over MgSO4 and the volatiles are evaporated 
yielding the crude product. Silica gel chromatography yields the desired product. 
 
 
28. Tsuji-Trost allylation (with allyl acetate) of β-diketones: 
R
O OH
3-5 equiv. K2CO3, 5 equiv. MeI
DMSO (0.5 M), rt, 1h R
O O
O Ac
NO2
O O
H
O O
Me
O O
Et
O Ac
OMe
O
O
A-26, 85%aA-25, >95%
O
O
A-27,>95 A-28,~85% A-29,99% A-30, >95% A-31,>95%
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Procedure A:  
 A flame-dried 25 mL Schlenk flask equipped with a stir bar and K2CO3 (9 mmol) is 
brought into a glove box and charged with Pd(PPh3)4 (1 mol%). The vessel is capped, removed 
from the glove box and attached to a Schlenk-argon line.  5 mL of THF is added to the flask 
followed by the substrate diketone (3 mmol) via syringe. The syringe is then rinsed in the 
reaction mixture to ensure complete transfer.  Allyl acetate (often in excess as it can easily be 
removed by rotary evaporation) is added as a shot and the reaction mixture is stirred at room 
temperature until reaction completion (1-12h) as monitored by TLC. Heating to 60 °C could also 
be done to speed up the reactions with no noticeable effect on the yields. 
 Once the reaction is complete, the reaction mixture is diluted with 15% EtOAc in 
hexanes and filtered through a pad of SiO2.  The vessel and the silica plug are rinsed with 50-75 
mL of the 15% EtOAc solution.  Evaporation followed by column chromatography yields the 
pure compounds A32-43. 
 
Procedure B:  
R
O OH Procdure A:3-5 equiv. K2CO3, 1 mol% Pd(PPh3)4, THF, rt
Procedure B:
or 1 equiv. NaH, THF, 1 mol% Pd(PPh3)4 R
O Ac
OAc
1.2-3 equiv.
O
NO2
Ac O
COMe
Ac O Ac
O Ac
F F
O
CN
Ac
O Ac
NO2
O
OMe
Ac O Ac O Ac
O AcO Ac
MeO
F
O Ac
OMe
>95% all cases
A-32 A-33 A-34 A-35 A-36 A-37
A-38 A-39 A-40 A-41 A-42 A-43
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The difference in this procedure is that 1 equiv. of NaH is used in lieu of 3-5 equiv. of 
K2CO3. As a full anion is formed, this reaction is often faster and just as high yielding. 
 
29. Tsuji-Trost allylation (with various allyl acetates) of β-diketones: 
 
“Procedure 28B” is utilized with the exception that only a single equivalent of the allyl 
acetate derivative is used as these allyl acetates are nonvolatile and/or more precious. 
 
30. Tsuji-Trost allylation (with technical grade allyl halides) of β-diketones: 
 
 “Procedure 28A” is utilized to couple the technical grade allyl halides. 
 
 
 
 
 
 
31. Tsuji-Trost allylation (with terpene allyl acetates) of β-diketones: 
O OH 1 Equiv. or NaH, THF
1 mol% Pd(PPh3)4 
 rt or 60 °C
OAc
1.05 equiv. R
O Ac
Ph
O Ac
Ph
O Ac
or or
A-44, 99% A-45, 99% A-46, 91%
O OH 1 mol%
Pd(PPh3)4
Cl
O
Ac
5 equiv. K2CO3, THF
60oC, 1h
Bror
technical grades from Aldrich
1.5 equivalents
O
Ac
A-48,83% YieldA-47, 91% Yield
or
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 “Procedure 28A” is used to couple terpene-based allyl acetates.  Excess of the terpene 
allyl acetate was required for the reaction to go to 100% conversion, presumably due to β-
elimination. 
 
32. Synthesis of the (±)-hamigeran precursor β-diketone:8 
 
 From the known tetralone A-52, the (±)-hamigeran precursor β-diketone A-53 is prepared 
using “procedures 25 and 27,” respectively. 
 
 
 
 
 
 
 
Synthesis of α-cyano ketones and esters: 
O OH
1 mol% Pd(PPh3)4OAc
O
Ac
R K2CO3, DMSO, 60oC
O
Ac
O
Ac
O
Ac
2-3 equiv.
A-49, 86% Yield A-50, 85% Yield A-51, 99% Yield
O
OMe
1 Ac2O, BF3•OEt2
2. K2CO3, MeI, DMSOOH
O
O
O O
OMe
Ac
A-52 A-53
known procedure:
J. Chem. Soc. 1956, 2173-2176.
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 33. Synthesis of α-aryl cyanoketones from benzyl cyanides: 
 
 “Procedure 26,” which prepared acetylated β-tetralone was utilized.  In turn, this 
procedure was based on a reported procedure for the acetylation of nitroalkanes. 
 
34. Methylation of α-aryl cyanoketones: 
 
“Procedure 27” for the methylation of β-diketones was utilized without incident. 
 
 
 
 
 
35. Tsuji-Trost allylation of α-aryl cyanoketones: 
NC
Ph
O NC
O
N
NC
O
NC
O
OMe
NC
O
OMe
MeO
NC
O
Cl
A-57, 94%A-53, 95% A-54, 86% A-55, 95% A-56, 95% A-58, 95%
N
N
O
2 equiv. NaH, DMSO, rt
Ar
NC
O
Ar
NC
1.05 equiv
modified from the known procedure:
J. Org. Chem. 1982, 47, 4040-4045.
NC
OH
5 equiv. K2CO3, 5 equiv. MeI
DMSO, rt, 1h
NC
Ph
O
NC
O
MeO OMe
Ph
NC
OH
OMe
OMe
or or
>95% Yields
A-59 A-60
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 “Procedure 28,” for the Tsuji-Trost allylation of β-diketones, was utilized. 
 
36. Synthesis of cyanoketone based verapamil precursor:  
 
A flame-dried 50 mL Schlenk flask is charge with 10 g of K2CO3 (72 mmol, FW = 138). 
10 mL of DMSO is added and the slurry is stirred. To this stirring mixture, acetyl 
homoveratronitrile (17.5 mmol, 3.9 g) is added as a solid. The sides of the vessel are washed 
with 10 mL DMSO. This ensures all reacts are in the solution.  2-iodopropane (72 mmol, 12.17 
g) is added via syringe in a single shot. After 4 hours, the reaction is complete (monitor by NMR 
via aliquot removal).   The reaction is transferred to a seperatory funnel and diluted with ~40 mL 
EtOAc.  The organic layer is extracted with 2 x 50 mL portions of aqueous NaHCO3 followed by 
brine (25 mL). The oganic layer is then dried, the volatiles are evaporated by rotary evaporation 
and the oily residuce is purified by gradient column chromatography, 10-15% w/v EtOAc in 
hexanes. 
Ar
NC
OH
5 equiv. K2CO3, 1 mol% Pd(PPh3)4, DMSO, rt, 1h
or 1 equiv. NaH, THF, 1 mol% Pd(PPh3)4 Ar
NC AcOAc
1.2-3 equiv.
NC
Ph
Ph
O NC
O
NC
Ph
Pr
O
NC
Ph
O
NC
O
N
NC
O
MeO
NC
O
Cl
A-61, 95% A-62, 89% A-63, 91% A-64, 75%a A-65, 95% A-66, 95% A-67, 95%
(a) use directly after isolation and purification due to decomposition
NC
O
OMe
OMe
5 equiv. K2CO3, DMSO, 5h, rt
NC
IPr
MeO OMe
O NC
MeO OMe
OiPr
I
~30%
S31a, FW: 219.24
17.5 mmol, 3.9g
FW: 169.99
72 mmol, 12.2 g
S31b, FW: 388.22
isoalted 3.1 g, 70%
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37. Tsuji-Trost allylation of cyanoacetic esters: 
 
 “Procedure 28” is utilized. 
 
38. Pd-catalyzed arylations of cyanoacetic esters:9 
 
 
39. Synthesis of verapamil precursor substrate from cyanoacetic ester:9 
 
 Hartwig’s known coupling or aryl bromides and cyano acetate is utilized in the first step 
of this reaction. “Procedure  27” is used to methylate the intermediate to arrive at the quaternized 
starting material S36a. 
 
Synthesis of allyl alcohols, acetates and carbonates: 
 
NC
Ph
OR
O
NC
Ph
OEt
O
NC
Ph
OiPr
O
OAc
5 equiv. K2CO3, 1 mol% Pd(PPh3)4, THF, rt, 1h
2 equiv. >95% yields
or
S33c S33d
Ph
NC
O
OiPr
Ph
NC
O
OR
Ph
ArBr, 2 mol% Pd(dba)2, 3 mol% PtBu3
5 equiv. Na3PO4, Tol, 70 °C, 12h
A-68 (S37a)
Ph
NC
O
OEt
CF3
or
A-69 (S37a)
known procedure:
J. Org. Chem. 2002, 67, 541-555.
CO2iPrNC
i. 2 mol% Pd(dba)2, 3 mol% PttBu3, NacPO4, Tol, 70oC
known procedure: J. Org. Chem. 2002, 67, 541-555.
ii 3 equiv. 2-iodopropane, 5 equiv. K2CO3, DMSO
CO2iPrNC
iPr
MeO OMe
Br
MeO OMe
3 equiv.
S36a
2 steps, 92% yield
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 40. Synthesis of various allyl tert-butyl carbonates10 
 
 
41. Synthesis of cyclopropylallyl alcohol and acetate:11 
 
 
42. Synthesis of dienylallyl alcohol 
 
 “Procedure 34” is utilized with acrolein in lieu of cyclopropyl carbaldehyde. 
 
43. Synthesis of β-phenylallyl alcohol and acetate:12 
 
 
  
44. Synthesis of Baylis-Hillman adduct allyl alcohol 
HO R
Boc2O, Bu4NHSO4, DCM:H2O
BocO BocO Ph BocO Pror or
known procedure:
Can. J. Chem. 1985, 63, 153-162.
H
O
PEtO
O
OEt OEt
O O
OEt
OH
OAc
NaH, THF, rt
AcCl, pyr, DCM, 0 °C-rt
2 equiv. DIBAL, -78°C-rt
quench: Rochelle's salt (aq)
known procedure:
J. Org. Chem. 2001, 66, 4433-4436.
OH
O
OEt
O Ph3P OEt
O DCM, rt, 3h 2 equiv. DIBAL, -78°C-rt
quench: Rochelle's salt (aq)
OH
Ph
OH PhMgBr
CuI, THF, 50 °C
OAc
PhAcCl, pyr, DCM, 0 °C-rt
known procedure:
J. Org. Chem. 2009, 74, 9191-9194.
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 A 250 mL round-bottom flask equipped with a stir bar is charged with DABCO (50 
mmol, 5.6g). 30 mL of H2O is then added followed by paraformaldehyde (100 mmol, 3.03 g).  
MeCN is then added with heating at 80 °C until the reaction mixture is homogeneous (~30 mL). 
Tert-butyl acrylate(50 mmol, 6.4 g, 7.3 mL) is then added as a shot.  The reaction mixture is 
heated for 2.5 h. 
 After the allotted reaction time, the reaction mixture is diluted with 100 mL of DCM and 
transferred to a seperatory funnel. An additional 100 mL DCM is used to wash the reaction 
vessel to ensure complete transfer.  The DCM layer is then extracted with 100 mL of 1N HCl 
followed by brine (50 mL).  The volatiles are removed by rotary evaporation and the crude oil is 
subjected to column chromatography (20% EtOAc in hexanes) to yield the desired product A-62. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spectral and chromatographic data:  
 
O
O
N
N
HCHOn
H2O/MeCN, 80oC
O
OHO
75% Yield
50 mmol
6.4g, 7.3mL
50 mmol
5.6g
100 mmol
3.03g
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1. Tertiary nitroalkanes and ketones: 
 
 
 
S8d: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
 δ = 5.48 (dt, J = 14.4, 6.9 Hz, 1H), 1H), 5.23 (dtt, J = 14.5, 7.2, 1.4 Hz, 1H), 4.48 (apparent 
sextet, J = 6.7 Hz, 1H), 2.57 (dt, J = 14.6, 7.4 Hz, 1H), 2.37 (dt, J = 13.6, 6.6 Hz, 1H), 1.90 
(apparent q, J =6.7 Hz, 2H), 1.45 (d, J =5.2 Hz, 3H), 1.29 (apparent sextet, J = 7.4 Hz, 2H), 0.81 
(t, J =7.3 Hz, 3H).   
 
13C NMR (126 MHz, CDCl3): 
 
 δ = 134.3, 121.2, 81.7, 36.7, 32.9, 20.7, 16.9, 11.9.  
 
GC-MS:  
 
e/z: found 157.1 (M-NO2) 46 (NO2+). 
 
S8e: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ = 7.25 (m, 4H), 7.20 – 7.14 (m, 1H), 6.43 (d, J =15.8 Hz, 1H), 6.00 (dt, J =15.7, 7.3 Hz, 1H), 
4.60 (apparent sextet, J = 13.4, 6.6 Hz, 1H), 2.82 (dtd, J = 14.7, 7.4, 1.3 Hz, 1H), 2.59 (dtd, J = 
14.0, 7.3, 1.3 Hz, 1H) 1H), 1.52 (d, J =6.7 Hz, 3H).  
O2N Pr O2N Ph
S8d S8e
CO2MeO2N
S8g
CO2MeO2N
S8f
O
C8H17
H
H H
O
Ph O O
EtO
O
S9gS9e S9fS9c S9d
O2N Pr
O2N Ph
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13C NMR (126 MHz, CDCl3): 
 
 δ = 136.5, 134.6, 128.6, 127.8, 126.3, 122.5, 82.9, 38.5, 18.7.   
 
GC-MS e/z: found 191.2 (M+), 145.2 (M-NO2) 46 (NO2+). 
 
S8f: 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ = 5.62 (m, 1H), 5.09 (d, J = 6.4 Hz, 1H), 5.08 (d, J = 10.5, 1H) 4.44 (m, 1H), 3.60 (s, 3H), 
2.60 (dt, J = 15.4, 8.1 Hz, 1H), 2.42 (dt, J = 13.3, 6.1 Hz, 1H), 2.25 (t, J =7.3 Hz, 2H), 2.93 (m, 
1H), 1.62 (m, 3H), 1.30 (m, 2H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ = 173.6, 131.4, 119.6, 87.9, 51.6, 37.9, 33.6, 32.9, 25.2, 24.2.  
 
GC-MS e/z: found 157.1 (M-NO2) 46 (NO2+). 
 
S8g: 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ = 5.63 (m, 1H), 5.08 (d, J = 7.5 Hz, 1H), 5.07 (d, J = 10.0 Hz, 1H) 4.43 (m, 1H), 3.61 (s, 3H), 
2.61 (dt, J = 15.3, 8.1 Hz, 1H), 2.41 (dt, J = 13.3, 6.0 Hz, 1H), 2.23 (t, J =7.4 Hz, 2H), 1.92 (m, 
1H), 1.66 (m, 1H), 1.55(m, 2H), 1.28 (m, 4H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ = 173.9, 131.5, 119.4, 88.1, 51.5, 37.9, 33.8, 33.0, 28.4, 25.4, 24.5. MS e/z: found 229.3 (M+) 
182.3 (M-NO2) 46.0 (NO2+). 
 
 
S9e: 
 
CO2MeO2N
CO2MeO2N
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Single diastereomer, relative stereochemistry currently unknown 
 
1H NMR (500 MHz, CDCl3) 
 
δ 7.70 (d, J = 7.9 Hz, 1H), 7.24 (dd, J = 7.4, 1.2 Hz, 1H), 7.17 (d, J = 7.8 Hz, 1H), 7.12 (d, J = 
7.6 Hz, 1H), 6.57 (d, J = 2.4 Hz, 1H), 5.76 (m, 1H), 5.01 (m, 2H), 2.92 (ddd, J = 17.1, 12.8, 4.6 
Hz, 1H), 2.87 (m, 1H), 2.72 (m, 1H), 2.63 (m, 1H), 2.36 (m, 1H), 2.15 (dt, J = 13.02, 4.15 Hz, 
1H), 2.10 (dd, J = 14.12, 6.72 Hz, 1H), 1.99 (ddd, J = 12.6, 6.8, 4.2 Hz, 1H), 1.53 (m, 2H). 
 
13C NMR (126 MHz, CDCl3) 
 
δ 200.93, 157.65, 139.69, 136.38, 131.23, 130.49, 129.67, 126.61, 125.28, 120.39, 116.75, 45.61, 
37.59, 35.52, 33.74, 30.60, 29.99. 
 
S9f: 
 
 
 
Isolated at a ~3:1 mixture of diastereomers: 
 
1H NMR (500 MHz, CDCl3): 
 
δ 5.69 (m, 1H), 4.93 (m, 3H), 2.50 (m, 1H), 2.41 (m, 3H), 2.27 (m, 3H), 2.00 (m, 2H), 1.83 (t, J 
= 1.4 Hz, 3H), 1.75 (m, 4H), 1.68 (s, 4H), 1.61 (m, 1H), 1.32 (m, 1H), 0.96 (d, J = 6.5 Hz, 3H), 
0.82 (d, J = 7.1 Hz, 1H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 206.99, 206.86, 140.52, 138.47, 136.95, 136.18, 132.99, 132.44, 116.23, 115.88, 57.49, 55.84, 
34.73, 33.87, 33.66, 31.15, 30.94, 30.71, 28.02, 26.93, 22.59, 22.55, 21.71, 21.51, 20.43, 14.70. 
 
S9g: 
 
O
O
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1H NMR (500 MHz, CDCl3): 
 
δ 5.71 (m, J = 7.6 Hz, 1H), 5.64 (d, J = 1.6 Hz, 1H), 4.97 (m, 2H), 2.63 (m, 1H), 2.31 (m, J = 
4.4 Hz, 2H), 2.20 (m, 1H), 1.98 (m, 3H), 1.76 (m, 2H), 1.12 (alaphatics, 36H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 200.41, 170.56, 136.57, 123.50, 116.47, 56.10, 55.86, 54.19, 42.36, 41.56, 41.48, 39.62, 39.50, 
39.16, 36.11, 35.75, 35.48, 33.43, 32.54, 31.98, 28.17, 28.02, 24.17, 23.82, 22.83, 22.57, 20.90, 
18.64, 17.52, 11.96. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O
C8H17
H
H H
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2. DaA products: nitro compounds: 
 
 
 
S14a: 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ = 5.61 (m, 2H), 5.12 (d, J = 8.9 Hz, 2H), 5.09 (d, J = 16.3 Hz, 2H), 2.67 (dd, J = 14.2, 7.3 Hz, 
2H), 2.48 (dd, J =14.2, 7.3 Hz, 2H), 1.47 (s, 3H).  
 
13C NMR (126 MHz, CDCl3): 
 
δ = 128.7, 118.4, 88.3, 41.2, 19.6. 
 
GC-MS e/z: found 109.2 (M-NO2) 46.0 (NO2+). 
 
S14b = S39b = S39b’: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ = 7.25 (m, 4H), 7.17 (m, 2H), 6.41 (d, J =15.7 Hz, 1H), 5.96 (dt, J = 15.3, 7.5 Hz, 1H), 5.63 
(m, 1H), 5.14 (d, J = 9.2 Hz, 1H), 5.11 (d, J = 16.36 Hz, 1H) 2.83 (ddd, J = 14.2, 7.3, 1.3 Hz, 
1H), 2.72 (dd, J = 14.2 7.3 Hz, 1H), 2.63 (ddd, J = 14.2, 7.8, 1.3 Hz, 1H), 2.52 (dd, J = 14.2, 7.7 
Hz, 1H), 1.51 (s, 3H). 
 
O2N O2N
S14e
O2N
S14f
O2N Ph O2N Pr O2N
S14a, S14b = S39b = S39b' S14c = S39c - S39c' S14d
O2N
Ph
Ph
O2N
Bn
Ph
S39e S39f
O2N
Ph
Pr
S39d
O2N
Ph
MeO2C
O2N
Pr
MeO2C
S39g S39h
O2N
Ph
MeO2C
Pr
S39i
MeO2C
NO2
Ph
S40b
O2N
Ph
PhS41b
O2N
O2N Ph
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13C NMR (126 MHz, CDCl3) 
 
δ = 136.6, 135.4, 130.8, 128.6, 127.8, 126.3, 122.0, 120.7, 90.9, 43.5, 42.6, 22.1. 
 
GC-MS e/z: found 231.2(M+) 185.2 (M-NO2) 46.0 (NO2+). 
 
S14c = S39c = S39c’: 
 
 
 
1H NMR (500 MHz, CDCl3) δ = 5.60 (m, 1H), 5.47 (dt, J =14.6, 6.8 Hz, 1H), 5.20 (dt, J = 14.7, 
7.3 Hz, 1H), 5.10 (d, J = 9.1 Hz, 1H), 5.07 (d, J = 16.2 Hz, 1H) 2.66 (dd, J = 14.2, 7.3 Hz, 1H), 
2.59 (dd, J = 14.2, 7.3 Hz, 1H), 2.42 (m, 2H), 1.91 (apparent q, J = 6.6 Hz, 2H), 1.43 (s, 2H), 
1.30 (apparent sextet, J = 7.4 Hz, 2H), 0.80 (t, J =7.4 Hz, 3H).  
 
13C NMR (126 MHz, CDCl3) δ = 135.1, 129.2, 120.4, 118.6, 89.2, 41.6, 40.7, 32.8, 20.6, 20.0, 
11.8.  
 
GC-MS e/z: found 151.3 (M-NO2) 46.0 (NO2+). 
 
S14d: 
 
 
 
Major Diastereomer Reported 
 
1H NMR (500 MHz, CDCl3): 
 
δ = 5.59 (m, 2H), 5.49 (m, 1H), 5.22 (dtq, J = 14.8, 7.5, 1.6 Hz, 1H), 5.10 (d, J = 9.1 Hz, 1H), 
5.07 (d, J = 15.1 Hz) 2.65 (dd, J = 14.4, 7.1 Hz, 1H), 2.57 (dd, J =14.4, 7.5 Hz, 1H), 2.42 (m, 
2H), 1.60 (d, J = 6.8 Hz, 3H), 1.43 (s, 3H). 
 
13C NMR (126 MHz, CDCl3) δ = 131.4, 131.1, 123, 120, 90, 43, 42, 21, 18. MS e/z: found 169.2 
(M+) 123.2 (M-NO2) 46.0 (NO2+). 
 
S14e: 
 
 
1H NMR (500 MHz, CDCl3): 
O2N Pr
O2N
O2N
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δ = 5.60 (m, 1H), 5.11 (d, J = 10.1 Hz, 2H), 5.08 (d, J = 17.8 Hz, 1H) 4.86 (s, 1H), 4.67 (s, 1H), 
2.78 (d, J =14.2 Hz, 1H), 2.72 (dd, J =14.1, 7.0 Hz, 1H), 2.41 (dd, J = 14.1, 7.6 Hz 1H), 2.40 (d, 
J = 14.2 Hz, 1H) 1.61 (s, 3H), 1.47 (s, 3H). 
 
13C NMR (126 MHz, CDCl3) δ = 139.4, 130.9, 120.7, 116.7, 90.5, 47.3, 44.6, 23.4, 21.4. 
 
GC-MS e/z: found 123.2 (M-NO2) 46.0 (NO2+). 
 
S14f: 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 6.22 (dt, J = 16.9, 10.3 Hz, 1H), 6.06 (dd, J = 15.1, 10.5 Hz, 1H), 5.60 (m, 1H), 5.45 (dt, J = 
15.1, 7.8, Hz, 1H), 5.11 (d, J = 9.35 Hz, 2H), 5.08 (d, J = 8.4 Hz, 1H), 5.01 (d, J = 10.3 Hz, 1H), 
2.68 (dt, J = 14.7, 7.2 Hz, 2H), 2.49 (dt,  J = 22.8, 7.5 Hz,  2H), 1.46 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 135.23, 135.16, 129.77, 125.02, 119.64, 116.49, 89.72, 42.38, 41.17, 20.98. 
 
GC/MS data: 181.4 (M+), 135.3 (M-NO2), 67.1 (base peak). 
 
S39g: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ = 7.25(m, 4H), 7.18 (m, 2H), 6.43 (d, J =15.7 Hz, 1H), 5.92 (dt, J = 15.8, 7.5 Hz, 1H), 5.61 
(m, 1H), 5.18 (d, J = 5.7 Hz, 1H), 5.15 (d, J = 14.8 Hz, 1H), 3.62 (s, 3H), 2.80 (ddd, 15.8, 7.5, 
1.2 Hz, 1H), 2.72 (dd, J =13.9, 7.2 Hz, 1H), 2.69 (dd, J = 13.9, 7.6 Hz, 1H) 2.62 (dd, 14.6, 7.5 
Hz, 1H), 2.27 (m, 4H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ = 172.4, 136.5, 135.7, 130.4, 128.6, 127.9, 126.4, 121.4, 121.1, 92.8, 51.9, 39.7, 39.1, 30.9, 
28.5.  
 
O2N
O2N
Ph
MeO2C
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MS e/z: found 257.2 (M-NO2) 46.0 (NO2+). 
 
S39h: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ = 5.57 (m, 1H), 5.52 (m, 1H) 5.16 (dt, J = 15.7, 7.3 Hz, 1H), 5.13 (d, J = 9.1 Hz, 1H), 5.12 (d, 
J = 17.6 Hz, 1H), 3.62 (s, 3H), 2.56 (m, 4H), 2.24 (m, 2H), 2.18 (m, 2H), 1.92 (apparent q, J = 
7.0 Hz, 2H), 1.29 (apparent sextet, J = 7.3 Hz, 2H), 0.81 (t, J = 7.3 Hz, 3H).  
 
13C NMR (126 MHz, CDCl3) δ = 172.5, 137.2, 130.5, 121.6, 120.8, 92.9, 51.9, 39.5, 38.7, 34.7, 
30.6, 28.5, 22.3, 13.6.  
 
GC-MS e/z: found 223.3 (M-NO2) 46.0 (NO2+). 
 
S39i: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ = 7.26 (m, 3H), 7.17 (m, 2H), 6.42 (d, J =15.7 Hz, 1H), 5.92 (dt, J = 15.7, 7.5 Hz, 1H), 5.53 
(dt, J = 15.2, 6.9 Hz, 1H), 5.21 (dt, J = 15.2, 7.25 Hz, 1H), 3.62 (s, 3H), 2.78 (ddd, J = 14.6, 7.5, 
1.2 Hz, 1H), 2.70 (ddd, J = 14.6, 7.5, 1.0 Hz, 1H) 2.61 (dd, J = 14.6, 7.3 Hz, 1H), 2.54 (dd, J = 
14.6, 7.3 Hz, 1H) 2.29 (m, 2H), 2.23 (m, 2H), 1.94 (apparent quartet, J = 7.1 Hz, 2H), 1.32 
(apparent sextet, J = 7.1 Hz, 2H), 0.82 (t, J =7.2 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ = 172.5, 137.3, 136.5, 135.4, 128.6, 127.8, 126.3, 121.6, 93.1, 51.9, 38.9, 38.8, 34.6, 30.7, 
28.5, 22.3, 13.6.  
 
GC-MS e/z: found 299.2 (M-NO2) 46.0 (NO2+). 
 
S39e: 
 
O2N
Pr
MeO2C
O2N
Ph
MeO2C
Pr
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1H NMR (500 MHz, CDCl3): 
 
δ = 7.32 (m, 5H), 7.20 (m, 5H), 6.40 (d, J =15.8, 1H), 5.74 (dt, J = 15.8, 7.5 Hz, 1H), 5.45 (m, 
1H) 5.13 (d, J =  6.1 Hz, 1H), 5.12 (d, J = 10.9 Hz, 1H), 3.29 (dd, J = 14.3, 7.8 Hz, 1H), 3.16 
(m, 2H), 3.04 (dd, J = 14.0, 6.8 Hz, 1H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ = 138, 136, 135, 130, 129, 128, 128, 127, 126, 125, 121, 120, 95, 39, 39. 
 
GC-MS e/z: found 293.2 (M+) 247.2 (M-NO2) 46.0 (NO2+). 
 
S39f: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ = 7.25 (m, 8H), 7.07 (m, 2H), 6.45 (d, J =15.8 Hz, 1H), 6.01 (dt, J = 15.8, 7.4 Hz, 1H), 5.73 
(m, 1H), 5.21 (d, J = 10.2 Hz, 1H), 5.18 (d, J =  17.4 Hz, 1H), 3.20 (s, 2H), 2.84 (dd, J = 14.6, 
7.2 Hz, 1H), 2.69 (m, 2H), 2.58 (dd, J = 14.6, 7.3 Hz, 1H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ = 136.7, 135.6, 134.4, 130.9, 129.9, 128.7, 127.8, 127.6, 126.3, 122.1, 120.9, 94.3, 42.6, 39.2, 
38.4.  
 
GC-MS e/z: found 307.3 (M+) 261.3 (M-NO2) 46.0 (NO2+). 
 
S39d: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ = 7.32 – 7.12 (m, 5H), 6.40 (d, J =15.7 Hz, 1H), 5.96 (dt, J = 15.7, 7.6 Hz, 1H), 5.49 (dt, J = 
15.2, 6.8 Hz, 1H), 5.23 (dt, J = 15.2, 7.4 Hz, 1H), 2.82 (ddd, J = 14.4, 7.3, 1.2 Hz, 1H), 2.63 (m, 
O2N
Ph
Ph
O2N
Bn
Ph
O2N
Ph
Pr
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2H), 2.45 (dd, J = 14.2, 7.5 Hz, 1H), 1.92 (apparent quartet, J = 7.3 Hz, 2H), 1.49 (s, 3H), 1.36 – 
1.25 (apparent sextet, J = 7.3 Hz, 2H), 0.82 (t, J = 7.3 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ = 136.9, 136.6, 135.2, 128.6, 127.7, 126.3, 122.3, 122.2, 91.2, 42.6, 42.6, 34.7, 22.3, 22.0, 
13.6.  
 
GC-MS e/z: found 273.3 (M+) 227 (M-NO2) 46.0 (NO2+). 
 
S40b: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ = 7.35 (m, 4H), 7.27 (m, 2H), 6.51 (d, J =15.7 Hz, 1H), 5.91 (dt, J = 15.7, 7.6 Hz, 1H), 5.69 
(m, 1H), 5.15 (d, J = 5.2 Hz, 1H), 5.12 (d, J = 14.2 Hz, 1H), 3.60 (s, 3H), 2.74 (m, 2H), 2.64 (m, 
2H), 2.25 (t, J =7.3 Hz, 2H), 1.97 (m, 2H), 1.67 (m, 2H), 1.35 (m, 2H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ = 173.6, 136.6, 135.3, 130.8, 128.6, 127.8, 126.3, 121.9, 120.6, 93.7, 51.6, 39.6, 38.9, 35.4, 
33.5, 24.7, 22.9. 
 
GC-MS e/z: found 331.2 (M+) 285.2 (M-NO2) 46.0 (NO2+). 
 
S41b: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ = 7.25 (m, 8H), 7.18 (m, 2H), 6.45 (d, J =15.7 Hz, 2H), 5.98 (dt, J = 15.5, 7.5 Hz, 2H), 5.68 
(m, 1H), 5.17 (d, J = 4.4 Hz, 1H), 5.15 (d, J = 11.9 Hz, 1H), 2.80 (dd, J =7.5 Hz, 1.1, 4H), 2.69 
(d, J =7.3 Hz, 2H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ = 136.6, 135.5, 130.6, 128.6, 127.8, 126.3, 121.8, 120.9, 93.6, 39.9, 39.1. 
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3. DaA products: ketone compounds (from acetylacetone): 
 
 
 
S16b: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
O
O2N
O
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O
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O
O2N
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O
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δ = 8.16 (d, J = 8.9 Hz, 2H), 7.30 (d, J = 8.9 Hz, 2H), 5.35 (m, 2H), 5.02 (s, 2H), 5.00 (d, J = 
5.8 Hz,, 2H), 2.70 (d, J =7.2 Hz, 4H), 1.86 (s, 3H).  
 
13C NMR (126 MHz, CDCl3): 
 
δ = 207.6, 148.7, 146.9, 132.0, 127.7, 123.9, 119.6, 59.5, 37.5, 26.5.  
 
GC-MS e/z: found 259.3 (M+) 213.3 (M-NO2) 46.0 (NO2+). 
 
S16c = S42c 
 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ = 8.18 (d, J = 8.9 Hz, 2H), 7.34 (d, J = 8.9 Hz, 2H), 7.18 (m, 6H), 6.33 (d, J = 15.7 Hz, 1H), 
5.68 (dt, J = 15.7, 7.3 Hz, 1H), 5.42 (m, 1H), 5.05 (m, 2H), 2.85 (d, J = 5.5 Hz, 2H), 2.75 (d, J = 
7.2 Hz, 2H), 1.91 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ = 207.6, 148.7, 147.0, 136.8, 134.4, 132.0, 128.5, 127.8, 127.6, 126.1, 124.0, 123.4, 119.7, 
59.8, 37.6, 37.0, 26.5. 
 
GC-MS e/z: found 289.2 (M-NO2) 46.0 (NO2+). 
 
S16d: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ = 8.16 (d, J = 8.9 Hz, 2H), 7.29 (d, J = 8.9 Hz, 2H), 5.36 (m, 2H), 4.97 (m, 3H), 2.67 (m, 4H), 
1.85 (s, m, 5H), 1.23 (m, 2H), 0.77 (t, J = 7.3 Hz, 3H). 
 
O
O2N
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O
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13C NMR (126 MHz, CDCl3): 
 
δ = 207.9, 149.0, 146.9, 135.8, 132.3, 127.8, 123.9, 123.2, 119.4, 59.8, 37.7, 36.3, 34.7, 26.58, 
22.5, 13.6. 
 
GC-MS e/z: found 301.2 (M+). 
 
S16e: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ = 8.16 (d, J = 8.9 Hz, 2H), 7.34 (d, J = 8.9 Hz, 2H), 5.44 (m, 1H), 5.04 (m, 2H), 4.78 (s, 1H), 
4.55 (s, 1H), 2.87 (m, 1H), 2.78 (m, 2H), 2.64 (d, J =14.6 Hz, 1H), 1.88 (s, 3H), 1.28 (s, 3H). 
 
13C NMR (126 MHz, CDCl3) 
 
δ = 207.9, 149.3, 146.8, 140.7, 132.3, 127.9, 123.8, 119.6, 116.0, 59.4, 41.2, 37.1, 26.6, 24.3.  
 
GC-MS e/z: found 273.2 (M+) 227.2 (M-NO2) 46.0 (NO2+). 
 
S16g = S17b = S18a: 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.25 (m, aromatics, 3H), 7.11 (m, aromatics, 2H), 5.37 (m, 2H), 4.98 (dd, J = 15.3, 6.0 Hz, 
4H), 2.67 (m, 4H), 1.83 (s, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 209.45, 141.13, 133.24, 128.81, 127.14, 126.66, 118.57, 58.93, 37.44, 26.24. 
 
GC/MS data: 214.1 (M+), 271.1 (M-Ac, base peak). 
 
S18b = S42a: 
 
O
O2N
O
Ph
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1H NMR (500 MHz, CDCl3): 
 
δ 7.31 (m, 2H), 7.18 (m, 9H), 6.32 (d, J = 15.8 Hz, 1H), 5.72 (dt, J = 15.7, 7.4 Hz, 1H), 5.44 (m, 
1H), 5.02 (dd, J = 12.1, 3.57 2H), 2.80 (dd, J = 7.4, 1.3 Hz, 2H), 2.71 (dd, J = 8.4, 7.3 Hz, 2H), 
1.85 (s, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 209.46, 141.13, 137.29, 133.51, 133.19, 128.89, 128.47, 127.23, 126.68, 126.09, 125.03, 
118.73, 59.31, 37.54, 36.94, 26.30. 
 
GC/MS data: 290.2 (M+), 247.1 (M-Ac, base peak). 
 
S18c: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.28 (m, 2H), 7.20 (m, 1H), 7.10 (m, 2H), 5.36 (m, 2H), 4.96 (m, 3H), 2.62 (m, 4H), 1.86 
(apparent quartet, J = 7.12, 2H), 1.82 (s, 3H), 1.25 (apparent sextet, J = 7.12, Hz, 2H), 0.77 (t, J 
= 7.12 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
13C NMR (126 MHz, CDCl3) δ 209.70, 141.39, 134.76, 133.54, 128.72, 127.01, 126.71, 124.26, 
118.29, 59.15, 37.65, 36.03, 34.75, 26.29, 22.60, 13.60. 
 
GC/MS data: 256.2 (M+), 213.1 (M-Ac, base peak). 
 
S18d: 
 
 
 
1H NMR (500 MHz, CDCl3): 
O
Ph
Ph
O
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Pr
O
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δ 7.27 (m, aromatics, 2H), 7.20 (m, aromatics, 1H), 7.14 (m, 2H), 5.48 (m, 1H), 5.01 (dd, J = 
16.85, 7.71,  2H), 4.74 (s, 1H), 4.56 (s, J = 0.9 Hz, 1H), 2.84 (dd, J = 5.86, 5.86 Hz, 1H), 2.73 
(dt, 2H), 2.59 (d, J = 14.4 Hz, 1H), 1.83 (s, 3H), 1.22 (s, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 209.78, 141.89, 141.68, 133.53, 128.76, 127.14, 126.85, 118.63, 115.17, 58.80, 41.13, 36.77, 
26.32, 24.15 
 
GC/MS data: 228.2 (M+), 185.1 (M-Ac, base peak). 
 
S42b: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.29 (m, 2H), 7.18 (m, 8H), 6.35 (d, J = 15.8 Hz, 1H), 5.80 (dt, J = 15.8, 8.0, Hz, 1H), 4.78 (s, 
1H), 4.61 (s, 1H), 2.98 (dd, J = 14.5, 6.4, Hz, 1H), 2.89 (dd, J = 14.5, 8.1 Hz, 1H), 2.78 (d, J = 
14.5 Hz, 1H), 2.65 (d, J = 14.5 Hz, 1H), 1.88 (s, 3H), 1.29 (s, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 209.84, 141.80, 141.64, 137.30, 133.60, 128.83, 128.49, 127.26, 127.22, 126.85, 126.14, 
126.10, 125.26, 115.22, 59.04, 41.25, 36.25, 26.38, 24.20. 
 
GC/MS data: 304.2 (M+), 261.1 (M-Ac, base peak). 
 
S18g: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.89 (d, J = 8.5 Hz, 2H), 7.22 (d, J = 8.5 Hz, 2H), 5.36 (m, 2H), 5.00 (dd, J = 8.0, 10.2 Hz, 
4H), 2.69 (d, J = 7.3 Hz, 4H), 2.54 (s, 3H), 1.84 (s, 3H). 
 
Ph
Ph
O
O
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13C NMR (126 MHz, CDCl3):  
 
δ 208.43, 197.60, 146.63, 135.98, 132.61, 128.81, 127.00, 119.10, 59.33, 37.45, 26.64, 26.41. 
 
GC/MS data: 256.1 (M+), 114.2 (M-Ac), 173.1 (base peak). 
 
S42d: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.90 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 7.17 (m, 5H), 6.36 (d, J = 15.8 Hz, 1H), 
5.78 (dt, J = 15.8, 7.6 Hz, 1H), 4.80 (s, 1H), 4.61 (s, 1H), 2.99 (dd, J = 14.8, 6.5 Hz, 1H), 2.94 
(dd,  J = 14.8, 8.1 Hz, 1H), 2.81 (d, J = 14.8 Hz, 1H), 2.69 (d, J = 14.8 Hz, 1H), 2.56 (s, 3H), 
1.85 (s, 3H), 1.31 (s, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 208.84, 197.62, 147.19, 141.19, 137.06, 136.00, 134.04, 128.81, 128.53, 127.44, 127.20, 
126.12, 124.48, 115.65, 59.45, 41.26, 36.34, 26.66, 26.54, 24.29. 
 
GC/MS data: 346.2 (M+), 303.2 (M-Ac, base peak). 
 
S18e: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.97 (d, J = 8.6 Hz 2H), 7.35 (d, J = 8.6 Hz 2H), 5.47 (m, 1H), 5.04 (dd, J = 12.4, 4.3 Hz 2H), 
2.71 (d, J = 7.3 Hz, 2H), 2.62 (s, 3H), 1.95 (s, 3H), 1.52 (s, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
Ph
O
MeOC
O
MeOC
232 
δ 209.36, 197.62, 147.76, 135.89, 133.47, 128.81, 126.72, 118.71, 55.87, 42.26, 26.64, 26.09, 
21.11. 
 
GC/MS data: 230.1 (M+), 188.2 (M-Ac, base peak). 
 
S18f: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.96 (d, J = 8.7 Hz, 2H), 7.39 (d, J = 8.7 Hz, 2H), 4.80 (s,1H), 4.58 (s, 1H), 2.79 (d, J = 13.9, 
1H), 2.69 (d, J = 14.0 Hz, 1H), 2.62 (s, 3H), 1.95 (s, 3H), 1.58 (s, 3H), 1.32 (s, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 209.54, 197.63, 148.10, 141.79, 135.86, 128.71, 126.98, 115.54, 55.60, 45.56, 26.64, 26.04, 
24.19, 20.65. 
 
GC/MS data: 244.1(M+), 201.2 (M-Ac, base peak). 
 
S18l: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 8.17 (m, aromatics, 2H), 7.57 (m, aromatics, 2H), 5.48 (m, 1H), 5.07 (m, 2H), 2.73 (d, J = 7.6 
2H), 1.98 (s, 3H), 1.58 (s, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 208.76, 148.67, 144.64, 132.96, 132.91, 129.74, 122.26, 121.32, 119.27, 55.65, 42.33, 26.09, 
21.24. 
 
GC/MS data: 233.1 (M+), 190.1 (M-Ac, base peak). 
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S18m: 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 8.22 (t, J = 2.0 Hz, 1H), 8.17 (ddd, J = 8.0, 2.2, 1.2 Hz, 1H), 7.61 (ddd, J = 7.8, 1.8, 1.2 Hz, 
1H), 7.56 (t, J = 7.9 Hz, 1H), 4.83 (apparent quintet, J = 1.5 Hz, 1H), 4.57 (s, 1H), 2.83 (d, J = 
14.1 Hz, 1H), 2.69 (d, J = 14.1 Hz, 1H), 1.99 (s, 3H), 1.63 (s, 3H), 1.36 (s, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 208.97, 148.61, 145.02, 141.16, 133.19, 129.61, 122.26, 121.49, 116.02, 55.37, 45.60, 26.07, 
24.29, 20.90. 
 
GC/MS data: 247.1 (M+), 204.1 (M-Ac, base peak). 
 
S18n 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 8.10 (ddd, J = 8.1, 2.2, 1.1 Hz, 1H), 8.05 (t, J = 2.0 Hz, 1H), 7.49 (t, J = 7.9 Hz, 1H), 7.42 
(ddd, J = 7.8, 1.8, 1.1 Hz, 1H), 5.36 (m, 2H), 5.01 (m, 4H), 2.72 (d, J = 7.2 Hz, 4H), 1.87 (s, 
3H). 
 
13C NMR (126 MHz, CDCl3):  
 
13C NMR (126 MHz, CDCl3) δ 207.83, 148.67, 143.56, 133.18, 132.04, 129.80, 122.40, 121.59, 
119.60, 59.10, 37.55, 26.38. 
 
GC/MS data: 259.1 (M+), 216.1 (M-Ac, base peak). 
 
S18o = S42g: 
O
NO2
O
NO2
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1H NMR (500 MHz, CDCl3): 
 
δ 8.11 (m, 2H), 7.51 (t, J = 7.9 Hz, 1H), 7.46 (d, J = 7.5  1H), 7.16 (m, 5H), 6.34 (d, J = 15.7 
Hz, 1H), 5.71 (dt, J = 16.2, 7.5 1H), 5.42 (m, 1H), 5.05 (m, 2H), 2.87 (d, J = 7.2 Hz, 2H), 2.77 
(d, J = 7.2 Hz, 2H), 1.92 (s, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 207.84, 148.72, 143.58, 136.84, 134.49, 133.19, 132.05, 129.87, 128.56, 127.58, 126.15, 
123.48, 122.49, 121.62, 119.73, 59.47, 37.77, 36.99, 26.45. 
 
GC/MS data: 335.2 (M+), 292.2 (M-Ac, base peak). 
 
S18p: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 8.09 (ddd, J = 8.1, 2.2, 1.0 Hz, 1H), 8.04 (t, J = 2.0 Hz, 1H), 7.48 (t, J = 7.9 Hz, 1H), 7.41 
(ddd, J = 7.8, 1.7, 1.1 Hz, 1H), 5.36 (m, 2H), 4.98 (m, 3H), 2.69 (d, J = 7.3 Hz, 2H), 2.66 (d, J = 
7.3 Hz, 2H), 1.87 (s, 3H), 1.84 (apparent quartet, J = 6.9 Hz, 2H), 1.23 (apparent sextet, J = 6.9 
Hz, 2H), 0.77 (t, J = 6.9, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 208.10, 148.63, 143.84, 135.84, 133.25, 132.30, 129.68, 123.14, 122.28, 121.66, 119.37, 59.36, 
37.73, 36.26, 34.70, 26.45, 22.50, 13.56. 
 
GC/MS data: 301.2 (M+), 258.1 (M-Ac, base peak). 
 
S42f: 
 
O
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O
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1H NMR (500 MHz, CDCl3): 
 
δ 8.11 (m, 2H), 7.50 (m, 2H), 7.18 (m, 6H), 6.36 (d, J = 15.7 Hz, 1H), 5.77 (dt, J = 15.7, 7.7, 
Hz, 1H), 4.82 (s, 1H), 4.60 (s, 1H), 3.03 (dd, J = 14.7, 6.7 Hz, 1H), 2.95 (dd, J = 14.7, 7.8 Hz, 
1H), 2.84 (d, J = 14.7 Hz, 1H), 2.71 (d, J = 14.7 Hz, 1H), 1.91 (m, 3H), 1.35 (s, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 208.25, 148.67, 144.08, 140.59, 136.87, 134.50, 133.40, 129.74, 128.57, 127.58, 126.14, 
123.77, 122.46, 121.77, 116.09, 59.23, 41.35, 36.59, 26.50, 24.38. 
 
GC/MS data: 349.2 (M+), 306.1 (M-Ac, base peak). 
 
S18i: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.69 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 8.4 Hz, 2H), 5.43 (m, 2H), 5.08 (m, 4H), 2.76 (d, J = 7.2 
Hz, 4H), 1.93 (s, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 207.81, 146.70, 132.58, 132.14, 127.62, 119.47, 118.46, 111.29, 59.43, 37.42, 26.46. 
 
GC/MS data: 239.1 (M+), 196.1 (M-Ac, base peak). 
 
S18j: 
 
Ph
O
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O
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1H NMR (500 MHz, CDCl3): 
 
δ 7.59 (d, J = 8.7 Hz, 2H), 7.22 (d, J = 8.7 Hz, 2H), 5.37 (m, 1H), 5.31 (m, 1H), 4.96 (m, 3H), 
2.64 (d, J = 7.3 Hz, 2H), 2.61 (d, J = 7.3 Hz, 2H), 1.86 (second order apparent quartet, J = 7.0 
Hz, 1H), 1.83 (s, 3H), 1.24 (apparent sextet, J = 7.3 Hz, 2H), 0.77 (t, J = 7.3 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 208.08, 147.00, 135.68, 132.50, 132.40, 127.66, 123.24, 119.22, 118.53, 111.13, 59.68, 37.59, 
36.09, 34.69, 26.52, 22.50, 13.57. 
 
GC/MS data: 281.2 (M+), 238.1 (M-Ac, base peak). 
 
S18k: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.59 (d,  J = 8.3 Hz, 2H), 7.22 (d, J = 8.3 Hz, 2H), 5.29 (m, 1H), 4.96 (m, 4H), 2.65 (d, J = 7.3 
Hz, 2H), 2.59 (d, J = 7.4 Hz, 2H), 1.85 (s, 3H), 1.22 (m, 1H), 0.58 (dd, J = 8.1, 2.0 Hz, 2H), 
0.19 (m, 2H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 208.12, 146.97, 139.23, 132.50, 132.40, 127.67, 120.52, 119.23, 118.52, 111.14, 59.72, 37.59, 
35.98, 26.52, 13.64, 6.60, 6.53. 
 
GC/MS data: 279.2 (M+), 236.1 (M-Ac, base peak). 
 
S42e: 
 
O
NC
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O
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1H NMR (500 MHz, CDCl3): 
 
δ 7.61 (d,  J = 8.5 Hz, 2H), 7.31 (d,  J = 8.5 Hz, 2H), 7.18 (m, 7H), 6.34 (d, J = 15.6 Hz, 1H), 
5.75 (dt, J = 15.6, 7.6,Hz, 1H), 4.81 (s, 1H), 4.60 (s, 1H), 2.96 (dd,  J = 14.6, 6.7 Hz, 1H), 2.90 
(dd, J = 14.6, 7.9 Hz, 1H), 2.79 (d, J = 14.6 Hz, 1H), 2.66 (d, J = 14.6 Hz, 1H), 1.89 (s, 3H), 
1.33 (s, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 208.25, 147.25, 140.73, 136.88, 134.37, 132.55, 128.58, 127.82, 127.58, 126.12, 123.89, 
118.46, 115.94, 111.33, 59.58, 41.23, 36.39, 26.59, 24.30. 
 
GC/MS data: 329.2 (M+), 286.1 (M-Ac, base peak). 
 
S18h: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 6.67 (m, 3H), 5.35 (m, 2H), 5.01 (dd, J = 12.9, 3.1 Hz, 4H), 2.62 (d, J = 7.4 Hz, 4H), 1.87 (s, 
3H). 
 
13C NMR (126 MHz, CDCl3):δ 207.74, 163.30 (d, J = 249.5 Hz), 132.27, 131.16 (d, J = 645.5 
Hz), 119.31, 109.93 (d, J = 19.5 Hz), 102.85 (d, J = 27.4 Hz), 58.89, 37.33, 26.20. 
 
GC/MS data: 250.1 (M+), 207.1 (M-Ac, base peak). 
 
S18q: 
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1H NMR (500 MHz, CDCl3): 
 
δ 7.12 (d J = 9.0 Hz, 2H), 6.91 (d, J = 9.0 Hz, 2H), 5.47 (m, J = 17.1, 10.1, 7.2 Hz, 2H), 5.08 (d, 
J = 14. 8 Hz, 2H), 5.05 (d ,J = 6.7 Hz, 2H), 3.83 (s, 3H), 2.72 (m, 4H), 1.92 (s, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 209.69, 158.55, 133.38, 133.05, 127.72, 118.46, 114.13, 58.19, 55.24, 37.48, 26.03. 
 
GC/MS data: 244.1 (M+), 201.2 (M-Ac, base peak). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O
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4. DaA products: ketone compounds (from tetralone): 
 
 
 
S20b: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.98 (dd, J = 7.9, 1.2 Hz, 1H), 7.39 (td, J = 7.5, 1.4 Hz, 1H), 7.24 (t, J = 7.9  Hz, 1H), 7.15 (m, 
1H), 5.72 (m, 1H), 5.03 (d, J = 0.91 Hz, 1H), 5.00 (d, J = 4.8 Hz, 1H), 2.91 (m, 2H), 2.40 (dd, J 
= 13.8, 7.3 Hz, 1H), 2.21 (ddt, J = 13.8, 7.5, 1.1 Hz, 1H), 2.01 (m, 1H), 1.84 (m, 1H), 1.12 (s, 
3H). 
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13C NMR (126 MHz, CDCl3): 
 
δ 202.09, 143.33, 133.98, 133.08, 131.59, 128.68, 128.03, 126.64, 118.22, 44.62, 41.12, 33.35, 
25.35, 21.92. 
 
GC/MS data: 212.1 (M+), 170.0, 128.1 (base peak). 
 
S20c = S43a 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.32 (d, J = 7.9 Hz, 1H), 7.25 (td, J = 7.9, 1.4 Hz, 1H), 7.14 (m, 3H), 7.08 (m, 4H), 6.16 (d, J 
= 15.8 Hz, 1H), 5.67 (m, 1H), 5.32 (m, 1H), 4.86 (d, J = 17.2 Hz, 1H), 4.81 (d, J = 10.2 Hz, 
1H), 2.85 (m, 3H), 2.77 (dd, J = 13.6, 8.3 Hz, 1H), 2.56 (ddd, J = 13.6, 6.8, 1.5 Hz, 1H), 2.51 
(ddt, J = 13.6, 6.8, 1.1 Hz, 1H) 2.45 (ddd, J = 7.8, 6.5, 3.4 Hz, 2H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 213.96, 139.07, 137.21, 137.10, 133.37, 133.27, 128.42, 128.10, 127.18, 126.99, 126.98, 
126.46, 126.08, 124.86, 118.37, 56.35, 44.95, 44.53, 40.42, 27.80. 
 
GC/MS data: 302.2 (M+). 
 
S20d: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.25 (dd, J = 7.9, 1.1 Hz, 1H), 7.22 (td,  J = 7.3, 1.4 Hz, 1H), 7.12 (td, J = 7.3, 1.4 Hz, 1H), 
7.08 (dd, J = 7.9, 1.1 Hz, 1H), 5.29 (m, 1H), 5.21 (dt, J = 15.0, 6.8 Hz, 1H), 4.90 (m, 1H), 4.83 
(d,  J = 17.3 Hz, 1H), 4.78 (d,  J =  10.1 Hz, 1H), 2.87 (t, J = 6.9 Hz, 2H), 2.71 (dd, J = 13.6, 8.2 
Hz, 1H), 2.63 (dd, J = 13.4, 8.3 Hz, 1H), 2.44 (td,  J = 6.8, 2.5 Hz, 2H), 2.41 (dd, J = 13.4, 6.4 
Hz, 1H), 2.36 (dd, J = 13.4, 6.4 Hz, 1H), 1.71 (m, 2H), 1.13 (apparent sextet, J = 7.4 Hz, 2H), 
0.67 (t, J = 7.4 Hz, 3H). 
O Ph
O Pr
241 
 
13C NMR (126 MHz, CDCl3):  
 
δ 214.06, 139.41, 137.07, 134.52, 133.60, 127.92, 127.04, 126.81, 126.22, 124.51, 118.11, 56.28, 
44.90, 44.41, 40.44, 34.57, 27.84, 22.43, 13.55. 
 
GC/MS data: 268.2 (M+) 268.18 (base peak). 
 
S20e: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.29 (m, 3H), 7.17 (m, 2H), 7.14 (d, J = 7.5 Hz, 1H), 5.34 (m, 1H), 5.03 (m, Hz, 1H), 4.88 (d, 
J = 16.8 Hz, 3H), 4.83 (d, J = 10.0 Hz, 1H), 4.79 (dd, J = 15.3, 8.6 Hz, 1H), 2.94 (t, J = 6.9 Hz, 
2H), 2.77 (dd, J = 13.6, 8.2 Hz, 1H), 2.66 (dd, J = 13.6, 8.2 Hz, 1H), 2.50 (m, 3H), 2.40 (ddd, J 
= 13.5, 6.3, 1.2 Hz, 1H), 1.13 (m, 1H), 0.53 (dd, J = 8.2, 2.0 Hz, 2H), 0.15 (m, 2H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 214.15, 139.39, 137.99, 137.18, 133.58, 127.92, 127.02, 126.81, 126.23, 121.91, 118.11, 56.39, 
44.71, 44.22, 40.46, 27.82, 13.41, 6.35, 6.27. 
 
GC/MS data: 266.1 (M+), 223.1 (M-Ac, base peak). 
 
S20f: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.28 (d,  J = 7.5 Hz, 1H), 7.20 (td,  J = 7.3, 1.3 Hz, 2H), 7.12 (td, J = 7.3, 1.3 Hz, 1H), 7.07 (d, 
J = 7.5, 0.7 Hz, 1H), 5.28 (m, J = 16.7, 10.1, 8.3, 6.4 Hz, 1H), 4.84 (d,  J = 16.9 1H), 4.80 (d,  J 
=  10.0 Hz, 1H), 2.91 (m, 2H), 2.82 (d, J = 13.5 Hz, 1H), 2.71 (dd, J = 13.5, 8.3 Hz, 1H), 2.50 
(m, 3H), 2.35 (d, J = 13.5 Hz, 1H), 1.19 (s, 3H). 
O
O
242 
 
13C NMR (126 MHz, CDCl3):  
 
δ 213.64, 141.87, 139.42, 136.76, 133.31, 128.08, 127.35, 126.71, 126.38, 118.35, 115.11, 56.17, 
48.26, 46.04, 40.28, 27.80, 24.22. 
 
GC/MS data: 240.2 (M+), 199.2 (base peak). 
 
S20g: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.25 (d, J = 7.5 Hz, 1H), 7.20 (td, J = 7.3, 1.4 Hz, 2H), 7.12 (td, J = 7.3, 1.4 Hz, 1H), 7.08 (d, 
J = 7.5, 1H), 5.29 (m, 1H), 4.83 (d, J = 17.4 Hz, 1H), 4.78 (d, J = 10.1 Hz, 1H), 4.66 (t, 7.9 Hz, 
1H), 2.87 (t, J = 6.9 Hz, 2H), 2.73 (td, J = 14.8, 8.3 Hz, 2H), 2.45 (m, 3H), 2.30 (dd, J = 14.0, 
6.5 Hz, 1H), 1.46 (s, 3H), 1.34 (s, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 214.39, 139.57, 137.15, 134.65, 133.67, 127.89, 127.11, 126.78, 126.20, 118.95, 118.06, 56.12, 
44.60, 40.34, 39.93, 27.89, 25.82, 17.72. 
 
GC/MS data: 254.2 (M+), 186.2 (base peak). 
 
S43b: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
7.31 (d, J = 7.9 Hz, 1H), 7.24 (t, J = 7.9 Hz, 1H), 7.13 (m, 3H), 7.08 (m, 4H), 6.14 (d, J = 15.8 
Hz, 1H), 5.66 (m, 1H), 5.23 (dt, J = 14.9, 6.8 Hz, 1H), 4.92 (dt,  J = 14.9, 6.8 Hz 1H), 2.83 (m, 
3H), 2.68 (dd, J = 13.5, 8.4 Hz, 1H), 2.54 (dd, J = 13.5, 6.5 Hz, 1H), 2.46 (m, 3H), 1.72 
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(apparent quintet, J = 7.4 Hz, 2H), 1.14 (apparent sextet, J = 7.4 Hz, 2H), 0.67 (t, J = 7.4 Hz, 
3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 214.28, 139.34, 137.29, 137.15, 134.56, 133.08, 128.39, 127.99, 127.11, 127.00, 126.90, 
126.31, 126.05, 125.12, 124.51, 56.62, 44.31, 44.22, 40.53, 34.58, 27.79, 22.44, 13.55. 
 
GC/MS data: 344.2 (M+), 301.1 (M-Ac, base peak). 
 
S22d = S23c = S25d: 
 
 
 
1H NMR (500 MHz, CDCl3)  
 
δ 7.97 (dd, J = 7.9, 1.1 Hz, 1H), 7.39 (td, J = 7.5, 1.4 Hz, 1H), 7.23 (t, J = 7.8 Hz, 1H), 7.15 (d, 
J = 7.6 Hz, 1H), 5.72 (m, 1H), 5.02 (s, 1H), 5.00 (dm, J = 8.65 Hz, 1H), 2.91 (dd, J = 12.1, 5.1 
Hz, 2H), 2.40 (dd, J = 13.8, 7.3 Hz, 1H), 2.21 (ddt, J = 13.8, 7.5, 1.1 Hz, 1H), 2.01 (m, 1H), 
1.84 (ddd, J = 13.7, 7.1, 5.5 Hz, 1H), 1.12 (s, 3H). 
 
13C NMR (126 MHz, CDCl3) 
 
δ 202.09, 143.33, 133.98, 133.08, 131.59, 128.68, 128.03, 126.64, 118.22, 44.62, 41.12, 33.35, 
25.35, 21.92. 
 
Chiral Resolution: Chiracel OD-H column, mobile phose = Hexanes : 2-propanol 99.7 : 0.3, flow 
rate = 0.4 µL/min 18.5 mins and 20.0 mins 
 
S23d = S26a = ent-S26a: 
 
 
 
1H NMR (500 MHz, CDCl3) 
 
δ 7.98 (dd, J = 7.9, 1.1 Hz, 1H), 7.39 (td, J = 7.5, 1.4 Hz, 1H), 7.24 (t, J = 7.51 Hz, 1H), 7.15 (d, 
J = 7.6 Hz, 1H), 5.72 (m, 1H), 5.03 (dm, J = 4.61 Hz, 1H), 5.00 (dm, J = 14.02 Hz, 1H), 2.92 
(m, 2H), 2.67 (d, J = 13.6 Hz, 1H), 2.44 (dt, J = 13.9, 7.03, 1.03 Hz 1H), 2.16 (m, 2H), 1.98 
(ddd, J = 13.9, 8.6, 5.3 Hz, 1H), 1.90 (ddd, J = 14.0, 6.4, 5.3 Hz, 1H), 1.53 (s, 3H). 
 
O
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13C NMR (126 MHz, CDCl3) 
 
δ 200.01, 142.11, 141.41, 132.87, 132.09, 130.99, 127.62, 127.09, 125.66, 117.46, 114.04, 46.66, 
41.73, 39.07, 29.19, 24.14, 23.40. 
 
Chiral Resolution: Chiracel OD-H column, mobile phose = Hexanes : 2-propanol 99.6 : 0.8, flow 
rate = 0.4 µL/min 6.8 mins and 7.5 mins 
 
S23e: 
 
 
 
1H NMR (500 MHz, CDCl3) 
 
δ 7.96 (dd, J = 7.9, 1.2 Hz, 1H), 7.38 (td, J = 7.51, 1.4 Hz, 1H), 7.23 (t, J = 7. 73 Hz, 1H), 7.14 
(d, J = 7.6 Hz, 1H), 6.09 (d, J = 1.8 Hz, 1H), 5.45 (s, 1H), 4.74 (s, 1H), 4.61 (s, 1H), 3.02 (ddd, J 
= 17.0, 9.3, 4.8 Hz, 1H), 2.88 (dt, J = 17.05, 5.76 Hz, 1H), 2.74 (d, J = 13.8 Hz, 1H), 2.71 (d, J 
= 13.8 Hz, 1H), 2.61 (d, J = 13.4 Hz, 1H), 2.08 (m, 1H), 2.02 (d, J = 13.7 Hz, 1H), 1.78 (ddd, J 
= 14.0, 6.4, 4.9 Hz, 1H), 1.52 (s, 3H), 1.35 (s, 9H). 
 
13C NMR (126 MHz, CDCl3) 
 
δ 200.16, 166.86, 143.11, 142.40, 138.32, 133.12, 132.36, 128.61, 128.12, 126.64, 115.35, 80.62, 
48.73, 43.86, 36.40, 30.24, 27.89, 25.26, 24.52. 
 
S23f: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 8.00 (dd, J = 7.9, 1.1 Hz, 1H), 7.39 (ddd, J = 7.5, 5.8, 1.4 Hz, 1H), 7.24 (m, 6H), 7.14 (m, 3H), 
6.36 (d, J = 15.7 Hz, 1H), 6.13 (m, 1H), 2.93 (t, J = 6.3 Hz, 3H), 2.59 (ddd, J = 13.8, 7.4, 1.1 
Hz, 1H), 2.35 (ddd, J = 13.8, 7.7, 1.1 Hz, 1H), 2.07 (dt, J = 13.5, 6.7 Hz, 1H), 1.87 (dt, J = 13.7, 
6.0 Hz, 1H), 1.17 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
O
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δ 202.08, 143.34, 137.40, 133.26, 133.16, 131.56, 129.72, 128.72, 128.51, 128.06, 127.16, 
126.69, 126.12, 125.86, 45.21, 40.52, 33.48, 25.43, 22.13. 
 
S23g: 
 
 
 
1H NMR (500 MHz, CDCl3) 
 
δ 7.80 (dd, J = 7.9, 1.1 Hz, 1H), 7.35 (td, J = 7.5, 1.4 Hz, 1H), 7.19 (m, 8H), 7.09 (d, J = 7.6 Hz, 
1H), 5.63 (m, 1H), 5.20 (d, J = 1.7 Hz, 1H), 5.03 (s, 1H), 4.96 (dm, J = 10.21 1H), 4.90 (dm, J = 
17.0, 1.3 Hz, 1H), 2.95 (d, J = 13.9 Hz, 1H), 2.81 (m, 2H), 2.75 (d, J = 13.9 Hz, 1H), 2.43 (dd, J 
= 14.0, 6.7 Hz, 1H), 2.06 (dd, J = 14.0, 7.9 Hz, 1H), 1.83 (m, 2H). 
 
13C NMR (126 MHz, CDCl3) 
 
δ 200.67, 145.51, 142.91, 134.12, 132.99, 132.15, 128.52, 128.16, 128.03, 127.26, 126.63, 
126.55, 118.36, 118.11, 48.90, 39.79, 39.48, 30.41, 25.08. 
 
S23h = S43c: 
 
 
 
1H NMR (500 MHz, CDCl3) 
 
δ 8.00 (dd, J = 7.9, 1.2 Hz, 1H), 7.40 (td, J = 7.5, 1.4 Hz, 1H), 7.26 (m, 3H), 7.21 (t, J = 7.43 
Hz, 2H), 7.13 (m, 2H), 6.36 (d, J = 15.7 Hz, 1H), 6.12 (m, 1H), 4.76 (s, 1H), 4.63 (s, 1H), 2.95 
(dd, J = 12.3, 6.0 Hz, 2H), 2.69 (d, J = 13.6 Hz, 1H), 2.63 (ddd, J = 14.0, 7.2, 1.3 Hz, 1H), 2.31 
(ddd, J = 14.0, 7.8, 1.1 Hz, 1H), 2.20 (d, J = 13.7 Hz, 1H), 1.99 (m, 2H), 1.56 (s, 3H). 
 
13C NMR (126 MHz, CDCl3) 
 
δ 201.13, 143.13, 142.34, 137.38, 133.47, 133.19, 132.03, 128.70, 128.51, 128.14, 127.19, 
126.75, 126.14, 125.79, 115.23, 48.28, 43.02, 39.42, 30.52, 25.26, 24.46. 
 
S23i: 
 
O
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1H NMR (500 MHz, CDCl3) 
 
δ 7.98 (dd, J = 7.9, 1.1 Hz, 1H), 7.38 (td, J = 7.5, 1.4 Hz, 1H), 7.23 (t, J = 7.5 Hz, 1H), 7.14 (d, 
J = 7.6 Hz, 1H), 5.39 (dt, J = 14.9, 7.4 Hz, 1H), 4.94 (dd, J = 15.1, 8.6 Hz, 1H), 4.72 (dd, J = 
2.1, 1.5 Hz, 1H), 4.61 (s, 1H), 2.90 (m, 2H), 2.66 (d, J = 13.6 Hz, 1H), 2.35 (ddd, J = 14.0, 7.1, 
1.1 Hz, 1H), 2.12 (d, J = 13.7 Hz, 1H), 2.07 (ddd, J = 14.1, 7.6, 0.9 Hz, 1H), 1.92 (m, 2H), 1.54 
(s, 3H), 1.28 (m, 1H), 0.58 (m, 2H), 0.24 (m, 2H). 
 
13C NMR (126 MHz, CDCl3) 
 
δ 201.30, 143.21, 142.65, 138.16, 133.04, 132.11, 128.64, 128.08, 126.64, 122.46, 114.91, 48.00, 
42.73, 38.72, 30.03, 25.22, 24.46, 13.68, 6.56, 6.56. 
 
S23j: 
 
 
 
1H NMR (500 MHz, CDCl3) 
 
δ 7.98 (d,  J = 8.14 Hz, 1H), 7.38 (td, J = 7.5, 1.4 Hz, 1H), 7.23 (t, J = 7.6 Hz, 1H), 7.14 (d, J = 
7.7 Hz, 1H), 5.41 (m, 1H), 5.33 (m, 1H), 4.73 (s, 1H), 4.60 (s, 1H), 2.91 (m, 2H), 2.66 (d, J = 
13.7 Hz, 1H), 2.35 (dd,  J = 14.22, 6.81 Hz, 1H), 2.10 (m, 2H), 1.92 (m, 2H), 1.59 (dd, J = 6.2, 
1.2 Hz, 2H), 1.52 (s, 3H). 
 
13C NMR (126 MHz, CDCl3) 
 
δ 201.29, 143.22, 142.67, 133.07, 133.04, 132.08, 129.12, 128.64, 128.09, 126.67, 126.64, 
126.05, 114.96, 114.88, 47.88, 42.75, 38.82, 30.04, 25.21, 24.46, 18.12. 
 
S23k = S26k 
 
 
 
O
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1H NMR (500 MHz, CDCl3): 
 
δ 7.98 (dd, J = 7.9, 1.1 Hz, 1H), 7.38 (td, J = 7.5, 1.4 Hz, 1H), 7.23 (t, J = 7.4 Hz, 1H), 7.14 (d, 
J = 7.6 Hz, 1H), 5.70 (m, 1H), 5.06 (t,  J = 7.35 1H), 4.99 (s, 1H), 4.97 (m, 2H), 2.90 (t, J = 6.3 
Hz, 2H), 2.45 (dd, J = 13.9, 7.0 Hz, 1H), 2.33 (dd, J = 14.6, 7.0 Hz, 1H), 2.19 (m, 2H), 1.96 (m, 
6H), 1.54 (s, 3H), 1.52 (s, 6H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 201.32, 143.27, 137.93, 134.31, 133.02, 132.01, 131.39, 128.65, 127.99, 126.60, 124.26, 
119.32, 117.98, 48.58, 40.02, 39.29, 32.99, 30.39, 26.51, 25.68, 25.27, 17.71, 16.26. 
 
Chiral Resolution: Chiracel OD-H column, mobile phase = Hexanes : 2-propanol 99.7 : 0.3, flow 
rate = 0.4 µL/min 26.3 mins and 27.8 mins 
 
S23l: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.98 (dd, J = 7.9, 1.2 Hz, 1H), 7.38 (td, J = 7.5, 1.4 Hz, 1H), 7.23 (t, J = 7.34 Hz, 1H), 7.14 (d, 
J = 7.6 Hz, 1H), 5.70 (m, 1H), 5.04 (m, 1H), 5.00 (s, 1H), 4.97 (m, 1H), 2.91 (t, J = 6.4 Hz, 2H), 
2.46 (ddt, J = 14.14, 6.45, 1.45 Hz, 1H), 2.32 (dd, J = 14.6, 7.0 Hz, 1H), 2.19 (ddd, J = 14.0, 
9.2, 8.2 Hz, 2H), 1.96 (t, J = 6.41 Hz, 2H), 1.63 (s, 3H), 1.50 (s, 3H). 
 
13C NMR (126 MHz, CDCl3) 
 
δ 201.30, 143.25, 134.45, 134.26, 133.02, 132.00, 128.66, 127.99, 126.60, 119.19, 118.01, 48.53, 
39.27, 33.08, 30.45, 26.08, 25.23, 18.02. 
 
S23m = S26b 
 
 
 
1H NMR (500 MHz, CDCl3) 
 
δ 7.99 (dd, J = 7.9, 1.1 Hz, 1H), 7.38 (td, J = 7.5, 1.4 Hz, 1H), 7.23 (t, J = 7.32 Hz, 1H), 7.14 (d, 
J = 7.7 Hz, 1H), 5.07 (m, 1H), 4.72 (s, 1H), 4.60 (s, 1H), 2.90 (m, 2H), 2.69 (d, J = 13.6 Hz, 
O
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1H), 2.30 (dd, J = 14.7, 6.9 Hz, 1H), 2.15 (m, 1H), 2.11 (d, J = 13.7 Hz, 1H), 1.93 (m, 2H), 1.64 
(s, 3H), 1.53 (s, 3H), 1.51 (s, 3H). 
 
13C NMR (126 MHz, CDCl3) 
 
δ 201.49, 143.23, 142.74, 134.70, 133.01, 132.13, 128.62, 128.09, 126.63, 119.21, 114.84, 48.45, 
42.68, 33.96, 29.97, 26.12, 25.33, 24.48, 18.08. 
 
Chiral Resolution: Chiracel OD-H column, mobile phase = Hexanes : 2-propanol 99.7 : 0.3, flow 
rate = 0.4 µL/min 17.95 mins and 18.45 mins 
 
S23n: 
 
 
 
1H NMR (500 MHz, CDCl3) 
 
δ 7.97 (m, 1H), 7.38 (t, J = 7.6 Hz 1H), 7.23 (t, J = 7.6 Hz, 1H), 7.14 (d, J = 7.6 Hz, 1H), 5.22 
(s, 1H), 4.70 (m, 1H), 4.59 (d, J = 6.8 Hz, 1H), 2.98 (m, 1H), 2.87 (m, 1H), 2.73 (d, J = 13.6 Hz, 
1H), 2.37 (d, 1H), 2.03 (m, 9H), 1.51 (s, 2H), 1.18 (s, 2H), 0.77 (s, 2H). 
 
13C NMR (126 MHz, CDCl3) 
 
δ 201.33, 144.00, 143.19, 143.08, 143.04, 133.01, 132.97, 132.38, 128.57, 128.54, 128.10, 
128.08, 126.63, 126.61, 122.59, 122.46, 114.91, 114.85, 48.93, 48.02, 47.39, 43.66, 43.62, 43.27, 
42.98, 40.36, 40.22, 37.87, 31.83, 31.78, 31.67, 31.66, 29.76, 29.45, 26.40, 26.36, 25.63, 25.46, 
24.62, 24.58, 21.32, 21.27. 
 
S23o = S26d = ent-S26d 
 
 
 
1H NMR (500 MHz, CDCl3) 
 
δ 7.64 (dd, J = 9.3, 2.7 Hz, 1H), 7.11 (m, 2H), 5.70 (ddt, J = 17.3, 10.2, 7.3 Hz, 1H), 5.01 (m, 
2H), 4.75 (s, 1H), 4.61 (s, 1H), 2.87 (m, 2H), 2.65 (d, J = 13.7 Hz, 1H), 2.42 (dd, J = 14.0, 7.1 
Hz, 1H), 2.15 (m, 2H), 1.93 (m, 2H), 1.52 (s, 3H). 
 
13C NMR (126 MHz, CDCl3) 
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δ 200.03, 161.68 (d, 249.9 Hz), 142.17, 138.77 (d, J = 2.97 Hz), 133.61, 130.48 (d, J = 7.03 Hz  
120.55 (d, J = 22.21 Hz), 118.73, 115.28, 113.87 (d, J = 22.0 Hz), 47.49, 42.67, 39.99, 30.27, 
24.49, 24.42. 
 
Chiral Resolution: Chiracel OD-H column, mobile phase = Hexanes : 2-propanol 99.9 : 0.1, flow 
rate = 0.4 µL/min 9.65 mins and 10.05 mins 
 
S23p = S26e = ent-S26e 
 
 
 
1H NMR (500 MHz, CDCl3) 
 
δ 7.96 (d, J = 8.8 Hz, 1H), 6.76 (dd, J = 8.8, 2.5 Hz, 1H), 6.59 (d, J = 2.5 Hz, 1H), 5.72 (m, 1H), 
5.02 (dm,  J = 3.29 Hz 1H), 4.99 (dm,  J = 11.31 Hz 1H), 4.73 (s, 1H), 4.61 (s, 1H), 3.78 (s, 3H), 
2.88 (m, 2H), 2.67 (d, J = 13.6 Hz, 1H), 2.42 (dd, J = 14.0, 7.0 Hz, 1H), 2.15 (m, 1H), 2.11 (d, J 
= 13.7 Hz, 1H), 1.95 (ddd, J = 14.0, 8.9, 5.2 Hz, 1H), 1.88 (ddd, J = 14.0, 8.9, 5.2 Hz 1H), 1.53 
(s, 3H). 
 
13C NMR (126 MHz, CDCl3) 
 
δ 199.81, 163.37, 145.61, 142.65, 134.10, 130.57, 125.68, 118.34, 114.91, 113.31, 112.29, 55.42, 
47.39, 42.90, 40.37, 30.20, 25.62, 24.42. 
 
Chiral Resolution: Chiracel OD-H column, mobile phase = Hexanes : 2-propanol 99.7 : 0.3, flow 
rate = 1 µL/min 12.05 mins and 12.85 mins 
 
S23q = S27c 
 
 
 
1H NMR (500 MHz, CDCl3) 
 
δ 7.40 (s, 1H), 6.76 (s, 1H), 5.71 (ddt, J = 16.6, 10.5, 7.4 Hz, 1H), 5.01 (m, 1H), 4.98 (dm, J = 
9.53 Hz, 1H), 3.78 (s, 3H), 2.76 (m, 2H), 2.35 (dd, J = 13.8, 7.3 Hz, 1H), 2.30 (s, 3H), 2.18 (dd, 
J = 13.8, 7.5 Hz, 1H), 1.95 (ddd, J = 13.6, 7.1, 5.4 Hz, 1H), 1.80 (m, 1H), 1.09 (s, 3H). 
 
O
MeO
O
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13C NMR (126 MHz, CDCl3) 
 
δ 202.59, 156.60, 136.79, 134.11, 132.14, 129.41, 119.60, 118.07, 115.05, 55.59, 44.28, 40.92, 
32.78, 21.78, 21.53, 18.86. 
 
Chiral Resolution: Chiracel OD-H column, mobile phase = Hexanes : 2-propanol 99.7 : 0.3, flow 
rate = 0.8 µL/min 14.6 mins. and 15.4 mins. 
 
S23r: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.55 (d, J = 7.7 Hz, 1H), 7.39 (td, J = 7.5, 1.1 Hz, 1H), 7.22 (d, J = 7.7 Hz, 1H), 7.17 (t, J = 
7.5 Hz, 1H), 5.45 (m, 1H), 4.87 (d, J = 17.0 Hz, 1H), 4.81 (d, J = 10.1 Hz, 1H), 2.97 (d, J = 17.2 
Hz, 1H), 2.64 (d, J = 17.2 Hz, 1H), 2.19 (ddt, J = 13.6, 6.7, 1.2 Hz, 1H), 2.10 (dd, J = 13.7, 8.0 
Hz, 1H), 1.02 (s, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 210.81, 152.60, 135.87, 134.90, 133.89, 127.42, 126.60, 124.27, 118.36, 48.84, 42.54, 39.41, 
23.81. 
 
GC/MS data: 186.1 (M+), 145.1 (base peak). 
 
S23s: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.37 (m, 1H), 7.27 (m, 2H), 7.13 (d, J = 7.5 Hz, 1H), 5.75 (ddt, J = 16.3, 10.7, 7.5 Hz, 1H), 
5.07 (m, 1H), 5.04 (ddd, J = 4.9, 2.2, 1.3 Hz, 1H), 2.80 (m, 2H), 2.34 (ddd, J = 7.1, 3.2, 2.1 Hz, 
2H), 1.93 (m, 2H), 1.78 (m, 1H), 1.62 (m, 2H), 1.20 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 214.45, 141.58, 137.22, 133.70, 130.73, 128.40, 127.15, 126.55, 118.33, 49.11, 43.86, 34.52, 
32.88, 22.79, 22.26. 
O
O
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5. DaA products: cyano compounds: 
 
 
 
S30b = S33e: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.33 (m, 4H), 7.24 (m, 1H), 5.58 (dddd, J = 23.6, 10.3, 7.5, 6.9 Hz, 2H), 5.08 (m, 4H), 2.63 
(m, 4H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 137.62, 131.65, 128.84, 127.88, 126.28, 121.68, 120.20, 47.68, 44.18. 
 
GC/MS data: 197.1 (M+), 156.1, 129.0 (base peak). 
 
S30c = S44a = S45a: 
 
 
NC
NC
N
NC
MeO
NC
Ph
NC
MeO OMe
S30b = S33e
NC
Ph
S30e
S30f
S30g
S30h S30i
NC
Ph
Ph
NC
Ph
Ph
NC Ph
NC
Ph
Ph
Ph
NC
Ph
Ph
S30j
S30l S30m S30o = S44eS30n
NC
Ph
Ph
NC
Ph
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1H NMR (500 MHz, CDCl3): 
 
δ 7.35 (m, 4H), 7.25 (m, 1H), 7.19 (m, 5H), 7.14 (m, 1H), 6.39 (d, J = 15.8 Hz, 1H), 5.96 (dt, J 
= 15.3, 7.6 Hz, 1H), 5.61 (m, 1H), 5.09 (m, J = 9.3, 3.0, 1.6 Hz, 2H), 2.78 (m, 2H), 2.68 (m, 
2H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 137.66, 136.71, 135.05, 131.68, 128.91, 128.52, 127.95, 127.66, 126.36, 126.30, 122.96, 
121.77, 120.24, 47.98, 43.97, 43.62. 
 
GC/MS data: 273.2 (M+), 117.1 (base peak), 115.1, 91.1. 
 
S30d = S44b: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.27 (m, 6H), 5.58 (m, 1H), 5.45 (dt, J = 15.1, 6.9 Hz, 1H), 5.19 (dt,  J = 15.1, 6.9 Hz, 1H), 
5.07 (d,  J = 7.9 Hz, 1H), 5.04 (s, 1H), 2.59 (m, 4H), 1.85 (apparant quartet, J = 7.5 Hz, 2H), 
1.24 (apparent sextet, J = 7.5 Hz, 2H), 0.74 (t, J = 7.5 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 137.92, 136.56, 131.86, 128.73, 127.72, 126.33, 123.03, 121.91, 119.98, 48.05, 43.97, 43.27, 
34.55, 22.33, 13.50. 
 
GC/MS data: 239.2 (M+), 157.1, 156.2 (base peak). 
 
S30e: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.37 (m, 2H), 7.32 (m, 2H), 7.25 (m, 1H), 5.64 (m, 1H), 5.11 (m, 1H), 5.08 (d, J = 8.2 Hz, 1H), 
2.61 (ddt, J = 13.9, 6.7, 1.1 Hz 1H), 2.55 (ddt, J = 13.9, 7.5, 1.1 Hz, 1H), 1.65 (s, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 139.83, 131.90, 128.89, 127.86, 125.61, 123.14, 120.20, 46.32, 42.17, 26.56. 
NC
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GC/MS data: 171.1 (M+), 130.0, 103.0, 83.0 (base peak). 
 
 
S30j: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
 δ 7.40 (m, 2H), 7.34 (m, 2H), 7.26 (m, 2H), 7.21 (m, 7H), 7.14 (m, 2H), 6.41 (d, J = 15.8 Hz, 
2H), 5.98 (dt, J = 15.7, 7.4 Hz, 2H), 2.84 (m, 4H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 137.72, 136.71, 135.10, 128.98, 128.53, 128.03, 127.68, 126.38, 126.32, 122.98, 121.85, 48.27, 
43.43. 
 
GC/MS data: 349.2 (M+), 115.0, 117.1 (base peak). 
 
S30k: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
 δ 7.33 (m, 4H), 7.23 (m, 6H), 7.13 (m,  1H), 6.37 (d, J = 15.8 Hz, 1H), 5.95 (dt, J = 15.7, 7.8, 
Hz, 1H), 5.47 (dt, J = 15.0, 6.9 Hz, 1H), 5.22 (dt,  J = 15.0, 6.9 Hz, 1H), 2.76 (m, 2H), 2.60 (m, 
2H), 1.87 (apparent quartet, J = 7.4 Hz, 2H), 1.25 (apparent sextet, J = 7.4 Hz Hz, 2H), 0.76 (t, J 
=7.4 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 137.96, 136.78, 136.61, 134.85, 128.80, 128.50, 127.79, 127.59, 126.35, 123.22, 123.05, 
121.99, 48.33, 43.41, 43.06, 34.57, 22.35, 13.52. 
 
GC/MS data: 315. 2 (M+). 
 
S30l: 
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1H NMR (500 MHz, CDCl3): 
 
δ 7.38 (m, 2H), 7.31 (m, 2H), 7.24 (m, 1H), 7.19 (m, 4H), 7.14 (m, 1H), 6.40 (d, J = 15.7, Hz, 
1H), 5.97 (dt, J = 15.7, 7.4 Hz, 1H), 4.80 (s, 1H), 4.67 (s, 1H), 2.80 (dt, J = 7.5, 1.1 Hz, 2H), 
2.71 (d, J = 14.1 Hz, 1H), 2.60 (d, J = 14.1 Hz, 1H), 1.48 (s, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 139.81, 137.86, 136.74, 135.05, 128.81, 128.51, 127.88, 127.63, 126.38, 126.31, 123.08, 
122.09, 116.68, 47.71, 47.65, 44.87, 23.66. 
 
GC/MS data: 287.2 (M+), 117.1 (base peak), 91.1. 
 
S30m & S30n: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
Linear diastereomer reported. 
 
 δ 7.23 (m, 10H), 6.40 (m, 2H), 5.96 (m, 1H), 5.03 (m, 1H), 2.80 (m, 4H), 1.61 (s, 3H), 1.49 (s, 
3H), 1.16 (s, 3H). 
 
GC/MS data: 301.2 (M+), 172.1, 117.1 (base peak), 69.1. 
 
S30g: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.86 (d, J = 1.8 Hz, 1H), 7.78 (m, 3H), 7.45 (m, 2H), 7.38 (dd, J = 8.7, 2.0 Hz, 1H), 5.59 (m, 
2H), 5.09 (d, J = 17.0 Hz, 2H), 5.05 (d, J = 9.9 Hz, 2H), 2.74 (m, 4H). 
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13C NMR (126 MHz, CDCl3):  
 
δ 134.79, 133.07, 132.65, 131.61, 128.87, 128.20, 127.56, 126.69, 126.57, 126.16, 123.08, 
121.74, 120.26, 47.98, 44.11. 
 
GC/MS data: 247.1 (M+), 206.2, 179.1 (base peak). 
 
S30o = S44e: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.88 (d, J = 1.9 Hz, 1H), 7.80 (m, 3H), 7.44 (m,  3H), 7.17 (m, 5H), 7.12 (m, 1H), 6.44 (d, J = 
15.7 Hz, 1H), 5.97 (dt, J = 15.7, 7.2 Hz 1H), 5.61 (m, 1H), 5.11 (d, J = 17.0, 1H), 5.06 (d, J = 
10.1 Hz 1H), 2.88 (dd, J = 7.4, 1.2 Hz, 2H), 2.77 (d, J = 7.4 Hz, 2H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 136.64, 135.11, 134.86, 133.12, 132.70, 131.64, 128.92, 128.50, 128.23, 127.66, 127.58, 
126.70, 126.59, 126.38, 126.12, 123.15, 122.90, 121.81, 120.31, 48.27, 43.98, 43.55. 
 
GC/MS data: 323.2 (M+), 179.0, 117.1 (base peak), 115.1, 91.1. 
 
S30f: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 8.56 (ddd, J = 4.8, 1.8, 1.1 Hz, 1H), 7.63 (td, J = 7.9, 1.8 Hz, 1H), 7.48 (dt, J = 7.9, 1.1 Hz, 
1H), 7.16 (ddd, J = 7.9, 4.8, 1.1 Hz, 1H), 5.57 (m, 2H), 5.03 (m, 4H), 2.82 (ddt, J = 13.7, 6.8, 
1.1 Hz, 2H), 2.66 (dd, J = 13.7, 7.8 Hz, 2H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 156.57, 149.69, 136.79, 131.78, 122.68, 122.18, 121.52, 120.08, 49.72, 43.17. 
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GC/MS data: 198.1 (M+), 157.1 (base peak), 83.0. 
 
S44c: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 8.60 (dd, J = 4.8, 1.8 Hz, 1H), 7.61 (td, J = 7.7, 1.8 Hz, 1H), 7.50 (d, J = 7.9 Hz, 1H), 7.15 (m, 
13H), 6.37 (d, J = 15.7 Hz, 2H), 5.99 (m, 2H), 3.01 (ddd, J = 13.7, 7.1, 1.3 Hz, 2H), 2.88 (ddd, J 
= 13.8, 7.9, 1.1 Hz, 2H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 156.63, 149.77, 136.94, 136.80, 134.98, 128.49, 127.59, 126.35, 123.18, 122.81, 122.27, 50.34, 
42.51. 
 
GC/MS data: 350.2 (M+). 
 
S44d: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 8.58 (dd, J = 4.8, 1.8, 1H), 7.62 (td, J = 7.7, 1.8 Hz, 1H), 7.49 (dt, J = 7.9, 1.0 Hz, 1H), 7.15 
(m, 6H), 6.35 (d, J = 15.7 Hz, 1H), 5.97 (dt,  J = 15.7, 7.6 Hz, 1H), 5.60 (m, 1H), 5.05 (m, 2H), 
2.97 (ddd, J = 13.7, 7.1, 1.3 Hz, 1H), 2.86 (m, 2H), 2.71 (dd, J = 13.7, 7.8 Hz, 1H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 156.60, 149.73, 136.86, 136.79, 134.93, 131.81, 128.48, 127.58, 126.33, 123.16, 122.75, 
122.23, 121.60, 120.13, 50.03, 43.18, 42.49. 
 
GC/MS data: 274.1 (M+) 
 
S30h: 
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1H NMR (500 MHz, CDCl3): 
 
δ 7.24 (d, J = 9.1 Hz, 2H), 6.84 (d, J = 9.1 Hz, 2H), 5.58 (m, 2H), 5.07 (m, 4H), 3.74 (s, 3H), 
2.59 (m, 4H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 159.02, 131.79, 129.57, 127.43, 121.94, 120.08, 114.10, 55.30, 46.94, 44.27. 
 
GC/MS data: 227.1 (M+), 186.1 (base peak). 
 
S30i: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 6.90 (dd, J = 8.3, 2.3 Hz, 1H), 6.87 (d, J = 2.3 Hz, 1H), 6.79 (d, J = 8.4 Hz, 1H), 5.64 (m, 1H), 
5.09 (m, 2H), 3.84 (s, 3H), 3.82 (s, 3H), 2.59 (dd,  J = 13.6, 6.7 Hz,  1H), 2.52 (dd, J = 13.6, 6.7 
Hz, 1H), 1.63 (s, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 149.05, 148.55, 132.32, 131.99, 123.34, 120.12, 117.72, 111.12, 109.12, 56.02, 55.95, 46.40, 
41.73, 26.67. 
 
GC/MS data: 231.1 (M+), 190.1 (base peak). 
 
S31c: 
 
 
 
NC
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1H NMR (500 MHz, CDCl3): 
 
δ 6.94 (dd, J = 8.4, 2.2 Hz, 1H), 6.87 (m, 2H), 5.51 (m, 1H), 5.11 (d, J = 16.9 Hz, 1H), 5.06 (d, J 
= 10.1 Hz, 1H) 3.92 (s, 3H), 3.90 (s, 3H), 2.85 (dd, J = 14.0, 7.6 Hz, 1H), 2.63 (dd, J = 14.0, 6.6 
Hz, 1H), 2.15 (apparent septet, J = 6.7 Hz, 1H), 1.22 (d, J = 6.7 Hz, 3H), 0.85 (d, J = 6.7 Hz, 
3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 148.87, 148.29, 132.34, 130.00, 121.10, 119.39, 119.02, 110.91, 109.93, 55.99, 55.87, 53.33, 
42.17, 37.23, 18.81, 18.56. 
 
GC/MS data: 259.2 (M+), 218.2 (base peak), 138.0, 76.9. 
 
S44f: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.54 (dd, J = 6.0, 3.5 Hz, 1H), 7.35 (dd, J = 6.0, 3.5 Hz, 1H), 7.19 (m, 6H), 7.14 (ddd, J = 9.3, 
6.2, 3.3 Hz, 1H), 6.44 (d, J = 15.7 Hz, 1H), 5.96 (dt, J = 15.6, 7.4 Hz, 1H), 5.60 (m, 1H), 5.14 
(d, J = 17.0 Hz, 1H), 5.06 (d, J = 10.1 Hz, 1H), 3.28 (ddd, J = 14.2, 7.2, 1.3 Hz, 1H), 3.20 (ddt, 
J = 14.2, 7.2, 1.0 Hz, 1H), 2.96 (ddd, J = 14.2, 7.7, 1.2 Hz, 1H), 2.82 (ddt, J = 14.2, 7.4, 1.0 Hz, 
1H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 136.73, 134.89, 133.24, 132.23, 132.08, 131.69, 130.79, 129.52, 128.50, 127.63, 127.28, 
126.36, 123.02, 121.63, 120.12, 49.21, 40.57, 39.87. 
 
GC/MS data: 307.1 (M+). 
 
S37b: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.57 (s, 1H), 7.51 (d, J = 7.8 Hz, 2H), 7.42 (t, J = 7.8 Hz, 1H), 7.29 (m, 5H), 5.62 (m, 1H), 
5.15 (d, J = 12.2 Hz, 1H), 5.12 (d, J = 4.6 Hz, 1H), 3.08 (m, 2H). 
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GC/MS data: 301.1 (M+), 260.1 (base peak), 233.0, 190.1. 
 
S37c: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.56 (s, 1H), 7.49 (m,, 2H), 7.41 (t, J = 7.8 Hz, 1H), 7.28 (m, 5H), 5.49 (dt, J = 15.1, 6.9 Hz, 
1H), 5.23 (dt,  J = 15.1, 6.9 Hz, 1H), 3.02 (m, 2H), 1.86 (apparent quartet, J = 7.4 Hz, 2H), 1.21 
(apparent sextet, J = 7.4 Hz 2H), 0.72 (t, J = 7.4 Hz, 3H). 
 
 
GC/MS data: 343.2 (M+), 261.2 (base peak), 190.1, 165.0. 
 
S37d: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.27 (m, 10H), 5.64 (m, 1H), 5.14 (d, J = 17.0 Hz, 1H), 5.10 (d, J = 10.2, 1H), 3.07 (dt, J = 
7.0, 1.1 Hz, 2H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 139.74, 131.79, 128.86, 127.95, 127.06, 121.97, 120.44, 51.72, 43.95. 
 
GC/MS data: 233.1 (M+), 192.1, 165.1 (base peak). 
 
S37e: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.26 (m, 10H), 5.50 (dt, J = 15.1, 6.9 Hz, 1H), 5.24 (dt, J = 15.1, 6.9 Hz, 1H), 2.99 (d, J = 7.0, 
Hz, 2H), 1.86 (apparent quartet, J = 7.4 Hz, 2H), 1.22 (apparent sextet, J = 7.4 Hz, 3H), 0.73 (t, 
J = 7.4 Hz, 3H). 
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13C NMR (126 MHz, CDCl3):  
 
δ 140.00, 136.83, 128.76, 127.81, 127.14, 123.15, 52.13, 42.96, 34.58, 22.30, 13.50. 
 
 
GC/MS data: 275.2 (M+), 193.1 (base peak), 165.1. 
 
S37f: 
 
 
 
1H NMR (500 MHz, CDCl3)  
 
δ 7.30 (m, 8H), 7.22 (m, 2H), 4.85 (s, 1H), 4.69 (s,, 1H), 3.05 (s, 2H), 1.46 (s, 3H). 
 
13C NMR (126 MHz, CDCl3):  
 
δ 140.32, 139.48, 128.77, 127.89, 127.10, 122.36, 117.07, 51.08, 46.90, 23.74. 
 
GC/MS data: 247. (M+), 192.1, 165.1 (base peak). 
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6. Characterization of synthetic intermediates: 
 
 
NOTE* Compounds note explicitly given a number in Chapter 3 are given an “appendix 
number” in the form A-1, A-2, etc. 
 
 
S41a: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 5.25 (s, 2H), 2.25 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 193.94, 83.78, 27.46. 
 
S8a: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 5.24 (q, J = 7.1 Hz, 1H), 2.32 (s, 3H), 1.74 (d, J = 7.1 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 197.15, 89.36, 26.16, 14.86. 
 
A-1 (S40a): 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.35 (m, 5H), 7.22 (d, J = 7.1 Hz, 2H), 5.41 (dd, J = 9.4, 5.6 Hz, 1H), 3.47 (m, 2H), 2.32 (s, 
3H) 
 
A-2 (S40a): 
O2N
O
O2N
O
O2N
O
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1H  NMR (500 MHz, CDCl3): 
 
δ 5.29 (m, 1H), 3.64 (s, 3H), 2.40 (m, 4H), 2.27 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 196.18, 172.19, 172.15, 93.03, 52.07, 29.35, 26.79, 24.40. 
 
A-3 (S40a) 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.50 (m, 5H), 6.34 (s, 1H), 2.24 (s, 3H). 
 
13C NMR (126 MHz, CDCl3) 
 
δ 195.32, 130.98, 130.24, 129.52, 128.25, 97.49, 27.50. 
 
S8b = S40a: 
 
 
 
NMR shows cyclic nitro ketone exists as a 0.8:1 mixture ketone:enol tautaumers 
 
1H NMR (500 MHz, CDCl3) 
 
δ 13.82 (enol proton, s, 1H), 5.16 (ketone α-proton, dd, J = 11.95, 6.12 Hz, 1H), 2.60 (m, 1H), 
2.51 (m, J = 6.5, 4.0, 1.4 Hz, 2H), 2.45 (m, 3H), 2.37 (m, J = 12.7, 6.9, 6.5, 2.4 Hz, 1H), 2.05 
(m, J = 3.9, 2.9, 1.8 Hz, 1H), 1.98 (m, 1H), 1.70 (m, 6H). 
 
Carbon-NMR agrees (12 unique carbon atoms) 
 
13C NMR (126 MHz, CDCl3): 
O2N
O
CO2Me
O2N
O
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δ 197.89, 172.54, 124.70, 91.83, 40.78, 31.63, 29.93, 26.44, 23.80, 22.60, 22.00, 21.18. 
 
S8c 
 
 
Interestinly, 7-membered α-nitroketone exists exclusively as the ketone (no enol tautamer). 
 
1H NMR (500 MHz, CDCl3): 
 
δ 5.34 (dd, J = 9.7, 3.8 Hz, 1H), 2.66 (m, 1H), 2.56 (ddd, J = 16.5, 10.8, 3.5 Hz, 1H), 2.28 (m, 
1H), 2.15 (dddd, J = 14.8, 11.3, 9.7, 2.6 Hz, 1H), 1.95 (m, 1H), 1.84 (m, 2H), 1.60 (m, 2H), 1.41 
(m, 1H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 201.16, 93.83, 41.61, 29.13, 28.99, 26.57, 23.54. 
 
A-4: 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 5.55 (m, 1H), 5.16 (dm, J = 6.28 Hz, 1H), 5.13 (dm, J = 14.77 Hz, 1H), 2.90 (dd, J = 14.4, 7.1 
Hz, 1H), 2.69 (dd, J = 14.4, 7.6 Hz, 1H), 2.16 (s, 3H), 1.62 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 199.11, 129.51, 121.60, 96.93, 40.19, 24.53, 20.13. 
 
A-5: 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
O NO2
O2N
O
O
H
OH
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δ 14.63 (d, J = 6.6 Hz, 1H), 8.25 (d, J = 6.5 Hz, 1H), 8.00 (t, J = 9.5 Hz, 1H), 7.47 (t, J = 7.5 
Hz, 1H), 7.37 (t, J = 7.5 Hz, 1H), 7.26 (d, J = 7.6 Hz, 1H), 2.93 (t, J = 7.12 Hz, 2H), 2.61 (t, J = 
7.12 Hz, 2H). 
 
A-6: 
 
 
 
1H NMR (400 MHz, CDCl3) δ 14.49 (d, J = 1.7 Hz, 1H), 9.07 (d, J = 1.6 Hz, 1H), 7.66 (s, 1H), 
7.43 (m, 4H), 7.34 (m, 1H), 2.74 (m, 2H), 2.51 (m, 2H), 1.78 (m, 2H). 
 
A-7: 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 13.93 (d, J = 10.3 Hz, 1H), 7.21 (d, J = 9.8 Hz, 1H), 5.35 (s, 1H), 3.95 (q,  J = 7.14 Hz, 2H), 
2.45 (m, 4H), 1.40 (t, J = 7.14 Hz, 3H). 
 
A-8: 
 
 
 
1H NMR (500 MHz, CDCl3) 
 
δ 14.10 (d, J = 8.4 Hz, 1H), 7.86 (d, J = 8.0 Hz, 1H), 7.74 (m, 1H), 7.34 (td, J = 7.4, 1.3 Hz, 
1H), 7.28 (m, 2H), 7.21 (d,  J = 7.67 Hz, 1H), 6.75 (d, J = 2.4 Hz, 1H), 2.92 (dd, J = 8.5, 3.4 Hz, 
2H), 2.74 (m, 1H), 2.55 (dd,  J = 14.38, 5.51 Hz, 1H), 2.41 (td, J = 14.2, 1.4 Hz, 1H), 2.12 (m, 
1H), 1.62 (m, 1H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 187.95, 168.15, 155.08, 140.27, 130.98, 130.48, 129.64, 126.75, 125.11, 119.08, 107.93, 37.46, 
30.59, 30.14, 29.59. 
 
Ph O
H
OH
EtO
O
H
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O
H
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A-9: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 15.65 (d, J = 4.8 Hz, 1H), 8.43 (d, J = 4.7 Hz, 1H), 2.61 (m, 1H), 2.43 (m, 2H), 2.28 (s, 3H), 
1.91 (s, 3H), 1.77 (m, 1H), 1.53 (m, 1H), 1.13 (d, J = 6.9 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 183.22, 181.62, 148.12, 125.93, 115.55, 30.26, 29.20, 24.83, 24.42, 24.33, 20.94. 
 
A-10: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 13.68 (d, J = 7.3 Hz, 1H), 7.29 (s,1H), 5.70 (s, 1H), 2.31 (m, 2H), 2.22 (m, 2H), 1.96 (dt, J = 
12.7, 3.4 Hz, 1H), 1.76 (m, 2H), 1.54 (m, 1H), 1.40 (m, 5H), 1.23 (m, 7H), 1.07 (m, 8H), 0.94 
(m, 8H), 0.84 (m, 4H), 0.80 (m, 9H), 0.63 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 189.32, 170.59, 165.00, 122.88, 106.59, 56.12, 55.87, 53.15, 42.38, 39.88, 39.65, 39.50, 37.55, 
36.12, 35.75, 35.73, 32.57, 31.42, 28.18, 28.02, 24.24, 23.82, 22.83, 22.57, 22.36, 21.41, 18.66, 
18.07, 14.08, 11.92. 
 
A-11: 
 
 
 
1H NMR (500 MHz, CDCl3) 
O
H
OH
O
C8H17
H
H HHO
H
O
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δ 7.70 (d, J = 8.0 Hz, 1H), 7.25 (td, J = 7.5, 1.0 Hz, 1H), 7.16 (t, J = 7.6 Hz, 1H), 7.12 (d, J = 
7.6 Hz, 1H), 2.88 (m, 2H), 2.58 (m, 1H), 2.50 (m, 1H), 2.39 (ddd, J = 16.7, 14.9, 5.0 Hz, 1H), 
2.13 (dtd, J = 12.9, 4.7, 2.6 Hz, 1H), 1.99 (m, 1H), 1.75 (dddd, J = 15.5, 13.2, 11.4, 4.4 Hz, 1H), 
1.54 (qd, J = 12.8, 5.0 Hz, 1H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 200.29, 158.29, 139.84, 131.31, 130.58, 129.68, 126.63, 125.22, 120.44, 37.43, 37.17, 30.58, 
30.34, 30.03. 
 
A-12 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 7.39 (m, 3H), 7.19 (m, 2H), 1.92 (s, 6H). 
 
A-13: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 8.01 (d, J = 8.10 Hz,  2H), 7.32 (d, J = 8.10 Hz, 2H), 2.66 (s, 3H), 1.91 (s, 6H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 197.66, 190.64, 142.10, 136.28, 131.47, 128.86, 114.48, 26.67, 24.20. 
 
A-14: 
 
O O
O O
COMe
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1H NMR (500 MHz, CDCl3): 
 
δ 8.29 (d, J = 8.85 Hz, 2H), 7.41 (d, J = 8.85 Hz 2H), 1.92 (s, 6H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 190.53, 147.36, 144.09, 132.23, 124.10, 113.68, 24.25. 
 
A-15: 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 7.73 (d, J = 8.19 Hz, 2H), 7.35 (d, J = 8.19 Hz, 2H), 1.91 (s, 6H). 
 
A-16: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.10 (d, J = 8.67 Hz, 2H), 6.94 (d, J = 8.67 Hz, 2H), 3.86 (s, 3H), 1.91 (s, 6H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 191.25, 158.89, 132.14, 129.10, 114.17, 55.26, 24.17. 
O O
NO2
O O
CN
O O
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A-17: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 6.84 (tt, J = 8.84, 2.24 Hz, 1H), 6.76 (dd, J = 7.8, 2.2 Hz, 2H), 1.94 (s, 6H). 
 
A-18: 
 
 
 
1H  NMR (500 MHz, CDCl3): 
 
δ 8.25 (ddd, J = 8.2, 2.3, 1.2 Hz, 1H), 8.11 (t, J = 1.9 Hz, 1H), 7.63 (t, J = 7.9 Hz, 1H), 7.57 (dt, 
J = 7.74, 1.28 Hz, 1H), 1.93 (s, 6H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 190.83, 138.82, 137.44, 129.94, 126.02, 122.75, 113.51, 24.27. 
 
A-19: 
 
 
 
1H  NMR (400 MHz, CDCl3) 
 
δ 16.36 (s, 1H), 7.95 (d, J = 7.6 Hz, 1H), 7.41 (dt, J = 7.4, 3.7 Hz, 1H), 7.34 (t, J = 7.5 Hz, 1H), 
7.22 (d, J = 8.0 Hz, 1H), 2.89 (t, J = 7.11 Hz, 2H), 2.65 (t, J = 7.11 HzHz, 2H), 2.59 (q, J = 7.4 
Hz, 2H), 1.21 (t, J = 7.4 Hz, 3H). 
 
A-20: 
 
O O
F F
O O
NO2
O OH
Et
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1H  NMR (400 MHz, CDCl3): 
 
δ 7.93 (d, J = 8.7 Hz, 1H), 6.86 (dd, J = 8.5, 2.6 Hz, 1H), 6.73 (s, 1H), 3.88 (s, J = 2.4 Hz, 3H), 
2.87 (m, 2H), 2.64 (m, 2H), 2.22 (s, 3H). 
 
A-21: 
 
 
 
1H  NMR (400 MHz, CDCl3): 
 
δ 7.80 (dm, J = 9.28 Hz, 1H), 7.29 (m, J = 4.8 Hz, 2H), 2.98 (t, J = 7.4 Hz, 2H), 2.74 (t, J = 7.4 
Hz, 2H), 2.44 (s, 3H). 
 
A-22: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 16.45 (s, 1H), 7.65 (dd, J = 7.5, 1.4 Hz, 1H), 7.41 (td, J = 7.4, 1.5 Hz, 1H), 7.36 (td, J = 7.5, 
1.3 Hz, 1H), 7.22 (d, J = 7.4 Hz, 1H), 2.71 (t, J = 7.0 Hz, 2H), 2.27 (s, J = 3.5 Hz, 3H), 2.18 (t, J 
= 6.9 Hz, 2H), 2.04 (m, 2H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 190.38, 188.19, 139.88, 137.49, 131.08, 128.84, 127.55, 126.70, 109.59, 31.29, 31.02, 23.78, 
22.99. 
 
A-23: 
 
O OH
MeO
O OH
F
O HO
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1H  NMR (500 MHz, CDCl3): 
 
δ 16.42 (s, 1H), 7.42 (s, 1H), 6.83 (s, 1H), 3.87 (s, 3H), 2.83 (t, J = 7.5 Hz, 2H), 2.59 (t, J = 7.5 
Hz, 2H), 2.40 (s, 3H), 2.25 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 193.43, 177.48, 155.82, 137.03, 131.90, 126.54, 118.28, 114.77, 105.95, 55.65, 23.84, 22.31, 
21.60, 20.28. 
 
A-24: 
 
 
 
 
1H NMR (400 MHz, CDCl3) 
 
δ 7.23 (m, J = 13.2, 7.1 Hz, 3H), 7.15 (m, 1H), 2.88 (m, 2H), 2.58 (m, 2H), 2.40 (s, 3H). 
 
A-25: 
 
 
 
 
1H  NMR (400 MHz, CDCl3): 
 
δ 8.25 (d, J = 7.8 Hz, 1H), 8.18 (m, 1H), 7.62 (t, J = 7.6 Hz, 1H), 7.58 (d, J = 7.9 Hz, 1H), 2.20 
(s, 6H), 1.93 (s, 3H). 
 
A-26: 
 
O OH
OMe
O OH
O Ac
NO2
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1H NMR (500 MHz, CDCl3): 
 
δ 9.77 (s, 1H), 8.07 (dd, J = 7.9, 1.1 Hz, 1H), 7.53 (td, J = 7.5, 1.4 Hz, 1H), 7.36 (t, J = 7.5 Hz, 
1H), 7.27 (d, J = 7.8 Hz, 1H), 3.05 (m, 2H), 2.53 (ddd, J = 13.7, 7.7, 5.1 Hz, 1H), 2.03 (m, 1H), 
1.44 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 200.84, 197.34, 143.46, 134.10, 131.42, 128.83, 127.84, 127.02, 57.99, 29.45, 25.30, 18.55. 
 
A-27: 
 
 
 
 
1H NMR (400 MHz, CDCl3) 
 
δ 8.08 (d, J = 6.9 Hz, 1H), 7.51 (dt, J = 7.38, 1.35 Hz 1H), 7.35 (t, J = 7.6 Hz, 1H), 7.25 (d, J = 
7.9 Hz, 1H), 3.07 (ddd, J = 18.07, 9.7, 4.8 Hz, 1H), 2.96 (dt, J = 14.0, 8.6 Hz, 1H), 2.63 (m, 
1H), 2.16 (s, 3H), 1.99 (m, 1H), 1.46 (s, 3H). 
 
A-28: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 8.08 (dd, J = 7.9, 1.0 Hz, 1H), 7.50 (td, J = 7.5, 1.4 Hz, 1H), 7.34 (t, J = 7.6 Hz, 1H), 7.24 (d, 
J = 7.6 Hz, 1H), 3.04 (m, 1H), 2.92 (dt, J = 17.4, 5.1 Hz, 1H), 2.67 (m, 2H), 2.27 (dq, J = 18.3, 
7.2 Hz, 1H), 1.98 (ddd, J = 13.7, 10.0, 4.9 Hz, 1H), 1.44 (s, 3H), 1.00 (t, J = 7.2 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 209.54, 198.75, 143.66, 133.77, 131.86, 128.95, 127.80, 126.81, 59.79, 32.77, 32.29, 25.92, 
21.18, 7.86. 
 
O O
H
O O
Me
O O
Et
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A-29: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.50 (s, 1H), 6.86 (s, 1H), 3.86 (s, 3H), 2.86 (t, J = 6.15 Hz, 2H), 2.60 (dt, J = 13.7, 5.4 Hz, 
1H), 2.39 (s, 3H), 2.13 (s, 3H), 1.92 (dt, J = 14.1, 7.2 Hz, 1H), 1.41 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 207.14, 198.96, 156.75, 137.07, 132.37, 129.71, 119.31, 115.70, 59.60, 55.61, 31.82, 26.58, 
21.52, 20.43, 19.42. 
 
A-30: 
 
 
 
 
A-31: 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 7.52 (d, J = 7.5 Hz, 1H), 7.43 (t, J = 7.5 Hz, 1H), 7.32 (t, J = 7.6 Hz, 1H), 7.17 (d, J = 7.5 Hz, 
1H), 2.83 (t, J = 6.5 Hz, 2H), 2.33 (ddd, J = 14.5, 9.0, 5.7 Hz, 1H), 2.11 (s, 3H), 2.03 (dt, J = 
12.7, 6.6 Hz, 1H), 1.88 (m, 1H), 1.67 (dt, J = 14.2, 5.7 Hz, 1H), 1.45 (s, 3H). 
 
A-32: 
O Ac
OMe
O
O
O
O
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1H NMR (500 MHz, CDCl3): 
 
δ 8.18 (d,  J = 9.04 Hz,  2H), 7.39 (d,  J = 9.04 Hz, 2H), 5.52 (m, 1H), 5.07 (dd, J = 11.4, 1.5 
Hz, 1H), 5.04 (m, 1H), 3.03 (dt, J = 7.0, 1.3 Hz, 2H), 2.09 (s, 5H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 204.02, 147.31, 143.70, 131.92, 129.51, 123.84, 119.85, 75.02, 37.88, 27.99. 
 
A-33: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.91 (d, J = 8.63 Hz, 2H), 7.31 (d, J = 8.63 Hz, 2H), 5.59 (m, 1H), 5.06 (dq, J = 17.1, 1.6 Hz, 
1H), 5.02 (dq, J = 10.2, 1.5 Hz, 1H), 3.01 (dt, J = 7.0, 1.3 Hz, 2H), 2.55 (s, 3H), 2.06 (s, 6H). 
 
13C  NMR (126 MHz, CDCl3) 
 
δ 204.93, 197.39, 141.91, 136.57, 132.81, 128.79, 128.52, 119.18, 75.02, 37.67, 28.05, 26.66. 
 
A-34: 
 
 
 
1H NMR (500 MHz, CDCl3): 
O
NO2
Ac
O
COMe
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δ 7.42 (m, 2H), 7.37 (m, 1H), 7.28 (m, 3H), 5.74 (m, 1H), 5.14 (dd, J = 17.1, 1.7 Hz, 1H), 5.10 
(dd, J = 10.2, 1.7 Hz, 1H), 3.08 (dt, J = 7.0, 1.3 Hz, 2H), 2.14 (s, 6H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 206.00, 137.02, 133.64, 129.03, 128.15, 128.03, 118.56, 74.76, 37.58, 28.01. 
 
A-35: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 6.84 (m, 3H), 5.64 (m, 1H), 5.15 (m, 2H), 3.04 (d, J = 7.0 Hz, 2H), 2.17 (s, 6H). 
 
A-36: 
 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.71 (d, J = 8.35 Hz, 2H), 7.42 (d, J = 8.35 Hz, 2H), 5.60 (m, 1H), 5.14 (dm, J = 12.50 Hz 
1H), 5.12 (dm, J = 5.64 Hz 1H), 3.08 (d, J = 7.0 Hz, 2H), 2.16 (s, 6H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 204.18, 141.80, 132.49, 132.08, 129.25, 119.70, 118.19, 112.10, 75.03, 37.68, 27.98. 
 
A-37: 
 
O Ac
F F
O
CN
Ac
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1H NMR (500 MHz, CDCl3): 
 
δ 7.10 (d, J = 8.97 Hz, 2H), 6.85 (d,  J = 8.97 Hz, 2H), 5.64 (m, 1H), 5.04 (dq, J = 17.1, 1.7 Hz, 
1H), 5.00 (dq, J = 10.2, 1.7 Hz, 1H), 3.75 (s, 3H), 2.96 (dt, J = 7.0, 1.3 Hz, 2H), 2.04 (s, 6H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 206.20, 159.26, 133.69, 129.20, 128.77, 118.45, 114.38, 73.99, 55.31, 37.61, 27.87. 
 
A-38: 
 
 
 
1H NMR (500 MHz, CDCl3) 
 
δ 8.23 (m, 2H), 7.61 (m, 2H), 5.61 (m, 1H), 5.16 (m, 2H), 3.14 (dt, J = 7.0, 1.3 Hz, 2H), 2.19 (s, 
6H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 204.08, 148.44, 138.49, 134.84, 131.79, 129.68, 123.41, 123.06, 119.96, 74.63, 37.71, 27.88. 
 
A-39: 
 
 
 
1H NMR (500 MHz, CDCl3) 
 
O Ac
OMe
O Ac
NO2
O
OMe
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δ 7.19 (d, J = 8.91 Hz 2H), 6.94 (d,  J = 8.91 Hz, 2H), 5.73 (m, 1H), 5.13 (dq, J = 17.1, 1.6 Hz, 
1H), 5.09 (dq, J = 10.2, 1.6 Hz, 1H), 3.84 (s, 3H), 3.05 (dt, J = 7.0, 1.3 Hz, 2H), 2.13 (s, 6H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 206.19, 159.26, 133.69, 129.20, 128.77, 118.45, 114.38, 73.99, 55.31, 37.61, 27.87. 
 
A-40: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.29 (m, 3H), 7.08 (m, 1H), 5.48 (m, 1H), 4.98 (m, 2H), 3.18 (m, 2H), 2.99 (dd, J = 13.90, 
8.08 Hz, 1H), 2.89 (dd, J = 13.9, 5.6 Hz, 1H), 2.80 (dt, J = 15.0, 5.31 Hz, 1H), 2.68 (dt, J = 
15.0, 8.31 Hz 1H), 1.92 (s, 3H). 
 
A-41: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.64 (dt, J = 9.0, 1.7 Hz, 1H), 7.13 (d, J = 1.7 Hz, 1H), 7.12 (d, J = 2.1 Hz, 1H), 5.62 (m, 1H), 
5.06 (m, 1H), 5.03 (m, 1H), 2.96 (m, 1H), 2.81 (dt, J = 17.41, 4.68 Hz, 1H), 2.61 (m, 2H), 2.49 
(dt, J = 13.9, 4.6 Hz, 1H), 2.06 (s, 3H), 1.96 (ddd, J = 13.9, 10.8, 5.0 Hz, 1H). 
 
13C NMR (126 MHz, CDCl3) 
 
δ 205.19, 196.32, 196.30, 161.65 (J = 241.5 Hz), 139.44 (J = 3.23 Hz), 133.49, 132.53, 130.76 
(J = 6.96 Hz), 121.38 (J = 22.2 Hz), 119.28, 113.60 (J = 22.4 Hz), 63.47, 39.00, 29.26, 27.01, 
25.06. 
 
A-42: 
 
 
O Ac
O
Ac
F
O Ac
MeO
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1H NMR (500 MHz, CDCl3): 
 
δ 8.05 (d, J = 8.8 Hz, 1H), 6.85 (dd, J = 8.8, 2.5 Hz, 1H), 6.66 (d, J = 2.5 Hz, 1H), 5.71 (m, 1H), 
5.13 (m, 1H), 5.10 (m, 1H), 3.87 (s, 3H), 3.06 (dd, J = 11.2, 5.2 Hz, 1H), 2.87 (dt, J = 13.4, 8.7 
Hz, 1H), 2.70 (d, J = 7.3 Hz, 2H), 2.56 (dt, J = 17.36, 4.7 Hz, 1H), 2.15 (s, 3H), 2.01 (ddd, J = 
13.7, 10.8, 4.9 Hz, 1H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 205.80, 195.71, 164.02, 146.46, 133.02, 130.42, 125.66, 118.89, 113.64, 112.36, 63.40, 55.50, 
39.23, 29.22, 27.03, 26.14. 
 
A-43: 
 
 
 
1H NMR (400 MHz, CDCl3) 
 
δ 8.08 (d, J = 6.9 Hz, 1H), 7.50 (t, J = 6.9 Hz, 1H), 7.34 (t, J = 7.7 Hz, 1H), 7.23 (d, J = 7.6 Hz, 
1H), 5.73 (m, 1H), 5.15 (d, J = 9.4 Hz, 1H), 5.11 (m, 1H), 3.08 (m, 1H), 2.91 (dt, J = 17.4, 5.38 
Hz, 1H), 2.71 (d, J = 7.6 Hz, 2H), 2.59 (dt, J = 14.12, 4.6 Hz, 1H), 2.15 (s, 3H), 2.08 (m, 1H). 
 
A-44: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 8.00 (dd, J = 7.9, 1.1 Hz, 1H), 7.46 (td, J = 7.5, 1.4 Hz, 1H), 7.32 (m, 4H), 7.27 (m, 1H), 7.15 
(d, J = 7.7 Hz, 1H), 5.30 (d, J = 1.4 Hz, 1H), 5.14 (d, J = 1.1 Hz, 1H), 3.42 (d, J = 14.3 Hz, 1H), 
3.17 (d, J = 14.3 Hz, 1H), 3.00 (m, J = 12.0, 5.0 Hz, 1H), 2.75 (m, 1H), 2.49 (ddd, J = 13.9, 4.7, 
3.6 Hz, 1H), 2.02 (s, 3H), 1.86 (ddd, J = 13.9, 11.7, 5.0 Hz, 1H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 204.38, 197.06, 144.44, 143.88, 142.07, 133.86, 132.04, 128.86, 128.23, 127.90, 127.55, 
126.71, 126.58, 118.26, 64.52, 39.93, 29.37, 27.12, 25.82. 
 
A-45: 
O Ac
O Ac
Ph
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1H NMR (500 MHz, CDCl3): 
 
δ 8.01 (dd, J = 7.9, 1.1 Hz, 1H), 7.42 (td, J = 7.5, 1.4 Hz, 1H), 7.25 (m, 3H), 7.21 (m, 3H), 7.13 
(m, 2H), 6.38 (d, J = 15.8 Hz, 1H), 6.04 (m, 1H), 2.99 (dd, J = 11.0, 5.1 Hz, 1H), 2.82 (m, 2H), 
2.71 (ddd, J = 14.1, 7.6, 1.2 Hz, 1H), 2.54 (dt, J = 13.8, 4.7 Hz, 1H), 2.10 (s, 3H), 2.02 (ddd, J = 
13.8, 10.7, 5.0 Hz, 1H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 205.60, 197.32, 143.80, 136.97, 133.98, 131.99, 128.99, 128.51, 127.92, 127.43, 126.80, 
126.24, 124.48, 64.07, 38.34, 29.42, 27.18, 25.74. 
 
A-46 
 
 
 
1H NMR (500 MHz, CDCl3) 
 
δ 8.07 (dd, J = 7.9, 1.1 Hz, 1H), 7.50 (td, J = 7.5, 1.4 Hz, 1H), 7.33 (t, J = 7.6 Hz, 1H), 7.23 (d, 
J = 7.7 Hz, 1H), 5.39 (dt, J = 15.0, 7.4 Hz, 1H), 5.07 (dd, J = 15.2, 8.6 Hz, 1H), 3.08 (m, 1H), 
2.91 (dt, J = 17.37, 4.62 Hz, 1H), 2.63 (m, 2H), 2.57 (dt, J = 13.8, 4.7 Hz, 1H), 2.14 (s, 3H), 
2.05 (ddd, J = 13.8, 10.8, 5.0 Hz, 1H), 1.34 (m, 1H), 0.67 (dd, J = 6.9, 3.5 Hz, 2H), 0.33 (m, 
2H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 205.73, 197.40, 143.88, 138.77, 133.83, 132.09, 128.94, 127.85, 126.69, 121.41, 64.07, 37.88, 
29.06, 27.09, 25.74, 13.60, 6.63, 6.61. 
 
A-47: 
 
 
 
1H NMR (500 MHz, CDCl3): 
O Ac
Ph
O Ac
O
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δ 8.08 (dd, J = 7.9, 1.1 Hz, 1H), 7.50 (td, J = 7.5, 1.4 Hz, 1H), 7.33 (t, J = 7.6 Hz, 1H), 7.23 (d, 
J = 7.7 Hz, 1H), 4.86 (m, 1H), 4.74 (s, 1H), 3.11 (m, 1H), 2.96 (d, J = 14.0 Hz, 1H), 2.90 (dt, J 
= 17.31, 4.20 Hz, 1H), 2.64 (dd, J = 13.9, 0.5 Hz, 1H), 2.59 (dt, J = 13.9, 4.4 Hz, 1H), 2.18 (s, 
3H), 2.02 (ddd, J = 13.9, 11.4, 4.9 Hz, 1H), 1.64 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 205.83, 197.05, 143.92, 141.07, 133.92, 132.00, 128.91, 128.02, 126.70, 115.93, 63.64, 42.65, 
28.73, 27.12, 25.91, 23.92. 
 
A-48: 
 
 
 
Isolated as a 5:1 mixture of E:Z diastereomers 
 
1H NMR (400 MHz, CDCl3) δ 8.08 (d, J = 7.5 Hz, 1H), 7.50 (t, J = 7.4 Hz, 1H), 7.33 (t, J = 7.5 
Hz, 1H), 7.23 (d, J = 7.4 Hz, 1H), 5.55 (m, 1H), 5.34 (m, 1H), 3.08 (m, 1H), 2.90 (dt, J = 17.24, 
5.81 Hz, 1H), 2.64 (d, J = 7.1 Hz, 2H), 2.57 (dt, J = 13.9, 4.8 Hz, 1H), 2.15 (s, 3H), 2.04 (ddd, J 
= 13.9, 10.7, 5.0 Hz, 1H), 1.66 (dd, J = 6.4, 1.5 Hz, 3H). 
 
A-49 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 8.08 (dd, J = 7.9, 1.1 Hz, 1H), 7.49 (td, J = 7.5, 1.4 Hz, 1H), 7.33 (t, J = 7.6 Hz, 1H), 7.22 (d, 
J = 7.7 Hz, 1H), 5.03 (m, 1H), 3.09 (m, 1H), 2.87 (dt, J = 17.5, 4.7 Hz, 1H), 2.68 (t, J = 7.6 Hz, 
2H), 2.59 (dt, J = 13.8, 4.6 Hz, 1H), 2.15 (s, 3H), 2.03 (ddd, J = 13.8, 11.0, 4.9 Hz, 1H), 1.70 (s, 
3H), 1.64 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 205.91, 197.60, 143.94, 135.56, 133.81, 132.14, 128.93, 127.86, 126.67, 118.17, 64.29, 33.42, 
28.97, 27.01, 26.00, 25.82, 18.02. 
 
A-50: 
 
O
Ac
O
Ac
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1H NMR (400 MHz, CDCl3): 
 
δ 8.08 (d, J = 7.8 Hz, 1H), 7.49 (t, J = 6.8 Hz, 1H), 7.33 (t, J = 7.7 Hz, 1H), 7.22 (d, J = 7.7 Hz, 
1H), 5.04 (m, 2H), 3.10 (m, 1H), 2.88 (dt, J = 17.48, 4.66  Hz, 1H), 2.69 (d, J = 7.3 Hz, 2H), 
2.57 (dt, J = 13.90, 4.54 Hz, 1H), 2.16 (s, 4H), 2.04 (m, 6H), 1.64 (s,s, 6H), 1.58 (s, 3H). 
 
A-51: 
 
 
 
Isolated as a 1:1 mixture of diastereomers and reported as a mixture 
 
1H NMR (400 MHz, CDCl3): 
 
δ 8.06 (d, J = 8.1 Hz, 2H), 7.49 (t, J = 7.5 Hz, 2H), 7.32 (t, J = 7.8 Hz, 2H), 7.22 (d, J = 7.6 Hz, 
2H), 5.31 (d, J = 14.0 Hz, 2H), 3.10 (m, 2H), 2.87 (dt, J = 17.5, 4.11 Hz, 2H), 2.73 (m, 3H), 
2.62 (m, 2H), 2.31 (m, 2H), 2.22 (d, 3H), 2.18 (s, 3H), 2.16 (s, 3H), 2.01 (m, 5H), 1.93 (d, J = 
5.3 Hz, 1H), 1.25 (s, 2H), 1.24 (s, 3H), 0.83 (s, 2H), 0.78 (s, 3H). 
 
A-52: 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 7.50 (s, 1H), 6.87 (s, 1H), 3.87 (s, 3H), 2.87 (t, J = 6.3 Hz, 2H), 2.63 (m, 2H), 2.39 (s, 3H), 
2.12 (m, 2H). 
 
A-53 
 
 
 
O
Ac
O
Ac
O
OMe
NC
Ph
O
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Isolated as a mixture of keto-enol tautomers 
 
1H NMR (400 MHz, CDCl3): 
 
δ 7.44 (m, 9H), 4.70 (s, 1H), 2.37 (s, 2H), 2.29 (s, 3H). 
 
A-54: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.80 (t, J = 5.32 Hz, 1H), 7.72 (ddd, J = 8.8, 7.2, 1.6 Hz, 1H), 7.33 (dd, J = 8.8, 1.1 Hz, 1H), 
6.90 (m, 1H), 2.34 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 192.56, 155.12, 140.49, 135.56, 120.39, 119.99, 116.18, 26.73. 
 
A-55: 
 
 
 
1H NMR (400 MHz, DMSO): 
 
δ 8.09 (s, 1H), 7.89 (m, 3H), 7.82 (m, 1H), 7.49 (m, 2H), 2.40 (s, 3H). 
 
A-56: 
 
 
NC
O
N
NC
O
NC
O
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1H NMR (500 MHz, CDCl3): 
 
δ 7.23 (d, J = 8.7 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 4.56 (s, 1H), 3.75 (s, 3H), 2.17 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 196.82, 160.31, 129.22, 121.47, 116.42, 115.08, 55.43, 50.74, 26.82. 
 
A-57: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 6.89 (dd, J = 8.3, 2.1 Hz, 1H), 6.83 (d, J = 8.3 Hz, 1H), 6.75 (d, J = 2.2 Hz, 1H), 4.56 (s, 1H), 
3.82 (s,s, J = 7.6 Hz, 7H), 2.18 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 196.79, 149.86, 149.84, 121.73, 120.66, 116.34, 111.71, 110.40, 56.09, 56.01, 51.09, 26.78. 
 
A-58: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.43 (m, 2H), 7.32 (m, 2H), 5.14 (s, 1H), 2.26 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 195.12, 133.54, 130.85, 130.34, 130.11, 128.46, 128.11, 115.49, 48.28, 27.97. 
 
A-59: 
 
NC
O
OMe
MeO
NC
O
Cl
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1H NMR (500 MHz, CDCl3): 
 
δ 7.37 (t, J = 4.5 Hz, 4H), 7.32 (m, 2H), 2.19 (s, 3H), 1.74 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 198.72, 135.13, 129.58, 128.95, 125.92, 120.12, 54.29, 26.12, 23.35. 
 
A-60: 
 
 
 
1H NMR (500 MHz, CDCl3) δ 7.02 (ddd, J = 8.4, 2.1, 0.8 Hz, 1H), 6.90 (d, J = 8.4 Hz, 1H), 
6.86 (d, J = 1.7 Hz, 1H), 3.90 (s,s, 6H), 2.27 (s, 3H), 1.81 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 198.91, 149.65, 149.49, 127.27, 120.29, 118.49, 111.56, 108.71, 56.05, 56.00, 53.83, 25.90, 
23.26. 
 
A-61: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.43 (m, 5H), 5.64 (m, 1H), 5.20 (m, 2H), 3.03 (dd, J = 14.1, 7.3 Hz, 1H), 2.80 (dd, J = 14.2, 
7.2 Hz, 1H), 2.30 (s, 3H). 
 
A-62: 
 
NC
Ph
O
NC
O
MeO OMe
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O
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1H NMR (500 MHz, CDCl3): 
 
δ 7.35 (m, 4H), 7.31 (m, 1H), 5.49 (m, 1H), 5.17 (m, 1H), 2.88 (ddd, J = 14.0, 7.3, 0.7 Hz, 1H), 
2.63 (ddd, J = 14.0, 7.3, 0.8 Hz, 1H), 2.21 (s, 3H), 1.86 (q, J = 7.2 Hz, 2H), 1.24 (dd, J = 14.7, 
7.4 Hz, 2H), 0.75 (t, J = 7.4 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 198.65, 137.27, 133.45, 129.42, 128.89, 126.42, 122.33, 119.09, 60.37, 39.63, 34.53, 27.09, 
22.25, 13.48. 
 
A-63: 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 7.46 (m, 5H), 7.30 (m, 4H), 7.25 (m, 1H), 6.53 (d, J = 15.6 Hz, 1H), 6.02 (dt, J = 15.2, 7.5 Hz, 
1H), 3.19 (dd, J = 14.2, 7.2 Hz, 1H), 2.93 (dd, J = 14.2, 7.2 Hz, 1H), 2.32 (s, 3H). 
 
A-64: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 8.65 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 7.82 (td, J = 7.8, 1.8 Hz, 1H), 7.63 (dt, J = 8.0, 1.0 Hz, 
1H), 7.34 (ddd, J = 7.6, 4.8, 1.0 Hz, 1H), 5.70 (m, 1H), 5.20 (m, 1H), 5.18 (m, 1H), 3.11 (ddt, J 
= 14.0, 7.14, 1.02 Hz, 1H), 2.97 (ddt, J = 14.0, 7.14, 1.02 Hz, 1H), 2.30 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 197.15, 153.45, 150.16, 137.68, 130.87, 123.59, 122.09, 120.92, 118.53, 58.96, 39.56, 27.11. 
NC
Ph
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A-65: 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 7.36 (d, J =  9.11 Hz, 2H), 6.96 (d, J =  9.11 Hz, 2H), 5.65 (m, 1H), 5.20 (m, 2H), 3.84 (s, 3H), 
2.98 (dd, J = 14.2, 7.4 Hz, 1H), 2.77 (dd, J = 14.2, 7.0 Hz, 1H), 2.29 (s, 3H). 
 
A-66: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.60 (m, 1H), 7.37 (m, 1H), 7.32 (pd, J = 7.4, 3.7 Hz, 2H), 5.60 (m, 1H), 5.12 (m, 1H), 5.09 
(m, 1H), 3.02 (m, 2H), 2.24 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 197.97, 132.49, 132.17, 131.46, 130.67, 130.51, 130.29, 127.71, 121.02, 117.82, 58.96, 38.13, 
27.15. 
 
A-67: 
 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
NC
O
MeO
NC
O
Cl
NC
O
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δ 7.95 (d, J = 1.9 Hz, 1H), 7.83 (d, J = 8.0 Hz, 2H), 7.79 (m, 1H), 7.49 (dt, J = 5.5, 3.1 Hz, 2H), 
7.33 (dd, J = 8.7, 2.1 Hz, 1H), 5.56 (m, 1H), 5.14 (ddd, J = 17.0, 2.8, 1.3 Hz, 1H), 5.08 (dm, J =  
9.62 Hz, 1H), 3.01 (dd,  J = 14.46, 7.42, 0.92 Hz,  1H), 2.83 (dd, J = 14.46, 7.42, 0.92 Hz, 1H), 
2.23 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 198.32, 133.23, 133.08, 130.96, 130.39, 129.64, 128.26, 127.71, 127.24, 127.14, 126.48, 
122.81, 120.93, 118.94, 60.05, 40.43, 27.00. 
 
S31b: 
 
 
 
1H NMR (500 MHz, CDCl3): 
 
δ 7.09 (dd, J = 8.4, 2.3 Hz, 1H), 6.91 (d, J = 2.3 Hz, 1H), 6.89 (d, J = 8.5 Hz, 1H), 3.91 (s,s, 
6H), 2.78 (m, 1H), 2.33 (s, 3H), 1.16 (d, J = 6.5 Hz, 3H), 0.78 (d, J = 6.9 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3): 
 
δ 199.46, 149.50, 149.40, 125.42, 119.41, 118.52, 111.32, 109.10, 66.08, 56.01, 55.95, 34.11, 
28.00, 19.44, 17.64. 
 
S33c: 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 7.57 (d, J = 6.9 Hz, 2H), 7.43 (m, 3H), 5.76 (m, 1H), 5.27 (m, 2H), 4.28 (m, 2H), 3.14 (dd, J = 
13.9, 7.3 Hz, 1H), 2.87 (dd, J = 13.9, 6.7 Hz, 1H), 1.28 (t, J = 7.1 Hz, 3H). 
 
A-68 
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1H NMR (500 MHz, CDCl3): 
 
δ 7.42 (m, 10H), 5.19 (m, 1H), 1.33 (d, J = 6.2 Hz, 6H). 
 
A-69: 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 7.69 (d, J = 5.9 Hz, 2H), 7.63 (d, J = 7.9 Hz, 1H), 7.56 (t, J = 8.0 Hz, 1H), 7.44 (m, 5H), 4.40 
(q, J = 7.1 Hz, 2H), 1.36 (t, J = 7.1 Hz, 3H). 
 
S36a: 
 
 
 
1H NMR (400 MHz, CDCl3): 
 
δ 7.20 (dd, J = 8.5, 2.4 Hz, 1H), 7.12 (d, J = 2.3 Hz, 1H), 6.88 (d, J = 8.4 Hz, 1H), 5.06 (m, 1H), 
3.92 (s,s, 6H), 2.77 (m, 1H), 1.32 (d, J = 6.3 Hz, 3H), 1.23 (d, J = 6.6 Hz, 3H), 1.20 (d, J = 6.3 
Hz, 4H), 0.84 (d, J = 6.8 Hz, 3H). 
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